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Abstract 
 
 
 
 
Breast cancer is the most common cancer in the UK, and mammographic density (‘density’) is 
one of its strongest known risk factors. At present, most research focuses on static measures of 
density to determine population effects. The central hypothesis of this thesis is that repeated 
measures of density are more valuable for personalised breast cancer prevention. This 
hypothesis was tested through the following research. 
 
Study-I investigated within-women associations between body mass index (BMI) and density, 
to assess whether density (visual/Cumulus/volumetric ‘Stepwedge’) acts as a mediator for breast 
cancer risk reduction during a premenopausal weight-loss intervention (n=65). Study-II 
evaluated the benefit of using a woman’s longitudinal history of (BI-RADS) density to improve 
breast cancer risk estimation (n=132,439). Study-III was a Cochrane systematic review 
investigating the association between endocrine therapy-induced density reduction and breast 
cancer risk and mortality. Studies-IV and V (n=575) evaluated visually-assessed density 
reduction with prophylactic anastrozole during the International Breast Cancer Intervention 
Study-II, and its use as a biomarker for concurrent breast cancer risk reduction, respectively. 
 
In Study-I, change in BMI was associated with change in breast fat but not dense tissue, 
negating density reduction as a biomarker for risk reduction with weight-loss. In Study-II, 
longitudinal density provided approximately a quarter more statistical information than most 
recent density and improved discriminatory accuracy. Study-III found evidence that density 
reduction may be a biomarker for reduction in risk and mortality with tamoxifen, but the level 
of evidence was limited by some study quality issues. Study-IV indicated that preventive 
anastrozole might marginally reduce density, but statistical significance was not obtained. In 
Study-V, sample size was too small to draw definitive conclusions. 
 
Overall, changes in density were useful for the study of breast cancer risk and should be 
considered for personalised breast cancer prevention strategies. 
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Chapter 1: Thesis background, rationale and aims 
 
1.1 Thesis background and rationale 
 
1.1.1 Introduction to breast cancer 
 
Breast cancer is the most common cancer in the UK, with approximately 55,000 new cases of 
invasive breast cancer diagnosed every year (1). An estimated 1 in 7 women in the UK will be 
diagnosed with the disease in their lifetime (based on multiple primary incidences) and around 
11,000 women will die from breast cancer in the UK each year; that’s 31 women every day (1). 
Worldwide, breast cancer is the second most common cancer, with an estimated 2.1 million new 
cases and 600,000 deaths recorded in 2018 (2). 
 
There is higher incidence of the disease in the Western world, which is thought to be a result of 
lifestyle factors such as delayed age at first full term birth, nulliparity, use of exogenous 
hormones and obesity (3-8). Implementation of routine mammographic screening programmes 
has also been linked to an increase in annual breast cancer incidence due to greater and earlier 
detection of tumours (6-8). Furthermore, early detection programmes allow treatment to be 
administered at an early stage of progression when it is most effective, thereby improving 
survival and reducing mortality as a result of the disease (6-10). Other factors, such as wider use 
of chemotherapy and adjuvant hormone therapy, have also contributed to reduced breast cancer 
mortality rates (6-8, 11). 
 
1.1.2 Anatomy of the breast 
 
The breast is part of the female reproductive system, and its main function is to produce and 
secrete milk. It consists of fatty adipose tissue, stroma (fibrous connective tissue), lobules 
(mammary glands), milk ducts, the lymphatic network, the nipple, the areola, blood vessels and 
Copper’s ligaments. Individual structures, known as terminal ductal lobular units (TDLUs), 
consist of a lobule and an extra-lobular duct connected to a larger milk duct. Milk production 
occurs in TDLUs, which is then transported through the milk ducts to the nipple. TDLUs are 
also the site of hormonal exchange, hence their number and size changes in response to 
hormone fluctuations during different reproductive stages such as menstruation, pregnancy, 
lactation and menopause. Most breast cancers develop in the epithelial cells lining TDLUs (12). 
Cancers developing in the lobules are known as lobular breast cancers, and cancers developing 
in the extra-lobular ducts are known as ductal breast cancers. 
 
24 
 
1.1.3 Principles of mammography 
 
In the UK, women aged 50-70yr (or 47-73yr in some areas) are invited to attend a 
mammography screening appointment every three years. At their first screen, mammograms are 
used to assess the presence of an already existent prevalent breast cancer, and at their 
subsequent screens, mammograms are used to detect incident breast cancers that have 
developed since the last screening appointment. Breast cancers which develop or are detected in 
between screens are known as interval breast cancers, which usually present as a result of 
symptoms such as a breast lump, skin dimpling or thickening, breast or nipple pain, and nipple 
retraction or discharge. Diagnostic mammograms are used to image the breast after a screening 
mammogram with suspicious results or as a result of the patient reporting symptoms that the 
physician believes warrants further investigation. 
 
The mammogram examination is an x-ray of the breast. The breast is placed between two 
compression paddles and an x-ray beam is used to penetrate the breast, which is then detected at 
the other side of the breast by a receptor (film-screen or digital detector). During screening 
mammography, women undergo two-view assessment: the cranio-caudal (CC) view and the 
medio-lateral oblique (MLO) view. These two complementary views capture the breast from 
different angles to image as much tissue as possible. 
 
Various imaging factors affect the quality of the image produced during a mammogram. The 
optimal mammogram is a trade-off between factors such as contrast (x-ray tube kilovoltage 
peak, kVp), exposure (milliampere-seconds, mAs) and breast compression. A lower level of 
kilovoltage peak produces a higher contrast (desirable), and a lower level of exposure produces 
a lower radiation dose (desirable) but grainy images (undesirable). However, a lower 
kilovoltage peak does not penetrate through thick or dense breast tissue, and requires higher 
exposure to produce the necessary dose for penetration through the breast to the receptor below. 
Therefore, exposure and dose generally increase with increased breast size and density. Breast 
compression can be described by the force (Newton, N) or pressure (kiloPascal, kPa); the latter 
being a measure of the force divided by the contact area (13). Contact area depends on the 
breast size and deformation of breast tissue under pressure. A higher breast compression leads 
to a smaller breast thickness (millimetres, mm) and increased spread of tissue which reduces the 
required dose whilst producing a higher quality image. These factors work in tandem and can be 
largely dependent on the patient and radiographer’s technique at the time of mammography 
examination. However, most (digital) mammography machines nowadays use calibration 
techniques to automate the process and determine the optimal factors for each examination, 
negating the need for radiographers to subjectively determine the imaging factors. 
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Mammography can either be film-screen or full-field digital mammography (FFDM). FFDM 
generates a ‘raw’ (‘for processing’) mammogram whereby the pixel values are linearly related 
to the exposure. These raw mammograms then undergo image processing to make the 
mammogram visible to the naked eye, which varies depending on the mammography machine’s 
manufacturer. The applied algorithms are usually unspecified and irreversible, so the 
appearance of ‘for presentation’ mammograms can differ from one mammography machine to 
another. 
 
1.1.4 Mammographic density – literature review 
 
1.1.4.1 Mammographic density 
 
Mammographic density is also referred to as ‘density’ or ‘breast density’. 
 
Broadly, the breast has two main components when assessed via mammography: dense and 
fatty tissue. The dense tissue are stroma (fibrous connective tissue) and duct epithelium 
(parenchyma or glandular tissue) within the breast; collectively known as the fibroglandular 
tissue. This fibroglandular tissue appears as white, radio-dense material on an x-ray, whereas the 
fatty adipose tissue is dark and translucent. 
 
The degree of density involvement within the breast can be described in a variety of ways. It is 
often defined as the area of fibroglandular tissue, known as the absolute dense area (DA); or as 
the percent dense area (PDA), which is a measure of the DA over the total breast area (TA). 
This TA is comprised of the DA and the fatty adipose tissue within the breast, also known as the 
absolute non-dense or fat area (FA). With the introduction of volumetric methods, density has 
also recently been described in terms of absolute dense volume (DV), percent dense volume 
(PDV), total breast volume (TV) and non-dense or fat volume (FV). Measurement of these area-
based and volumetric density measures are described in detail in the following section. 
 
 
 
Figure 1.1 Mammograms depicting low (left) and high (right) density. Images from the International 
Breast Cancer Intervention Study-I. 
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1.1.4.2 Measurement of mammographic density 
 
The first reference to density as a risk factor for breast cancer was made by Dr John Wolfe in 
1969 (14) who categorised density based on variations in the appearance of mammographic 
parenchymal patterns as well as the approximate proportion of the breast occupied by these 
patterns. These ‘Wolfe grades’ were described as: N1 (predominantly fat), P1 (ductal 
prominence in <25% of the breast), P2 (ductal prominence in >25% of the breast) and DY 
(extensive dysplasia). Wolfe observed that women with extensive dysplasia (DY) had an 
incidence of breast cancer that was 22 times higher than those with predominantly fatty breasts 
(N1). 
 
A similar method of assessment, known as the Tabar classification, was developed by Gram et 
al. in 1997 (15). This measurement of density is categorised into: I (scalloped contours and 
Cooper's ligaments, evenly scattered terminal ductal lobular units, 1-2 mm nodular densities and 
oval-shaped lucent areas corresponding to fatty replacement), II (complete fatty replacement), 
III (retro-areolar prominent duct pattern due to fatty involution), IV (extensive nodular and 
linear densities) and V (homogenous ground glass like, structure-less fibrosis with convex 
contour). The major difference between Wolfe and Tabar categorisations is the closer 
representation of premenopausal density seen with the Tabar grades. Since premenopausal 
women have denser breasts than postmenopausal women, Tabar I is thought to represent the 
high density patterns commonly observed in premenopausal women, whilst Tabar II, III, IV and 
V would represent Wolfe grades N1, P1, P2 and DY, respectively (16).  
 
Another assessment of density, the Breast Imaging Reporting and Data System (BI-RADS) 
lexicon, was first proposed by the American College of Radiology (ACR) in 1993 (17). In the 
third edition of the lexicon, BI-RADS density was defined qualitatively: BI-RADS I 
(predominantly fat), BI-RADS II (scattered fibroglandular density), BI-RADS III 
(heterogeneously dense) and BI-RADS IV (extremely dense), but in the fourth edition, 
quantitative descriptions of PDA were also included: BI-RADS I (<25%, predominantly fat), 
BI-RADS II (25%-50%, scattered fibroglandular density), BI-RADS III (50%-75%, 
heterogeneously dense) and BI-RADS IV (>75%, extremely dense) (18). These have since been 
dropped in the fifth edition which is again purely qualitative: BI-RADS I (predominantly fat), 
BI-RADS II (scattered fibroglandular density), BI-RADS III (heterogeneously dense breasts 
which may obscure small masses) and BI-RADS IV (extremely dense breasts which lower the 
sensitivity of mammography) (17). 
 
Since Wolfe, Tabar and BI-RADS grades assess density with a maximum of five categories; 
substantial risk information could be lost due to the grouping of density. An alternative 
measurement method, known as the visual assessment score (VAS), was therefore developed to 
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aid in the assessment of PDA on a continuous and quantitative scale. Visual assessment scoring 
ranks PDA from 0% to 100%; although PDA is sometimes also described in 5% incremental 
scores, creating a semi-continuous 21 point scale (19). 
 
Although the methods outlined so far are thought to do well in describing density, a major 
limitation is their subjective nature; basing measurements on a radiologist’s visual interpretation 
of density. Only moderate inter-observer (kappa score=0.54) and intra-observer (kappa 
score=0.71) agreements have been reported with BI-RADS assessment (20), and studies on 
visual assessment have reported differences as high as 30% and 35% for intra- and inter-
observer scores, respectively (21). This means that adequate reader training is essential in order 
to reduce the heterogeneity of density scores assessed subjectively (22). 
 
As well as purely visual assessments, computer-assisted methods of density measurement have 
also been introduced. In 1994, a computer-assisted thresholding technique, known as 
‘Cumulus’, was introduced to improve on the subjective nature of scoring (23). Cumulus is an 
interactive thresholding technique which requires its users to set pixel thresholds on a digitised 
(23) or digital (24, 25) mammogram. The user sets an initial grey-level threshold, iedge, to 
separate the breast edge from the background, for which any pixel with grey-level higher than 
this threshold is classed as the breast and any pixel with a lower grey-level is considered 
background. Another threshold, iDY, is then determined to separate the dense tissue (pixels 
higher than iDY) from the fatty tissue (pixels lower than iDY) within the breast. The user can also 
mask out the pectoral muscle (particularly visible in MLO views). Cumulus then sums the 
number of pixels categorised as breast, dense and non-dense tissue to provide information on 
compartmentalised breast composition i.e. TA, DA and FA, respectively. PDA can then be 
calculated by dividing the DA over the TA. Before Cumulus, a similar method of assessment 
called ‘planimetry’ was used to provide information on separate areas of breast tissue. This 
worked by tracing around the breast edge and regions of dense tissue on an acetate overlay and 
measuring TA and DA using an outlining tool (26). However, this method is somewhat 
cumbersome and requires greater user involvement than Cumulus, so is rarely used. 
 
The semi-automated, semi-subjective and quantitative nature of Cumulus provides a density 
score that has shown strong associations with breast cancer risk  (23, 27, 28); produces 
comprehensive information about separate breast tissue components; and reports high levels of 
agreement within and between adequately trained observers (intraclass correlation coefficient 
between observers >0.9 in Byng et al. (23)). In addition to the continuous Cumulus score, Boyd 
et al. introduced a categorisation of Cumulus, known as the Boyd classification, which sees 
density grouped into: none, <10%, 10 to <25%, 25 to <50%, 50 to <75% and ≥75% (27). Other 
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fully-automated or semi-automated area-based segmentation methods exist, including 
AutoDensity (29), fuzzy c-means-based methods (30) and an ImageJ-based method (31). 
 
 
 
Figure 1.2 Cumulus thresholds (23) applied to a mammogram. Image from the International Breast 
Cancer Intervention Study-I. 
Red pixels indicate the image background (excluded from area calculations); green pixels indicate the 
outline of dense tissue such that pixels inside the green boundary are dense tissue and pixels outside of 
the green boundary are non-dense breast fat. 
 
The methods introduced so far have their limitations. Manual (or semi-manual) density readings 
would be too labour-intensive and time-consuming to be incorporated into the UK National 
Health Service (NHS) breast screening programme (NHSBSP), which requires high-throughput 
mammography for approximately two million women per year (32); and subjective (or semi-
subjective) density readings are only practical with sufficient reader training (22). Incorporation 
of these density methods into the NHSBSP would place a time and cost burden on health 
services in order to cover extra staffing and training costs. Furthermore, the insufficient 
reproducibility and large intra- and inter-reader variability that occur with subjective density 
measures (21, 22) might make these methods of assessment unreliable in guiding clinical 
decisions about a woman’s healthcare. In addition to this, these measurement methods are based 
on a 2-dimensional projection of the breast, which undoubtedly loses information regarding the 
anatomical breast structure. Even with sufficient compression, superimposition can occur during 
mammography, creating an overlap of structures which may distort area-based interpretations. 
 
With the aim of resolving many of these issues, various volumetric methods based on two-class 
tissue models and FFDM have now been developed. These volumetric methods are intended to 
give a more realistic representation of dense tissue in the breast and provide objective, 
automated measures of absolute fibroglandular and non-dense tissue (33-36). The breast is 
assumed to contain only 2 mediums, dense and fatty tissue, which have separate x-ray 
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attenuation coefficients. Greyscale levels at each pixel in the mammogram are modelled as a 
function of these x-ray attenuations and the initial x-ray beam. This function is then used to 
produce estimates of the different amounts of dense and fatty tissue within each ‘stack’ of breast 
tissue at each pixel. Summing over the pixels in the whole breast gives the total volume of 
breast tissue (33). The most widely used and commercially available volumetric software is 
Volpara (36), but alternative approaches also exist (37-43). Volpara is a development of the 
standard mammographic form (SMF) (33) that produces estimates of TV, DV, FV and PDV. 
 
 
 
Figure 1.3: Representation of Volpara volumetric density physics model to estimate dense volume. 
Total breast thickness at 𝑃(𝑥, 𝑦) (i.e. pixel value of pixel (𝑥, 𝑦)) is made up of the thickness of dense and 
fatty tissue. The thickness of dense tissue at 𝑃(𝑥, 𝑦) is ℎ𝑑𝑒𝑛𝑠𝑒 (𝑥, 𝑦). The energy penetrating the breast 
is 𝐼0 , and the energy reaching the detector is assumed to be linearly related to  𝑃(𝑥,𝑦) . The pixel value o f 
pure fat, 𝑃𝑓𝑎𝑡 , is determined by finding the pixel value with the least x-ray attenuation (using an itera t ive 
approach to find the fatty, uncompressed breast edge). The linear x-ray attenuation coefficients for dense 
and fatty tissue using a particular filter, tube voltage and breast thickness are 𝜇𝑑𝑒𝑛𝑠𝑒  and 𝜇𝑓𝑎𝑡 , 
respectively. Values for 𝑃(𝑥, 𝑦)  and 𝑃𝑓𝑎𝑡  are measured on the ‘raw’ mammogram, and 𝜇𝑑𝑒𝑛𝑠𝑒  and 𝜇𝑓𝑎𝑡  
are assumed from reported data. Summing values of ℎ𝑑𝑒𝑛𝑠𝑒(𝑥,𝑦) over all pixels of the breast gives an 
estimate of the volume of dense tissue in the breast. Derived from the physics model based on (44). 
 
An advantage of volumetric methods is that they offer high levels of agreement with magnetic 
resonance imaging (MRI)-assessed breast density (often seen as the ground truth for volumetric 
tissue distributions) (40, 44, 45). A study by Gilhuijs et al. found Pearson correlations of 0.93, 
𝐼0 
ℎ𝑑𝑒𝑛𝑠𝑒 (𝑥, 𝑦) =
ln(𝑃(𝑥, 𝑦)/𝑃𝑓𝑎𝑡)
𝜇𝑓𝑎𝑡 − 𝜇𝑑𝑒𝑛𝑠𝑒
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0.97 and 0.85 for PDV, TV and DV, respectively, when comparing Volpara-assessed density to 
density measured using segmentation techniques in MRI scans (45). With such good 
representation of breast tissue and high reproducibility (46), it was hypothesised that volumetric 
density would also improve breast cancer risk prediction. However, studies have indicated a 
somewhat similar performance to area-based methods (41, 47-51). 
 
Some researchers have also hypothesised that density may be acting as a risk factor not purely 
through the amount of fibroglandular tissue it encompasses, but also through its distribution and 
pattern complexity (52, 53). This idea has led to a focus on structural components and spatial 
distributions (‘texture features’) of mammographic images, to assess whether they could have 
an effect on breast cancer risk, independent of the amount of density (52, 54-62). Some studies 
suggest that these textural features could add to or even outweigh the predictive power of 
density (52, 54-56, 61, 62), but these are less well validated than volumetric or visual density. 
 
Even though most measures of density involve assessment of mammograms, the breast may be 
assessed by other modalities. Density can be read from computed tomography (CT) (63-65), 
ultrasound (66, 67), MRI (68, 69) and dual energy x-ray (70) images. A relatively new approach 
to breast imaging comes in the form of digital breast tomosynthesis (DBT). DBT is an x-ray 
imaging modality which produces pseudo-3D images of the breast, using multiple low-dose 
exposures taken at different angles through 30° and reconstructed to produce image ‘slices’ 
through the breast (71). This provides a novel approach to density assessment, allowing cross-
sectional visualization through the breast to reduce the effect of superimposition of overlapping 
tissue. Since DBT is still relatively new, only a few studies have looked into its use in density 
assessment. Methods of density assessment using DBT include the application of Volpara (72) 
or the fully-automated volumetric software, Quantra, (73) to raw projections; a Cumulus-like 
threshold to reconstructed slices (74); Cumulus to a central projection (55); and integral curves 
(75), maximum entropy (75) or BI-RADS (73, 75, 76) to a set of projections. Density can then 
be calculated as the average density from all raw projections (72, 73, 75) or slices (74), or it can 
be calculated as the total number of voxels identified as dense over the total number of voxels in 
the DBT 3D reconstruction (74). Cumulus-assessed percent density from DBT (central 
projection, mean of all projections, or mean of reconstructed slices) has shown high correlation 
with Cumulus-assessed percent density from 2D mammography, with Pearson correlations 
ranging between 0.76 and 0.97 (77). Similarly, Volpara-assessed density from DBT (one 
projection) has shown high correlation with Volpara-assessed density from 2D mammography 
(Pearson correlation 0.903) (77). 
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Table 1.1: Overview of density measurement techniques. 
Wolfe Tabár BI-RADS VAS Planimetry 
Semi-automated 
area-based e.g. 
Cumulus 
Boyd 
Fully-automated 
volumetric e.g. 
Volpara 
Techniques 
applied to 
Tomosynthesis 
images 
Subjective Subjective Subjective Subjective Subjective Semi-subjective 
Semi-
subjective 
Objective 
Semi-
subjective/ 
Objective 
Qualitative and 
quantitative 
categorised 
Qualitative 
categorised 
Qualitative 
categorised 
Quantitative 
continuous 
Quantitative 
continuous 
Quantitative 
continuous 
Quantitative 
categorised 
Quantitative 
continuous 
Quantitative 
continuous 
2D 2D 2D 2D 2D 2D 2D Volumetric 
Volumetric/ 
Pseudo-3D 
Manual Manual Manual Manual Manual Semi-automated 
Semi-
automated 
Automatic 
Semi-
automated/ 
Automatic 
 
Favourable density measurement technique characteristics: 
 Objective–consistent and reproducible scores, intra- and inter-reader variability eliminated, does not require user training, ideal for use in clinical and screening environments.  
 Quantitative–larger gradients in risk than qualitative measures (78); fine scale and continuous description of density makes it easier to distinguish small differences in  densi ty 
(28). 
 Volumetric–more realistic representation of the 3D breast structure, takes into account the thickness of the breast. 
 Automatic–fast results, ideal for use in clinical and screening environments, not very labour or time-intensive. 
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1.1.4.3 Mammographic density as a breast cancer risk factor 
 
Mammographic density is one of the strongest known independent breast cancer risk factors; 
women with mostly dense breasts are at a 4 to 6-fold increased risk relative to women with fatty 
breasts (79). The density-risk association is seen with both qualitative and quantitative density 
measurements, however many studies show a better risk prediction for quantitative density (78-
81). In a meta-analysis of over 14,000 cases and 226,000 controls from 42 studies, McCormack 
and dos Santos Silva reported a pooled relative risk (RR) estimate of 3.98 (95% CI, 2.53 to 
6.27) for Wolfe grade DY relative to N1; 4.08 (95% CI, 2.96 to 5.63) for extremely dense 
relative to fatty BI-RADS scores; and 4.64 (95% CI, 3.64 to 5.91) for VAS PDA ≥75% relative 
to <5% (79). As for computerised methods, a study by Boyd et al. showed a fairly high relative 
risk of 4.04 (95% CI, 2.12 to 7.69) for Cumulus ≥75% density relative to no density (27).  
 
Risk associations with volumetric modalities have been somewhat mixed (41, 47-51, 82-84), 
with some studies suggesting a superior performance over area-based methods (82-84), but 
many reporting similar risk associations (41, 47-51). In a recent case-control study, the screen-
detected cancer odds ratios (ORs) for the highest quintile percent density (relative to the lowest 
quintile percent density) were 2.42 (95% CI, 1.56 to 3.78), 2.12 (95% CI, 1.30 to 3.45) and 2.17 
(95% CI, 1.41 to 3.33) for Volpara, Cumulus and the fully-automated area-based measure, 
Densitas, respectively. VAS was the strongest predictor with an OR of 4.37 (95% CI, 2.72 to 
7.03), whilst the fully-automated volumetric method, Quantra, had no significant association 
with risk, with an OR of 1.02 (95% CI, 0.67 to 1.54) (50). Another recent study reported similar 
risk associations for BI-RADS and Volpara (fractioned into categories analogous to BI-RADS 
categories) (85). It has also been suggested that a combination measure of Volpara DV and BI-
RADS may improve breast cancer risk estimation beyond using only one of the measures (86). 
 
As well as looking into the effects of qualitative and quantitative density measures on breast 
cancer risk, many studies have investigated whether the chosen description of density can vary 
the extent of risk. Both percent and absolute density are strongly and positively associated with 
breast cancer risk (87-90), but most literature suggests that PDA has stronger risk associations 
than DA (88-90).  
 
Other examinations of density as a risk factor for breast cancer suggest that risk is not specific 
to breast side or location of the eventual cancer (89), and risk associations are similar for both 
MLO and CC mammographic views and right or left side (91). Of note, even though risk 
profiles are similar between views, PDA does tend to differ between views, with CC views 
regularly reporting higher PDA estimates than MLO views (92). The reason for this is quite 
intuitive. Subcutaneous fat is more visible in MLO views than CC views, which leads to larger 
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TA values in MLO images, and subsequently lower PDA (93). It has been suggested, therefore, 
that both MLO and CC views should be used for density assessment, which is supported by 
evidence of a more consistent risk score when assessing density from two view mammography 
(93). 
 
With the advent of FFDM, differences in risk estimates may also exist depending on the type of 
mammogram used for density assessment. Density tends to appear darker and therefore less 
dense in FFDM images compared with film images (94), which can be partly explained by 
better recognition of the skin line on digital mammograms (94). There is also an increased 
variability in density measured using FFDM on different machine types. Each mammography 
machine uses its own processing algorithm to display mammograms ‘for presentation’, which 
can affect the perceived relationship between the input x-ray and received image signal (35). 
Volumetric measures use raw, pre-processed mammograms in their estimation of density (35), 
because these images represent the x-ray attenuation of the breast tissue directly. However, raw, 
processed and film images have different appearances, and adjustments may be required to 
calibrate their density-breast cancer risk associations. 
 
1.1.4.4 Mammographic density in screening 
 
There is some concern regarding density in screening; mainly due to the masking effect caused 
by dense breasts. Since dense tissue has a similar attenuation coefficient to many types of 
tumours, high density can cause an inability to detect breast cancers (95), resulting in higher 
levels of missed prevalent cancers at first screen in women with dense breasts. Because of this 
masking effect, many advocacy groups in the US, such as the ‘Are You Dense?’ campaign (96), 
have been arguing for access to information regarding density scores. In 2009, the first breast 
density legislation was subsequently passed in Connecticut, mandating the disclosure of BI-
RADS density to screened women (97). As of July 2019, a total of 38 US states now require 
some level of breast density notification (98). The ACR also addressed the issue of masking in 
their fifth edition BI-RADS lexicon. This latest fifth edition lexicon now includes guidance on 
grading breasts with high density behind the nipple as BI-RADS III or IV (99). This emphasis 
on masking effects has, however, also caused some concern that healthcare practitioners may be 
more likely to grade women as having dense breasts (100), perhaps as a safeguard for missing 
prevalent cancers at the time of screening. 
 
It was previously thought that this masking effect could introduce bias into the density-risk 
relationship (101). Masking bias arises from lower mammographic sensitivity in dense breasts 
compared with fatty breasts, creating higher rates of false negative screens. Prevalent, but 
missed, cancers might be detected after a negative screen, creating a high level of interval 
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cancers and low level of screen-detected cancers (95, 102, 103) (as shown by the 20-30% 
stronger density-risk association seen in studies of incident cancer (cancer diagnosed after a 
negative screen) compared with prevalent cancer (density assessment and diagnosis occurring at 
the same time) in McCormack and dos Santos Silva’s meta-analysis (79)). Supporting evidence 
for this masking effect comes from Boyd et al. (95) who found an increased probability of 
interval cancer detection within 12 months after a negative screen (OR=17.8, 95% CI, 4.8 to 
65.9) for women with >75% visually-assessed density relative to women with <10% visually-
assessed density, suggesting that these cancers were likely already prevalent, but missed, at 
screening. It has also been hypothesised that masking bias could cause an overestimation of 
incident cancers in cohort studies, and an underestimation in case-control studies (22). The 
reason for the overestimation in cohort studies would be due to missed prevalent cancers in 
dense breasts at study entry being revealed during follow-up, whilst the underestimation in case-
control studies is thought to be due to the error in categorisation of women with dense breasts. 
Prevalent cancers in dense breasts could be missed and therefore misplaced as ‘healthy’, hence 
underrepresenting dense breasts amongst cases and over-representing dense breasts amongst 
controls. This would create an artificially low relationship between high density and the 
subsequent cancers detected. However, another study by Boyd et al. also reported that both 
cohort and case-control studies carried similar risk associations (22), which would disprove the 
idea that masking bias was an influence on these study designs. In addition to this, studies by 
Byrne et al. and Rebolj et al. have found that the risk effect of density exists for at least 10 years 
post mammogram examination (104, 105). Harvey et al. estimated that if masking bias did have 
a substantial effect on the density-risk relationship, about 75% of prevalent cancers in dense 
breasts of women in Byrne et al.’s study would have been missed and subsequently diagnosed 
10 or more years later, which is a highly unlikely scenario (106). It is therefore now commonly 
accepted that the effect of density on breast cancer risk is not a result of masking (79). 
 
A further issue regarding density and screening is the debate surrounding the treatment of 
women who present dense breasts at screening. Due to the masking effect, dense breasts tend to 
decrease both sensitivity and specificity of breast cancer detection during mammography (107, 
108). This effect is especially apparent in younger women (for example, <50 years old) who are 
likely to have denser breasts than older screening ages (108). Sensitivity has been shown to 
improve with digital mammography in pre- and perimenopausal women <50 years old with 
dense breasts (109, 110) but with film mammography in postmenopausal women >65 years old 
with fatty breasts (109). Specificity is somewhat different between digital and film 
mammography (109), if not slightly improved with film mammography in younger women 
(aged 40-49) (110). The lower levels of sensitivity and specificity seen in dense breasts assessed 
by mammography have led many to advocate the need for stratified surveillance dependent on 
density. 
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One proposed method of stratified screening in women with dense breasts is the use of 
supplemental or adjunct imaging. These may be particularly useful in young, high-risk or 
symptomatic women requiring frequent examinations throughout their lifetime. Whilst 
mammography in these women would increase lifetime exposure to x-ray ionisation, the use of 
MRI or ultrasound (which do not use ionising radiation) would lower this lifetime x-ray 
exposure. Adjunct automated whole-breast ultrasound (111-115) and MRI (113, 114, 116) have 
the potential to improve sensitivity compared with mammography alone in women with dense 
breasts. However, compared with mammography alone, specificity has been shown to fall with 
these modalities, which could increase the number of false positives (111, 114). Supplemental 
screening using ultrasound or MRI in women with dense breasts given the ‘all-clear’ after a 
negative mammogram has also been suggested (117). A simulation study by Sprague et al. 
(118) found that supplemental screening ultrasound after a negative mammogram in women 
with BI-RADS III or IV would avert 0.36 additional breast cancer deaths and gain 1.7 quality-
adjusted life years per 1000 women. However, they also found that there would be an additional 
354 false-positive biopsy recommendations per 1000 women with supplemental ultrasound 
screening. With an estimated cost-benefit ratio of $325,000 per quality-adjusted life years 
gained, this study suggested that supplemental ultrasound screening for women with 
heterogeneously or extremely dense breasts could greatly increase costs while producing 
relatively small benefits in comparison.  
 
Another increasingly popular imaging modality is DBT. Although relatively new, this imaging 
modality is progressively replacing FFDM in the US and it is quickly gathering more interest in 
other countries. DBT has been shown to lower the effects of masking and provide better 
imaging for the detection of tumours within dense breasts (119-121). It is also possible to 
capture a DBT image in the same compression as FFDM imaging with little added dose and 
little extra resource (117). Since MRI is a relatively expensive modality requiring a large 
amount of user training, and both MRI and ultrasound still produce relatively high false positive 
rates in comparison to tomosynthesis (122), DBT could be a prime candidate for adjunct or 
supplemental screening, particularly since its U.S. Food and Drug Administration approval in 
2011. However, adjunct screening tomosynthesis may increase the time required to interpret a 
mammographic examination (123); but one could argue that with the increased specificity of 
tomosynthesis (120), this additional reading time would be balanced by the reduced number of 
non-cancers recalled for diagnostic tests. It is also possible to produce a synthesised 2D image 
with DBT that replicates projections captured with FFDM. Studies of DBT + synthesised 2D 
mammography have shown similar results to DBT + FFDM (124); and with no additional x-ray 
dose than DBT alone, DBT + synthesised 2D mammography could negate the need for both 
FFDM and DBT.  
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Whilst supplemental screening in women with dense breasts is promising, recent evidence 
suggests that this implementation may be too premature (125). For supplemental screening to be 
beneficial, it must improve sensitivity as well as reducing the number of interval cancers, 
advanced-stage disease or breast cancer-specific mortality (125). However, so far, studies have 
shown only a small reduction in breast cancer deaths (118) and many have been underpowered 
to show an effect on women with advanced-stage disease (126). There is also limited evidence 
for the effects of supplementary screening on interval cancers in women with dense breasts. A 
large randomised control trial (RCT), DENSE, is currently underway to assess whether 
supplementary MRI can reduce rates of interval cancer amongst women with dense breasts 
(127). 
 
Not only does high density increase the risk of an incorrect ‘all-clear’ mammographic 
examination, but density has also been shown to increase the risk of more aggressive (107, 128, 
129) or larger (128, 130) cancers due to its masking effect. In the UK, women between 50-70 
years (or 47-73 years in some areas) are currently invited for screening every three years 
regardless of their level of density (131). However, shorter screening intervals in women with 
dense breasts may be more beneficial. More frequent screening in women with dense breasts 
could increase the likelihood of catching rapidly progressing cancers and existent cancers 
missed by masking on previous screens, at an earlier stage. One must note, however, that basing 
surveillance frequency on density alone would ignore women who are at an increased risk of 
more severe tumours but who do not necessarily have dense breasts. It may therefore be better 
to base stratified surveillance on risk assessment from established risk models rather than 
density alone, to ensure that those at the highest risk of breast cancer are given frequent 
examinations, even if they perhaps have low density. This idea has already been implemented in 
some healthcare services, such as the NHS, who now offer more frequent surveillance to women 
at a high risk of breast cancer based on family history (132, 133). 
 
Whilst stratified screening could potentially improve efficiency and provide more targeted 
surveillance for the most at-risk women (131, 134), there are still questions surrounding the 
cost-effectiveness of supplemental screening as well as the advantages of notifying women of 
their density (135). For example, a study by Hooley et al. found that only 45% of women in 
Connecticut referred for supplemental ultrasound screening actually received it (136). This 
raises concerns over the inconsistency of implementing breast density legislation. It also creates 
a problem whereby women may be informed of their dense breasts but are not offered suitable 
treatment to decrease their risk or to reduce the effects of masking. Whether this lack of follow-
through is due to personal choice, inefficiencies in healthcare services or possibly insufficient 
medical insurance to cover further examinations, appropriate care should be available to women 
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with dense breasts if they are to be notified of their high density and increased risk of incidence 
and masking. 
 
1.1.4.5 Mammographic density and breast cancer risk factors 
 
Mammographic density is associated with many other breast cancer risk factors including age, 
body mass index and reproductive factors such as parity and menopause. These relationships are 
discussed in more detail below. 
 
1.1.4.5.1 Age 
 
Density decreases with age (137-141). Adjustments are therefore necessary in order to 
counteract the negative confounding of age on the density-risk relationship (27, 104). If no 
adjustment is made for age, the effect of density on risk will be underestimated (142). This 
creates a contradiction between density, age and breast cancer risk, since age and density are 
positively associated with risk, but inversely associated with each other. To help to understand 
this inconsistency, one could consider the cumulative rate of ‘breast tissue aging’ (i.e. 
cumulative rate of exposure to hormones) rather than chronological age, as suggested in Pike’s 
model (143, 144). Risk from density might reflect the breast tissue response to lifetime exposure 
of reproductive hormones (such as oestrogen) and growth factors (such as insulin-like growth 
factor (IGF-I) or prolactin) which stimulate epithelial and stromal cell division in the breast (78, 
145-149). According to Pike’s model, the rate of breast tissue aging is most rapid at the time of 
menarche, slows with each pregnancy, slows further in the perimenopausal period, and is lowest 
after the menopause. This implies that an earlier age at menarche, nulliparity, later age at first 
birth and later age at menopause will increase cumulative exposure to hormones. Later 
menarche, parity, earlier age at first birth and earlier age at menopause are suggested to decrease 
cumulative exposure to hormones (27, 143, 144). It has been hypothesised that the higher the 
cumulative exposure to hormones, the higher the density. Hormonal exposures in early life 
might therefore be the most important predictors in the development of density, since this stage 
in life sees the highest rates of breast tissue aging. 
 
Furthermore, the density and breast cancer risk association can be seen in both younger and 
older women (27, 79, 104). However, one must bear in mind that density estimates in women 
younger than the screening age may not be fully applicable to general populations of women. 
Since these younger women do not undergo routine mammography, density measures taken 
from this age group may be skewed by the potentially symptomatic or high-risk populations of 
women examined. 
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Figure 1.4: Pike’s model showing rates of breast tissue aging with chronological age. 
The rate of breast tissue aging is greatest after menarche, declines with successive pregnancies and in the 
perimenopausal period, and is lowest after the last menstrual period i.e. post-menopause. This model is 
used as a theory to explain the increasing incidence rate of breast cancer with increasing age . Derived 
from Boyd et al. (78) which uses data from Pike et al. (143) and Rosner and Colditz (144). 
 
1.1.4.5.2 Menarche  
 
There is only a small amount of literature regarding the association between age at menarche 
and breast density, but according to Pike’s model, one would expect there to be a correlation 
between early menarche and both increased density and increased breast cancer risk. There is 
some evidence to suggest that density is higher in women with early menarche (150), but this is 
not always the case (138). On the other hand, breast cancer risk increases with earlier menarche, 
but the effects are only marginal (151). 
 
1.1.4.5.3 Parity 
 
Density reduces with a first full-term pregnancy (152, 153), and reduces even further with each 
subsequent pregnancy (81, 153). This is thought to be due to the lower levels of reproductive 
hormones circulating post-pregnancy. Lower density is therefore associated with parity (81, 
138, 152, 153) and earlier age at first full-term birth (152, 153). 
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1.1.4.5.4 Menopause 
 
Density reductions occur over the menopause (140, 154). This effect is thought to reflect the 
decrease in circulating reproductive hormones and increase in breast tissue involution that occur 
at this stage of female reproduction (155). Density is also positively associated with age at 
menopause, with lower densities existing in women who begin menopause at an earlier age 
(154). The density and breast cancer risk association is not limited to a particular menopausal 
status, with both premenopausal and postmenopausal women seeing higher risk with increasing 
density (104). 
 
1.1.4.5.5 Body Mass Index 
 
As well as age, systemic adiposity (commonly measured as body mass index (BMI)) is one of 
the strongest confounders of density (138, 156). Percent density, whether measured as PDA or 
PDV, is negatively associated with BMI (88, 157-165); as women with higher BMI are more 
likely to have higher non-dense tissue and total breast tissue (157, 166, 167) which will lead to 
lower percentage estimates of density. Absolute dense area has a less consistent relationship 
with BMI (87, 157-160, 168, 169). DV, on the other hand, has shown positive associations with 
BMI (161-165). These relationships are further complicated by the fact that density and 
excessive postmenopausal BMI are both positively associated with risk of breast cancer (170-
173), but (percent) density reduces with increasing BMI (88, 157-165). Relationships involving 
(percent) density as a risk factor therefore require an adjustment for BMI, otherwise breast 
cancer risk will be underestimated (174).  
 
Some studies have also suggested a protective effect of BMI on breast cancer risk in 
premenopausal women (172, 175, 176). However, others have argued that these contrary 
findings are a result of negative confounding by density (166, 169).  
 
To understand the contradictory relationships between adiposity, density and breast cancer risk, 
it helps to first understand the biological mechanisms behind the positive effect of BMI on 
breast cancer risk in postmenopausal women. This can largely be explained by the high levels of 
oestrogen present in overweight or obese postmenopausal women, as a result of the aromatase 
enzyme converting androgens to oestrogen in peripheral adipose tissue. This process of 
aromatisation acts as the main source of oestrogen in postmenopausal women whose hormonal 
production in the ovaries has ceased (177). Elevated levels of oestrogen act as a risk factor by 
binding to oestrogen receptor (ER)-positive tumour cells and stimulating their growth and 
proliferation (177). 
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1.1.4.5.6 Endogenous hormones 
 
Circulating endogenous oestrogen levels have been shown to influence the growth of density 
(146, 147, 178), making density a potential mediator for the effects of reproductive hormones 
on breast cancer risk. It has been theorised that density is a reflection of the breast tissue 
response to lifetime hormone exposure, as outlined in Pike’s model (143, 144). According to 
this theory, variations in density would mirror different levels of cumulative hormonal 
stimulation. However, this relationship between systemic hormones and density might not be 
applicable to all women, since little to no association between density and blood serum 
oestrogen has been seen in postmenopausal women (179-181). Some studies have investigated 
the role of local environments surrounding density, suggesting that certain hormones produced 
locally at these sites, may be stimulating the proliferation of epithelial cells. Most evidence 
suggests that a relationship exists between circulating oestrogens and density in premenopausal 
women, but not in postmenopausal women, with local breast tissue perhaps acting as the main 
oestrogen source in postmenopausal women (180-182). 
 
Other hormones that are known to influence density include IGF-I and prolactin. High levels of 
serum IGF-I in premenopausal women and prolactin in postmenopausal women have shown 
significantly positive associations with density (145, 183, 184). Recent evidence to support this 
suggests that the breast cancer risk associations of plasma prolactin and mammographic density 
are independent in premenopausal women (185). It has also been suggested that consideration 
of both density and endogenous hormones (such as prolactin, circulating testosterone and 
estrone sulphate) may add to current breast cancer risk prediction models (185, 186). 
 
1.1.4.5.7 Exogenous hormones 
 
Hormone replacement therapy (HRT) increases both risk of breast cancer (142, 187, 188) and 
density (189-194). Specifically, combined oestrogen and progesterone HRT has greater 
associations with density than oestrogen only HRT (192-194), and continuous use of combined 
HRT is also associated with higher density than cycled HRT use (191, 194). However, the 
effects of HRT are only short-term, with a decrease in density visible just 4 weeks after HRT 
cessation (195, 196) and a decrease in risk (to the level of a non-HRT user) is apparent within a 
few years of stopping treatment (197). 
 
Whilst HRT increases both risk of breast cancer and density, selective oestrogen receptor 
modulators (SERMs) have been shown to decrease risk (198-202), and certain SERMs, such as 
tamoxifen, can also reduce density (203-206). A study from the International Breast Cancer 
Intervention Study-I (IBIS-I) found that visually-assessed density reductions of 10% or more 
after 12-18 months of tamoxifen treatment were associated with an approximately 63% 
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reduction in breast cancer risk (OR=0.37, 95% CI, 0.20 to 0.69), p=0.002) compared with 
placebo, whereas smaller reductions or increases in density on tamoxifen had the same 
association with risk as placebo (OR=1.13, 95% CI, 0.72 to 1.77), p=0.60) (19). This suggests 
that change in density could be used as a biomarker to measure the efficacy of tamoxifen for 
prevention. Aromatase inhibitors (AIs), such as anastrozole, can also be used to treat and 
prevent breast cancer (207, 208). However, the effect of AIs on density is less clear, and it is yet 
unknown whether change in density can also be used as a biomarker for response to treatment 
with these drugs. 
 
1.1.4.5.8 Heritability 
 
Family history and heritability can also influence mammographic density. Twin studies have 
shown a 60% correlation between Cumulus-assessed PDA in monozygotic twins compared with 
30% in dizygotic twins (209), and findings suggest that heritability can explain around two 
thirds of the residual variance seen in Cumulus-assessed PDA (209).  
 
There has also been interest in the links between women with BRCA1/2 mutations and density 
(210, 211). Weak evidence suggests that BRCA1/2 carriers have higher density that is lower in 
contrast and coarser than low-risk women without these genetic mutations (210). However, 
studies also show similar relative risks of developing breast cancer for high density relative to 
low density amongst carriers of the BRCA1/2 mutation and non-carriers (211), proposing no 
effect modification by genetic mutations. 
 
In addition to this, a series of genome-wide association studies (GWAS) have so far identified at 
least 100 Single Nucleotide Polymorphisms (SNPs) that are thought to be associated with breast 
cancer susceptibility (212, 213). Each of these SNPs has been shown to slightly modify an 
individual woman’s risk, but together, they could provide a significant amount of information 
regarding a woman’s risk. Attention has therefore turned towards these SNPs and investigations 
are on-going to ascertain their effect on density (212, 214-220). Candidate SNPs suggested to 
have an association between both breast cancer risk and density include SNPs located within the 
HSD17B1, CYP1B1 and COMT oestrogen-related genes (218, 220), rs6220 (IGF-1) (217), 
rs3817198 (LSP1) (214), rs13281615 (8q) (214) and rs10509168 (ZNF365) (216), but the 
effects of these latter SNPs on density require validation. A particular SNP, rs10995190 
(ZNF365), has shown significance in more than one study (215, 216), suggesting a promising 
locus for further genetic evaluation. However, not all studies report an association between 
density and those SNPs identified in GWAS (219), and some studies suggest that independent 
information can be gained from the two risk factors (221); hence the relationship between SNPs, 
density and breast cancer risk remains an active area of research. 
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1.1.4.6 Mammographic density and breast cancer risk models 
 
Various breast cancer risk models aim to distinguish between women at different levels of risk. 
These include the Gail (222), Tyrer-Cuzick (223), BCSC (224), BOADICEA (225), Claus (226) 
and Ford (227) models. The Tyrer-Cuzick model is used in the UK and US, whilst the Gail 
model is more commonly used in the US. The Gail model includes age, age at menarche, age at 
first full-term birth, family history, number of biopsies, presence of atypical hyperplasia and 
ethnicity. A major limitation of the Gail model, however, is that it includes only first-degree 
relatives, which can result in underestimation of risk in women with a familial risk of cancer 
from the paternal side, for example. The Tyrer-Cuzick model expands on this by incorporating 
extensive family history information. The Tyrer-Cuzick model also includes age, age at 
menarche, BMI, age at first full-term birth, menopausal status, age at menopause, benign breast 
disease, presence of atypical hyperplasia, HRT use and length, Ashkenazi Jewish heritage, and 
genetic mutations in the BRCA1/2 genes, as well as a lower-penetrance ‘unknown’ BRCAX gene 
which may increase susceptibility to hereditary breast cancer, and is used to account for residual 
familial clustering. 
 
The Gail model has shown good calibration between predicted and observed numbers of breast 
cancer (228), but there is some evidence that including more risk factors provides better 
discriminatory accuracy (229-234).  
 
Breast cancer risk models are continually being updated, and attempts to include density into the 
models have shown promising results (235-244). One early study investigating the inclusion of 
density in a breast cancer risk model was conducted by Tice et al., who compared a risk model 
containing age and ethnicity-adjusted BI-RADS density only, the Gail model, and a combined 
version of the two. The age and ethnicity-adjusted BI-RADS model was shown to perform just 
as well as the Gail model. However, adding density to the Gail model modestly but significantly 
increased the discriminatory accuracy of the Gail model (237). Further studies by Chen et al. 
(241) and Barlow et al. (240) have also found slight improvements in discriminatory power after 
adding visually-assessed (241) or BI-RADS (240) density to the Gail model, and a recent study 
by Rice et al. found an improvement in the Rosner-Colditz breast cancer risk model when 
percent density was included (245). In 2014, Warwick et al. showed that density significantly 
added to the Tyrer-Cuzick model in a case–control analysis of high-risk women from the 
placebo arm of the IBIS-I trial (242). In this study, the area under the receiver operator 
characteristic curve (AUC) increased from 0.51 in the Tyrer-Cuzick model to 0.62 in the model 
containing both Tyrer-Cuzick risk and a density residual (p=0.002). More recently, Brentnall et 
al. showed that visually-assessed density improved the Tyrer-Cuzick model (235). Using data 
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from the PROCAS cohort study of around 55,000 women attending screening, they found that 
AUC (0.57) and IQR-OR (an odds ratio for the 75th vs. 25th percentile; 1.36, 95% CI, 1.25 to 
1.48) for the Tyrer-Cuzick model increased with the addition of density (AUC=0.61; IQR-
OR=1.47, 95% CI, 1.33 to 1.62). In another study, Brentnall et al. also showed that more high-
risk screened women can be identified when using the Tyrer-Cuzick model with BI-RADS or 
volumetric density than without (without: 4.8% identified, with BI-RADS: 7.1% identified, with 
volumetric density: 6.8% identified) (246). The Tyrer-Cuzick model now includes VAS, BI-
RADS and Volpara-assessed density in its latest version of risk calculation (243, 244). 
 
1.1.5 Changes in mammographic density – literature review 
 
Mammographic density is a promising tool, with great potential for breast cancer prevention. 
However, most research has so far focused on static measures of density, giving insight into 
population-based relationships. Density is a dynamic phenotype, so repeated measures of 
density may be more informative for predicting individual breast cancer risk and for developing 
personalised breast cancer prevention strategies. Assessing individual women’s repeated 
measures could help to reveal within-women relationships between density and other breast 
cancer risk factors, to help to understand the aetiology of breast cancer development and the 
interacting influences of different risk factors. It may also provide information on risk of breast 
cancer for individual women and hence be useful for personalised breast cancer risk estimation. 
Consideration of changes in density may also be useful for indicating a woman’s response to 
breast cancer treatment, such as endocrine therapy. If reductions in risk are mirrored by 
reductions in density, change in density could be used as a potential biomarker for decrease in 
risk as a result of the drug. It is therefore hypothesised that changes in density may be of greater 
use in breast cancer prevention than fixed density measures.  
 
Several studies have previously looked into the benefit of using repeated measures of density 
for breast cancer risk and prevention. A review of key studies is outlined below, along with 
further research ideas arising from the studies that formed the rationale for this thesis. 
 
1.1.5.1 Repeated measures of mammographic density and other breast cancer risk factors (body 
mass index) 
 
An important breast cancer risk factor and confounder of density is BMI. BMI is a well-
established risk factor for postmenopausal women (170, 172, 173), but weight gain across 
premenopausal years has also been linked to an increased risk of postmenopausal breast cancer 
(173, 247). However, this can be reversible with short-term weight-loss through dietary (248) or 
surgical (249) means. For example, the Iowa Women’s Health Study showed a 25-40% decrease 
in postmenopausal breast cancer risk in women who sustained a 5% loss of body weight 
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compared with women who continued to gain weight at different periods of time between 18 
years of age and menopause (250). However, the effects of short-term weight-loss on density 
are less well understood. 
 
There have been few studies assessing the effect of short-term weight change on density, 
particularly over the premenopausal years when a loss in weight is most effective. A dietary 
intervention study by Boyd et al. assessed the effect of a two year low-fat, high-carbohydrate 
diet on density, and found that women on the weight-loss intervention saw a reduction in 
Cumulus TA (2.4% reduction), whereas the control group had increased TA (0.3% increase), 
and DA decreased in the intervention group more so than the control group (6.1% reduction vs. 
2.1% reduction, respectively). The reduction in dense area was particularly apparent in women 
who transitioned from pre- to postmenopausal or who remained premenopausal during the study 
(251). Other studies exploring the effect of more drastic weight-loss after bariatric surgery on 
premenopausal dense tissue have not shown any consistent effect of the weight-loss intervention 
on dense tissue (252, 253). 
 
If weight-loss-induced reductions in risk are shown to be mediated by density, a reduction in 
density could act as a possible biomarker for risk reduction as a result of weight-loss and 
lifestyle interventions. However, with only one known study published to have previously 
assessed dietary-based weight-loss on density in premenopausal women, more studies are 
required to assess this mediating pathway, and to test this possible risk reduction biomarker. 
 
1.1.5.2 Repeated measures of mammographic density for breast cancer risk estimation 
 
Several studies have made use of repeated measures of density to predict breast cancer risk in 
populations of women attending screening (254-261). These have mainly focused on change in 
density between two serial mammograms and its effect on breast cancer risk. For instance, in a 
case-control study of 85 breast cancer cases and 85 matched controls in the Women at Risk 
(WAR) Columbia University study, Work et al. reported that Cumulus-assessed density 
between two pre-diagnostic mammograms (median 4 years apart) decreased in time with 
controls (p=0.004), but not with cases (p=0.6) (259). This suggested that a lack of density 
reduction over time may be indicative of a future risk of breast cancer. Another study from the 
Breast Cancer Surveillance Consortium (BCSC) tested whether changes in density between 
current and previous mammograms (average 3 years apart) were associated with risk of breast 
cancer. This study involved a large cohort of over 300,000 women screened at various US 
registries, with around 2600 subsequent breast cancers diagnosed during follow-up. Here, 
Kerlikowske et al. found that within-women changes in BI-RADS categories were associated 
with risk in women with previous BI-RADS categories I, II and III, but not for women with 
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previous BI-RADS category IV (258), suggesting a potential residual effect of high density. 
However, these interpretations were limited by the small number of women in the most extreme 
categories (for instance, only 0.1% of controls and 0.2% of cases moved from BI-RADS IV to 
I). Furthermore, no adjustments could be made for BMI which may have introduced negative 
confounding to the density-risk association. 
 
The null effect seen in Kerlikowske et al.’s study in women with initially high density, was also 
reported in a study by vans Gils et al. (257). Fully computerised methods were used to measure 
density change over a 10 year period in over 100 postmenopausal breast cancer patients and 400 
matched controls. This study found that women who started the study with high density (>25%) 
which decreased over time, experienced the same risk as women who had prolonged levels of 
high density. However, similar to Kerlikowske et al., very few women moved between the 
extreme density categories (only 12 women had initial density >25% which reduced to <5% 
during the study). Another key finding suggested that women whose density decreased from 
moderate (5-25%) to low (<5%), had (non-significantly) higher risk than women who had 
consistently low density (OR=1.9, 95% CI, 0.6 to 6.1). Compared with the consistently low 
group, women with consistently moderate density had an OR of 5.7 (95% CI, 2.2 to 15.2), and 
women whose density increased from moderate to high had an OR of 6.9 (95% CI, 2.1 to 22.9). 
 
However, not all studies show an effect of change in serial density measurements on breast 
cancer risk. Longitudinal studies by Maskarinec et al. and Vachon et al. showed that changes in 
Cumulus percent density did not differ between women with and without breast cancer (255, 
256). Nonetheless, both studies were limited by their collection of BMI information. 
Maskarinec et al. reported that many of their mammograms did not have corresponding BMI 
measurements taken at the same time as mammography, and Vachon et al. also reported 
differences in the timings of BMI assessments, with 17% of women having BMI data extracted 
over a year after their mammogram. BMI is not a static measurement and may have changed 
between the time of mammography and BMI assessment, potentially affecting the results. 
 
Whilst, changes between two measures of density may have an effect on breast cancer risk, little 
is known as to whether repeated measures of density add information to risk estimation beyond 
what’s already explained by a woman’s current density. Only one other known study has 
evaluated this by assessing the predictive ability of using two density measures. Kerlikowske et 
al., again using data from the BCSC, found that the BCSC 5-year risk model better 
discriminated between cases and controls with a two-measure density predictor than with a one-
measure density predictor (AUCs 0.640 vs. 0.635, respectively) (262). However, no studies 
have evaluated the benefit of including more than two density measures; particularly an 
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unlimited number of mammograms taken at arbitrary points in time, as would be seen in a 
screening environment. 
 
1.1.5.3 Repeated measures of mammographic density for breast cancer risk with endocrine 
therapy interventions 
 
IBIS-I was the first trial to show that change in density could reflect the beneficial effect of 
tamoxifen in the primary prevention of breast cancer. A nested case-control study within the 
trial assessed 123 breast cancer cases and 942 controls to test whether density reduction on 
tamoxifen was associated with risk of developing breast cancer. Cuzick et al. found that women 
who had at least a 10% reduction in VAS density in the first 12-18 months after the start of 
tamoxifen had an approximately 63% reduction in breast cancer risk compared with women on 
placebo, whilst women who experienced <10% density reduction on tamoxifen had no 
difference in risk compared with women on placebo (19). This result suggested that density 
change could be used as an early biomarker to assess the efficacy of prophylactic tamoxifen in 
order to predict a woman’s response to treatment. With the help of this biomarker, healthcare 
practitioners may advise women who see at least a 10% density reduction after 12-18 months of 
treatment to continue with their 5 year course of chemoprevention, whereas those who see a 
more modest reduction or increase in density might not be responding to treatment and would 
perhaps benefit from alternatives such as lifestyle interventions or chemoprevention with other 
SERMs or AIs (19). 
 
Other studies have since tested the biomarker in the adjuvant setting for breast cancer patients 
on endocrine therapy for treatment of the disease. Some studies have suggested that a reduction 
in density may be used as a biomarker for breast cancer recurrence on tamoxifen (263, 264) and 
AIs (264), and others have suggested its use for predicting a reduction in mortality for 
tamoxifen treatment (265, 266). However, there are currently no systematic reviews focussing 
on the evidence to suggest that mammographic density reduction in women receiving endocrine 
therapy is a biomarker for breast cancer outcomes such as reduction in risk, recurrence, 
mortality and incidence of contralateral breast cancer. A review of this sort is essential to 
determine the strength of certainty for this biomarker before it can be implemented into clinical 
practice. 
 
There is also very little evidence for the mammographic density biomarker in women treated 
with AIs, and there are no known studies in women on preventive AI therapy. The IBIS-II trial 
showed that the AI, anastrozole, reduced the risk of ER+ breast cancer in high-risk 
postmenopausal women by 60% (208), and it is a good resource to test this biomarker for 
preventive anastrozole therapy. 
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Previous studies assessing the effect of AIs on density have reported only modest (and often 
underpowered) results (267-270). In the preventive setting, the NCIC CTG MAP.1 prevention 
trial of letrozole vs. placebo found that 12 and 24 month changes in Cumulus-assessed PDA 
were small and similar between arms (12 months: mean PDA change -1.74 on letrozole, -0.24 
on placebo (adjusted p=0.61); 24 months: mean PDA change -0.01 on letrozole, -1.32 on 
placebo (adjusted p=0.61)) (268). Vachon et al. also found similar results in a study of over 100 
postmenopausal women (adjusted mean PDA change -1.0% on letrozole vs. -0.3% on placebo 
(p=0.58)) (270). The NCIC CTG MAP.2 prevention trial found similar results for exemestane 
(mean 12 month Cumulus-assessed PDA change: 0.56 on exemestane and 0.58 on placebo 
(adjusted mean difference between arms p=0.96), mean 24 month PDA change: -0.17 on 
exemestane and -2.93 on placebo (adjusted mean difference between arms p=0.52)) (269). 
Studies in the adjuvant setting have shown similar results (267), but there has been some 
suggestion of a small effect of AIs on volumetric density with a larger sample size (271). 
However, there are currently no studies testing the effect of AIs on density in the preventive 
setting with a similarly sufficient sample size. The IBIS-II trial could be an important resource 
for testing the effect of preventive AIs on density with the potential to provide an adequately 
sized sample of women. 
 
1.2 Aims and thesis outline 
 
1.2.1 Repeated measures of mammographic density and other breast cancer risk factors 
(body mass index) 
 
Chapter two aimed to assess the dynamic relationship between BMI and density during a 
dietary-based weight-loss intervention in premenopausal women to help assess whether weight-
loss-induced reductions in risk are potentially mediated by reductions in density. Repeated 
measures data on density (visual, Cumulus and a ‘Stepwedge’ volumetric method) and BMI 
were collected over 2 years during the weight-loss intervention (Lifestyle study) in Manchester, 
UK (n=65). The intention of this intervention was to reduce postmenopausal breast cancer risk 
in susceptible premenopausal women who had gained weight since the age of 20 years through 
improvements in diet and exercise. Each woman’s measure of BMI varied across the study as 
she actively lost weight, and density was measured at the same time as BMI in order to assess 
concurrent changes in density. These within-women associations were tested using repeated 
measures correlation coefficients and a linear mixed model for short-term BMI change on 
density. 
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1.2.2 Repeated measures of mammographic density for breast cancer risk estimation 
 
Chapter three aimed to develop a longitudinal density measure that accounted for individual 
women’s changing density values, and to assess the benefit of using this longitudinal density 
measure for breast cancer risk assessment. Repeated measures data on density and BMI were 
collected as part of the Kaiser Permanente Washington Breast Cancer Surveillance Consortium 
breast imaging registry, taken over a period of up to 20 years in an at-risk screening population 
in Washington State, USA. Substantial follow-up and linkage to cancer registries recording 
breast cancer incidence allowed for long-term assessment of density over time and its effect on 
breast cancer risk. The longitudinal density measure was developed using a linear mixed model 
for age and BMI on density (BI-RADS). The benefit of using longitudinal density for breast 
cancer risk assessment was tested using likelihood ratio statistics to assess the predictive ability 
of proportional-hazards Cox models for time to breast cancer diagnosis with baseline, most 
recent or longitudinal density. Discriminatory accuracy was also tested using a yearly at-risk 
concordance index. 
 
1.2.3 Repeated measures of mammographic density for breast cancer risk with 
endocrine therapy interventions 
 
Most breast cancer risk factors are difficult to change, for example: age, female sex, family 
history, genetics and endogenous hormone levels; or can jeopardise a woman’s integrity and 
significant life-choices, such as reproductive events. However, density is a dynamic trait and it 
is modifiable. Density has also been shown to decrease in response to risk-reducing therapy by 
tamoxifen (19, 203). This is a promising result since an endocrine therapy-induced reduction in 
density that is concomitant with a reduction in risk could be used as a potential biomarker for 
monitoring the efficacy of risk-reducing endocrine therapies. Use of this biomarker would be 
more beneficial than the current “wait-and-see” approach, and because mammography is less 
invasive than the alternative tissue and blood sample biomarkers, change in density is a 
particularly appealing tool for indicating risk. 
 
Chapter four is a Cochrane systematic review of the published evidence to suggest that 
endocrine therapy-induced reduction in density can be used as a biomarker to predict breast 
cancer risk and mortality. This biomarker may exist in both the preventive and adjuvant 
settings, hence both risk and mortality outcomes were considered. 
 
Chapter five aimed to assess whether reductions in density occur with preventive anastrozole 
therapy. This is because it is important to first establish whether anastrozole has the potential to 
change density before assessing the biomarker’s association with breast cancer risk. This study 
was nested within the IBIS-II international, double-blind, randomised placebo-controlled 
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prevention trial of anastrozole vs. placebo in high-risk postmenopausal women. Change in 
density at approximately 2 and 5 years after initiation of treatment was compared between 
women on anastrozole or placebo, to determine whether preventive anastrozole treatment 
reduces density more than the natural decline that occurs with age. 
 
Chapter six aimed to assess whether preventive anastrozole-induced density reduction at 
approximately 2 years after the start of therapy is associated with a reduction in breast cancer 
risk. This study used the same data as Chapter 5, but with density change and treatment as 
predictors and breast cancer incidence as the outcome. 
 
Chapter seven concludes the thesis with a discussion of findings and future direction for 
research on changes in mammographic density and breast cancer risk. 
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Chapter 2: The relationship between body mass index and mammographic 
density during a premenopausal weight-loss intervention study 
 
2.1 Introduction 
 
As discussed in Chapter 1, mammographic density is one of the strongest risk factors for breast 
cancer. Percent breast density is measured as the relative proportion of dense tissue in the 
breast, either in terms of area or volume depending on the measurement method. Visual 
assessment measures the percent density with respect to the TA; whilst automated and semi-
automated methods can also measure the extent of dense and fatty tissue separately. Both DA 
and PDA are positively associated with risk of premenopausal (and postmenopausal) breast 
cancer (27, 104, 272), and absolute DV and PDV have also shown positive relationships (82, 
246). Associations of FA and FV with breast cancer risk are unclear, although there is some 
suggestion of an inverse relationship with premenopausal breast cancer risk (246, 272). 
 
In postmenopausal women, higher attained BMI is associated with a higher risk of breast cancer 
(170, 172, 173), with an estimated 40% increase in risk for every 10kg/m2 of BMI in never users 
of hormone replacement therapy (172). This increase in risk is partly explained by increased 
aromatisation of androgens to oestrogen in peripheral adipose tissue, which promotes cell 
proliferation (273, 274), carcinogenesis (273, 274) and insulin resistance (275). Whilst BMI is a 
widely accepted risk factor for breast cancer in postmenopausal women, there may be an inverse  
relationship in premenopausal women (175). However, this is not always consistent (276). For 
example, a 5kg/m2 increase is sometimes associated with a reduction in risk of premenopausal 
breast cancer risk amongst Caucasian and African women, but an increase amongst Asian 
women (276). 
 
Weight gain across the premenopausal years has also been linked to an increased risk of 
postmenopausal breast cancer. Every 5kg of adult weight gain is associated with an approximate 
10% increase in risk amongst never users (or low dose users) of hormone replacement therapy 
(173, 247). However, a number of studies (as summarised by Hardfeldt et al. (248)) suggest that 
these effects are reversible with efficient weight-loss, whereby short-term weight-loss is 
associated with an overall 20% breast cancer risk reduction (248). A reduction in risk of 
approximately 40% can also be seen with large weight-losses as a result of bariatric surgery in 
populations of pre- and postmenopausal women (249). 
 
The effects of short-term weight change on breast density are less well understood, particularly 
those as a result of dietary weight-loss. Mammographic density is a dynamic phenotype, and has 
the potential to respond to short-term weight changes, making density reduction a possible 
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biomarker for reduction in risk as a result of weight-loss. This study aims to explore the effect 
of short-term dietary weight change on density using both area-based and volumetric methods in 
a cohort of premenopausal women, to ascertain whether the relationship between weight-loss 
and reduced postmenopausal breast cancer risk could, in part, be mediated by reductions in 
mammographic tissue. 
 
2.2 Methods 
 
2.2.1 Study design and participants 
 
The Lifestyle study (277-279) was a 1 year diet and exercise weight-loss intervention study 
amongst 79 high-risk premenopausal women who attended annual screening within the Breast 
Cancer Family History clinic at the Prevent Breast Cancer research unit at the Manchester 
University Hospital Foundation NHS Trust between 2002 and 2004. Women were required to 
be aged 35-45 years, premenopausal with regular menstrual cycles, non-smokers, have a self-
reported adult weight gain ≥7kg, and a sedentary lifestyle (<40 minutes moderate physical 
activity per week). All women had a family history of breast cancer (with lifetime risk 16–40% 
as assessed by the Tyrer-Cuzick model (223, 243)), but were excluded if they had a known 
BRCA1/2 mutation or a previous history of cancer. Women were also excluded if they were 
already successfully dieting or losing weight, were pregnant or planning to become pregnant 
over the next year, had used hormonal oral contraceptives in the last 6 months, or had 
psychiatric or physical co-morbidities that could affect their ability to take part in a diet and 
physical activity weight-loss programme. In the intervention group, 40 women were assigned to 
a 12 month intensive supervised weight-loss programme which involved a 25% energy-
restricted Mediterranean type diet and an individualised physical activity program (150 minutes 
moderate intensity physical activity and 40 minutes of resistance exercise per week). A further 
39 women were separately recruited to a limited intervention control group who received 
standard written advice about diet and physical activity but no additional support for weight-
loss. 
 
The objective of this analysis was to assess the relationship between BMI and density in a 
cohort of women with changing BMI measures, regardless of their method of weight-loss. Since 
women from both the intervention and control groups were given lifestyle advice to lose weight 
(although less so for the control group), all women had within-women variation in BMI. To 
increase power, the analysis combines both intervention arms. Additionally, to limit the effect 
of women contributing observations to an area-based measure or volumetric measure only, the 
cohort is restricted to those with both an area and volumetric density measurement at any one or 
more time points (n=65, 82% of the cohort). 
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2.2.2 Mammographic density 
 
Mammographic films were digitised using a Kodak LS85 digitiser at a pixel size of 50µm and 
with 12-bits (4096 grey levels) pixel depth. Mammograms were analysed using three different 
methods: (1) a visual assessment score of percentage density read to the nearest 5% by two 
experienced readers (Dr Ruth Warren, Caroline Boggis), expressed as an average of the two 
scores to calculate PDA, (2) a semi-automated area-based measure based on computer-assisted 
thresholding (Cumulus, Sunnybrook health sciences centre, Toronto, Canada, (23)) (Dr Ruth 
Warren), and (3) an automated volumetric ‘Stepwedge’ method developed at Manchester 
University (280) (Dr Sue Astley). The Manchester Stepwedge method used markers on the 
compression paddle to determine breast thickness, and a calibration device (Stepwedge) to 
match each pixel density in the mammogram with the equivalent density in the Stepwedge. This 
method therefore required availability of the Stepwedge so that it could be imaged alongside the 
breast at the time of mammography. The Manchester Stepwedge method calculated TV, DV, 
FV and PDV and Cumulus was used to calculate TA, DA, FA and PDA. Density assessments 
were made at 3 time points: baseline, 1yr follow-up (at the end of the intervention) and 1yr after 
the end of the intervention. Baseline mammograms were taken at the point of entry to the study; 
for those women with a mammogram performed within one year of entry, their most recent 
mammogram within the last 12 months was used. Each woman had four mammographic views 
taken at each time point: left CC, right CC, left MLO and right MLO, and a final 
mammographic score at each time point was calculated using an average of the four views. The 
primary analysis refers to Cumulus-assessed DA, FA and PDA, and Stepwedge-assessed DV, 
FV and PDV to assess the effect of BMI on dense and non-dense tissue separately. Visually-
assessed density had similar results to Cumulus-assessed PDA so is included as a secondary 
density measure only. Results for TA and TV are also reported as secondary density measures 
in the results tables. 
 
2.2.3 Body weight and body composition 
 
Weight, BMI and a variety of different measures of body composition were assessed at baseline, 
1yr and 2yr after the start of the intervention. Weight (kg) and height at baseline (m) were 
determined using a calibrated beam balance and stadiometer, and used to calculate BMI 
(kg/m2). Other body composition assessments were also made i.e. waist circumference 
(measured by a trained research nurse using a measuring tape); total body fat, fat free mass and 
% body fat (assessed using a DXA whole body scanner (Hologic Inc., Bedford, MA, USA) and 
bioelectrical impedance (Tanita TBF-300A, Tanita Europe B.V., Hoogoorddreef 56E, 1101 BE 
Amsterdam, The Netherlands)); and intra-abdominal and abdominal subcutaneous area 
(assessed using an MRI scan with a single transverse scan taken at the level of the intervertebral 
disc between the L2 and L3 vertebrae). Weight, BMI, waist circumference, and total body fat, 
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fat free mass and % body fat (impedance) were recorded at all 3 time points. Intra-abdominal 
area, abdominal subcutaneous area, and total body fat, fat free mass and % body fat (DXA) 
were only measured at baseline and at 1yr. Weight at age 20yr was self-reported via 
questionnaire, and BMI at age 20yr was calculated using weight at age 20yr and height at study 
entry. Long-term BMI gain was calculated as the difference between baseline BMI and BMI at 
age 20yr. BMI is discussed as the primary measure of body weight throughout the analysis 
because BMI is a commonly used adjustment for density and it is a well-established risk factor 
for breast cancer. BMI also provided the most longitudinal information because it was only 
missing for 1 observation at 2yr, whereas other measures had more missing data (such as 
impedance which was missing for 19 observations). Other body composition measures gave 
similar correlations with density to those of BMI and were highly correlated with BMI. 
Therefore, other body composition measures are included as secondary analyses. Weight gain 
during the intervention was defined as ≥+3% of baseline weight, weight-loss was defined as ≤ -
3% of baseline weight, and a weight change >-3% to <+3% of baseline weight was defined as a 
stable weight (281). 
 
2.2.4 Statistical methods 
 
This analysis used the statistical software, R (282). All tests were two-sided and considered 
significant at the 5% level. 
 
2.2.4.1 Repeated measures correlation coefficients (primary analysis) 
 
Correlation (r) between BMI and mammographic density was assessed on a cross-sectional 
basis (between-women), and within-women as their short-term BMI changed, using repeated-
measures methods as described by Bland and Altman (283, 284). These correlations used all of 
the available data together to get an overall statistic across repeated measures. Between-women 
correlations were used to evaluate the relationship between breast density measures and BMI 
cross-sectionally across the group of women, for example, whether heavier women were more 
likely to have dense breasts. Within-women correlations were used to assess whether breast 
density changed for an individual woman in line with their changing BMI. If there was little 
relationship seen between-women, then it was unlikely that there would be a relationship 
within-women. 
 
A Pearson correlation coefficient could have been used to calculate between-women correlation, 
however this does not take into account the different number of observations contributed by 
each woman. Repeated measures correlation coefficients overcome this issue by calculating a 
54 
 
weighted Pearson correlation coefficient. With summations for woman 𝑖 = 1 … 𝑛, the weighted 
Pearson correlation coefficient is defined as: 
 
∑ 𝑚𝑖?̅?𝑖𝑦𝑖 −
∑ 𝑚𝑖?̅?𝑖 ∑ 𝑚𝑖𝑦𝑖
∑ 𝑚𝑖
√(∑ 𝑚𝑖?̅?𝑖
2 −
(∑ 𝑚𝑖?̅?𝑖)
2
∑𝑚𝑖
) − (∑ 𝑚𝑖𝑦𝑖
2 −
(∑ 𝑚𝑖𝑦𝑖)
2
∑ 𝑚𝑖
)
 ; 
 
where 𝑚𝑖 is the number of observations for woman 𝑖; and 𝑥̅𝑖 and 𝑦𝑖 are the mean BMI and 
density measures for woman 𝑖, respectively (284). Missing pairs of density and BMI were 
excluded. 
 
The within-women correlation coefficients effectively remove the differences between subjects 
to assess the changes within subjects only. The measure is based on the decomposition of sums 
of squares from an Analysis of variance (ANOVA). A linear model was first fit with a factor for 
each woman 𝑖 = 1 … 𝑛 at each time point 𝑗 = 1, 2, 3 so that: 
 
𝑦𝑖𝑗 = 𝛽0 + 𝜓𝑖 + 𝛽1𝑥𝑖𝑗 + 𝑒𝑖𝑗 ; 
 
where 𝑦𝑖𝑗 is the density measure for woman 𝑖 at time point 𝑗; 𝑥𝑖𝑗 is the BMI for woman 𝑖 at time 
point 𝑗; 𝛽1 is the parameter for BMI; 𝛽0 is an overall intercept; 𝜓𝑖  is a categorical factor variable 
with 𝑛 factors (dummy variables); and 𝑒𝑖𝑗 is the random error for each observation with mean 
zero and unknown variance. Missing pairs of density and BMI were excluded. 
 
The ANOVA table for this linear regression model is: 
 
Source of 
variation 
Degrees of 
freedom 
Sum of 
squares 
Mean square 
error 
F-ratio 
Women 𝑛 − 1 𝑆𝑆𝑤𝑜𝑚𝑒 𝑛  𝑆𝑆𝑤𝑜𝑚𝑒𝑛
𝑛 − 1
 
𝑀𝑆𝐸𝐵𝑀𝐼
𝑀𝑆𝐸𝑒𝑟𝑟𝑜𝑟
 
BMI 1 𝑆𝑆𝐵𝑀𝐼  𝑆𝑆𝐵𝑀𝐼
1
 
 
Residual 𝑛(𝑘 − 1) − 1 𝑆𝑆𝑒𝑟𝑟𝑜𝑟  𝑆𝑆𝑒𝑟𝑟𝑜𝑟
𝑛(𝑘 − 1) − 1
 
 
Total (𝑛𝑥𝑘) − 1 𝑆𝑆𝑡𝑜𝑡𝑎𝑙 𝑆𝑆𝑡𝑜𝑡𝑎𝑙
(𝑛𝑥𝑘) − 1
 
 
 
where 𝑛 is the sample size; and 𝑘 is the total number of observations divided by 𝑛 i.e. mean 
number of observations per woman. Proof of the number of degrees of freedom has been 
described elsewhere (285). 
 
55 
 
ANOVA assessed the variability in density partitioned into components based on the source of 
the variation. Removing the variation from women (𝑆𝑆𝑤𝑜𝑚𝑎𝑛), the within-women correlation 
coefficient was obtained: 
 
(±)√
𝑆𝑆𝐵𝑀𝐼
𝑆𝑆𝐵𝑀𝐼 + 𝑆𝑆𝑒𝑟𝑟𝑜𝑟
  ; 
 
where the sign is equal to that of 𝛽1 (283). 
 
As a secondary analysis, these repeated measures correlation coefficients were also completed 
for all mammographic density measures against each other and for all adiposity measures 
against each other. As an exploratory analysis, DXA bone density was also measured and added 
to the list of adiposity measures. 
 
2.2.4.2 Tadpole plots 
 
Density data were also plotted against BMI using ‘tadpole plots’ to show simultaneous between- 
and within-women associations graphically. In these scatter plots, each tadpole represents a 
woman: the head of the tadpole represents a woman’s density and BMI at their last 
mammogram, and the tail shows the same but for previous follow-ups (if density was available). 
This way, the reader may assess a woman's joint between- and within-women effects over the 2-
year period, for example, assess whether the tadpole tails (within-women effects) followed the 
pattern seen by comparing the tadpole heads (between-women effects). If there was no 
relationship between-women, the heads would be horizontal, and if density did not change as a 
woman lost weight, the tails would be horizontal. 
 
2.2.4.3 Empirical bootstrap 
 
95% confidence intervals for correlation coefficients were estimated using an empirical 
bootstrap with 10,000 resamples. The idea behind this non-parametric method is to generate a 
random bootstrap sample from the original dataset sample using ‘with replacement’ selection so 
that each unit of the original sample may be selected more than once. The bootstrap sample is 
selected so that it is of the same size as the original dataset sample. The statistic of interest can 
then be calculated (here, this was the correlation coefficient). This is repeated a number of times 
(for example, 10,000 times) to get a distribution of bootstrapped statistics. From this, the 2.5th 
percentile and 97.5th percentile can be obtained to give the empirical lower and upper bounds 
for the 95% confidence interval, respectively (286). 
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2.2.4.4 Linear mixed models (1) 
 
The ANOVA method for within-women correlations does not account for unbalanced data. 
Namely, some women were missing a density-BMI pair at one or more of their time points, 
therefore each woman contributed a different number of repeated measurements. Additionally, 
including a factor for each woman in the linear model for the ANOVA method might be 
affected by overfitting. Therefore, to check the robustness of repeated measure correlation 
coefficients, a multivariable linear mixed model was also fitted (287). Linear mixed models are 
robust to unbalanced data and reduce overfitting by including random effects per woman, as 
opposed to factors for each woman. The linear mixed model also allowed for assessment of the 
simultaneous association of between- and within-women correlations, alongside the adjustment 
for age. 
 
Linear mixed models are frequently used to model repeated measures. Repeated measures give 
rise to clustered data where data points within the same group more closely resemble each other 
than data points in other groups. Clustered or grouped measurements, for example, within-
person, tend to have high correlation with each other which results in lower variance than 
independent measurements. The linear mixed model overcomes this by introducing random 
effects in the linear regression model alongside the usual fixed effects representing population 
predictors. Estimated fixed effects are shared across all observations, whereas random effects 
vary across clusters. 
 
Random effects are comprised of two or more levels. The lowest base level represents each 
outcome measurement and the level above represents the grouping of repeated measures, for 
example, each individual woman (as seen in this study). If the data structure were to involve 
additional grouping such as hospitals or regions, a higher level could have been included to 
account for further clustering. These random effects are used to model deviations of each level’s 
groups about population mean effects (after accounting for the deviations for the levels below). 
Each level above the base level therefore separates the variance into two components: one that 
comprises the unobservable variance from that level and one comprising the variance from the 
level(s) below. Random effects can be modelled using random intercepts and random slopes. A 
random intercept allows for deviations about the mean fixed intercept and a random slope 
allows for deviations about a mean fixed effect slope so that each woman’s slope is not 
necessarily parallel to that of the population. 
 
In this chapter, the hierarchical structure of the linear mixed model includes two levels: the base 
level for each density measure at each time point, and the second level representing each 
woman. A diagram of this model is represented in Figure 2.1; which is also depicted as an 
equation (Equation 2.1). 
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Figure 2.1: Representation of the 2-level linear mixed model. 
 
Equation 2.1: The univariate linear mixed model. 
Level 1:         𝑦𝑖𝑗 = 𝛽0𝑖 + 𝛽1𝑖𝑥𝑖𝑗 + 𝑒𝑖𝑗 
Level 2:                    𝛽0𝑖 = 0 + 𝑢0𝑖 
                     𝛽1 𝑖 = 1 + 𝑢1𝑖  
 
where 𝑦𝑖𝑗 is the outcome for woman 𝑖 = 1, … , 𝑛 at time point 𝑗 = 1, … , m𝑖 , 0 is the population 
fixed intercept, 1 is the population fixed parameter for variable 𝑥𝑖𝑗, 𝑒𝑖𝑗 is the conditional 
random error (residual), 𝑢0𝑖 is the random intercept for woman 𝑖, and 𝑢1𝑖  is the random slope 
for woman 𝑖. 
 
The basic model assumptions used in the analysis are: 
 
 The random effects 𝒖𝑖 = (𝑢0𝑖, 𝑢1𝑖) are normally-distributed, such that 𝒖𝑖 ∼ 𝑁 (𝝁𝑢, 𝚺) 
where 𝝁𝑢 = (
0
0
) and 𝚺 is the 2x2 square, symmetric, and positive semi-definite variance-
covariance matrix, defined as: 𝚺 = ( 
𝜏00 
2 𝜏01 
2
𝜏10 
2 𝜏11 
2
 
) , where 𝜏00 
2 is the variance of the random 
intercept, 𝜏11
2  is the variance of the random slope, and  𝜏01 
2 and 𝜏10 
2  represent the covariance 
of the random intercept and slope. Different structures can be assumed for 𝚺. The two main 
structures mentioned in this thesis are: independent (covariance elements, 𝜏01 
2 and 𝜏10
2 , are 
constrained to be zero, hence random effects are uncorrelated) which is the simplest 
assumed structure, and unstructured (all elements are estimated and each of the random 
effects is allowed to be correlated with each other) which is commonly used for repeated 
measures data. 
 The random errors (residuals) 𝒆𝑖 =  (𝑒𝑖1, … , 𝑒𝑖m𝑖) are normally-distributed, such that 𝒆𝑖 ∼
𝑁 (𝝁𝑒 , 𝑬𝑖) where 𝝁𝑒𝑚𝑖𝑥1 =
(
0
⋮
0
) and  𝑬𝑖 = σ
2𝑰𝑚𝑖 with σ
2 being the sample residual 
….. 
… … 
Woman 1 
𝑦11 𝑦12 𝑦1𝑚1 
… 
Woman 2 
𝑦21 𝑦22 𝑦2𝑚2 
Woman n 
𝑦𝑛1 𝑦𝑛2 𝑦𝑛𝑚𝑛 
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variance and 𝑰𝑚𝑖 is the 𝑚𝑖 x 𝑚𝑖 identity matrix. This is the most common structure 
assumption and the only assumption mentioned in this thesis, although other structures, 
such as compound symmetry or autoregressive, can be assumed. 
 For the same woman: 
 All residuals are independent. 
 All random effects are (conditionally) independent of all residuals. 
 For different women: 
 All random effects for one woman are independent of all random effects for another 
woman. 
 All residuals for one woman are independent of all residuals for another woman. 
 All random effects for one woman are independent of all residuals for another woman. 
 
The linear mixed model for this study is described below. 
 
Breast density 𝑦𝑖𝑗 for woman 𝑖 = 1, … , 𝑛 at time 𝑗 = 1, 2, 3 was modelled as: 
 
Equation 2.2 
                𝑦𝑖𝑗 = 𝛼 + 𝛽𝑎𝑔𝑒𝑖𝑗 + 𝛾𝑥̅𝑖. + 𝛿(𝑥𝑖𝑗 − 𝑥̅𝑖.) + 𝑢0𝑖 + 𝑒𝑖𝑗;        
 
where α is an overall intercept, 𝑎𝑔𝑒𝑖𝑗 is the age for woman 𝑖 at time 𝑗, 𝛽 is the parameter for 
age, 𝑥̅𝑖. is mean BMI for woman 𝑖, 𝛾 is the between-women BMI parameter, 𝑥𝑖𝑗 is the BMI of 
woman 𝑖 at time 𝑗, 𝛿 is the within-women parameter, and 𝑒𝑖𝑗 is an independent random error. 
The term that allowed for differences between women in their overall density level is the 
independent random intercept 𝑢0𝑖 for woman 𝑖. The model is completed by assuming normal 
distributions for 𝑢0i and 𝑒𝑖𝑗, with zero mean, unknown variances and: zero covariance between 
𝑒𝑖𝑗 of the same woman or different women, zero covariance between 𝑢0i and 𝑒𝑖𝑗 of the same 
woman or different women, and zero covariance between 𝑢0i of different women. Missing pairs 
of density and BMI were excluded. The model was fitted by maximum likelihood (2.2.4.7). To 
aid interpretation of the estimates across different measures of density, the density values were 
first standardised (2.2.4.6). To test 𝛾=0 (between-women correlation) and 𝛿=0 (within-women 
correlation) a Wald test was applied (2.2.4.9). 
 
A secondary analysis was also undertaken to assess the effect of adding BMI gain since 20yr of 
age to the model. The model was extended to consider BMI gain from age 20yr: 
 
Equation 2.3 
                         𝑦𝑖𝑗 = 𝛼 + 𝛽𝑎𝑔𝑒𝑖𝑗 + 𝛾𝑥̅𝑖. + 𝛿(𝑥𝑖𝑗 − 𝑥̅𝑖.) + 𝑢0𝑖 + 𝑧𝑖 + 𝑒𝑖𝑗; 
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where 𝑧𝑖 is the BMI gain since age 20yr for woman 𝑖: calculated as the difference between 
baseline BMI for woman 𝑖 and BMI at age 20yr for woman 𝑖, and  is the parameter for BMI 
gain since age 20yr. To test =0 a Wald test was applied (2.2.4.9). 
 
In the linear mixed model, BMI was modelled as both a between-women and within-women 
effect to mirror the repeated measures correlation coefficients. Using the mean BMI for the 
between-women effect ensured that all of the data across the intervention was used for each 
woman, whilst determining a stable reference point from which a relative within-women change 
measure could be calculated. As this model contained repeated measures, random variation 
about the overall population mean density was allowed by including random intercepts.  
 
Likelihood ratio tests were conducted to test for inclusion of random slopes which would allow 
individual-woman deviation about the within-women population effect, 𝛿. These likelihood 
ratio tests are explained in more detail in section 2.2.4.8. No interactions were considered so 
that effects from the linear mixed model were the same as the repeated measures correlation 
coefficients. 
 
2.2.4.5 Transformations 
 
Diagnostic Q-Q plots were used to check the normality assumption of residual errors and 
random effects i.e. 𝒆𝑖 ∼ 𝑁 (𝝁𝑒 ,𝑬𝑖) and 𝒖𝑖 ∼ 𝑁 (𝝁𝑢, 𝚺). Quantiles of the estimated residual 
errors, ?̂?, and predicted random effects, ?̂?, were plotted against theoretical quantiles from a 
standard normal distribution, to visually assess whether plots formed a straight line and were 
thus normally distributed (288). To make density measures more symmetric and approximately 
normal-distributed they were transformed: a square root transformation for area measures and a 
cube root transformation for volumetric measures. 
 
2.2.4.6 Standardisation 
 
To help with comparisons across different measures of breast density, the breast density values 
were first standardised for woman 𝑖 = 1, … , 𝑛 at time point 𝑗 = 1, 2, 3 using: 
 
an overall mean:               𝑥̅ =
∑ ?̅?𝑖
𝑛 
𝑖=1
𝑛
 , 
 
and variance:            𝜎2 =
∑ (?̅?𝑖−?̅?)
2𝑛
𝑖=1
𝑛−1
 , 
 
to get a standardised density measure:          𝜑𝑖𝑗 =
𝑑𝑖𝑗−?̅? 
𝜎
 ;  
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where 𝑥̅𝑖 is the mean density for woman 𝑖 and 𝑑𝑖𝑗 is the density measure for woman 𝑖 at time 
point 𝑗. 
 
2.2.4.7 Maximum likelihood 
 
The likelihood of a parameter, 𝜃, given the observed data, 𝑥1, … , 𝑥𝑛 = 𝒙, is ℒ(𝜃|𝒙). The aim is 
to find the value for 𝜃 that maximises the likelihood function by taking the supremum (‘sup’) of 
ℒ(𝜃|𝒙), also known as the maximum likelihood estimator (MLE). The natural logarithm of the 
likelihood (denoted with a lower case symbol, ℓ(𝜃|𝒙)) is also often used. An estimated MLE 
(?̂?) can be found by taking the derivative of ℒ(𝜃|𝒙) or ℓ(𝜃|𝒙) with respect to 𝜃 and equating 
this to zero to find the global maximum and then solving the resulting equation. 
 
One problem that arises when using maximum likelihood (ML) for linear mixed models is that 
variance component estimators, ?̂? and σ̂2, tend to be negatively biased because fixed 
coefficients are assumed to be known without uncertainty. As a solution, unbiased restricted 
maximum likelihood estimation (REML) can be used instead (289). Briefly, maximum 
likelihood is applied to the residuals from the fixed part of the model therefore estimation of the 
variance components is independent of the fixed effects coefficients. A limitation of REML is 
that it is biased when comparing nested models that differ in their fixed effects. On the other 
hand, ML is biased when comparing nested models that differ in their random effects, however 
this bias decreases as the sample size increases (290). 
 
2.2.4.8 Likelihood ratio tests 
 
For a statistical model with parameter space, 𝛺: the null hypothesis (𝐻0) states that parameter 
𝜃 ∈ 𝛺0, where 𝛺0 is a subset of 𝛺, and the alternative hypothesis (𝐻1) states that 𝜃 ∈ 𝛺0
𝐶, where 
𝛺0
𝐶 is the complement of 𝛺0 (291). 
 
The likelihood ratio statistic for testing 𝐻0 vs. 𝐻1 is defined as: 
 
𝜆(𝒙) =
sup (ℒ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺0)
 sup (ℒ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺)
 
 
Assuming the null hypothesis is true, Wilks’ theorem (292) can be used to conduct tests on 
whether to reject 𝐻0 in nested models. Asymptotically (as the sample size  𝑛 → ∞), the statistic 
−2 log(𝜆) follows a chi-squared distribution i.e. −2 log(𝜆) ~ 𝜒2 with degrees of freedom equal 
to: dimensionality (𝛺) - dimensionality(𝛺0). 
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The natural logarithm of the likelihood, ℓ(𝜃|𝒙), is often used because with logarithms, products 
become summations and division becomes subtraction: 𝑙𝑜𝑔(𝑎𝑏) = 𝑙𝑜𝑔(𝑎) + 𝑙𝑜𝑔(𝑏) ; 
𝑙𝑜𝑔 (
𝑎
𝑏
) = 𝑙𝑜𝑔(𝑎) − 𝑙𝑜𝑔(𝑏).  
 
In this case:            −2 log(𝜆) = −2 log (
sup(ℒ(𝜃|𝒙)∶𝜃∈𝛺0)
 sup (ℒ(𝜃|𝒙)∶𝜃∈𝛺)
) 
                                                        = 2(log(sup(ℒ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺)) − log(sup(ℒ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺0))); 
 
And since the logarithm function on the set of positive real numbers is a monotonically 
increasing function, log(sup(ℒ(𝜃|𝒙))) = sup (log(ℒ(𝜃|𝒙))). 
 
Therefore −2 log(𝜆) can be rewritten as: 
 
                       −2 log(𝜆) =  2(sup((ℓ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺)) − sup((ℓ(𝜃|𝒙) ∶ 𝜃 ∈ 𝛺0))) 
 
The significance of a model compared with its nested model can then be tested by assessing the 
statistic −2 log(𝜆) using a 𝜒2 distribution. 
 
2.2.4.9 Wald tests 
 
A Wald test is used to assess how far an estimated parameter is from 0 (the value under the null 
hypothesis) in terms of its standard error. A Wald test that fails to reject the null hypothesis 
suggests that the estimated parameter is very small relative to its standard error and that 
removing this coefficient from the model will not harm the model fit. 
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2.3 Results 
 
2.3.1 Baseline characteristics 
 
Baseline characteristics of the cohort are shown in Table 2.1. Median age was 41yr 
(interquartile range (IQR), 38-43), and the majority of women were Caucasian (n=60, 92%) and 
parous (n=55, 85%). At baseline, 27 women (42%) were classified as overweight (BMI ≥25 
kg/m2 and <30 kg/m2), 20 (31%) were obese (BMI ≥30 kg/m2) and 18 (28%) were in the normal 
BMI range (BMI ≥18.5 kg/m2 and <25 kg/m2). All women gained at least 7kg of weight from 
the age of 20yr. By the end of the study, 16 women (25%) had gained weight, 22 (34%) had lost 
weight and 26 (41%) maintained their original weight. 
 
2.3.2 Mammographic density measurements 
 
Median PDA, DA and FA of each woman’s average density measure over the intervention were 
37.1% (IQR, 2.5%-71.3%), 59.9cm2 (IQR, 5.8cm2-158.4cm2) and 107.3cm2 (IQR, 23.6cm2-
405.1cm2), respectively. For Stepwedge measures, PDV, DV and FV were 22.7% (IQR, 6.7%-
69.4%), 191.5cm3 (IQR, 56.7cm3-710.4cm3) and 573.0cm3 (IQR, 72.8cm3-1992.1cm3), 
respectively. There was a large amount of missing data for volumetric density at baseline 
because of unavailability of the Stepwedge calibration tool, therefore volumetric density was 
only available for 36 women at baseline. Non-missing data was adequate for Stepwedge 
measurements at the other time points (n at 1yr and 2yr = 60 and 61, respectively) and for 
Cumulus measurements at all time points (n at baseline, 1yr and 2yr = 61, 64 and 55, 
respectively). 
 
2.3.3 Repeated measures correlation coefficients – body mass index and mammographic 
density 
 
The estimated repeated measure correlations are shown in Table 2.3. DV was positively 
correlated with BMI between-women (r=0.41, 95% CI, 0.17 to 0.61) but less so within-women 
(r=0.08, 95% CI, -0.16 to 0.28). There was little association between DA and BMI (between-
women r=-0.12, 95% CI, -0.38 to 0.16; within-women r=0.01, 95% CI, -0.24 to 0.25). PDV was 
inversely associated with BMI between- and within-women (between r=-0.48, 95% CI, -0.64 to 
-0.33; within r=-0.36, 95% CI, -0.54 to -0.12), and PDA was inversely associated with BMI 
between-women (r=-0.58, 95% CI, -0.72 to -0.42), but less so within-women (r=-0.22, 95% CI, 
-0.44 to 0.01). FV and FA were positively correlated with BMI between- and within-women 
(volume: between r=0.77, 95% CI, 0.69 to 0.84, within r=0.58, 95% CI, 0.36 to 0.75; area: 
between r=0.74, 95% CI, 0.63 to 0.82, within r=0.45, 95% CI, 0.23 to 0.63). The magnitude and 
significance of correlations were weaker within-women than between-women. 
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Table 2.1: Participant characteristics at baseline. 
 
Factor Summary 
Age (years) 41 (38-43)* 
Baseline BMI (kg/m2) 
       Normal (≥18.5 to <25) 
       Overweight (≥25 to <30) 
       Obese (≥30) 
27.1 (24.7-33.4)* 
18 (28%) 
27 (42%) 
20 (31%) 
Height (m) 1.64 (1.60-1.68)* 
Age at menarche (years) 12 (12-13)* 
Number of live births 
Nulliparous 
1-2 
3-4 
≥5 
 
10 (15%) 
41 (63%) 
12 (18%) 
2 (3%) 
Age first live birth (years) 27 (22-29)* 
Ethnicity (% Caucasian) 60 (92%) 
Previous smoker 
Never 
Ever 
 
54 (83%) 
11 (17%) 
Previous oral contraception use 
Never 
Ever 
Missing 
 
5 (8%) 
58 (89%) 
2 (3%) 
Breastfed 
Never 
Ever 
Missing 
 
22 (34%) 
41 (63%) 
2 (3%) 
10 year Tyrer-Cuzick risk (%) 4.0 (3.0-5.0)* 
Alcohol intake (units per week) 11 (3-24)* 
Physical activity (kJ/kg per week) 974 (945-999)* 
 
*Median (interquartile range); Body mass index (BMI). 
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Table 2.2: Mammographic density measure counts during the intervention . 
 
Factor N (%) 
N women with VAS density at 3 time points 53 (82%) 
N women with VAS density at 2 time points 7 (11%) 
N women with VAS density at 1 time point 5 (8%) 
N women with Cumulus density at 3 time points 51 (78%) 
N women with  Cumulus density at 2 time points 13 (20%) 
N women with  Cumulus density at 1 time point 1 (2%) 
N women with Stepwedge density at 3 time points 31 (48%) 
N women with  Stepwedge density at 2 time points 29 (45%) 
N women with  Stepwedge density at 1 time point 5 (8%) 
 
Visual assessment score (VAS). 
 
Table 2.3: Repeated-measures between-women and within-women correlations (95% confidence 
intervals) for density and body mass index. 
Field 
VAS 
(95% CI) [sqrt%] 
PDA 
(95% CI) [sqrt%] 
PDV 
(95% CI) [cbrt%] 
Cross-sectional 
BMI (between-
women) 
-0.62 
 (-0.74 to -0.47) 
-0.58  
(-0.72 to -0.42) 
-0.48  
(-0.64 to -0.33) 
Short-term BMI 
change (within-
women) 
-0.27 
 (-0.48 to -0.05) 
-0.22 
 (-0.44 to 0.01) 
-0.36 
 (-0.54 to -0.12) 
 
Field 
FA 
(95% CI) [sqrt] 
FV 
(95% CI) [cbrt] 
DA 
(95% CI) [sqrt] 
DV 
(95% CI) [cbrt] 
Cross-sectional 
BMI (between-
women) 
0.74  
(0.63 to 0.82) 
0.77  
(0.69 to 0.84) 
-0.12  
(-0.38 to 0.16) 
0.41  
(0.17 to 0.61) 
Short-term BMI 
change (within-
women) 
0.45 
 (0.23 to 0.63) 
0.58  
(0.36 to 0.75) 
0.01 
 (-0.24 to 0.25) 
0.08  
(-0.16 to 0.28) 
 
Visual assessment score (VAS), percent dense area (PDA), percent dense volume (PDV), fat area (FA), 
fat volume (FV), dense area (DA), dense volume (DV), square root transformed (sqrt), cube root 
transformed (cbrt), body mass index (BMI). 
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Figure 2.2: Tadpole plots showing density measures by body mass index during the intervention.  
Each tadpole represents a woman: the head shows density and body mass index (BMI) at their last 
mammogram; the tail shows the same but for previous follow-ups (if density available). 
 
2.3.4 Tadpole plots 
 
Tadpole plots showed similar patterns to those seen with the repeated measures correlation 
coefficients (Figure 2.2). For Cumulus and Stepwedge, the heavier the woman was the fattier 
her breasts (between-women correlation of the tadpole heads). As women lost weight, their 
breast fat also decreased (within-women correlation depicted by the direction of tadpole tails). 
Tadpole heads for DA remained flat, suggesting that there was little association with BMI 
between-women; and lack of a discernible pattern for the tails indicated that there was little 
association within-women too. Tadpole heads for DV suggested that heavier women had higher 
dense volume (between-women), but the direction of tadpole tails (within-women associations) 
was less evident between BMI and DV. In general, the tadpole tails more-or-less followed the 
pattern for the tadpole heads, providing some evidence that the relationship between BMI and 
density reported in population studies can be applied to make predictions about the breast 
density of a woman as she diets. 
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2.3.5 Repeated measures correlation coefficients - other adiposity measures and 
mammographic density 
 
There were similar associations between breast density and other body fat compositions as with 
BMI (Table 2.4, Table 2.5). There was a positive association for DV between-women of 
approximately 0.4 (although less so in DXA %fat, MRI subcutaneous and MRI abdominal fat), 
and little association within-women. There was also little association for DA and other body fat 
compositions between- or within-women. There was an inverse association for PDV between-
women (approximately -0.5) and within-women (approximately -0.3), although within-women 
associations were less strong than between with only weight and impedance total fat showing 
significant effects. Similarly, there was an inverse association for PDA between-women 
(approximately -0.5), but less so within-women (only impedance %fat showed a significant 
effect of approximately -0.3). FV and FA were positively associated with other body fat 
compositions between-women (approximately 0.7) and within-women (approximately 0.4). 
However, the within-women correlations for FV and DXA %fat or MRI measures, and within-
women correlations for FA and DXA lean mass or MRI total fat were not significant. 
 
2.3.6 Repeated measures correlation coefficients – adiposity measures (between-
women) and mammographic density measures (between-women) 
 
Exploratory between-women correlations were also performed amongst the different body 
composition measures (Table 2.6) and amongst the different density measures (Table 2.7). As 
expected, associations between body composition measures were strong, albeit slightly weaker 
for measures of lean mass (DXA lean and impedance lean mass). Associations between 
different density measures were mostly expected for percent density where a strong positive 
association was seen between different percentage density methods and an inverse relationship 
was seen between percent density and both breast fat and total area or volume. However, a 
positive association was only seen between percent density methods and DA, but not DV 
(except for PDV which had a modest correlation with DV). Breast fat measures were strongly 
and positively correlated with each other and with total area or volume. Breast fat measures 
were moderately positively correlated with DV. There was some indication of an inverse 
relationship between FA and DA, but this was less so when assessing the association between 
FV and DA. Similarly, TA and TV were strongly positively correlated with each other, and both 
were moderately correlated with DV; but little association was seen with DA. A moderately 
positive association was seen between DA and DV. 
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Table 2.4: Complete results for repeated-measures between-women correlations (95% confidence 
intervals) for density and body composition measures. 
 
VAS 
(95% CI) 
[sqrt%] 
PDA 
(95% CI) 
[sqrt%] 
PDV 
(95% CI) 
[cbrt%] 
FA 
(95% CI) 
[sqrt] 
DA 
(95% CI) 
[sqrt] 
Weight 
-0.55 
(-0.70 to -0.37) 
-0.49 
(-0.64 to -0.30) 
-0.40 
(-0.56 to -0.23) 
0.69 
(0.59 to 0.79) 
0.00  
(-0.28 to 0.27) 
BMI 
-0.62 
(-0.74 to -0.47) 
-0.58 
(-0.72 to -0.42) 
-0.48 
(-0.64 to -0.33) 
0.74 
(0.63 to 0.82) 
-0.12  
(-0.38 to 0.16) 
Waist 
-0.63 
(-0.76 to -0.46) 
-0.59 
(-0.73 to -0.41) 
-0.54 
(-0.67 to -0.38) 
0.77 
(0.67 to 0.85) 
-0.09  
(-0.34 to 0.18) 
Imped(total fat) 
-0.57 
(-0.71 to -0.39) 
-0.53 
(-0.68 to -0.35) 
-0.42 
(-0.58 to -0.26) 
0.71 
(0.61 to 0.80) 
-0.03  
(-0.32 to 0.25) 
Imped(% fat) 
-0.57 
(-0.71 to -0.40) 
-0.55 
(-0.69 to -0.38) 
-0.49 
(-0.66 to -0.30) 
0.71 
(0.60 to 0.80) 
-0.06  
(-0.33 to 0.22) 
Imped(lean) 
-0.40 
(-0.58 to -0.17) 
-0.34 
(-0.55 to -0.13) 
-0.26 
(-0.45 to -0.07) 
0.57 
(0.44 to 0.69) 
0.06  
(-0.23 to 0.33) 
DXA(total fat) 
-0.55 
(-0.69 to -0.36) 
-0.53 
(-0.68 to -0.35) 
-0.54 
(-0.68 to -0.39) 
0.69 
(0.58 to 0.79) 
-0.02  
(-0.32 to 0.26) 
DXA(lean) 
-0.36 
(-0.56 to -0.15) 
-0.30 
(-0.52 to -0.07) 
-0.23 
(-0.41 to -0.04) 
0.53 
(0.39 to 0.66) 
0.13  
(-0.21 to 0.42) 
DXA(% fat) 
-0.53 
(-0.69 to -0.31) 
-0.55 
(-0.70 to -0.36) 
-0.64 
(-0.77 to -0.49) 
0.63 
(0.48 to 0.76) 
-0.09 
 (-0.35 to 0.17) 
DXA(bone) 
-0.23 
(-0.47 to 0.03) 
-0.08 
(-0.31 to 0.17) 
-0.03 
(-0.31 to 0.25) 
0.17 
(-0.08 to 0.41) 
0.11  
(-0.14 to 0.37) 
MRI(subcutaneous
) 
-0.64 
(-0.77 to -0.46) 
-0.62 
(-0.76 to -0.46) 
-0.60 
(-0.73 to -0.48) 
0.74 
(0.64 to 0.83) 
-0.13  
(-0.42 to 0.15) 
MRI(abdominal) 
-0.65 
(-0.76 to -0.48) 
-0.65 
(-0.77 to -0.49) 
-0.60 
(-0.73 to -0.48) 
0.78 
(0.68 to 0.86) 
-0.15  
(-0.42 to 0.10) 
MRI(total fat) 
-0.57 
(-0.69 to -0.42) 
-0.61 
(-0.73 to -0.47) 
-0.52 
(-0.66 to -0.38) 
0.76 
(0.61 to 0.86) 
-0.18  
(-0.39 to 0.05) 
 
 
TA 
(95% CI) [sqrt] 
FV 
(95% CI) [cbrt] 
DV 
(95% CI) [cbrt] 
TV 
(95% CI) [cbrt] 
Weight 
0.71 
(0.61 to 0.80) 
0.74 
(0.65 to 0.82) 
0.49 
(0.28 to 0.66) 
0.77 
(0.69 to 0.85) 
BMI 
0.72 
(0.59 to 0.82) 
0.77 
(0.69 to 0.84) 
0.41 
(0.17 to 0.61) 
0.78 
(0.70 to 0.86) 
Waist 
0.76 
(0.64 to 0.85) 
0.80 
(0.72 to 0.87) 
0.37 
(0.12 to 0.59) 
0.79 
(0.69 to 0.87) 
Imped(total fat) 
0.72 
(0.61 to 0.81) 
0.76 
(0.67 to 0.84) 
0.48 
(0.26 to 0.66) 
0.79 
(0.70 to 0.86) 
Imped(% fat) 
0.71 
(0.59 to 0.81) 
0.78 
(0.68 to 0.86) 
0.43 
(0.20 to 0.62) 
0.79 
(0.69 to 0.87) 
Imped(lean) 
0.59 
(0.47 to 0.71) 
0.60 
(0.46 to 0.71) 
0.45 
(0.25 to 0.62) 
0.64 
(0.51 to 0.74) 
DXA(total fat) 
0.69 
(0.57 to 0.79) 
0.76 
(0.68 to 0.84) 
0.35 
(0.06 to 0.58) 
0.77 
(0.68 to 0.85) 
DXA(lean) 
0.59 
(0.45 to 0.71) 
0.58 
(0.45 to 0.70) 
0.52 
(0.29 to 0.70) 
0.64 
(0.51 to 0.74) 
DXA(% fat) 
0.61 
(0.45 to 0.74) 
0.72 
(0.60 to 0.81) 
0.16 
(-0.12 to 0.43) 
0.69 
(0.55 to 0.80) 
DXA(bone) 
0.22 
(-0.03 to 0.47) 
0.26 
(0.00 to 0.50) 
0.33 
(0.09 to 0.54) 
0.31 
(0.06 to 0.54) 
MRI(subcutaneous) 
0.73 
(0.62 to 0.81) 
0.78 
(0.70 to 0.85) 
0.25 
(-0.04 to 0.48) 
0.77 
(0.67 to 0.85) 
MRI(abdominal) 
0.76 
(0.63 to 0.85) 
0.80 
(0.73 to 0.86) 
0.28 
(-0.01 to 0.51) 
0.79 
(0.70 to 0.86) 
MRI(total fat) 
0.73 
(0.55 to 0.85) 
0.75 
(0.65 to 0.83) 
0.34 
(0.07 to 0.54) 
0.75 
(0.64 to 0.84) 
Significant, non-significant, borderline significance, visual assessment score (VAS), percent dense area 
(PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), dense area (DA), dense volume 
(DV), total area (TA), total volume (TV), square root transformed (sqrt), cube root transformed (cbrt), 
body mass index (BMI), impedance (Imped). 
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Table 2.5: Complete results for repeated-measures within-women correlations (95% confidence 
intervals) for density and body composition measures. 
 
VAS 
(95% CI) 
[sqrt%] 
PDA 
(95% CI) 
[sqrt%] 
PDV 
(95% CI) 
[cbrt%] 
FA 
(95% CI) 
[sqrt] 
DA 
(95% CI) 
[sqrt] 
Weight 
-0.27 
(-0.49 to -0.05) 
-0.22 
(-0.44 to 0.02) 
-0.37 
(-0.55 to -0.13) 
0.46 
(0.24 to 0.65) 
0.01 
(-0.24 to 0.25) 
BMI 
-0.27 
(-0.48 to -0.05) 
-0.22 
(-0.44 to 0.01) 
-0.36 
(-0.54 to -0.12) 
0.45 
(0.23 to 0.63) 
0.01 
(-0.24 to 0.25) 
Waist 
-0.17 
(-0.38 to 0.06) 
-0.10 
(-0.31 to 0.12) 
-0.23 
(-0.42 to 0.00) 
0.25 
(0.03 to 0.47) 
0.01 
(-0.19 to 0.21) 
Imped(total fat) 
-0.22 
(-0.44 to 0.03) 
-0.24 
(-0.46 to 0.01) 
-0.32 
(-0.52 to -0.09) 
0.44 
(0.22 to 0.63) 
-0.07 
(-0.31 to 0.17) 
Imped(% fat) 
-0.14 
(-0.35 to 0.10) 
-0.28 
(-0.47 to -0.03) 
-0.23 
(-0.45 to 0.03) 
0.44 
(0.21 to 0.62) 
-0.10 
(-0.29 to 0.11) 
Imped(lean) 
-0.29 
(-0.63 to 0.03) 
-0.25 
(-0.67 to 0.28) 
-0.34 
(-0.64 to 0.03) 
0.51 
(0.05 to 0.81) 
-0.12 
(-0.57 to 0.40) 
DXA(total fat) 
-0.08 
(-0.51 to 0.34) 
-0.24 
(-0.56 to 0.16) 
-0.27 
(-0.61 to 0.24) 
0.46 
(0.12 to 0.71) 
0.07 
(-0.31 to 0.41) 
DXA(lean) 
-0.05 
(-0.50 to 0.33) 
-0.07 
(-0.47 to 0.25) 
-0.39 
(-0.75 to 0.08) 
0.27 
(-0.02 to 0.63) 
0.01 
(-0.42 to 0.43) 
DXA(% fat) 
-0.09 
(-0.48 to 0.32) 
-0.32 
(-0.61 to 0.06) 
-0.26 
(-0.61 to 0.28) 
0.49 
(0.15 to 0.74) 
-0.02 
(-0.29 to 0.23) 
DXA(bone) 
-0.07 
(-0.48 to 0.30) 
-0.01 
(-0.33 to 0.34) 
-0.07 
(-0.52 to 0.43) 
-0.21 
(-0.52 to 0.14) 
-0.14 
(-0.45 to 0.20) 
MRI(subcutaneous
) 
-0.24 
(-0.59 to 0.18) 
-0.38 
(-0.68 to 0.01) 
-0.38 
(-0.71 to 0.19) 
0.55 
(0.22 to 0.78) 
-0.01 
(-0.38 to 0.32) 
MRI(abdominal) 
-0.23 
(-0.57 to 0.19) 
-0.33 
(-0.65 to 0.08) 
-0.28 
(-0.63 to 0.28) 
0.49 
(0.09 to 0.77) 
0.01 
(-0.39 to 0.37) 
MRI(total fat) 
-0.17 
(-0.53 to 0.22) 
-0.21 
(-0.61 to 0.20) 
-0.08 
(-0.50 to 0.42) 
0.32 
(-0.13 to 0.71) 
0.04 
(-0.44 to 0.41) 
 
 
TA 
(95% CI) [sqrt] 
FV 
(95% CI) [cbrt] 
DV 
(95% CI) [cbrt] 
TV 
(95% CI) [cbrt] 
Weight 
0.54 
(0.36 to 0.69) 
0.59 
(0.37 to 0.76) 
0.07 
(-0.17 to 0.28) 
0.75 
(0.55 to 0.85) 
BMI 
0.54 
(0.35 to 0.69) 
0.58 
(0.36 to 0.75) 
0.08 
(-0.16 to 0.28) 
0.74 
(0.54 to 0.85) 
Waist 
0.32 
(0.10 to 0.51) 
0.37 
(0.09 to 0.58) 
0.05 
(-0.15 to 0.24) 
0.46 
(0.14 to 0.68) 
Imped(total fat) 
0.47 
(0.27 to 0.63) 
0.47 
(0.20 to 0.67) 
0.01 
(-0.24 to 0.24) 
0.58 
(0.29 to 0.76) 
Imped(% fat) 
0.43 
(0.19 to 0.62) 
0.36 
(0.05 to 0.60) 
0.09 
(-0.15 to 0.29) 
0.48 
(0.15 to 0.70) 
Imped(lean) 
0.65 
(0.26 to 0.85) 
0.52 
(0.06 to 0.79) 
-0.03 
(-0.46 to 0.38) 
0.55 
(-0.04 to 0.83) 
DXA(total fat) 
0.55 
(0.27 to 0.75) 
0.48 
(0.03 to 0.77) 
0.19 
(-0.22 to 0.53) 
0.65 
(0.15 to 0.87) 
DXA(lean) 
0.31 
(0.06 to 0.63) 
0.53 
(0.12 to 0.80) 
-0.13 
(-0.58 to 0.37) 
0.48 
(0.08 to 0.78) 
DXA(% fat) 
0.52 
(0.20 to 0.74) 
0.44 
(-0.12 to 0.79) 
0.20 
(-0.21 to 0.48) 
0.63 
(-0.03 to 0.87) 
DXA(bone) 
-0.31 
(-0.61 to 0.05) 
-0.06 
(-0.62 to 0.48) 
-0.29 
(-0.60 to 0.20) 
-0.25 
(-0.70 to 0.27) 
MRI(subcutaneous) 
0.64 
(0.38 to 0.81) 
0.48 
(-0.13 to 0.80) 
-0.01 
(-0.47 to 0.47) 
0.56 
(-0.19 to 0.87) 
MRI(abdominal) 
0.57 
(0.27 to 0.77) 
0.42 
(-0.16 to 0.77) 
0.10 
(-0.37 to 0.54) 
0.53 
(-0.21 to 0.83) 
MRI(total fat) 
0.37 
(0.04 to 0.67) 
0.24 
(-0.25 to 0.66) 
0.21 
(-0.25 to 0.61) 
0.38 
(-0.23 to 0.75) 
Significant, non-significant, borderline significance, visual assessment score (VAS), percent dense area 
(PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), dense area (DA), dense volume 
(DV), total area (TA), total volume (TV), square root transformed (sqrt), cube root transformed (cbrt), 
body mass index (BMI), impedance (Imped). 
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Table 2.6: Complete results for repeated-measures between-women correlations (95% confidence 
intervals) for different body composition measures. 
 
Weight 
(95% CI) 
BMI (95% 
CI) 
Waist (95% 
CI) 
Imped(total 
fat) 
(95% CI) 
Imped(% 
fat) 
(95% CI) 
Imped(lean) 
(95% CI) 
DXA(total 
fat) 
(95% CI) 
Weight 
1.00 (1.00 to 
1.00) 
0.92 (0.88 to 
0.95) 
0.87 (0.81 to 
0.91) 
0.98 (0.98 to 
0.99) 
0.91 (0.87 to 
0.94) 
0.93 (0.88 to 
0.96) 
0.95 (0.93 to 
0.97) 
BMI 
0.92 (0.88 to 
0.95) 
1.00 (1.00 to 
1.00) 
0.87 (0.81 to 
0.92) 
0.94 (0.91 to 
0.96) 
0.89 (0.85 to 
0.94) 
0.79 (0.65 to 
0.88) 
0.94 (0.91 to 
0.97) 
Waist  
0.87 (0.81 to 
0.91) 
0.87 (0.81 to 
0.92) 
1.00 (1.00 to 
1.00) 
0.89 (0.84 to 
0.93) 
0.87 (0.82 to 
0.91) 
0.72 (0.61 to 
0.83) 
0.89 (0.83 to 
0.93) 
Imped(total 
fat) 
0.98 (0.98 to 
0.99) 
0.94 (0.91 to 
0.96) 
0.89 (0.84 to 
0.93) 
1.00 (1.00 to 
1.00) 
0.96 (0.94 to 
0.97) 
0.85 (0.77 to 
0.91) 
0.97 (0.96 to 
0.98) 
Imped(% fat) 
0.91 (0.87 to 
0.94) 
0.89 (0.85 to 
0.94) 
0.87 (0.82 to 
0.91) 
0.96 (0.94 to 
0.97) 
1.00 (1.00 to 
1.00) 
0.71 (0.58 to 
0.81) 
0.94 (0.92 to 
0.97) 
Imped(lean) 
0.93 (0.88 to 
0.96) 
0.79 (0.65 to 
0.88) 
0.72 (0.61 to 
0.82) 
0.85 (0.77 to 
0.91) 
0.71 (0.58 to 
0.81) 
1.00 (1.00 to 
1.00) 
0.82 (0.70 to 
0.90) 
DXA(total 
fat) 
0.95 (0.93 to 
0.97) 
0.94 (0.91 to 
0.97) 
0.89 (0.83 to 
0.93) 
0.97 (0.96 to 
0.98) 
0.94 (0.92 to 
0.97) 
0.82 (0.70 to 
0.90) 
1.00 (1.00 to 
1.00) 
DXA(lean) 
0.88 (0.81 to 
0.92) 
0.72 (0.59 to 
0.81) 
0.64 (0.50 to 
0.75) 
0.82 (0.72 to 
0.89) 
0.70 (0.56 to 
0.80) 
0.93 (0.90 to 
0.96) 
0.70 (0.58 to 
0.79) 
DXA(% fat) 
0.75 (0.65 to 
0.83) 
0.81 (0.75 to 
0.87) 
0.80 (0.71 to 
0.88) 
0.81 (0.73 to 
0.88) 
0.87 (0.81 to 
0.91) 
0.50 (0.30 to 
0.67) 
0.90 (0.86 to 
0.94) 
DXA(bone) 
0.31 (0.11 to 
0.50) 
0.18 (-0.03 to 
0.40) 
0.11 (-0.11 to 
0.34) 
0.27 (0.07 to 
0.47) 
0.25 (0.02 to 
0.46) 
0.40 (0.18 to 
0.61) 
0.17 (-0.04 to 
0.38) 
MRI(subcuta
neous) 
0.86 (0.80 to 
0.92) 
0.90 (0.85 to 
0.94) 
0.89 (0.85 to 
0.94) 
0.88 (0.84 to 
0.93) 
0.87 (0.83 to 
0.92) 
0.72 (0.55 to 
0.84) 
0.93 (0.88 to 
0.96) 
MRI(abdomi
nal) 
0.87 (0.82 to 
0.92) 
0.92 (0.88 to 
0.96) 
0.93 (0.89 to 
0.96) 
0.90 (0.86 to 
0.94) 
0.89 (0.85 to 
0.92) 
0.73 (0.58 to 
0.85) 
0.93 (0.89 to 
0.96) 
MRI(total fat) 
0.77 (0.69 to 
0.88) 
0.84 (0.77 to 
0.90) 
0.88 (0.80 to 
0.93) 
0.80 (0.72 to 
0.90) 
0.79 (0.71 to 
0.87) 
0.66 (0.51 to 
0.84) 
0.80 (0.71 to 
0.90) 
 
 
DXA(lean) 
(95% CI) 
DXA(% fat) 
(95% CI) 
DXA(bone) 
(95% CI) 
MRI(subcutane
ous) (95% CI) 
MRI(abdominal
) 
(95% CI) 
MRI(total fat) 
(95% CI) 
Weight 
0.88 (0.81 to 
0.92) 
0.75 (0.65 to 
0.83) 
0.31 (0.11 to 
0.50) 
0.86 (0.80 to 
0.92) 
0.87 (0.82 to 
0.92) 
0.77 (0.69 to 
0.87) 
BMI 
0.72 (0.58 to 
0.81) 
0.81 (0.75 to 
0.87) 
0.18 (-0.03 to 
0.39) 
0.90 (0.85 to 
0.94) 
0.92 (0.88 to 
0.96) 
0.84 (0.77 to 
0.90) 
Waist  
0.64 (0.50 to 
0.75) 
0.80 (0.71 to 
0.88) 
0.11 (-0.11 to 
0.34) 
0.89 (0.85 to 
0.94) 
0.93 (0.89 to 
0.96) 
0.88 (0.79 to 
0.93) 
Imped(total 
fat) 
0.82 (0.72 to 
0.89) 
0.81 (0.73 to 
0.88) 
0.27 (0.07 to 
0.47) 
0.88 (0.84 to 
0.93) 
0.90 (0.86 to 
0.94) 
0.80 (0.72 to 
0.90) 
Imped(% fat) 
0.70 (0.55 to 
0.80) 
0.87 (0.81 to 
0.91) 
0.25 (0.02 to 
0.46) 
0.87 (0.83 to 
0.92) 
0.89 (0.85 to 
0.92) 
0.79 (0.71 to 
0.87) 
Imped(lean) 
0.93 (0.90 to 
0.96) 
0.50 (0.30 to 
0.67) 
0.40 (0.18 to 
0.61) 
0.72 (0.55 to 
0.84) 
0.73 (0.59 to 
0.85) 
0.66 (0.51 to 
0.84) 
DXA(total fat) 
0.70 (0.58 to 
0.80) 
0.90 (0.86 to 
0.94) 
0.17 (-0.04 to 
0.38) 
0.93 (0.88 to 
0.96) 
0.93 (0.89 to 
0.96) 
0.80 (0.71 to 
0.90) 
DXA(lean) 
1.00 (1.00 to 
1.00) 
0.36 (0.18 to 
0.52) 
0.47 (0.30 to 
0.62) 
0.58 (0.44 to 
0.69) 
0.61 (0.47 to 
0.71) 
0.57 (0.41 to 
0.73) 
DXA(% fat) 
0.36 (0.18 to 
0.53) 
1.00 (1.00 to 
1.00) 
-0.03 (-0.27 to 
0.21) 
0.86 (0.79 to 
0.91) 
0.85 (0.78 to 
0.90) 
0.71 (0.60 to 
0.82) 
DXA(bone) 
0.47 (0.30 to 
0.62) 
-0.03 (-0.27 to 
0.21) 
1.00 (1.00 to 
1.00) 
0.16 (-0.07 to 
0.38) 
0.13 (-0.09 to 
0.37) 
0.06 (-0.15 to 
0.32) 
MRI(subcutan
eous) 
0.58 (0.44 to 
0.70) 
0.86 (0.79 to 
0.90) 
0.16 (-0.07 to 
0.39) 
1.00 (1.00 to 
1.00) 
0.98 (0.97 to 
0.99) 
0.80 (0.72 to 
0.89) 
MRI(abdomin
al) 
0.61 (0.48 to 
0.71) 
0.85 (0.78 to 
0.90) 
0.13 (-0.09 to 
0.37) 
0.98 (0.97 to 
0.99) 
1.00 (1.00 to 
1.00) 
0.90 (0.86 to 
0.94) 
MRI(total fat) 
0.57 (0.42 to 
0.73) 
0.71 (0.60 to 
0.82) 
0.06 (-0.15 to 
0.32) 
0.80 (0.72 to 
0.89) 
0.90 (0.86 to 
0.94) 
1.00 (1.00 to 
1.00) 
 
Significant, non-significant, borderline significance, repeated, body mass index (BMI), impedance 
(Imped). 
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Table 2.7: Complete results for repeated-measures between-women correlations (95% confidence 
intervals) for different density measures. 
 
VAS 
(95% CI) [sqrt%] 
PDA 
(95% CI) [sqrt%] 
PDV 
(95% CI) [cbrt%] 
FA 
(95% CI) [sqrt] 
DA 
(95% CI) [sqrt] 
VAS (sqrt%) 
1.00  
(1.00 to 1.00) 
0.90  
(0.83 to 0.95) 
0.79 
 (0.70 to 0.86) 
-0.83  
(-0.89 to -0.77) 
0.50  
(0.29 to 0.67) 
PDA (sqrt%) 
0.90 
 (0.83 to 0.95) 
1.00 
 (1.00 to 1.00) 
0.78 
 (0.71 to 0.85) 
-0.84 
 (-0.90 to -0.78) 
0.68  
(0.52 to 0.80) 
PDV (cbrt%) 
0.79  
(0.70 to 0.86) 
0.78 
 (0.71 to 0.85) 
1.00  
(1.00 to 1.00) 
-0.67  
(-0.77 to -0.56) 
0.48  
(0.29 to 0.64) 
FA (sqrt) 
-0.83  
(-0.89 to -0.77) 
-0.84  
(-0.90 to -0.78) 
-0.67  
(-0.77 to -0.56) 
1.00 
 (1.00 to 1.00) 
-0.23 
 (-0.41 to -0.01) 
DA (sqrt) 
0.50  
(0.30 to 0.67) 
0.68 
 (0.51 to 0.80) 
0.48 
 (0.29 to 0.64) 
-0.23  
(-0.42 to -0.01) 
1.00  
(1.00 to 1.00) 
TA (sqrt) 
-0.67  
(-0.77 to -0.54) 
-0.62  
(-0.75 to -0.46) 
-0.48  
(-0.64 to -0.28) 
0.94 
 (0.89 to 0.97) 
0.11 
 (-0.10 to 0.34) 
FV (cbrt) 
-0.81  
(-0.88 to -0.73) 
-0.74 
 (-0.83 to -0.63) 
-0.72  
(-0.81 to -0.60) 
0.94 
 (0.92 to 0.97) 
-0.10 
 (-0.30 to 0.12) 
DV (cbrt) 
-0.09  
(-0.31 to 0.14) 
0.02 
 (-0.20 to 0.24) 
0.30 
 (0.05 to 0.52) 
0.42 
 (0.23 to 0.58) 
0.55 
 (0.32 to 0.74) 
TV (cbrt) 
-0.71  
(-0.81 to -0.59) 
-0.63  
(-0.75 to -0.49) 
-0.55  
(-0.69 to -0.37) 
0.92 
 (0.87 to 0.95) 
0.05 
 (-0.16 to 0.28) 
 
 
TA 
(95% CI) [sqrt] 
FV 
(95% CI) [cbrt] 
DV 
(95% CI) [cbrt] 
TV 
(95% CI) [cbrt] 
VAS (sqrt%) 
-0.67 
(-0.77 to -0.53) 
-0.81  
(-0.88 to -0.72) 
-0.09  
(-0.31 to 0.13) 
-0.71  
(-0.81 to -0.59) 
PDA (sqrt%) 
-0.62  
(-0.75 to -0.46) 
-0.74  
(-0.83 to -0.63) 
0.02  
(-0.20 to 0.23) 
-0.63 
 (-0.75 to -0.49) 
PDV (cbrt%) 
-0.48 
 (-0.64 to -0.28) 
-0.72  
(-0.81 to -0.60) 
0.30  
(0.05 to 0.52) 
-0.55  
(-0.69 to -0.38) 
FA (sqrt) 
0.94  
(0.89 to 0.97) 
0.94  
(0.92 to 0.97) 
0.42  
(0.23 to 0.58) 
0.92  
(0.87 to 0.95) 
DA (sqrt) 
0.11  
(-0.10 to 0.34) 
-0.10  
(-0.30 to 0.12) 
0.55  
(0.32 to 0.74) 
0.05  
(-0.16 to 0.28) 
TA (sqrt) 
1.00  
(1.00 to 1.00) 
0.92  
(0.87 to 0.95) 
0.66  
(0.54 to 0.76) 
0.96  
(0.93 to 0.98) 
FV (cbrt) 
0.92  
(0.87 to 0.95) 
1.00  
(1.00 to 1.00) 
0.43  
(0.22 to 0.61) 
0.97  
(0.95 to 0.98) 
DV (cbrt) 
0.66  
(0.54 to 0.75) 
0.43  
(0.23 to 0.62) 
1.00 
 (1.00 to 1.00) 
0.63  
(0.49 to 0.75) 
TV (cbrt) 
0.96  
(0.93 to 0.98) 
0.97  
(0.95 to 0.98) 
0.63  
(0.49 to 0.75) 
1.00  
(1.00 to 1.00) 
 
Significant, non-significant, borderline significance, repeated, visual assessment score (VAS), percent 
dense area (PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), dense area (DA), dense 
volume (DV), total area (TA), total volume (TV), square root transformed (sqrt), cube root transformed 
(cbrt). 
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2.3.7 Linear mixed model 
 
The between- and within-women associations for density and BMI measures were also 
estimated jointly in an age-adjusted linear mixed model. Q-Q plots for conditional residuals and 
predicted random effects showed a slight improvement when area density measures were square 
root transformed and volumetric density measures were cube root transformed since lines 
became straighter after these transformations (Figure 2.3). 
  
VAS 
 
 
PDA 
 
 
PDV 
 
Figure 2.3: Q-Q plots for conditional residuals and predicted random effects. 
Visual assessment score (VAS), percent dense area (PDA), percent dense volume (PDV), fat area (FA), 
fat volume (FV), dense area (DA), dense volume (DV) . 
72 
 
FA 
 
FV 
 
DA 
 
DV 
 
 
Figure 2.3 continued 
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Tests for random slopes in the linear mixed model for within-women BMI and age were not 
significant (Table 2.8, Table 2.9). The parameters, 𝛽 and 𝛿, from Equation 2.2 are therefore 
assumed to be the same for all women. No covariance structure was required because only one 
random effect was included (intercept). 
 
Table 2.8: Linear mixed model likelihood ratio tests for within-women body mass index random slope. 
 
Likelihood ratio 
test 
Density outcome ΔLR-χ² P-value 
VAS (sqrt%) 0.86 0.65 
PDA (sqrt%) 0.35 0.84 
PDV (cbrt%) 1.71 0.43 
FA (sqrt) 4.13 0.13 
FV (cbrt) 1.23 0.54 
DA (sqrt) 1.13 0.57 
DV (cbrt) 0.00 1.00 
 
ΔLR-χ² represents the difference in likelihood ratio for Equation 2.2 with and without a within-women 
BMI random slope (test with 2 degrees of freedom: random slope and covariance), visual assessment 
score (VAS), percent dense area (PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), 
dense area (DA), dense volume (DV), square root transformed (sqrt), cube root transformed (cbrt). 
Table 2.9: Linear mixed model likelihood ratio tests for age random slope. 
 
Likelihood ratio 
test 
Density outcome ΔLR-χ² P-value 
VAS (sqrt%) 0.00 1.00 
PDA (sqrt%) 0.01 0.99 
PDV (cbrt%) 0.00 1.00 
FA (sqrt) 0.00 1.00 
FV (cbrt) 0.00 1.00 
DA (sqrt) 0.04 0.98 
DV (cbrt) 0.11 0.95 
 
ΔLR-χ² represents the difference in likelihood ratio for Equation 2.2 with and without an age random 
slope (test with 2 degrees of freedom: random slope and covariance), visual assessment score (VAS), 
percent dense area (PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), dense area (DA), 
dense volume (DV), square root transformed (sqrt), cube root transformed (cbrt). 
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In a sensitivity analysis, the linear mixed model was fit using weight instead of BMI but it had a 
worse model fit for almost all density measures Table 2.10. All models (except DV) had a 
higher log-likelihood when fitting with BMI compared to weight. 
 
Table 2.10: Multivariable linear mixed model fit results for Equation 2.2 using either body mass index  or 
weight. 
 
Log-likelihood 
 
BMI Weight 
VAS (sqrt%) -105.9 -109.7 
PDA (sqrt%) -147.6 -151.8 
PDV (cbrt%) -171.3 -173.5 
FA (sqrt) -77.8 -81.4 
FV (cbrt) -88.4 -90.1 
DA (sqrt) -180.5 -180.9 
DV (cbrt) -156.3 -153.4 
 
Model fit with body mass index (BMI) or weight. Model: density on age and BMI (between and within) or 
weight (between and within), with a random per-woman intercept; between-women BMI calculated as the 
mean BMI for each woman; within-women BMI calculated as the difference between each woman’s BMI 
and her mean BMI; between-women weight calculated as the mean weight for each woman; within-
women weight calculated as the difference between each woman’s weight and her mean weight. Visual 
assessment score (VAS), percent dense area (PDA), percent dense volume (PDV), fat area (FA), fat 
volume (FV), dense area (DA), dense volume (DV) , square root transformed (sqrt), cube root transformed 
(cbrt). 
 
The jointly-fit and age-adjusted between- and within-women associations (Table 2.11) were 
very similar to those using repeated measures correlation coefficients (Table 2.3), showing the 
robustness of the estimates using either method. 
 
When a term for BMI gain since age 20yr was added to the linear mixed model, the model fit 
improved for PDA, PDV, FV and DA (all ΔLR-χ2 p<0.05) (Table 2.12). Within-women effects 
of BMI on density were almost unchanged when including BMI gain since age 20yr (Table 
2.11, Table 2.12). After including BMI gain since age 20yr, between-women associations for 
BMI became more strongly inversely associated with percent density (coefficient approximately 
-0.5 to -0.8), and more strongly positively associated with breast fat (coefficient approximately 
0.6 to 0.8). BMI became more strongly inversely associated with DA (coefficient -0.1 to -0.5) 
and less strongly positively associated with DV between-women (coefficient 0.4 to 0.2). BMI 
gain from age 20yr was positively associated with DA, PDA and PDV (5kg/m2 increase in BMI 
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gain since age 20yr associated with 0.61 (95% CI, 0.12 to 1.09), 0.61 (95% CI, 0.21 to 1.02) and 
0.47 (95% CI, 0.05 to 0.88) standard deviation increase in breast density (β), respectively), and 
inversely associated with FV (β=-0.31, 95% CI, -0.62 to 0.00), but less association was seen 
with DV (β=0.15, 95% CI, -0.29 to 0.59) and FA (β=-0.32, 95% CI, -0.67 to 0.03). 
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Table 2.11: Multivariable linear mixed model fit results (95% confidence intervals) for density on body mass index (between- and within-women), adjusted for age (Equation 2.2). 
 
Density outcome Intercept (95% CI) 
Age (95% CI) [per 
10yr] 
BMI (95% CI) [between] 
[per 5kg/m2] 
BMI (95% CI) 
[within] [per 5kg/m2] 
VAS (sqrt%) 3.75 (1.88 to 5.61) -0.19 (-0.56 to 0.19) -0.51 (-0.68 to -0.35) -0.27 (-0.44 to -0.10) 
PDA (sqrt%) 2.87 (0.57 to 5.17) -0.05 (-0.53 to 0.43) -0.46 (-0.63 to -0.30) -0.32 (-0.59 to -0.05) 
PDV (cbrt%) 1.73 (-1.07 to 4.53) 0.12 (-0.48 to 0.71) -0.39 (-0.57 to -0.21) -0.85 (-1.32 to -0.39) 
FA (sqrt) -3.63 (-5.25 to -2.02) 0.04 (-0.28 to 0.36) 0.60 (0.46 to 0.74) 0.43 (0.27 to 0.58) 
FV (cbrt) -3.46 (-5.27 to -1.64) -0.04 (-0.42 to 0.34) 0.63 (0.50 to 0.76) 0.79 (0.56 to 1.03) 
DA (sqrt) 0.57 (-2.13 to 3.27) -0.03 (-0.59 to 0.53) -0.08 (-0.28 to 0.11) 0.01 (-0.30 to 0.33) 
DV (cbrt) -2.39 (-5.11 to 0.33) 0.09 (-0.48 to 0.66) 0.35 (0.16 to 0.53) 0.16 (-0.24 to 0.55) 
 
Between-women body mass index (BMI) calculated as the mean BMI for each woman; within-women BMI calculated as the difference between each woman’s BMI and her mean 
BMI; density measures are standardised (2.2.4.6); 1 woman with missing BMI at age 20yr excluded. Visual assessment score (VAS), percent dense area (PDA), percent dense 
volume (PDV), fat area (FA), fat volume (FV), dense area (DA), dense volume (DV) , square root transformed (sqrt), cube root transformed (cbrt), 95% confidence interval (95% 
CI). 
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Table 2.12: Multivariable linear mixed model fit results (95% confidence intervals) for density on body mass index (between- and within-women) and body mass index gain since 
20yr of age, adjusted for age (Equation 2.3). 
 
Density 
outcome 
Intercept (95% CI) 
Age (95% CI) [per 
10yr] 
BMI (95% CI) 
[between] [per 5kg/m2] 
BMI (95% CI) [within] 
[per 5kg/m2] 
BMI gain since 20yr 
of age (95% CI) [per 
5kg/m2] 
ΔLR-χ2 p-
value Equation 
2.3 vs. 
Equation 2.2 
VAS (sqrt%) 5.47 (3.34 to 7.60) -0.25 (-0.61 to 0.12) -0.92 (-1.23 to -0.62) -0.27 (-0.45 to -0.10) 0.59 (0.20 to 0.97) 0.0031 
PDA (sqrt%) 4.90 (2.34 to 7.46) -0.16 (-0.63 to 0.31) -0.89 (-1.22 to -0.57) -0.32 (-0.59 to -0.06) 0.61 (0.21 to 1.02) 0.0033 
PDV (cbrt%) 3.35 (0.30 to 6.40) 0.01 (-0.57 to 0.60) -0.71 (-1.05 to -0.38) -0.85 (-1.32 to -0.39) 0.47 (0.05 to 0.88) 0.0267 
FA (sqrt) -4.59 (-6.49 to -2.69) 0.08 (-0.24 to 0.40) 0.82 (0.54 to 1.10) 0.43 (0.28 to 0.59) -0.32 (-0.67 to 0.03) 0.0704 
FV (cbrt) -4.42 (-6.44 to -2.40) 0.01 (-0.37 to 0.38) 0.84 (0.59 to 1.09) 0.79 (0.56 to 1.03) -0.31 (-0.62 to 0.00) 0.0476 
DA (sqrt) 2.58 (-0.48 to 5.64) -0.14 (-0.70 to 0.41) -0.51 (-0.90 to -0.12) 0.01 (-0.31 to 0.32) 0.61 (0.12 to 1.09) 0.0145 
DV (cbrt) -1.90 (-4.96 to 1.15) 0.06 (-0.51 to 0.64) 0.24 (-0.12 to 0.60) 0.16 (-0.24 to 0.55) 0.15 (-0.29 to 0.59) 0.4967 
 
Between-women body mass index (BMI) calculated as the mean BMI for each woman; within-women BMI calculated as the difference between each woman’s BMI and her mean 
BMI; BMI gain from age 20yr calculated as the difference between each woman’s BMI at baseline and her BMI at age 20yr; densit y measures are standardised (2.2.4.6); 1 woman 
with missing BMI at age 20yr excluded. Visual assessment score (VAS), percent dense area (PDA), percent dense volume (PDV), fat area (FA), fat volume (FV), dense area (DA), 
dense volume (DV), square root transformed (sqrt), cube root transformed (cbrt), 95% confidence interval (95% CI). ΔLR-χ² represents the difference in likelihood ratio for 
Equation 2.3 vs. Equation 2.2. 
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2.3.8 Exploratory analysis 
 
Finally, in tests of association between breast and bone density, there was little correlation 
within-women, but there was some indication of a positive between-women correlation for bone 
density and FV (r=0.26, 95% CI, 0.00 to 0.50), DV (r=0.33, 95% CI, 0.09 to 0.54) and TV 
(r=0.31, 95% CI, 0.06 to 0.54) (Table 2.4, Table 2.5). Correlations between DXA bone and 
other body composition measures (between-women) were weak to moderate and only 
significant for weight, DXA lean mass and impedance measures. 
 
2.4 Discussion 
 
In this dietary weight-loss intervention study amongst premenopausal women, changes in breast 
fat were seen within-women as they lost weight, but little change was seen in dense tissue. 
Effective weight-loss during premenopausal years has been shown to reduce risk of 
postmenopausal breast cancer (248), but this study suggests that the effect is unlikely to be 
mediated by a reduction in dense breast tissue. 
 
The between-women associations of attained premenopausal BMI and density observed in this 
study are consistent with the literature. Some of the effects of high attained BMI increasing 
breast cancer risk may be explained through its relationship with dense tissue. As suggested in 
this study (and others (161, 164, 165)), high BMI is associated with high DV in premenopausal 
women. The relationship between BMI and DA is less consistent. Some previous studies 
suggest an inverse association in premenopausal women (158, 169, 293) (which was also 
suggested in this study), but other studies have suggested a positive relationship (159). Since the 
breast is a deposit for adipose tissue, high attained BMI is strongly associated with high levels 
of FA (158, 159, 169, 293) and FV (161, 164), which in turn leads to an inverse association 
between BMI and both PDA (158, 159, 169, 293-295) and PDV (161-165). This is expected 
since increased breast fat contributes to an increased total breast area or volume, which is the 
denominator in percent density calculations. 
 
A reduction in postmenopausal risk can be seen with effective premenopausal weight-loss (248-
250). In a large cohort study of almost 34,000 women, the Iowa women’s health study showed 
that weight gain from 18yr to 30yr followed by weight-loss from 30yr to menopause had a risk 
comparable to weight maintenance in both time periods (RR=0.61; 95% CI, 0.46 to 0.80 and 
RR=0.73; 95% CI, 0.64 to 0.84, respectively, relative to women who gained weight during both 
time periods). Premenopausal women were therefore the target for recruitment in this weight-
loss intervention, because they were of an age that is thought to be the most important for 
reducing breast cancer risk later on in life. 
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There have been few studies assessing the effect of weight-loss on density. In this study, a 
positive within-women relationship was seen for short-term BMI change and breast fat, but no 
association was seen with dense tissue, resulting in an inverse association for percent density. 
Another dietary intervention trial showed reductions in TA with weight-loss, but unlike this 
study, they also found reductions in DA. Boyd et al. reported a 5.4% decrease in DA for 
premenopausal women on a 2 year low-fat, high-carbohydrate diet (n=249) compared with a 
2.5% decrease in the control group (n=264) (251). Since dietary interventions similar to Boyd et 
al. have reported lower blood levels of estradiol and estrone (particularly amongst 
premenopausal women (296)), one theory for this reduction in dense tissue is that the dietary-
induced reduction of oestrogen restricted fibroglandular tissue growth. Therefore, it is possible 
that a specific diet similar to that of Boyd et al.’s might be necessary to see an effect on dense 
tissue. Another intervention study in postmenopausal women showed a reduction in PDA after 2 
years of dieting or physical exercise (297). Other studies have explored the effect of weight-loss 
after bariatric surgery on dense tissue. Some studies suggest a decrease in dense tissue with 
bariatric surgery in premenopausal women (252), whilst others suggest little effect (253). 
Weight-loss interventions can also be exercise-induced. An intervention study of one year of 
moderate exercise amongst postmenopausal women reported results similar to those found in 
this chapter, reporting a decline in FA and FV with moderate to high exercise duration but no 
significant effect on absolute density (298). The within-women associations of short-term BMI 
change and density in this chapter are consistent with previous evidence for breast fat, but the 
effect of dietary weight-loss on dense tissue, particularly in premenopausal women, is still 
unclear. It may be that specific diets or an extended period of intervention time are required to 
see an effect on dense tissue. 
 
Adult weight gain over the premenopausal years is a risk factor for postmenopausal breast 
cancer (173, 247, 299-303). Some evidence in this chapter suggested that increased adult BMI 
gain was linked with higher dense tissue and percent density, which might partly explain an 
increase in risk with adult weight gain. In several studies, breast cancer risk from adult weight 
gain has been limited to (or has been stronger in) women who have never used HRT (299-301). 
Therefore, it has been suggested that this increase in risk may be oestrogen-related. HRT raises 
oestrogen levels; hence any breast cancer risk derived from elevated oestrogen would be 
attenuated in women with already high amounts of the hormone. Risk from adult weight gain 
may be mediated by higher amounts of dense tissue, which are thought to reflect cumulative 
lifetime exposure to oestrogen (143), and would explain the results seen in this study. Pollan et 
al. reported increased premenopausal PDA with adult weight gain (294); however, an inverse 
association was seen in a study by Samimi et al. (295). Tseng et al. found a positive association 
between adult weight gain and premenopausal DA, but very little association with PDA and FA 
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(159). Very few studies have assessed this relationship volumetrically. Alimujiang et al. 
suggested a positive association with premenopausal DV and FV, but an inverse association 
with PDV (164). Some of these conflicting results may be explained by the different 
adjustments used; for instance, some of the studies adjusted for current adiposity (294), some 
adjusted for adiposity at 18yr (164, 295), whilst others adjusted for both (159). To fully 
understand the long-term effects of weight on density it would be useful to assess life course 
effects in a large cohort of women. However, since mammography is not routinely conducted in 
young premenopausal women, alternative non-ionising methods of measuring density may 
prove to be more useful (304). 
 
The associations between adipose tissue, dense tissue and breast cancer risk are somewhat 
contradictory. A high BMI represents elevated amounts of adipose tissue, which is a main site 
of aromatisation of androgens to oestrogen. Oestrogen is known to promote cell proliferation 
and carcinogenesis (273, 274), which may explain the positive relationship between BMI, dense 
volume and breast cancer risk in postmenopausal women whose hormonal production in the 
ovaries has ceased and whose main oestrogen source is adipose tissue. However, the effect of 
aromatisation is negligible in premenopausal women whose main source of oestrogen is the 
ovaries. Moreover, the association between circulating blood serum oestrogen and density is 
seen in premenopausal (178) but not postmenopausal (180) women. One suggestion for these 
differences is that systemic oestrogens transported in the blood have an effect on dense tissue 
growth in premenopausal women, but not postmenopausal women; and local oestrogen from 
aromatisation in breast fat affects dense tissue development in postmenopausal women but less 
so in premenopausal women (182). This leads to the idea that adipose tissue has differing 
effects on dense tissue (and breast cancer risk) whether measured during pre- or postmenopausal 
years and whether distributed systemically or locally within the breast. The idea of systemic and 
local breast fat operating through different mechanisms may also explain the contradiction seen 
in weight-loss studies where decreased BMI reduces risk but also elevates percent density, 
which is itself associated with an increased risk of breast cancer. Perhaps the reduction in 
adipose tissue elsewhere in the body offsets the increased risk from a reduction in breast fat.  
 
There is some suggestion that BMI has a protective effect on dense tissue and breast cancer risk 
in premenopausal women (172, 175, 176). In this study, there was indication of an inverse effect 
of attained BMI and breast fat on DA, which has been seen previously in premenopausal 
women (attained BMI: (158, 169, 293); FA: (158, 305)). However, this effect is unclear since 
the study conversely found a positive effect of attained BMI and breast fat on DV. This positive 
association between attained BMI and DV has been seen previously in premenopausal women 
(161, 164, 165), but there have been few studies assessing the relationship between breast fat 
and DV. There is also some evidence to suggest a protective effect of breast fat on 
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premenopausal breast cancer risk (90, 175, 246, 272), however, some studies show that the 
protective effect of BMI on premenopausal risk is reversed after adjustment for percent density 
(166, 169). 
 
An exploratory analysis tested the association between breast density and DXA bone density. 
Both are considered to be markers of the cumulative rate of exposure to oestrogen (143, 306) 
(which is related to breast cancer risk (307)), but their association with each other has shown 
inconsistent results (308-311). There was some indication of a positive between-women 
correlation for bone density and FV, DV and TV, but little correlation within-women (which is 
expected since bone density is unlikely to have changed over a 2 year period). 
 
Strengths of this study include the use of Cumulus and the Stepwedge method which allowed 
for the assessment of dense and fatty tissue separately as well as volumetrically, which in theory 
should represent breast tissue more accurately than area-based methods by accounting for 
overlapping tissue. Additionally, this study used many different measures of body weight to 
assess adiposity overall and deposited in different parts of the body. All women were 
encouraged to lose weight (more so in the intervention arm), which provided data with large 
within-women variation in BMI, providing great potential to measure effects across the study. 
The intervention also took place at a time in a woman’s life that is thought to be the most 
influential for breast cancer prevention and risk reduction. Additionally, the Lifestyle study 
provided a data source to assess premenopausal density associations, which is not available in 
studies of routine screening data. Moreover, the analysis utilised repeated measures correlation 
coefficients and linear mixed models which are robust techniques that used all of the data and 
assessed all of the time points simultaneously to provide an overall estimate of effects across the 
intervention as a whole. 
 
Limitations of the study include the small sample size, which may have reduced power in the 
study. This may have been particularly relevant for volumetric measures which had a moderate 
amount of missing data at baseline. To increase statistical power, the two intervention arms 
were combined, but this limited the ability to determine the effects that were specific to the 
intervention. There may have also been methodological issues with these volumetric measures 
since a positive association was only seen between percent density measures and dense area, but 
not dense volume (except for PDV, which had a modest correlation with DV). Since both 
percent density and absolute density are risk factors for breast cancer, one would expect their 
measurements to be positively correlated. Volumetric measures are greatly influenced by breast 
thickness (312), which undoubtedly changed as BMI changed, and may have increased variation 
in serial measurements, reducing the accuracy of volumetric estimates. Different breast 
positioning between serial mammograms may have also introduced variation in both area-based 
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and volumetric measurements since radiographer technique can change from one examination to 
the next, causing different levels of breast compression, breast thickness and the amount of 
breast that is imaged. The latter is particularly relevant in MLO views since these views can 
capture subcutaneous fat (representing systemic BMI instead of breast fat) (93), which will be 
more prominent if the breast is adequately pulled onto the x-ray plate. This can make 
differentiation between breast adipose tissue and subcutaneous fat difficult, hence the effects of 
local and systemic adipose tissue can be hard to distinguish (313). At present, this is an 
unavoidable issue with subjective mammography techniques, and the need for image 
registration is essential for assessment of serial mammography. Another limitation of this study 
is the use of self-reported weight at age 20yr which may have suffered from recall bias. 
Nonetheless, a good correlation of 0.87 between recalled weight and actual weight in early 
adulthood has been reported previously in a similar cohort of young women, suggesting that this 
is a suitably robust measure (314). Finally, there was no adjustment for other lifestyle factors 
such as increased physical activity or reduced alcohol intake, which may have had independent 
effects on density beyond their indirect effect via weight-loss. However, these are unlikely to 
have confounded the results since no strong nor consistent effects of these variables have been 
reported previously, hence any influences are likely to be negligible (296). 
 
2.5 Conclusion 
 
This study suggests that premenopausal weight-loss reduced breast fat but did not reduce dense 
tissue. Short-term premenopausal weight-loss is likely to be linked to a lower postmenopausal 
breast cancer risk through reductions in adipose tissue but not fibroglandular tissue. This study 
suggests that density change is unlikely to be a useful biomarker for risk reduction associated 
with short-term weight-loss. 
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Chapter 3: Longitudinal modelling of mammographic density for accurate 
breast cancer risk estimation 
 
3.1 Introduction 
 
As described in Chapter 1, mammographic density is one of the strongest known risk factors for 
breast cancer (79) and inclusion of BI-RADS density in breast cancer risk models has been 
shown to improve the accuracy of assessments of individual risk (315). Providing accurate 
estimations of a woman’s risk of breast cancer could help with decisions regarding 
supplemental screening, risk-reducing behaviour strategies and chemoprevention, as well as 
providing a prerequisite for risk-stratified screening. 
 
Most studies assessing the effect of breast density on breast cancer risk are based on a  density 
value at a single time point. However, mammographic density is a dynamic trait that decreases 
with increasing age and BMI, and changes in response to endocrine treatment and hormone 
replacement therapy. Using a woman’s history of density might therefore be more informative 
for breast cancer risk estimation than density taken at a single point in time.  
 
Several studies have explored the use of two serial breast density values in the assessment of 
breast cancer risk (254-261), including a recent large US cohort study of over 700,000 women, 
which showed a small improvement in the discriminatory accuracy of a breast cancer risk 
prediction model when two BI-RADS density values were used instead of one (AUC 0.640 vs. 
0.635) (262). However, including information on the longitudinal history of density with more 
than two density values may improve risk prediction even further. Of particular importance is 
the ability to include information on an unlimited number of mammograms that are arbitrarily 
spaced through time, which reflects a screening environment in practice. No breast cancer risk 
model currently incorporates such information. The aims of this study are to develop a measure 
of density based on an individual woman’s complete history of density taken at arbitrary time 
points (longitudinal density), and to assess how much more information this longitudinal density 
measure provides for risk assessment than a density value taken at a single time point. 
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3.2 Methods 
 
3.2.1 Study design 
 
3.2.1.1 Study population 
 
This analysis is of a cohort of women from the Kaiser Permanente Washington Breast Cancer 
Surveillance Consortium breast imaging registry. All women were enrollees of Kaiser 
Permanente Washington, an integrated healthcare system that provides both insurance and 
healthcare in Washington State. The data were previously used to assess the long-term 
performance of breast cancer risk assessment with and without breast density (315). Women in 
the cohort attended screening from January 1, 1996, through December 31, 2013 (with follow-
up from January 1, 1996, through December 31, 2014) with no prior diagnosis of invasive 
breast cancer or ductal carcinoma in situ (DCIS) at study entry, or lobular carcinoma in situ 
(LCIS) at baseline mammogram. To ensure that the included cohort represented the screening 
population, women aged <40 years or >73 years at baseline mammogram were excluded. To 
also ensure that there were no prevalent breast cancers at the start of the study, women who 
were diagnosed with DCIS or invasive breast cancer within 6 months after their baseline 
mammogram were excluded. 
 
 
Figure 3.1: Flow diagram of the study population and reasons for exclusions. 
144,423 consenting women with at least a 
baseline mammogram (BI-RADS density 
available) and no prior invasive breast 
cancer or DCIS
Excluded: 110 women with LCIS at baseline mammogram
Excluded: 6 women aged <40yr or >73yr at baseline mammogram
Excluded: 11,868 women diagnosed with invasive breast cancer or DCIS 
within 6 months after their baseline mammogram
132,439 women included in the study
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3.2.1.2 Endpoints 
 
The primary outcome was diagnosis of invasive breast cancer. Women were followed from their 
first mammogram with an available density assessment (baseline mammogram) until the earliest 
of: diagnosis of invasive breast cancer or censoring (at 75 years of age (the recommended end of 
screening age), December 31, 2014 (the end of calendar time follow-up), diagnosis of DCIS, 
death, or health plan disenrollment). Outcomes were obtained through linkage with the regional 
population-based Surveillance, Epidemiology, and End Results (SEER) tumour registry and 
pathology databases. 
 
3.2.1.3 Exposure variables 
 
Mammographic breast density was recorded at each screening mammogram by the interpreting 
radiologist using BI-RADS density categories (1=almost entirely fat, 2=scattered fibroglandular, 
3=heterogeneously dense, or 4=extremely dense (18)). Only mammograms with a BI-RADS 
density were included. Self-reported height and weight were collected using a questionnaire 
completed at each screening mammogram. BMI was derived by dividing weight (kg) by height 
(m) squared. Values were also checked for validity at the time of scanning for research 
purposes. Approximately 5% of women who underwent screening opted out of having their 
questionnaire data used for research and were excluded. To enable a prognostic factor study 
design, any mammogram taken on the same date as a woman’s breast cancer event was removed 
(no women were excluded because all women had a baseline mammogram at least 6 months 
before an event, by definition of the study design). 
 
3.2.2 Statistical methods 
 
Analysis was conducted using the statistical software packages Stata (316) and R (282). 
Statistical tests were two-sided with a significance level of 5%. 
 
3.2.2.1 Missing data 
 
Missing BMI values were imputed to allow for adjustment of density and to ensure that no data 
points were dropped from the analysis due to missing data. If BMI was unavailable at baseline 
mammogram, it was imputed using the sample mean BMI given age at the baseline 
mammogram; otherwise, by carrying forward the last recorded BMI. This was considered to be 
a robust method because the number of women requiring BMI imputation was small relative to 
the large sample size (6,047/132,439 women (5%)) (appendix A.I). Imputation was not required 
for age or density since all mammograms had a matching age and density value (only 
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mammograms with a BI-RADS density value were included in the analysis, as outlined in 
section 3.2.1.3). BMI was then winsorised for values below 15kg/m2 and above 35kg/m2; hence 
women who were morbidly obese were given the same risk for adiposity as women who were 
obese, and extremely underweight women were given a similar risk for adiposity as 
underweight women. 
 
3.2.2.2 Linear mixed models (2) 
 
A model for longitudinal density was developed by fitting a linear mixed model with BI-RADS 
density as the outcome (treated as an integer to approximate linear relationships with density). 
This model uses a similar two-level hierarchical structure as that in Chapter 2, whereby the base 
level is each density measure at each time point, and the second level is each woman (2.2.4.4). 
 
The linear mixed model for this study is described below. Breast density 𝑦𝑖𝑗 for woman  𝑖 =
1, … , 𝑛 at time 𝑗 = 1, … , m𝑖  was modelled as: 
 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖 + (𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗 + 𝛽2𝑎𝑔𝑒𝑖𝑗
2 + 𝛽3𝑎𝑔𝑒𝑖𝑗
3 + 𝛽4𝑎𝑔𝑒𝑖𝑗
4 + 𝛽5𝐵𝑀𝐼𝑖𝑗
+ 𝛽6𝑎𝑔𝑒𝑖𝑗𝐵𝑀𝐼𝑖𝑗 + 𝑒𝑖𝑗 ; 
 
where 𝛽0 is an overall intercept, 𝑎𝑔𝑒𝑖𝑗 is the age for woman 𝑖 at time 𝑗, 𝛽1 is the slope for age, 
𝛽2 is the slope for age-squared, 𝛽3 is the slope for age-cubed, 𝛽4 is the slope for age to the 
power of four, 𝐵𝑀𝐼𝑖𝑗 is the BMI for woman 𝑖 at time 𝑗, 𝛽5 is the slope for BMI,  𝛽6 is the 
interaction effect for BMI and the linear age term, and 𝑒𝑖𝑗 is a random error. The term that 
allowed for differences between-women in their overall density level is the independent random 
intercept 𝑢0𝑖 for woman 𝑖. The term that allowed for differences between-women in their age 
slope is the independent random slope 𝑢1𝑖  for woman 𝑖. In other words, the random age slopes 
allowed each woman to have density trajectories that deviated from the average trajectory 
through time. Age had a non-linear relationship with density, as has been seen previously (141, 
255, 317). The model is completed by assuming normal distributions for 𝒖𝑖 =
 (𝑢0i ,𝑢1i ) and 𝑒𝑖𝑗, with zero mean, unknown variances and: zero covariance between 𝑒𝑖𝑗 of the 
same woman or different women, zero covariance between 𝒖𝑖 and 𝑒𝑖𝑗 of the same woman or 
different women, zero covariance between 𝒖𝑖  of different women, and unknown covariance 
between  𝑢0𝑖  and  𝑢1𝑖  of the same woman. The model was fitted by maximum likelihood 
(2.2.4.7). To test  𝛽𝑘 = 0 for 𝑘 = 0, … ,6, Wald tests were applied (2.2.4.9). 
 
The linear mixed model building strategy was based on a series of likelihood ratio tests to assess 
goodness of fit with various polynomial terms and interactions as well as visual assessment of 
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graphs plotting predicted density against age and BMI. Standard errors for the longitudinal 
model were calculated using robust sandwich estimators (318-320). These were calculated 
empirically without making any assumptions on the structure of heteroscedasticity (unequal 
variance across variable values) in the model. 
 
From this linear mixed model, each woman’s random effects, 𝒖𝑖 =  (𝑢0i, 𝑢1i ), were then 
predicted using Empirical Bayes, as described below (287).  
 
To better understand the Empirical Bayes prediction, it is useful to describe a linear mixed 
model in its matrix form, whereby, for woman 𝑖 = 1, … , 𝑛 with 𝑗 = 1, … , m𝑖  time points: 
 
𝒚𝑖 = 𝑿𝑖𝜷 + 𝒁𝑖𝒖𝑖 + 𝒆𝑖  ; 
where: 
 𝒚𝑖 =  (𝑦𝑖1,… , 𝑦𝑖m𝑖 )
𝑇
 is the m𝑖  x 1 column vector of observed outcomes for woman 𝑖 
 𝑿𝑖 =  (
𝑥𝑖11 … 𝑥𝑖1𝑎
⋮ ⋱ ⋮
𝑥𝑖m𝑖1 … 𝑥𝑖m𝑖𝑎
)  is the m𝑖  x 𝑎 design matrix of observed predictors for fixed 
effects 𝑝 = 1, … , 𝑎 for woman 𝑖 
 𝜷 =  (𝛽0, … , 𝛽a−1)
𝑇 is the 𝑎 x 1 column vector of regression coefficients for fixed effects 
𝑝 = 1, … , 𝑎 
 𝒁𝑖 =  (
𝑥𝑖11 … 𝑥𝑖1𝑏
⋮ ⋱ ⋮
𝑥𝑖m𝑖1 … 𝑥𝑖m𝑖𝑏
)  is the m𝑖  x 𝑏 design matrix of observed predictors for random 
effects 𝑞 = 1, … , 𝑏 for woman 𝑖 
 𝒖𝑖 =  (𝑢0i, … , 𝑢b−1 i)
𝑇 is the 𝑏 x 1 column vector of unobserved random effects 𝑞 = 1, … , 𝑏 
for woman 𝑖 
 𝒆𝑖 =  (𝑒𝑖1, … , 𝑒𝑖m𝑖 )
𝑇
 is the m𝑖  x 1 column vector of unobserved random errors for woman 𝑖 
 
Under the above model, density measures for woman 𝑖 have mean = 𝑿𝑖𝜷 + 𝒁𝑖𝒖𝑖  and variance = 
𝑽𝑖 =  𝒁𝑖𝚺𝒁𝑖
𝑇 +  σ2𝑰𝑚𝑖  . 
 
Recalling from Chapter 2, 𝚺 is the variance-covariance matrix, and σ2𝑰𝑚𝑖 = 𝑬𝑖 which is the 
variance of the residuals for woman 𝑖, with σ2 being the sample residual variance and 𝑰𝑚𝑖 being 
the 𝑚𝑖 x 𝑚𝑖 identity matrix. The values for 𝒚𝑖 ,  𝑿𝑖 and 𝒁𝑖  are measured, and estimates of 
parameters 𝜷, 𝚺 and σ2 are obtained by generalised least squares, which corresponds to 
maximum likelihood assuming normality of 𝒖𝑖 and 𝒆𝑖  (2.2.4.4). 
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Empirical Bayes can be used to predict the random effects, 𝒖𝑖, by entering the observed values 
and estimated parameters into the following equation: 
 
𝔼 (𝒖𝑖  | 𝑿𝑖 ,𝒁𝑖 , ?̂?, ?̂?, σ̂
2) = ?̂?𝒁𝑖
𝑇?̂?𝑖
−1 (𝒚𝑖 − 𝑿𝑖?̂?) 
 
In this study, the above equation was used to predict the random intercept and random slope for 
each woman 𝑖 = 1, … , 𝑛 at each time point 𝑗 = 1, … , m𝑖  using data from her most recent and 
previous observations only. Therefore, each woman’s individual observations had a uniquely 
determined predicted random intercept and random slope. 
 
A predicted density value was then calculated by entering the observed values, estimated 
parameters and predicted random effects into the equation: 
 
𝔼 (𝒚𝑖 | 𝑿𝑖 , 𝒁𝑖 , ?̂?, ?̂?, σ̂
2) = 𝑿𝑖?̂? + 𝒁𝑖?̂?𝑖 
 
In the analysis, these Bayes predicted density measures are referred to as the longitudinal 
density measures.  
 
At this point, each observation for each woman had a corresponding baseline density value (the 
starting value for woman 𝑖), most recent density value (the updated density value for woman  𝑖 
at time 𝑗), longitudinal density value (the updated Bayes predicted density for woman  𝑖 at 
time 𝑗), age at baseline (the baseline age for woman 𝑖), baseline BMI (the baseline BMI for 
woman 𝑖), and most recent BMI (the updated BMI for woman  𝑖 at time 𝑗). 
 
3.2.2.3 Proportional-hazards Cox models for breast cancer risk 
 
The primary analysis fitted proportional-hazards Cox models to assess the association between 
the survival time of women and density, age and BMI. Proportional-hazards Cox models were 
fit for an invasive breast cancer event using three different density measurements: baseline 
density (model 1), most recent density (model 2) and longitudinal density (model 3). Since all 
women had a value for baseline density, most recent density and longitudinal density as well as 
age and BMI at each of her observations, each woman contributed the same number of 
measurements to each model. Additionally, because the data consisted of repeated measures, the 
proportional-hazards Cox model equations used time-dependent covariates for density and BMI. 
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For model 1, the proportional-hazards Cox model equation for woman 𝑖 = 1, … , 𝑛 is defined as: 
 
𝜆𝑖(𝑡) = 𝜆0(𝑡)𝑒𝑥𝑝(𝛽1 𝑎𝑔𝑒(𝑡0)𝑖 + 𝛽2𝐵𝑀𝐼(𝑡0)𝑖 + 𝛽3𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡0)𝑖) ; 
 
where 𝜆𝑖(𝑡) is the hazard function at time 𝑡 for woman 𝑖; 𝜆0(𝑡) is the baseline hazard function; 
𝑡0 = time 0 i.e. baseline; 𝑎𝑔𝑒(𝑡0)𝑖  is the age at baseline for woman 𝑖; 𝐵𝑀𝐼(𝑡0)𝑖  is the BMI at 
baseline for woman 𝑖; 𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡0)𝑖  is the BI-RADS density at baseline for woman 𝑖; 𝛽1 is the 
effect of age at baseline; 𝛽2 is the effect of BMI at baseline; and 𝛽3 is the effect of density at 
baseline.  
 
For model 2, the proportional-hazards Cox model equation for woman 𝑖 = 1, … , 𝑛 is defined as: 
 
𝜆𝑖(𝑡) = 𝜆0(𝑡)𝑒𝑥𝑝(𝛽1 𝑎𝑔𝑒(𝑡0)𝑖 + 𝛽2𝐵𝑀𝐼(𝑡)𝑖 + 𝛽3𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡)𝑖) ; 
 
where 𝜆𝑖(𝑡) is the hazard function at time 𝑡 for woman 𝑖; 𝜆0(𝑡) is the baseline hazard function; 
𝑡0 = time 0 i.e. baseline; 𝑎𝑔𝑒(𝑡0)𝑖  is the age at baseline for woman 𝑖; 𝐵𝑀𝐼(𝑡)𝑖  is the BMI at 
time 𝑡 for woman 𝑖; 𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡)𝑖  is the BI-RADS density at time 𝑡 for woman 𝑖; 𝛽1 is the effect 
of age at baseline; 𝛽2 is the effect of BMI; and 𝛽3 is the effect of density.  
 
For model 3, the proportional-hazards Cox model equation for woman 𝑖 = 1, … , 𝑛 is defined as: 
 
𝜆𝑖(𝑡) = 𝜆0(𝑡)𝑒𝑥𝑝(𝛽1𝑎𝑔𝑒(𝑡0)𝑖 + 𝛽2𝐵𝑀𝐼(𝑡)𝑖 + 𝛽3𝑙𝑜𝑛𝑔_𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡)𝑖) ; 
 
where 𝜆𝑖(𝑡) is the hazard function at time 𝑡 for woman 𝑖; 𝜆0(𝑡) is the baseline hazard function; 
𝑡0 = time 0 i.e. baseline; 𝑎𝑔𝑒(𝑡0)𝑖  is the age at baseline for woman 𝑖; 𝐵𝑀𝐼(𝑡)𝑖  is the BMI at 
time 𝑡 for woman 𝑖; 𝑙𝑜𝑛𝑔_𝑑𝑒𝑛𝑠𝑖𝑡𝑦(𝑡)𝑖  is the longitudinal density at time 𝑡 for woman 𝑖; 𝛽1  is 
the effect of age at baseline; 𝛽2 is the effect of BMI; and 𝛽3 is the effect of longitudinal density.  
 
Each model was fitted by maximum partial likelihood (321). The coefficients 𝛽1, 𝛽2 and 𝛽3 
were different for each model and they were each tested using Wald tests (2.2.4.9). 
 
All models were adjusted for age at baseline (per year; continuous). Model 1 was additionally 
adjusted for BMI at baseline (per kg/m2; continuous) and models 2 and 3 were instead adjusted 
for most recent BMI (per kg/m2; continuous). This was done so that BMI matched the 
corresponding density value.  
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3.2.2.4 Model building 
 
To allow for a non-linear relationship between density and risk, density was included as a factor 
variable for models 1 and 2 (degrees of freedom (df)=3) (corresponding to the BI-RADS density 
value). Likelihood ratio tests were used to test for a non-linear fit with longitudinal density 
(2.2.4.8). The best fit for model 3 included longitudinal density modelled as a linear and 
quadratic variable (df=2). The rationale for including a quadratic longitudinal density term is 
described in section 3.3.4. 
 
3.2.2.5 Measures of predictive ability (primary analysis) 
 
To assess the predictive ability of each model, likelihood ratio statistics were estimated 
(2.2.4.8). Additionally, to account for the different number of parameters in each model, 
Akaike information criterion (AIC) were estimated. This is useful because the more parameters 
included in a model, the higher the likelihood. However, including too many parameters in a 
model can lead to overfitting which decreases the generalisability of results. There is a trade-off 
between developing a model that has both goodness of fit and parsimony. The AIC is a statistic 
that has been proposed to assess model fit by penalising overfitting. This is done by adding 
another term to the likelihood, namely: 
 
𝐴𝐼𝐶 = −2ℓ(𝜃|𝒙) + 2𝑘 ; 
 
where ℓ(𝜃|𝒙) is the log-likelihood and 𝑘 is the number of parameters in the model (322). 
 
3.2.2.6 Measures of discriminatory accuracy 
 
To measure the discriminatory accuracy of longitudinal density, a yearly mean at-risk 
concordance index (yC) was estimated through time. This is a non-standard method that was 
developed for the purpose of this longitudinal study. The method for calculating the at-risk 
concordance index is described below. 
 
Survival status for woman 𝑖 = 1, … , 𝑛 is denoted (𝑡𝑖 , 𝛿𝑖) for the time 𝑡𝑖 of breast cancer event 
(𝛿𝑖 = 1) or censoring (𝛿𝑖 = 0). A risk score, 𝑟𝑖𝑗, is determined for each woman 𝑖 = 1, … , 𝑛 at 
each breast cancer event 𝑗 = 1, … , 𝑚 using the estimated hazard ratio (HR) from the 
proportional-hazards model. That is, 𝑟 = exp(𝜷𝒙), where 𝒙 = (𝑥1, 𝑥2, 𝑥3) includes age (𝑥1), 
BMI (𝑥2) and breast density (𝑥3), with corresponding parameters 𝜷
𝑇 = (𝛽1 , 𝛽2, 𝛽3). BMI and 
breast density values are updated through time, hence  𝑥2 and 𝑥3 are time-varying covariates. 
 
91 
 
At each breast cancer event 𝑗 = 1, … , 𝑚 (occurring at time, 𝑆𝑗), a concordance index, 𝐶𝑗, is 
defined as: 
 
𝐶𝑗 =
∑ 𝐼(𝑡𝑖 ≥ 𝑆𝑗) {𝐼(𝑟𝑖𝑗 < ?̃?𝑗) +
1
2
𝐼(𝑟𝑖𝑗 = ?̃?𝑗)}
𝑛
𝑖=1
𝑖≠𝜔𝑗
∑ 𝐼(𝑡𝑖 ≥ 𝑆𝑗)
𝑛
𝑖=1
𝑖≠𝜔𝑗
  ;        (∗) 
 
where the risk score of the woman with the event 𝑗 = ?̃?𝑗, and the index of the woman with the 
event 𝑗 = 𝜔𝑗. That is, 𝐶𝑗 is the proportion of women with a risk score less than or equal to the 
risk score of the woman generating the breast cancer event (out of the total number of women 
still at-risk at the time of the breast cancer event). 
 
Generalising to include ties (≥1 woman (= ?̃?𝑗) with an event at the same time, 𝑆𝑗), (∗) is 
calculated separately for each tied woman 𝑘 = 1, … , ?̃?𝑗 at event 𝑗. The index, 𝜔𝑗, is extended to 
be a vector of indices, 𝝎𝒋 = (𝜔𝑗1, … , 𝜔𝑗?̃?𝑗), and the risk score of the tied woman 𝑘 at event 
𝑗 = ?̃?𝑗𝑘. Hence:  
 
𝐶𝑗𝑘 =
∑ 𝐼(𝑡𝑖 ≥ 𝑆𝑗){𝐼(𝑟𝑖𝑗 < ?̃?𝑗𝑘) +
1
2
𝐼(𝑟𝑖𝑗 = ?̃?𝑗𝑘)}
𝑛
𝑖=1
𝑖∉𝝎𝒋
∑ 𝐼(𝑡𝑖 ≥ 𝑆𝑗)
𝑛
𝑖=1
𝑖∉𝝎𝒋
 
 
In the results, a yearly mean concordance index, 𝑦𝐶𝑧, is presented at each yearly interval 𝑧 =
1, … , 18, starting at 0.5yr. So, for example, the yearly mean concordance index between 0.5yr 
and 1.5yr was defined as: 
 
𝑦𝐶1 =
∑ ∑ 𝐶𝑗𝑘  {𝐼(0.5 ≤ 𝑆𝑗 < 1.5)}
?̃?𝑗
𝑘=1
𝑚
𝑗=1
∑ ?̃?𝑗 {𝐼(0.5 ≤ 𝑆𝑗 < 1.5)}
𝑚
𝑗=1
 
 
The maximum follow-up time was 19yr, hence the final 𝑦𝐶𝑧 (= 𝑦𝐶18) was calculated between 
17.5yr and 18.5yr and the 4 women who developed breast cancer ≥18.5yr were excluded. 
 
The standard error on each 𝑦𝐶𝑧 was calculated by estimating the variance about the mean, 𝑦𝐶𝑧, 
(variance generated by the women with a breast cancer event, 𝑗, occurring in yearly interval, 𝑧). 
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So, for example, for 𝑧 = 1 (between 0.5yr and 1.5yr), the variance about the mean, 𝑦𝐶1, is 
defined as: 
𝑦1 =
∑ ∑ (𝐶𝑗𝑘 − 𝑦𝐶1)
2
 {𝐼(0.5 ≤ 𝑆𝑗 < 1.5)}
?̃?𝑗
𝑘=1
𝑚
𝑗=1
∑ ?̃?𝑗 {𝐼(0.5 ≤ 𝑆𝑗 < 1.5)}
𝑚
𝑗=1
  
 
Hence, the standard error (SE) on 𝑦𝐶1 is calculated as: 
 
𝑆𝐸1 = √
𝑦1
∑ ?̃?𝑗 {𝐼(0.5 ≤ 𝑆𝑗 < 1.5)}
𝑚
𝑗=1
 
               
An overall concordance index (mean concordance index across the entire follow-up) was also 
calculated, and a 95% confidence interval was estimated using an empirical bootstrap of the 
mean with 10,000 resamples (2.2.4.3). 
 
3.2.2.7 Assessment of risk stratification 
 
To assess the effect of using longitudinal history of density on risk stratification, the distribution 
of observed risk based on the proportional-hazards model was assessed using histograms at 6 
months, 5yr, 10yr and 15yr. Observed risk (i.e. relative hazard ratio (HR)) was generated by 
calculating each woman’s risk score at each mammogram (defined as 𝑟𝑖𝑗 from section 3.2.2.6) 
relative to the average risk at 6 months. The proportion of lowest risk women (<1/2 relative HR) 
and highest risk women (≥2 relative HR) were plotted at 6 months, 5yr, 10yr and 15yr to assess 
the distribution of risk through time for the most extreme risk categories. The greater the spread 
of risk, the greater the ability for risk stratification. This analysis was also conducted in 
subgroups of women aged 40-49/50-59/≥60 years at baseline. 
 
3.2.2.8 Secondary analyses 
 
To assess whether predictive ability varied for different subgroups of women, a series of 
secondary analyses calculated likelihood ratio statistics throughout the follow-up for models 1-3 
in:  
 
 Women aged 40-44/45-49/50-54/55-59/60-64/≥65 years at baseline. 
 Women with baseline mammogram before or after 2007 (as a proxy for film or digital 
mammography). 
 Women with baseline mammogram before or after 2003 (as a proxy for the 3rd or 4th BI-
RADS density lexicon (18). 
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 Premenopausal or postmenopausal women at baseline. 
 Women <60 years old at baseline with baseline mammogram taken before the year 2000 
(younger women starting the trial early enough to have a long follow-up before being 
censored at 75 years of age). 
 Premenopausal women <60 years old at baseline with baseline mammogram taken before 
the year 2000 (premenopausal women whose long follow-up was likely to include their 
transition into postmenopausal status). 
 
It was hypothesised that the random slopes (representing the likely future trajectory of density 
for each woman) would further improve the statistical output of the longitudinal model. Another 
secondary analysis tested the inclusion of the random slopes in model 3 by a likelihood ratio test 
(2.2.4.8). Furthermore, likelihood ratio tests were conducted to assess the benefit of an 
interaction between longitudinal density and age or BMI in model 3. 
 
A final secondary analysis tested the predictive ability, discriminatory ability and capacity for 
risk stratification of longitudinal density in the subgroup of women with at least 3 
mammograms (women with an adequate history of density), starting follow-up at their third 
mammogram. 
 
3.2.2.9 Sensitivity analyses 
 
To test the influence of BMI imputation on the results, predictive ability was also assessed in 
models 1-3 after removing mammograms with a missing corresponding BMI. Here, the start of 
follow-up began at the (potentially) new baseline mammogram for each woman. Additionally, 
to test the influence of screen-detected mammograms on results, predictive ability was also 
assessed in models 1-3 after removing mammograms taken within 6 months before a breast 
cancer event. Each woman had the same baseline mammogram (no breast cancer event occurred 
within 6 months after the baseline mammogram, by definition of the study design), so the start 
of follow-up remained the same as the primary analysis. 
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3.3 Results 
 
Table 3.1: Univariate hazard ratios of age, body mass index and BI-RADS density baseline variables. 
Baseline 
Variable 
No. (%) 
of 
Women 
Follow-up, 
1000 
Women-
years 
No. of 
Invasive 
Breast 
Cancer 
Cases 
Incidence 
Rate per 
1000 
Women/yr 
Univariate 
Hazard Ratio 
(95% CI) 
LR-
χ2(1) 
Trend 
Test 
P 
Total 
132,439 
(100) 
941 2,704 2.9 - - - 
Age (yr)  
40-49 
60,325 
(45.6) 
448 977 2.2 
1 
[Reference] 
309.1 <0.001 50-59 
43,878 
(33.1) 
339 1,057 3.1 
1.41  
(1.29-1.53) 
≥60 
28,236 
(21.3) 
153 670 4.4 
2.26  
(2.04-2.50) 
BMI (kg/m2)  
<18.5 
1,657 
(1.3) 
11 25 2.3 
0.88  
(0.59-1.31) 
5.5 0.019 
≥18.5 to 25 
48,713 
(36.8) 
355 931 2.6 
1 
[Reference] 
≥25 to 30 
42,868 
(32.4) 
299 962 3.2 
1.24  
(1.13-1.36) 
≥30 to 35 
20,791 
(15.7) 
146 415 2.8 
1.09  
(0.97-1.23) 
≥35 
18,410 
(13.9) 
129 371 2.9 
1.11  
(0.99-1.25) 
BI-RADS 
density 
 
Fatty 
10,387 
(7.8) 
66 107 1.6 
0.70  
(0.57-0.85) 
91.8 <0.001 
Scattered 
46,206 
(34.9) 
332 786 2.4 
1 
[Reference] 
Heterogeneous 
57,158 
(43.2) 
405 1,338 3.3 
1.40  
(1.28-1.53) 
Extremely dense 
18,688 
(14.1) 
137 473 3.4 
1.44  
(1.29-1.62) 
 
Hazard Ratios from a Proportional-hazards Cox model; 95% confidence intervals (CIs) from Wald tests; 
LR-χ2(1) trend test: represents the difference in likelihood ratio statistics (LR-χ2) between the nu l l  model  
and a model fit to the covariate (age and body mass index (BMI) fit as continuous variables; BI-RADS 
density fit as an integer); P-value from LR-χ2(1) trend test. 
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Table 3.2 Longitudinal model fit for BI-RADS density (integer) on age (continuous) and body mass index 
(continuous) 
Fixed effects 
Variable β-coefficient Robust standard error** 
Intercept 2.9659 0.0044 
Age (per 5yr) 0.0491 0.0079 
Age2 (per 52yr) -0.0780 0.0048 
Age3 (per 53yr) 0.0127 0.0011 
Age4 (per 54yr) -0.0006 0.0001 
BMI (per kg/m2) -0.0584 0.0005 
Age x BMI (per 5yr; per kg/m2) 0.0033 0.0001 
Random effects 
Variable 
Standard 
Deviation 
Robust standard error** Correlation 
Robust standard 
error** 
Intercept 0.5865 0.0027 
-0.4590 0.0068 
Age (per 5yr) 0.1107 0.0010 
**Standard errors calculated using robust sandwich estimators. Age from 40yr, body mass index (BMI) 
from 25kg/m2. 
 
Figure 3.2: Adjusted Hazard Ratios for longitudinal density: continuous and categorical.  
Hazard Ratios (HRs) from Proportional-hazards Cox models for longitudinal density: categorised into 6 
arbitrary groups (relative to HR for longitudinal density group ‘2 to <2.5’, plotted against mean 
longitudinal density in each group (x-axis)) and as a continuous variable (including a quadratic term, 
relative to HR for mean longitudinal density in group ‘2 to <2.5’ (longitudinal density=2.22)); adjusted 
for age at baseline (continuous) and most recent body mass index (BMI) (continuous), centred at 40y r a t  
baseline and BMI of 25kg/m2; y-axis on a log-scale; 95% confidence intervals (CIs) from Wald tests. 
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3.3.1 Details of the cohort 
 
In total, 132,439 women were included with a median follow-up of 5.2 years (interquartile 
range (IQR), 2.4-11.1 years) and maximum follow-up of 19 years. Younger women entered the 
cohort earlier and thus had greater follow-up (for example, median of 10.8 years (IQR, 3.8-17.2 
years) for 46,484 women younger than 60 years with baseline mammogram before 2000). 
Median time between mammograms was 1.8 years (IQR, 1.0-2.0 years) and the median number 
of mammograms per woman was 3 (IQR, 2-6), with 32,010 women (24.2%) having a baseline 
mammogram only. The number of mammograms was similar across different ages at baseline 
and throughout the follow-up (appendix A.II). In total, 2704 women (2.0%) were diagnosed 
with invasive breast cancer during the follow-up. 
 
3.3.2 Baseline characteristics 
 
At baseline, median age was 50 years (IQR, 44-58 years), median BMI was 26.8 kg/m2 (IQR, 
23.2-31.1 kg/m2) and the majority of women had dense breasts (75,846 (57.3%) of women had 
heterogeneous or extremely dense breasts). In the univariate model of variables at baseline, 
most statistical information was in age (LR-χ2(1)=309.1), followed by density (LR-χ2(1)=91.8) 
then BMI (LR-χ2(1)=5.5) (all p<0.05) (Table 3.1). 
 
3.3.3 Model building of the linear mixed model  
 
Hereafter, the model building strategy for the linear mixed model is described. Initially, the 
model included fixed effects for an intercept, age (per 5yr; continuous) and most recent BMI 
(per kg/m2; continuous). Age was centred at 40yr and modelled per 5yr to aid interpretation of 
the age coefficient, and BMI was centred at 25kg/m2. Random effects were also included for the 
intercept and age effect to account for each woman’s deviation from the population mean 
density and population mean age effect. Model fit improved considerably with an unstructured 
covariance matrix allowing for correlation between the random effects (ΔLR-χ2(1)=2473, 
p=2x10-308). Age was modelled as a quartic polynomial because this was determined to be the 
best fit after likelihood ratio tests of goodness of fit and visual assessment of plotted graphs 
(appendix A.III). For example, an improvement in model fit was seen until the 7th power of age 
(all p<0.05). However, when assessing plots of predicted density against age, polynomial terms 
past the 4th power appeared to be overfitting to the data for ages above 73yr (density is expected 
to decrease or plateau but it increased for these older women). For BMI, including a quadratic 
age term had little improvement on model fit (ΔLR-χ2(1)=4, p=0.06); but a cubic term improved 
the fit considerably (ΔLR-χ2(1)=655, p=1x10-144). This improvement continued until the 10th 
power of BMI (all p<0.05). However, the plots for predicted density against BMI were 
somewhat unchanged when quadratic or cubic terms were added and there was evidence of 
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overfitting with BMI to the 4th power or more due to the peaking curve for the relationship 
between BMI and density (appendix A.IV). Thus, no polynomial BMI terms were included in 
the model. An interaction between the linear age term and BMI further improved model fit 
(ΔLR-χ2(1)=619, p=1x10-136) and was therefore included. In order to minimise overfitting and to 
create a parsimonious model, only fixed effects were tested for polynomials and only the linear 
age fixed effect was tested for an interaction with BMI. Table 3.2 shows the results for the final 
linear mixed model. 
 
3.3.4 Model building of the proportional-hazards Cox models 
 
In the proportional-hazards Cox model (model 3), the addition of a quadratic longitudinal 
density term improved model fit (relative to the model including linear longitudinal density 
only: ΔLR-χ2(1)=15.0, p<0.001), but a cubic term did not improve model fit further (ΔLR-
χ2(1)=1.1, p=0.3). This non-linear relationship could also be seen in a plot of hazard ratios 
against longitudinal density. Figure 3.2 shows that the proportional-hazards model including a 
quadratic term for continuous longitudinal density mirrored the curved relationship seen 
between risk and longitudinal density when it was categorised into 6 arbitrary groups. There 
was little difference in risk between the highest 2 groups of longitudinal density; further 
showing the need for a quadratic term to capture the attenuating rate of increasing risk for the 
higher longitudinal density values. A non-linear relationship was also tested between breast 
cancer risk and age at baseline, BMI at baseline or most recent BMI, but model fit did not 
improve with inclusion of polynomial terms for these variables (likelihood ratio tests had 
p>0.05). 
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Table 3.3: Multivariable hazard ratios and statistical information on model fit from proportional-hazards Cox models using different breast density measures 
Model BMI Density 
No. of women at 
baseline (%) 
Multivariable Hazard 
Ratio (95% CI) 
df 
(model) 
LR-χ2 
(model) 
AIC 
(model) 
df 
(density) 
ΔLR-χ2 
(density) 
ΔAIC 
(density) 
1 Baseline 
Baseline BI-RADS  
5 607.4 58,361.0 3 296.2 290.2 
Fatty 10,387 (7.8) 0.59 (0.48-0.72) 
Scattered 46,206 (34.9) 1 [Reference] 
Heterogeneous 57,158 (43.2) 1.76 (1.61-1.93) 
Extremely dense 18,688 (14.1) 2.31 (2.04-2.63) 
2 
Most 
recent 
Most recent BI-RADS  
5 624.6 58,343.8 3 307.7 301.7 
Fatty 10,387 (7.8) 0.49 (0.40-0.60) 
Scattered 46,206 (34.9) 1 [Reference] 
Heterogeneous 57,158 (43.2) 1.71 (1.56-1.86) 
Extremely dense 18,688 (14.1) 2.11 (1.84-2.42) 
3 
Most 
recent 
Longitudinal density 
(continuous) 
 
4 696.5 58,269.9 2 379.6 375.6 
Linear (per unit) 132,439 (100) 5.53 (3.34-9.14) 
Quadratic (per unit2) 132,439 (100) 0.83 (0.76-0.92) 
4 
Most 
recent 
Longitudinal density (4 
category) 
 
5 629.3 58,339.2 3 312.3 306.3 
‘Fatty’ 10,383 (7.8) 0.59 (0.51-0.68) 
‘Scattered’ 46,208 (34.9) 1 [Reference] 
‘Heterogeneous’ 57,160 (43.2) 1.67 (1.52-1.83) 
‘Extremely dense’ 18,688 (14.1) 2.15 (1.89-2.46) 
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Table 3.3 continued 
5 
Most 
recent 
Longitudinal density (8 
category) 
 
9 692.1 58,284.4 7 375.1 361.1 
‘Fatty’ I 5,191 (3.9) 0.48 (0.36-0.63) 
‘Fatty’ II 5,192 (3.9) 0.83 (0.69-1.00) 
‘Scattered’ I 23,103 (17.4) 1 [Reference] 
‘Scattered’ II 23,105 (17.5) 1.43 (1.24-1.64) 
‘Heterogeneous’ I 28,569 (21.6) 1.82 (1.59-2.07) 
‘Heterogeneous’ II 28,591 (21.6) 2.44 (2.11-2.81) 
‘Extremely dense’ I 9,341 (7.1) 2.66 (2.23-3.17) 
‘Extremely dense’ II 9,347 (7.1) 3.03 (2.48-3.70) 
 
Hazard Ratios from Proportional-hazards Cox models for baseline BI-RADS density (model 1), most recent BI-RADS density (model 2), continuous longitudinal density (model 3), 4  
category longitudinal density (cut-points chosen so that 4 category longitudinal density and BI-RADS density have the same distribution of women at baseline (frequency matched) )  
and 8 category longitudinal density (cut-points chosen so that the distribution in each 4 category longitudinal density is halved); longitudinal density: predi cted density for each 
woman from linear mixed model; all models adjusted for age at baseline; baseline density additionally adjusted for baseline body mass index (BMI); most recent density and 
longitudinal density (continuous, 4 category and 8 category) additionally adjusted for most recent BMI; age, BMI and continuous longitudinal density fit as continuous variab les; 
continuous longitudinal density fit with a quadratic term; baseline, most recent, 4 category longitudinal and 8 category long itudinal density fit as factor variables; 95% confidence 
intervals (CIs) from Wald tests; ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age and BMI and a model additionally incorporating the 
density term(s); ΔAIC represents the difference in Akaike Information Criterion (AIC) between a model fit to age and BMI and a model additionally incorporatin g the density 
term(s). 
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Time (yr) 0-5 5-10 10-15 15+ 
No. at start of period 132,439 68,307 37,302 19,563 
No. of events 1,159 864 487 194 
ΔLR-χ2 (density)* 
Most recent 187.2 98.7 31.1 13.9 
Longitudinal 221.7 133.6 43.6 8.3 
Figure 3.3: Yearly mean concordance index (yC) through time for most recent density and longitudinal density. 
*ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at baseline and most recent body mass index (BMI) and a model additionally 
incorporating the density term(s). 
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Figure 3.4: Comparison of observed relative risk distributions for most recent density and longitudinal density.  
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for each model); (b) 
Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups at each 6 mon th period. 
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Table 3.4: Multivariable hazard ratios and statistical information on model fit from proportional -hazards Cox models using different breast density measures (subgroup of women 
with at least 3 mammograms (n=76,313), starting follow-up at third mammogram) 
 
Model BMI Density 
No. of women 
at baseline (%) 
Multivariable Hazard 
Ratio (95% CI) 
df 
(model) 
LR-χ2 
(model) 
AIC 
(model) 
df 
(density) 
ΔLR-χ2 
(density) 
ΔAIC 
(density) 
1 Baseline 
Baseline BI-RADS  
5 397.8 45,677.0 3 178.3 172.3 
Fatty 4,901 (6.4) 0.68 (0.54-0.84) 
Scattered 26,151 (34.3) 1 [Reference] 
Heterogeneous 36,351 (47.6) 1.65 (1.49-1.83) 
Extremely dense 8,910 (11.7) 2.11 (1.83-2.43) 
2 Most recent 
Most recent BI-RADS  
5 411.6 45,663.2 3 186.1 180.1 
Fatty 4,901 (6.4) 0.53 (0.42-0.66) 
Scattered 26,151 (34.3) 1 [Reference] 
Heterogeneous 36,351 (47.6) 1.58 (1.43-1.74) 
Extremely dense 8,910 (11.7) 1.85 (1.58-2.17) 
3 Most recent 
Longitudinal density (continuous)  
4 477.9 45,594.9 2 252.5 248.5 Linear (per unit) 76,313 (100) 5.35 (3.10-9.24) 
Quadratic (per unit2) 76,313 (100) 0.82 (0.74-0.91) 
4 Most recent 
Longitudinal density (4 category)  
5 434.4 45,640.4 3 208.9 202.9 
‘Fatty’ 4,899 (6.4) 0.51 (0.41-0.64) 
‘Scattered’ 26,152 (34.3) 1 [Reference] 
‘Heterogeneous’ 36,348 (47.6) 1.63 (1.48-1.81) 
‘Extremely dense’ 8,914 (11.7) 2.09 (1.78-2.46) 
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Table 3.4 continued 
5 Most recent 
Longitudinal density (8 category)  
9 465.2 45,617.6 7 239.8 225.8 
‘Fatty’ I 2,449 (3.2) 0.49 (0.35-0.69) 
‘Fatty’ II 2,450 (3.2) 0.65 (0.48-0.88) 
‘Scattered’ I 13,080 (17.1) 1 [Reference] 
‘Scattered’ II 13,072 (17.1) 1.28 (1.10-1.50) 
‘Heterogeneous’ I 18,178 (23.8) 1.69 (1.47-1.95) 
‘Heterogeneous’ II 18,170 (23.8) 2.21 (1.90-2.58) 
‘Extremely dense’ I 4,457 (5.8) 2.46 (1.99-3.05) 
‘Extremely dense’ II 4,457 (5.8) 2.57 (2.03-3.25) 
 
Hazard Ratios from Proportional-hazards Cox models for baseline BI-RADS density (model 1), most recent BI-RADS density (model 2), continuous longitudinal density (model 3), 4  
category longitudinal density (cut-points chosen so that 4 category longitudinal density and BI-RADS density have the same distribution of women at baseline (frequency matched) )  
and 8 category longitudinal density (cut-points chosen so that the distribution in each 4 category longitudinal density is halved); longitudinal density: predicted de nsity for each 
woman from linear mixed model; all models adjusted for age at baseline; baseline density additionally adjusted for baseline  body mass index (BMI); most recent density and 
longitudinal density (continuous, 4 category and 8 category) additionally adjusted for most recent BMI; age, BMI and c ontinuous longitudinal density fit as continuous variab les; 
continuous longitudinal density fit with a quadratic term; baseline, most recent, 4 category longitudinal and 8 category long itudinal density fit as factor variables; 95% confidence 
intervals (CIs) from Wald tests; ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age and BMI and a model additionally incorporating the 
density term(s); ΔAIC represents the difference in Akaike Information Criterion (AIC) b etween a model fit to age and BMI and a model additionally incorporating the density 
term(s). 
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Time (yr) 0-5 5-10 10-15 15+ 
No. at start of period 76,313 41,326 21,731 3,743 
No. of events 1,308 556 281 24 
ΔLR-χ2 
(density)* 
Most recent 119.1 57.4 15.4 6.4 
Longitudinal 168.5 78.3 13.8 3.2 
Figure 3.5: Yearly mean concordance index (yC) through time for most recent density and longitudinal density (subgroup of women with at  least 3 mammograms (n=76,313), 
starting follow-up at third mammogram). 
*ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at baseline and most recent body mass index (BMI) and a model additionally 
incorporating the density term(s). 
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Figure 3.6: Comparison of observed relative risk distributions for most recent density and longitudinal density ( subgroup of women with at least 3 mammograms (n=76,313), 
starting follow-up at third mammogram). 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for each model); (b) 
Graph showing the percentage of women in the lowest (<1/2 relative HR) and h ighest (2+ relative HR) risk groups at each 6 month period. 
106 
 
3.3.5 Measures of predictive ability  
 
As expected, baseline, most recent and longitudinal density were strongly associated with risk 
(Table 3.3). Longitudinal density added 28% more statistical information to a model with age 
and BMI than baseline density (ΔLR-χ2(2)=379.6 vs. ΔLR-χ2(3)=296.2, respectively) and 23% 
more statistical information than most recent density (ΔLR-χ2(2)=379.6 vs. ΔLR-χ2(3)=307.7, 
respectively). Similar results were observed with AIC statistics. Moreover, this improvement 
was attained with fewer degrees of freedom. Longitudinal density was also fit as a categorical 
variable to compare the model performance at different levels of granularity (frequency matched 
with baseline BI-RADS density). Eight-category longitudinal density had better model fit than 
four-category longitudinal density (ΔLR-χ2(7)=375.1 vs. ΔLR-χ2(3)=312.3), which improved 
further (and with fewer degrees of freedom) when fitting a continuous variable (ΔLR-
χ2(2)=379.6). The gradient of risk for longitudinal density also increased with finer granularity. 
With eight-category longitudinal density, the densest breasts had a six-fold greater risk than the 
fattiest breasts (‘Extremely dense’ II HR=3.03 (95% CI, 2.48 to 3.70) vs. ‘Fatty’ I HR=0.48 
(95% CI, 0.36 to 0.63)), but only a four-fold increased risk was seen with baseline density 
(Extremely dense HR=2.31 (95% CI, 2.04 to 2.63) vs. Fatty HR=0.59 (95% CI, 0.48 to 0.72)) 
and most recent density (Extremely dense HR=2.11 (95% CI, 1.84 to 2.42) vs. Fatty HR=0.49 
(95% CI, 0.40 to 0.60)). 
 
3.3.6 Measures of discriminatory accuracy 
 
Figure 3.3 compares the yearly mean concordance index measures for most recent density 
(model 2) and longitudinal density (model 3). Baseline density was not included at this stage 
because it was the worst performing density measure in terms of predictive ability. In the first 
13 years of follow-up, longitudinal density had better discriminatory accuracy than most recent 
density, as reflected in the likelihood ratio statistics for the first 15 years of follow-up. Of note, 
the concordance index measures differed at baseline between most recent density and 
longitudinal density because longitudinal density is adjusted for age and BMI and therefore 
takes into account their population effects. The overall mean concordance index was 0.634 
(95% CI, 0.623 to 0.645) for most recent density and 0.642 (95% CI, 0.631 to 0.652) for 
longitudinal density.  
 
3.3.7 Assessment of risk stratification 
 
In Figure 3.4, the relative distributions of risk using most recent and longitudinal density were 
similar, with a comparable proportion of women categorised as highest and lowest risk using 
either model 2 or 3. Therefore, the ability for risk stratification was somewhat similar when 
using longitudinal density or most recent density. When stratified by age at baseline, 
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longitudinal density categorised a greater proportion of women as high- and low-risk than most 
recent density in women 60 years or older (appendix A.V-A.VII). 
 
3.3.8 Secondary analyses 
 
In subgroup analyses, longitudinal density continued to provide greater statistical information 
than baseline density and most recent density regardless of age at baseline, before or after 2007 
(proxy for film or digital mammography), before or after 2003 (proxy for the 3rd or 4th BI-RADS 
density lexicon), or menopausal status. Longitudinal density also provided greater statistical 
information than baseline density and most recent density when assessed in the subgroup of 
women with long follow-up, including those likely to have been transitioning from 
premenopausal to postmenopausal status (appendix A.X-A.XV). 
 
Tests for the addition of density trajectories to the longitudinal model (LR-χ2(5)=700.5 and 
AIC=58,267.9) showed only a small improvement on model 3 in terms of predictive ability 
(ΔLR-χ2(1)=4.0, p=0.046, ΔAIC=2.0). This resulted in an additional 1% statistical information 
output than using longitudinal density alone. Tests for an interaction between longitudinal 
density and age or BMI were not significant (HR for the interaction with age at baseline=1.00 
(95% CI, 0.99 to 1.01), p=0.5; HR for the interaction with BMI=1.02 (95% CI, 1.00 to 1.03), 
p=0.08). Exploratory tests for an interaction between baseline density and age at baseline or 
BMI at baseline were not significant (p>0.05). Similarly, exploratory tests for an interaction 
between most recent density and age at baseline or most recent BMI were not significant 
(p>0.05). 
 
When analyses were restricted to women with at least three mammograms (n=76,313 (58% of 
the cohort), 2,169 invasive breast cancers), statistical information output increased to 42% more 
than baseline density (compared with a model including age and BMI only: ΔLR-χ2(2)=252.5 
vs. ΔLR-χ2(3)=178.3, respectively) and 36% more than most recent density (compared with a 
model including age and BMI only: ΔLR-χ2(2)=252.5 vs. ΔLR-χ2(3)=186.1, respectively), with 
similar results for AIC statistics (Table 3.4). Longitudinal density had better model fit as an 
eight-category variable than a four-category variable (ΔLR-χ2(7)=239.8 vs. ΔLR-χ2(3)=208.9), 
and an even better fit as a continuous variable (ΔLR-χ2(2)=252.5). Risk gradient between the 
densest and fattiest breasts was five-fold with eight-category longitudinal density (‘Extremely 
dense’ II HR=2.57 (95% CI, 2.03 to 3.25) vs. ‘Fatty’ I HR=0.49 (95% CI, 0.35 to 0.69)), but 
only three-fold with baseline density (Extremely dense HR=2.11 (95% CI, 1.83 to 2.43) vs. 
Fatty HR=0.68 (95% CI, 0.54 to 0.84)) and most recent density (Extremely dense HR=1.85 
(95% CI, 1.58 to 2.17) vs. Fatty HR=0.68 (95% CI, 0.54 to 0.84)). The overall mean 
concordance index measures for most recent and longitudinal density were 0.623 (95% CI, 
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0.611 to 0.635) and 0.633 (95% CI, 0.621 to 0.644), respectively. The graph of yearly mean 
concordance index measures in the subgroup of women with at least three mammograms is 
shown in Figure 3.5. This, however, is not comparable to Figure 3.3 since follow-up starts at the 
third mammogram so all women are older at baseline and the age range of the cohort decreases; 
therefore discriminatory accuracy reduces for both most recent and longitudinal density. In 
Figure 3.6, the relative distributions of risk using longitudinal density and most recent density in 
the subgroup of women with at least three mammograms were again similar. When stratified by 
age at baseline, longitudinal density categorised a greater proportion of women as high-risk for 
women 40-50 years at baseline, a greater proportion as low-risk for women 50-60 years at 
baseline, and a greater proportion as low- and high-risk for women 60 years at baseline 
(appendix A.XVI-A.XVIII). 
 
3.3.9 Sensitivity analyses 
 
In sensitivity analyses, longitudinal density provided 29% and 30% more information than 
baseline density and most recent density, respectively, when mammograms with a missing 
corresponding BMI were removed (n=129,748 (98% of the cohort), 2,668 invasive breast 
cancers) (appendix A.VIII). Furthermore, longitudinal density provided 31% and 23% more 
information than baseline density and most recent density, respectively, when screen-detected 
mammograms were removed (n=132,439 (100% of the cohort)) (appendix A.IX). 
 
3.4 Discussion 
 
This cohort study found that using a woman’s longitudinal history of breast density may 
improve risk prediction beyond using her baseline density or most recent density. Longitudinal 
density had the greatest predictive ability of the density measures, providing approximately a 
quarter more statistical information than baseline or most recent density. Women in the highest 
category of longitudinal density had a six-fold greater risk of developing breast cancer than 
women in the lowest category; but only a four-fold greater risk was seen with BI-RADS density 
at baseline or most recent mammogram. The benefit of longitudinal density for breast cancer 
risk estimation was not limited by age, menopausal status, image type or BI-RADS density 
classification lexicon. Discriminatory ability was also greatest with longitudinal density, 
whereby a small proportion more women were correctly classified as having breast cancer when 
using longitudinal density than when using the single measure for most recent density. 
 
These results support previous findings that suggest an improvement in predictive ability of 
breast cancer risk estimation when using breast density values from more than one time point 
(262). In 2015, Kerlikowske et al. assessed BI-RADS density in a screening cohort of over 
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700,000 women from the Breast Cancer Surveillance Consortium, where a two-measure density 
score was developed combining each woman’s first and last BI-RADS density taken on average 
1.8 years apart (262). They found a slight improvement to the Breast Cancer Surveillance 
Consortium 5-year risk model when using the two-measure BI-RADS score compared with the 
one-measure BI-RADS score, whereby AUC for the two-measure score was 0.005 units higher 
than that for the one-measure score. Several other studies have made use of two serial 
mammograms (254-261, 323), however these studies aimed to assess the association between 
change in density and breast cancer risk (no specific intervention) as opposed to assessing the 
predictive ability of using both mammograms compared with just one. Results from most of 
these studies suggest that density change between two serial mammograms is associated with 
change in breast cancer risk (254, 257-261), indicating the benefit of considering more than one 
time point for breast cancer risk estimation. However, the Breast Cancer Surveillance 
Consortium study is the only other known study to have evaluated predictive ability when using 
more than one density measure (262). 
 
The results suggest that the main advantage of longitudinal density is in its ability to act as a 
shrinkage estimator, making use of multiple data points to reduce measurement error (324). This 
is apparent because the predictive ability of longitudinal density improved substantially when it 
was modelled as a finer-grained variable which allowed density to be measured to a greater 
level of precision. Additionally, only a small benefit was seen when including random slopes to 
the model which represented each woman’s density trajectory over time; suggesting a high level 
of density tracking (which has been seen before (325, 326)). The ability of longitudinal density 
to act as a shrinkage estimator also makes it a potentially useful tool for other aspects of density 
assessment including use as an outlier detection technique whereby observed values that deviate 
significantly from a predicted value could be flagged-up for investigation. 
 
In this study, predictive and discriminatory ability improved with longitudinal density, however 
the capacity for risk stratification was somewhat similar for longitudinal density and most recent 
density. This may have been driven by the adjustment for age and BMI only. The ability to 
separate out extreme risk groups with longitudinal density might improve with the inclusion of 
other risk factors in the proportional-hazards Cox model alongside age and BMI, and remains a 
point for further investigation. There was better separation of high- and low-risk women with 
longitudinal density than most recent density for older ages (particularly 60 years and over). 
This is because the range of density values for most recent density in older women was small 
(all women were likely to have had fatty breasts), whereas longitudinal density accounted for 
previously high density values, hence giving it a greater range and ability to stratify risk. Of 
note, the proportion of women classified as high-risk increased and the proportion of women 
classified as low-risk decreased throughout follow-up when using either most recent or 
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longitudinal density. This is due to aging of the cohort. Risk scores were determined by age, 
which increased throughout the follow-up and hence increased the risk scores. Therefore, 
through time, women moved from a lower 10-year risk into a higher 10-year risk. Another 
notable point is the decreasing concordance index values for both most recent and longitudinal 
density throughout the follow-up. Again, this is due to aging of the cohort and narrowing of the 
age range through time. For example, at baseline the women at-risk were aged 40-73 years, but 
after 10 years the women at-risk would have been 50-74 years (the maximum is 74 years 
because of censoring at 75 years of age). Since the concordance index was based on a risk score 
that was indicated by age, it lost discriminatory ability through the follow-up regardless of the 
density measure. It is also noted that the improvement in discriminatory ability for longitudinal 
density compared with most recent density potentially attenuated towards the end of follow-up; 
which was possibly driven by fewer events occurring in this latter stage of follow-up which 
limited statistical power. 
 
The major strength of this study is the ability to model a woman’s entire history of density; 
including an unlimited number of mammograms arbitrarily spaced through time. This makes 
longitudinal density a particularly useful tool for clinical practice where women can have a 
number of mammograms taken at any point in time. Furthermore, predicting a woman’s 
longitudinal density at each time point using only her current and previous densities would 
allow for the measure to be continually updated at each screening visit. Longitudinal density is 
not limited to any one density measurement technique, and it could just as easily be developed 
using semi-automated or fully-automated area-based or volumetric techniques. Predictive 
accuracy of breast cancer risk models that estimate personal breast cancer risk scores, such as 
the Tyrer-Cuzick, Gail or BCSC model, may also improve with the inclusion of longitudinal 
density. Using longitudinal density to assess risk of breast cancer may also prevent fluctuations 
in classifying women into different risk categories. For example, a women who has always had 
a high BI-RADS category 4 density that decreases to a BI-RADS category 3 could drop into a 
lower risk category that excludes her from supplemental screening or eligibility for 
chemoprevention. However, assessing her breast cancer risk using longitudinal density would 
take into account all of her previous measures and hence be more conservative with decreasing 
her risk. 
 
A limitation of the study is that BI-RADS density categories were modelled as quantitative 
integer values to crudely approximate a linear association between density and the age and BMI 
predictors in the linear mixed model. It was considered best to first investigate longitudinal 
density using this simple linear model to identify if there is indeed an added benefit in assessing 
a woman’s history of density, and from this, a more complex model could be developed. It may 
be that other models, for example a multinomial or ordinal logit model, better fit the data and 
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perhaps outperform the linear model (327). Furthermore, the linear mixed model used to 
develop longitudinal density was adjusted for age and BMI only. Including additional 
confounders of density such as HRT use, benign breast disease or reproductive factors might 
improve model fit and also the approximation of longitudinal density. Finally, the distribution of 
breast cancer risk was somewhat similar when using most recent or longitudinal density. Again, 
including additional breast cancer risk factors could potentially improve this risk stratification.  
 
There are many ideas for future work on longitudinal density. These include evaluating the 
benefit of longitudinal density in different cohorts of women such as younger or older women 
outside of the routine screening age, or women at increased risk due to a family history of breast 
cancer. Assessment using other density measures including volumetric or semi/fully-automated 
methods would also be useful. Improving the prediction of longitudinal density is another area 
of future work. It is not yet known whether all previous density values are needed to predict 
longitudinal density, or whether the value of historical density measures reduces in time. It may 
be useful to up-weight more recent density measures or perhaps apply ‘forgetting factors’ to the 
linear mixed model to down-weight older measures (328). Moreover, previous research suggests 
a possible benefit of assessing the extent of density fluctuation through time (329), which has 
the potential to further improve the prediction of longitudinal density. Moreover, as mentioned 
earlier, a multinomial or ordinal logit model may improve model fit for the longitudinal density 
measure (327). The value of longitudinal density in assessing response to treatment also 
requires assessment in a future study. It may be that an observed decrease in density greater than 
that predicted from individual density trajectories is indicative of a response to treatment. 
Finally, the assessment of breast cancer risk with longitudinal density could potentially be 
improved by using different approaches for modelling risk. These include combining additional 
risk factors into the proportional-hazards Cox model, incorporating a longitudinal BMI measure 
(predicted using a similar linear mixed model approach), or using a joint longitudinal-survival 
model to maximise the likelihood of random effects that are common to both the mixed model 
and the proportional-hazards model simultaneously (327, 330, 331). 
 
3.5 Conclusion 
 
In this study, longitudinal density was shown to have greater predictive ability, better 
discriminatory accuracy and a higher risk gradient between the extreme density categories than 
a single measure of baseline or most recent density. Including information on a woman’s history 
of mammographic density has the potential to improve the accuracy of breast cancer risk 
estimation and its implementation in breast cancer prevention strategies should be considered. 
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Chapter 4: Mammographic density, endocrine therapy and breast cancer 
risk: a prognostic and predictive biomarker review 
 
4.1 Background 
 
4.1.1 Description of the intervention 
 
Selective oestrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) are two types 
of endocrine drug used as therapy for ER+ breast cancers. SERMs prevent breast cancer (198, 
200), and in the adjuvant setting, they reduce the chance that breast cancer will reoccur when it 
has been diagnosed at an early stage (332, 333). SERMs work by competing with oestrogen 
molecules for oestrogen receptor binding sites, hence reducing the amount of oestrogen uptake 
in breast tumours. SERMs are therefore effective in ER+ breast cancers only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Mechanism for selective oestrogen receptor modulators (SERMs) competing with oestrogen 
for binding sites. 
 
AIs are suitable for postmenopausal women only, and they are associated with greater average 
reductions in the risk of breast cancer (208, 334), and recurrence than SERMs (335). Like 
SERMs, AIs reduce oestrogen levels, but they instead work by inhibiting oestrogen synthesis in 
peripheral tissue by preventing the aromatase enzyme from converting adrenal androgens 
(androstenedione and testosterone) into oestrogens (estrone and estradiol). This process, known 
as aromatisation, is the main source of oestrogen after the menopause. 
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Figure 4.2: Mechanism for aromatase inhibitors (AIs) blocking oestrogen production in peripheral tissue 
(subcutaneous adipose tissue, liver, muscle, or brain). 
 
4.1.2 How the biomarker might be related to treatment response 
 
The biomarker for this review is mammographic density. As described in Chapter 1, exogenous 
hormones can change a woman’s mammographic density. For instance, HRT increases density 
as well as breast cancer risk (188, 189). However, after cessation of HRT, mammographic 
density has been shown to decrease in as little as four weeks (195), and within a couple of years, 
breast cancer risk is likely to return to the same level as a non-HRT user (197). Treatment with 
certain SERMs can also decrease density more so than would be expected with age (203-206, 
336), but the evidence for AIs is less clear (267-271, 337). There is evidence to suggest that 
increased risk from combination HRT is mediated by density (142, 338, 339), and that change 
in density may be an appropriate biomarker for response to SERMs used for both prevention 
(19) and treatment (263-266). A working hypothesis is that density reduction in women 
receiving endocrine therapy for treatment or prevention might indicate who is responding to the 
drug, making it a reliable surrogate outcome and biomarker for treatment efficacy. The 
underlying biological mechanism is still unclear, but one theory is that decreases in density 
reflect the body’s ability to effectively metabolise the drug (340). 
 
4.1.3 Why it was important to do this review 
 
This review firstly aimed to assess the evidence that endocrine therapy-induced change in 
mammographic density is a prognostic biomarker (341). A prognostic biomarker is a measure 
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associated with a clinical outcome of interest in a defined group of patients. This is standard in 
the adjuvant setting when the group of patients has a health condition such as breast cancer. 
Several prognostic factors in the adjuvant setting include tumour size, grade and lymph node 
involvement, as well as biomarkers such as Ki67 and genetic scores such as OncotypeDX (342, 
343). The terminology for prognostic biomarkers associated with breast cancer in healthy 
women in the preventive setting is less frequently used. Prognostic biomarkers in healthy 
women are more commonly called risk factors. These include age, a family history of breast 
cancer, BMI and reproductive factors such as age at first full term birth and number of children 
(223). 
 
The second aim of this review was to assess the evidence that endocrine therapy-induced change 
in mammographic density is a predictive biomarker, such that it is a measure that is different in 
the presence of treatment and is therefore associated with response to treatment (344). Some, 
but not all, prognostic biomarkers are predictive biomarkers. Two examples for women with 
breast cancer are human epidermal growth factor receptor (HER-2) and ER status. HER-2 was 
first identified as a prognostic factor for breast cancer, and was subsequently recognised as a 
predictive biomarker whereby treatment with trastuzumab was shown to be effective for women 
with HER-2 breast cancer. ER status is a prognostic biomarker and a predictive biomarker for 
SERM and AI treatments, whereby these treatments improve clinical outcomes in ER+ patients 
only. 
 
There are currently no systematic reviews that focus on the evidence that mammographic 
density reduction in women receiving endocrine therapy is a prognostic or predictive biomarker. 
However, some other reviews on the topic have been published, including a study by Shawky et 
al. (345). This reported seven studies of density change as a prognostic factor for women 
receiving a SERM or AI in the adjuvant setting, but there were no data from a randomised trial 
or otherwise to evaluate change in mammographic density after initiation of adjuvant treatment 
as a predictive biomarker. For prevention, only one study (a case-control study from within a 
randomised control trial) was identified that evaluated density change as a prognostic and 
predictive biomarker. Another recent review by Kanbayti et al. assessed the relationship 
between mammographic density reduction following breast cancer treatment and patient 
outcomes, although this was not specific to women receiving endocrine therapy (346). This 
review reported nine studies of density reduction as a prognostic factor for women receiving 
breast cancer treatment, but, again, there were no data to evaluate change in mammographic 
density as a predictive biomarker in the adjuvant setting. 
 
This review should help to guide clinical decisions about whether to continue treatment or 
switch to another treatment regime, understand the aetiology of breast cancer development, 
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improve the design of trials in terms of implementing a surrogate marker, and improve 
personalised risk assessment (347). Findings are likely to be important to: clinicians and their 
patients undergoing or considering endocrine therapy by helping to predict response to 
treatment beyond the current ‘wait and see’ approach; regulators and ethics boards considering 
trials of products that use mammographic density reduction as a surrogate endpoint; and those 
with an interest in mechanisms by which endocrine therapy improves clinical outcomes. 
Additionally, as discussed in the study by Mullooly et al., had the randomised trials of SERMS 
and AIs included density change as a potential prognostic or predictive biomarker, then different 
conclusions might have been drawn regarding their effectiveness (348). For instance, in the 
ATAC trial, the AI anastrozole was shown to be more effective than the SERM tamoxifen in 
reducing risk of postmenopausal breast cancer recurrence (349). However, it is possible that 
women who had density reductions with tamoxifen might have had greater treatment benefits 
than those on anastrozole. Another possibility is that women who see density increases 
following a short-term decrease might in fact show resistance to the treatment (350, 351), but 
this is still unknown and requires investigation. 
 
4.2 Objectives 
 
The objective of the review was to synthesise available evidence testing whether 
mammographic density reduction in the preventive or adjuvant setting is (i) a prognostic 
biomarker and (ii) a predictive biomarker. Both prognostic and predictive biomarker reviews 
considered prevention and treatment populations separately, and within these, SERMs and AIs 
were considered separately.  
 
4.3 Methods 
 
This review was written according to PRISMA (352) and Remark (353, 354) guidelines. 
 
The aim was to conduct a literature-based analysis to identify relevant studies that could then be 
used in a subsequent individual-level analysis. This individual-level meta-analysis is not 
included in the thesis, but is instead proposed as a future review that should help to account for 
heterogeneity between the studies in terms of the participants, length of follow-up, 
mammographic density measures, cut-points and overall study design (347, 355). 
 
The methods described in this chapter outline the proposed procedure for conducting the 
systematic review. A version of this review plan is published as a Cochrane review protocol 
(356). At the review stage, it was decided that the studies were too heterogeneous to be able to 
combine into a meaningful meta-analysis. However, the full methodology is still presented 
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because it contains important information regarding other elements of the review and it explains 
the approach taken for conducting the literature-based analysis. 
 
4.3.1 Criteria for considering studies for this review 
 
4.3.1.1 Types of study designs 
 
Randomised and non-randomised observational studies (prospective and retrospective cohort 
and case-control studies) were included for both the prognostic and predictive reviews. Studies 
based on exploratory biomarkers whereby density was one of several biomarkers were included. 
 
4.3.1.2 Types of participants 
 
Studies were included if they had subsets that met the following participant criteria, but only the 
relevant subset data was to be extracted for the meta-analysis. 
 
For both the prognostic and predictive biomarker reviews, all adult women aged 18 years or 
older, with or without breast cancer (denoted respectively as treatment and prevention) were to 
be included based on the following criteria. 
 
 Treatment: women with early stage hormone receptor (oestrogen (ER) or progesterone 
(PgR))-positive breast cancer. This was defined to be women who had been diagnosed with 
histologically proven operable invasive hormone receptor-positive breast cancer or DCIS, 
and who were candidates to receive adjuvant endocrine therapy. There was to be no clinical 
evidence of metastatic disease to minimise the risk of a recurrence or contralateral breast 
cancer being a misclassified metastasis. Women were to be considered ineligible if their 
breast density measurements were not made on the contralateral breast because there was a 
risk that tumours may have been misclassified as dense tissue. For this same reason, women 
were to be considered ineligible if they had bilateral breast cancer. 
 
 Prevention: women who had not previously been diagnosed with invasive breast cancer or 
DCIS. Women of all levels of increased risk due to genetic factors (including BRCA1/2 
gene mutations or a family history of the disease, or both) or otherwise assessed by an 
absolute or relative risk prediction model were to be included. If women had breast implants 
or if they had undergone risk-reducing mastectomies, they were to be excluded. This was 
considered because these factors affect the ability to produce accurate density estimates. 
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Women were to be at-risk for at least the length of time between baseline and follow-up 
mammogram. Women could be included if they changed treatment or discontinued treatment 
throughout their follow-up, but they were to be excluded if they changed treatment between 
their mammograms as this may have affected the change in density. However, women could be 
included if they discontinued treatment between mammograms. Women were to be excluded if 
they received another SERM or AI before treatment because these effects may have continued 
into the second period of treatment. 
 
For AI comparisons, women had to be postmenopausal at the start of treatment; for SERM 
comparisons, they were allowed to be pre- or postmenopausal. The definition of 
postmenopausal women included women who had undergone a bilateral oophorectomy, or 
women who were aged more than 60 years, or women who were aged 40 to 59 years with an 
intact uterus and who were amenorrhoeic for at least 12 months. Women were to be excluded if 
they were rendered temporarily postmenopausal through medical interventions (e.g. 
gonadotropin-releasing hormone (GnRH) analogues).  
 
4.3.1.3 Types of interventions 
 
4.3.1.3.1 Interventions 
 
Studies were included if they had subsets that met the following intervention criteria, but only 
the relevant subset data was to be extracted for the meta-analysis. Studies including women 
receiving doses lower or higher than those outlined below were included, but for the meta-
analysis, these women were to be included in a secondary dose-response analysis only. Studies 
involving a mixture of women receiving SERMs and AIs were included, but for the meta-
analysis, these studies were to be included in the main analysis if the results could be separated 
by treatment; otherwise they were to be included in a secondary analysis only. 
 
For both the prognostic and predictive biomarker reviews, women were to be included if they 
received SERMs at the following minimum doses (357): Tamoxifen, 20 mg daily; Raloxifene, 
60mg daily; Lasofoxifene, 0.25mg daily; Arzoxifene, 20mg daily; Droloxifene, 40 mg daily; 
Bazedoxifene, 20 mg daily; and Fulvestrant, 250 mg monthly. Women were to be included if 
they received AIs at the following minimum doses: Anastrozole, 1 mg daily; Letrozole, 2.5 mg 
daily; and Exemestane, 25 mg daily. All treatments were to be orally-consumed, except 
Fulvestrant (intramuscular). Treatment was to be received for at least the length of time between 
baseline and follow-up mammogram (i.e. intended for at least 1 year). 
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4.3.1.3.2 Co-interventions 
 
Studies were included if they had subsets that met the following co-intervention criteria, but 
only the relevant subset data was to be extracted for the meta-analysis. The same types of co-
interventions were allowed for both the prognostic and predictive biomarker reviews. 
 
For treatment, women were to be considered ineligible if they had not completed primary loco-
regional treatment (surgery or radiotherapy, or both) and systemic treatment (chemotherapy or 
targeted therapy, either neoadjuvant or adjuvant) with curative intent. Women were to be 
considered ineligible if there was a gap of more than eight weeks between different treatment 
interventions, for example, between surgery and the start of radiotherapy, or if endocrine 
treatment was started more than 28 days before surgery. 
 
If women used HRT either during the study or up to 2 years before baseline, they could be 
included, but this was to be noted in the ‘Risk of bias’ assessment where relevant. Other co-
interventions were permitted, including exercise and diet advice, but these were also to be noted 
in the ‘Risk of bias’ assessment where relevant. 
 
4.3.1.3.3 Comparators 
 
The main difference between the prognostic and predictive biomarker review was the 
comparator. 
 
 Prognostic biomarker review: The comparison was within each intervention group (SERM 
or AI), whereby assessment was on the association between density change and outcome in 
women receiving the treatment. 
 
 Predictive biomarker review: The comparison was within each study, whereby assessment 
was on the association between density change and outcome in the intervention group 
compared with a control group. The within-study comparator group was defined as a 
corresponding randomised placebo group, or a non-randomised control group of women not 
receiving endocrine therapy. 
 
4.3.1.4 Biomarker 
 
The same definition of biomarker was used for both the prognostic and predictive reviews. A 
measure of mammographic density was required at baseline (start of endocrine therapy or study 
entry in those from the control group) and follow-up mammogram.  
119 
 
 
Studies were included if they had subsets that met the following biomarker criteria, but only the 
relevant subset data was to be extracted for the meta-analysis. 
 
For treatment, baseline mammograms could be taken before or after diagnosis, but they were to 
be no more than 2 years before the initial breast cancer diagnosis so that they represented the 
breast at the time of diagnosis as closely as possible. For treatment and prevention, baseline 
mammograms had to be taken before the start of treatment (or study entry) so that they reflected 
the breast phenotype before the effects of endocrine treatment. A follow-up mammogram had to 
be performed 90 days to 3 years after the start of endocrine treatment (or study entry), with the 
density closest to 1 year from the start of endocrine therapy (or study entry) selected if there was 
a choice. 
 
Range and average timings were recorded for the following (if they were available): time 
between baseline mammogram and diagnosis, time between diagnosis and start of endocrine 
therapy (or study entry), and time between start of endocrine therapy (or study entry) and 
follow-up mammogram. 
 
Density methods had to have been shown in more than one study (outside of the review studies) 
to have a relationship with breast cancer risk. Acceptable density methods included (but were 
not limited to) the following percentage methods: 
 
 Visual assessment by expert in 5% bands (%). 
 Visual assessment by expert in 20% bands (Boyd categories). 
 Visual assessment by expert as continuous percentage (%). 
 Semi-automated thresholding such as using ‘Cumulus’ software (23) by expert (or trained) 
reader (%). 
 Fully-automated percentage (based on area of density) (%). 
 Fully-automated volumetric percentage (e.g. Volpara, (44)) (%). 
 
Acceptable absolute density methods included (but were not limited to) the following: 
 
 Semi-automated thresholding such as using ‘Cumulus’ software (23) by expert (or trained) 
reader (cm2). 
 Fully-automated absolute density (based on area of density) (cm2). 
 Fully-automated volumetric absolute density (e.g. Volpara, (44)) (cm3). 
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Acceptable categorical density measures included (but were not limited to) the following: 
 
 BI-RADS density (18). 
 Wolfe grade (358). 
 Tabar grade (15). 
 
Information on the reliability of density measures was also used to qualitatively assess the 'Risk 
of bias’ due to measurement of the biomarker. Such information included: 
 
 The correlation between repeated measures from repeat mammograms. 
 Whether different readers of density were used and whether the same reader assessed 
mammograms from the same woman. 
 Intra-class correlation coefficients and Bland-Altman limits of agreement (359) to assess 
intra- and inter-reader reliability. 
 Whether the reader was blinded to case status. 
 Whether the reader was blinded to treatment allocation. 
 Whether randomisation was per mammogram (mammograms read independently) or per 
woman (mammograms for each woman read with the knowledge of her other 
mammograms). 
 Whether the order of per woman mammograms was sequential or random and assessed one 
at a time or simultaneously. 
 
If different definitions or measures of mammographic density were used between the time-
points used to assess density change, these women or studies were excluded. 
 
4.3.1.5 Types of outcome measures 
 
The same outcome measures were used for both the prognostic and predictive reviews. 
 
Primary outcomes 
 
Potential benefits from treatment: 
 Treatment: breast cancer mortality (time to death caused by breast cancer).  
 Prevention: incidence of invasive breast cancer and DCIS.  
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Potential harms from treatment: 
 Treatment and prevention: rate of all serious adverse events. These included serious side 
effects noted for Tamoxifen (cataracts, pulmonary embolism or deep vein thrombosis and 
endometrial cancer) and Anastrozole (osteoporosis and bone fractures).  
 
Secondary outcomes 
 
Potential benefits from treatment: 
 Treatment: recurrence. 
 Treatment: incidence of a secondary primary breast cancer (e.g. in the contralateral breast). 
 Treatment: any recurrence or any death (disease-free survival).  
 Treatment: distant metastases. 
 Treatment: death from all causes (all-cause mortality).  
 Treatment: recurrence of invasive cancer only. 
 Treatment: recurrence of DCIS cancer only. 
 Prevention: incidence of invasive cancer only. 
 Prevention: incidence of DCIS cancer only. 
 
Potential harms from treatment: 
 Treatment and prevention: troublesome but not serious side effects observed for SERMs 
and AIs, including vasomotor symptoms and joint or muscle pain.  
 
’Summary of findings’ table for assessing the quality of the evidence  
 
A ’Summary of findings’ table was produced for each of the prognostic and predictive 
biomarker reviews, following the approach outlined by GRADE (360) and using GRADEpro 
GDT software (361). 
 
4.3.2 Search methods for identification of studies 
 
4.3.2.1 Electronic searches 
 
The following databases were searched: 
 
 The Cochrane Breast Cancer Group’s (CBCG’s) Specialised Register. Details of the search 
strategies used by the Group for the identification of studies and the procedure used to code 
references are outlined on the Group’s website (362). Trials were extracted and considered 
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for inclusion if they included the key words “Tamoxifen, Raloxifene, Lasofoxifene, 
Arzoxifene, Droloxifene, Bazedoxifene, Fulvestrant, Anastrozole, Letrozole, Exemestane, 
selective estrogen receptor modulator, aromatase inhibitor”. 
 CENTRAL (The Cochrane Library, latest issue). See appendix B.I. 
 MEDLINE (via OvidSP) from 1996 to present. See appendix B.II. 
 Embase (via OvidSP) from 1996 to present. See appendix B.III. 
 The World Health Organization (WHO) International Clinical Trials Registry Platform 
(ICTRP) search portal (363) for all prospectively registered and on-going trials. See 
appendix B.IV. 
 ClinicalTrials.gov (364). See appendix B.V. 
 
4.3.2.2 Searching other resources 
 
Bibliographic searching: Further studies were sort out from reference lists of identified relevant 
studies. A copy of the full article was to be obtained for each reference reporting a potentially 
eligible study. 
 
4.3.3 Data collection and analysis 
 
4.3.3.1 Selection of studies 
 
All retrieved titles and abstracts were independently reviewed by the author of this thesis 
(Emma Atakpa) and Dr Brentnall to assess eligibility against the inclusion criteria. Any 
disagreements at this stage were discussed and resolved. Full-text copies of all potentially 
eligible studies were then obtained and reviewed by the thesis author (Emma Atakpa) and Dr 
Brentnall. Any disagreements at this stage were resolved by Dr Mangesh Thorat (the clinical 
expert on the systematic review). There was only one disagreement which regarded the 
inclusion of grey literature such as conference abstracts. It was determined that (although not 
explicitly stated in the protocol) only studies published in a peer-reviewed journal would be 
included and abstract-only records would be excluded as implied by the quotes: “We will obtain 
a copy of the full article for each reference reporting a potentially eligible trial” and “We will 
only include studies published in English” (356). Duplicate studies were recorded as one 
reference (for example, the same study but multiple papers with slightly different aims or 
follow-up). In this situation, the reference considered to be the most recent or up-to-date (largest 
number of participants, longest follow-up time, or correction to previous analysis) was included 
as the primary reference. Only studies published in English were included. The selection 
process was recorded in a PRISMA flow diagram (352) in the Review Manager 5 software 
(365). The whole process was recorded using the Covidence system (366). 
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4.3.3.2 Data extraction and management 
 
Data extraction was independently completed by the thesis author (Emma Atakpa) and Dr 
Brentnall using custom forms (appendix B.VI). Again, any disagreement at this stage was to be 
resolved by Dr Thorat (although this was not required). The following information was 
collected (if available): 
 
 Study design: type of study. For example, a nested case-control study from a randomised 
trial, or a non-randomised cohort study, or a case-control study. If there was matching, then 
what matching was by and to what level (e.g. age to plus/minus 2 years). Control group 
(women without treatment): yes/no. Whether a prognostic or predictive study, or both. For 
prognostic factor studies, what phase (following (355, 367)). 
 Participants: demographic information, including the number of participants, age, BMI, 
ethnicity, education. Summary statistics such as mean, interquartile range (or standard 
deviation) and range for age, BMI and absolute or relative baseline risk, or both, from a risk 
model (e.g. Gail model (222), Tyrer-Cuzick (223), BCSC (239)). Total number (percentage) 
postmenopausal, perimenopausal or premenopausal. For the predictive review, the previous 
variables were split by treatment or control group. 
 Biomarker: whether mammograms were from film (digitised for density or not) or full field 
digital mammography. Manufacturer of digital mammogram machine. Whether any pre-
processing was carried out for quality control of mammographic density. Density 
measure(s), and the range and average time between baseline mammogram and diagnosis, 
between diagnosis and start of endocrine therapy (or study entry), and between start of 
endocrine therapy (or study entry) and the follow-up mammogram. 
 Setting: country, whether in a high-risk clinic, a treatment clinic, time period, urban/rural. 
 Co-interventions: HRT use, chemotherapy use (treatment), targeted therapy use (treatment), 
radiotherapy use (treatment), neoadjuvant endocrine therapy use (treatment). 
 Follow-up time period: minimum, mean, median, interquartile range, standard deviation, 
maximum follow-up. 
 Sources of funding and stated conflicts of interest: descriptive text copied from sections in 
each paper. 
 
4.3.3.3 Assessment of risk of bias in included studies 
 
For the prognostic biomarker review, a modified version of the QUIPS tool (368) was used to 
assess the risk of bias affecting the included studies (369) using six domains: 
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 Study participation. 
 Attrition. 
 Measurement of density. 
 Measurement of the outcomes. 
 Confounding. 
 Statistical analysis. 
 
For the predictive biomarker review, the QUIPS tool was augmented with the ROBINS-I tool 
(370) to assess the risk of bias in estimation of an interaction between mammographic density 
change and treatment.  
 
'Risk of bias’ was independently conducted by the thesis author (Emma Atakpa) and Dr 
Brentnall, with disagreements to be resolved by Dr Thorat (although this was not required). For 
both prognostic and predictive biomarker reviews, the included studies were considered together 
and an individual ‘Risk of bias’ table was produced for each study (appendix B.VII). In the 
results, a narrative is presented identifying the risk of bias in the six domains across studies. 
Studies that had substantial potential for bias were to be excluded in the meta-analysis for a 
sensitivity analysis of the results. 
 
4.3.3.4 Measures of biomarker response 
 
4.3.3.4.1 Effect measure 
 
Studies were included in the quantitative synthesis if they had subsets that reported the 
following effect measures, but only the relevant subset data was to be extracted for the meta-
analysis. 
 
In both the prognostic and predictive biomarker reviews, the primary measure was to be the 
mean effect of treatment-induced density change over a five-year follow-up period. Other time 
periods could be included, but if they were split into different periods (e.g. 0 to 5 years, 5 to 10 
years) then periods outside of the initial five years were to be treated as a secondary analysis 
only in the meta-analysis. Results of the meta-analysis were to be presented as subgroups of 
similar cut-points and biomarkers using continuous measures, and reported as ratios whereby 
less than 1.0 was to favour a risk reduction associated with a decrease in mammographic density 
and greater than 1.0 was to indicate a risk increase. 
 
 Prognostic biomarker review: The primary measure was to be a hazard ratio (cohort study 
with time to event) or an odds ratio (case-control study) for the effect of density change. 
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Odds ratios were to be treated as an equivalent measure of the hazard ratio, unless the rate 
of breast cancer outcome was high. In this case, the odds ratio estimates were to be included 
in the meta-analysis as a secondary analysis only. 
 
 Predictive biomarker review: The primary measure was to be the interaction between 
treatment and density change, expressed as a relative hazard (cohort study) or odds ratio 
(case-control study). 
 
4.3.3.4.2 Adjustment 
 
 Prognostic biomarker review: The primary effect estimate was to be adjusted. Estimates of 
the effect of prognostic factors tend to be more relevant when they are adjusted for potential 
confounders than when they are unadjusted (347). However, unadjusted estimates were to 
be included if adjusted estimates were not available because it was not expected that change 
in density would be associated with the baseline value of most other prognostic factors. 
Nonetheless, it is noted that changes in BMI may have affected changes in density because 
BMI is negatively associated with breast density, so one would ideally adjust for this in any 
analysis of density change as a prognostic biomarker. 
 
 Predictive biomarker review: The primary effect estimate was to be adjusted. There are 
currently no established predictive biomarkers for either prevention or treatment in the 
groups of included women, so the adjustments are less clear than for the prognostic density 
change biomarker. 
 
4.3.3.4.3 Dealing with missing data 
 
Where data were missing, contact was to be made with the study authors in an attempt to obtain 
the data. 
 
4.3.3.4.4 Assessment of heterogeneity 
 
Heterogeneity in the meta-analysis was to be measured using the estimated variance in a 
random-effects model (Tau2), and publication bias was to be measured using a funnel plot and 
Egger’s test (371). 
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4.3.3.4.5 Subgroup analysis and investigation of heterogeneity 
 
When sufficient studies existed, the following a priori subgroup analyses were to be conducted 
in the meta-analysis to explore reasons for heterogeneity within the predefined homogeneous 
groups described above. 
 
Between-studies: 
 Drug within SERM (Tamoxifen, Raloxifene, Lasofoxifene, Arzoxifene, Droloxifene, 
Bazedoxifene, Fulvestrant) and AI grouping (Anastrozole, Letrozole, Exemestane). 
 Type of study: case-control, observational cohort, randomised trial (nested case-control). 
 Type of cancer at baseline (treatment): (percentage DCIS). 
 Severity of cancer at baseline (treatment): stage (percentage regional spread). 
 Co-interventions (treatment): chemotherapy/targeted therapy. 
 Hormone therapy use during therapy (yes/no, percentage if it was available), or in previous 
two years (yes/no, percentage if it was available). 
 Time between start of therapy (or study entry) and follow-up mammogram (mean and 
range). 
 Menopausal status (percentage premenopausal). 
 Age (mean). 
 BMI (mean). 
 Digital or film mammography (percentage digital). 
 Distribution of density at baseline (some studies may have excluded women with low 
density). 
 
Within-study estimates of effect: 
 Type of cancer at baseline (treatment): DCIS vs. invasive. 
 Severity of cancer at baseline (treatment): stage (percentage regional spread). 
 Co-interventions (treatment): chemotherapy/targeted therapy. 
 Hormone therapy use: no HRT prior to endocrine therapy, some HRT 2 years or more than 
2 years prior to endocrine therapy, some HRT less than 2 years prior to endocrine therapy, 
some HRT during endocrine therapy. 
 Menopausal status (pre-, peri- or postmenopausal). 
 Age group (< 50 years or ≥50 years) as a proxy for menopausal status. 
 BMI (<25, 25 to <30, 30 to <35, ≥35 kg/m2). 
 Baseline density. 
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4.3.3.4.6 Data synthesis 
 
Heterogeneity between studies was expected because this is common in reviews of prognostic 
biomarkers (347). Therefore, it was decided that a meta-analysis would only be conducted for 
studies within predefined groups that were believed to be homogenous enough in advance to be 
meaningful for data synthesis. Namely, those with the same class of drug, same outcome, same 
density measure, same effect measure (same cut-point or continuous variable assessment). 
Where more than one study was available, estimates were to be combined using an inverse-
variance weighting (fixed-effect estimation); and if there was substantial variability then results 
were to be presented but it was to be stated that the overall effect estimate has very limited 
interpretation. Additionally, subgroups (4.3.3.4.5) were to be investigated to help to explain the 
heterogeneity. 
 
4.4 Results 
 
4.4.1 Description of studies  
 
4.4.1.1 Results of the search 
 
The database search identified 1180 records (see PRISMA follow diagram: Figure 4.3), and 
after deduplication, there were 888 records. Of these, 801 records were deemed ineligible 
according to their title and abstract and 87 records were selected for full-text review. Seventy-
nine of the 87 full-text articles were excluded, and eight eligible studies that fulfilled the 
inclusion criteria were included in the qualitative synthesis, with six of these contributing to the 
quantitative synthesis. A bibliography search of the reference lists in the eight included studies 
was also conducted. Titles were reviewed and if they were considered potentially eligible (and 
not already included in the 888 records), their abstracts were reviewed. Nine potential records 
were identified but these were considered ineligible after abstract review, hence no additional 
studies were found through the bibliographic search. 
 
4.4.1.2 Included studies 
 
There was a large amount of variation across the eight included studies (see ‘Characteristics of 
included studies’ table: Table 4.1). All were observational studies, with four case-controls (19, 
266, 372, 373) and four retrospective cohorts (263-265, 374). Of the four case-control studies, 
three studies used a matched design (266, 372, 373). Two studies were sub-studies from 
randomised controlled trials (one nested case-control (19) and one cohort study (374)). The 
studies ranged in size from 349 (266) to 1066 (263) women. Six studies included women from 
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Western populations (the UK (19), Finland (19), USA (266, 372), Canada (372), Sweden (265, 
373) and the Netherlands (374)) and two studies were in women from South Korea (263, 264). 
Follow-up ranged from 5 years (263) to 14 years (265), and only one study (19) was in the 
preventive setting, with the rest being in the adjuvant treatment setting for women with breast 
cancer. Half of the studies assessed tamoxifen treatment only (19, 263, 265, 266), two studies 
assessed tamoxifen and an AI (264, 374), and two studies were not specific to a particular 
endocrine therapy, whereby only a subset of women were on endocrine therapy during their 
adjuvant treatment (372, 373). Two studies included a placebo (19) or control group (265), 
although the latter study did not compare across the interventions and could only be used in the 
prognostic review. Therefore, only one study was assessed in the predictive biomarker review 
(19). There was a mixture of premenopausal and postmenopausal women, and in the treatment 
setting, the two South Korean studies included women with DCIS or invasive breast cancer, 
whereas the other studies included women with invasive disease only.  
 
The two sub-studies from clinical trials used visually-assessed density, with one assessing 
density to the nearest 5% (19) and the other assessing density in 20% Boyd categories (374). 
Two studies used a machine learning-based density assessment trained on Cumulus images 
(265, 373), three studies used Cumulus percent density (264, 266, 372) and one study used BI-
RADS density (263). Density change cut-points varied greatly, with some adopting a 5% (264), 
10% (19, 372, 373) or top tertile (determined by the distribution of controls) (266) absolute 
percent density reduction cut-point, one using a 20% relative dense area reduction cut-point 
(265), and another using reduction in BI-RADS category (263). One study did not report their 
definition of density change (374). 
 
Two studies had recurrence (recurrence-free survival) as their endpoint (263, 264), two studies 
had mortality as their endpoint (265, 266), two studies looked at incidence of contralateral 
breast cancer (372, 373), one study assessed incidence of contralateral breast cancer and 
recurrence as its endpoint (374), whilst the final study assessed risk of developing invasive or 
DCIS breast cancer in a sample of at-risk women (19). 
 
A detailed description of the included studies can be found in the data capture forms (appendix 
B.VI). 
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Figure 4.3: PRISMA flow diagram for the review. 
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Table 4.1: Characteristics of included studies 
Cuzick 2011 
Methods Nested case-control within a multi-centre international randomised 
controlled trial (IBIS-I). 
Recruitment April 1992-March 2001, diagnosis before 1 October 
2007. 
Prognostic and predictive biomarker. 
Prevention setting. 
Participants 123 cases from the UK and Finland, 942 controls from the UK. 
Age 35-70 years at recruitment to IBIS-I trial. 
Premenopausal and postmenopausal women. 
Approximately twice the population risk of developing breast 
cancer. 
Interventions Tamoxifen 20mg daily (n=507), placebo daily (n=558), 5 years of 
treatment. 
Visually-assessed percent density. 
Density reduction 10% or more vs. no change at 12-18 month 
follow-up mammogram in tamoxifen arm (prognostic biomarker). 
Density reduction 10% or more vs. less than 10% at 12-18 month 
follow-up mammogram in tamoxifen arm compared with placebo 
arm (interaction, predictive biomarker). 
Outcomes Incidence of invasive breast cancer and DCIS. 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Low risk Source population described, demographic factors 
(and tumour characteristics for cases) similar in 
included and not included women from the IBIS-I 
main trial. 
Study attrition Low risk Only 44 women withdrew who were not included in 
this sub-study (referenced (200)). 
Prognostic factor 
measurement 
Moderate 
risk 
Valid and reliable density measure, although density 
change measure was determined by the data (the cut-
point was chosen as “the minimum change that could 
be reproducibly detected”), the reader was not 
blinded to case-control status. 
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Outcome measurement Low risk From trial database. 
Study confounding Low risk Adequate adjustment. 
Statistical analysis and 
reporting 
Low risk Adequate analysis, although no interaction reported 
in the paper (worked out from raw data provided by 
the study authors). 
 
Kim 2012 
Methods Retrospective cohort, non-randomised. 
Initial ER+ breast cancer diagnosis October 2003-December 2006. 
Follow-up median 69 months. 
Prognostic biomarker. 
Treatment setting. 
Participants Seoul National University Hospital, South Korea. 
1065 women. 
Age 24-77 years. 
No information on menopausal status but likely includes 
premenopausal and postmenopausal women. 
12% DCIS, 88% invasive at first diagnosis. 
Interventions Tamoxifen 5 years (n=657), tamoxifen 2-3 years + AIs (total 5 
years) (n=41), tamoxifen 5 years + AIs (unknown total time) 
(n=192), AIs 5 years (n=175), at least 2 years of treatment. 
Cumulus percent density. 
Density reduction 5% or more vs. less than 5% at 8-20 month 
follow-up mammogram in tamoxifen. 
Density reduction 5% or more vs. less than 5% at 8-20 month 
follow-up mammogram in AIs. 
Outcomes Recurrence. 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate 
risk 
No information on source population or key 
characteristics in women included vs. not included 
from source population. 
Study attrition Moderate 
risk 
No information on participant drop-out, loss to 
follow-up or reasons for censoring. 
Prognostic factor Moderate No information on reader experience, blinding to 
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measurement risk treatment or time between baseline and follow-up 
mammogram. 
Outcome measurement Moderate 
risk 
No information on start of follow-up or reasons for 
censoring. 
Study confounding High risk No information on when confounding factors were 
measured, unclear adjustments (if any) for analysis 
separated by treatment. 
Statistical analysis and 
reporting 
High risk Unclear when follow-up started or reasons for 
censoring, unclear adjustments, unclear if subgroup 
analyses include women on tamoxifen only, AIs only 
or women who switched treatment. 
 
Knight 2018 
Methods Case-control (matched on follow-up time, geographical area, birth 
year, diagnosis year and ethnicity), non-randomised. 
Initial breast cancer diagnosis 1990-2008, recruitment 2009-2012. 
Follow-up mean 8 years. 
Treatment setting. 
Participants WECARE study (USA and Canada). 
224 cases and 243 controls with mammograms at both time points. 
Mean age 46 years at mammogram before or at first diagnosis. 
Premenopausal and postmenopausal women. 
All invasive at first diagnosis. 
Interventions Mainly tamoxifen, but specific treatments not reported. 
Cumulus percent density. 
Density reduction 10% or more vs. less than 10% at 6 month-4 
year follow-up mammogram. 
Outcomes Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast). 
Notes Cannot include as a prognostic or predictive biomarker because the 
analysis adjusted for tamoxifen use. 
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate 
risk 
No information on source population but comparisons 
conducted on key characteristics between women 
included vs. not included from source population. 
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Study attrition High risk Potential for survival bias whereby women included 
were more likely to have survived at the time of 
interview than the wider cohort. Unsure about density 
or outcome in women who died before the study or 
who did not have available mammograms. "All 
women had to be alive at the time of contact for 
interview" and "Women in whom we could not obtain 
a mammogram in an appropriate time window (see 
below) were more likely to have an earlier year of 
first breast cancer diagnosis (65% diagnosed in 1990–
1996 vs. 40% in 1990–1996)". 
Prognostic factor 
measurement 
Moderate 
risk 
No information on blinding to treatment, or why 
435/467 women were used in the analysis (could have 
been digital mammograms (instead of film like the 
rest of the study sample) or poor quality 
mammograms). 
Outcome measurement Low risk From population registry. 
Study confounding Moderate 
risk 
435/467 women used in the analysis (could have been 
missing data on adjusting factors), risk factors were 
obtained retrospectively by a telephone survey 
(potential for recall bias). 
Statistical analysis and 
reporting 
High risk Analysis adjusted for treatment so unable to extract 
the effect as a prognostic or predictive biomarker, the 
study may have included other endocrine therapies 
besides tamoxifen. 
 
Ko 2013 
Methods Retrospective cohort, non-randomised. 
Initial ER+ breast cancer diagnosis January 2003-December 2008. 
Follow-up mean 59 months. 
Prognostic biomarker. 
Treatment setting. 
Participants National Cancer Centre, Goyang, South Korea. 
1066 women. 
Age 25-78 years. 
Unclear information on menopausal status but likely includes 
premenopausal and postmenopausal women. 
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13% DCIS, 87% invasive at first diagnosis. 
Interventions Tamoxifen (all women), at least 2 years of treatment. 
BI-RADS density. 
Reduction of at least 1 category vs. no reduction of at least 1 
category at 10-34 month follow-up mammogram. 
Outcomes Recurrence. 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate 
risk 
No information on source population or key 
characteristics in women included vs. not included 
from source population. 
Study attrition Moderate 
risk 
No information on participant drop-out, loss to 
follow-up or reasons for censoring. 
Prognostic factor 
measurement 
Moderate 
risk 
No information on whether restricted to contralateral 
breast or time between baseline and follow-up 
mammogram, no test of intra-reader reproducibility. 
Outcome measurement Moderate 
risk 
No information on start of follow-up or reasons for 
censoring. 
Study confounding Moderate 
risk 
No information on when confounding factors were 
measured, no adjustment for chemotherapy although 
it was associated with mammographic density 
reduction. 
Statistical analysis and 
reporting 
High risk Unclear when follow-up started or reasons for 
censoring, title says 'premenopausal' women but 
likely includes postmenopausal women too since age 
range 25-78 years, no adjustment for confounding 
factors such as chemotherapy. 
 
Li 2013 
Methods Retrospective cohort, non-randomised. 
Initial breast cancer diagnosis 1993-1995, follow-up until 31 
December 2008. 
Follow-up median 14 years. 
Prognostic biomarker. 
Treatment setting. 
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Participants Sweden. 
974 women. 
Median age 62-63 years at diagnosis. 
Postmenopausal women. 
All invasive at first diagnosis. 
Interventions Tamoxifen 20mg daily (n=231), tamoxifen 40mg daily (n=123), 
tamoxifen 20+40mg daily (n=108), tamoxifen 'other' dose daily 
(n=12), median 60 months of treatment. 
Fully-automated area-based method measuring absolute dense 
area. 
Relative dense area reduction more than 20% vs. stable dense area 
(≤9% increase to ≤10% reduction) at 6-36 month follow-up 
mammogram. 
Outcomes Breast cancer mortality (time to death caused by breast cancer). 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate risk No information on source population or key 
characteristics in women included vs. not included 
from source population. 
Study attrition Low risk Follow-up information from population registry, 
participant drop-out and loss to follow-up as a result 
of emigration likely to be small. 
Prognostic factor 
measurement 
Moderate risk Cut-points chosen "a priori" but without 
justification. 
Outcome measurement Low risk From population registry, clear definitions of start 
of follow-up and reasons for censoring. 
Study confounding Low risk Adequate adjustment. 
Statistical analysis and 
reporting 
Low risk 
Adequate analysis. 
 
Nyante 2015 
Methods Case-control (matched on age at diagnosis, diagnosis year and 
disease stage), non-randomised. 
Initial ER+ breast cancer diagnosis 1990-2008, recruitment 1 
January 1991-31 December 2010 (end of follow-up). 
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Prognostic biomarker. 
Treatment setting. 
Participants Kaiser Permanente Northwest, USA. 
97 cases and 252 controls. 
Age 32-87 years at first diagnosis. 
No information on menopausal status but likely includes 
premenopausal and postmenopausal women. 
All invasive at first diagnosis. 
Interventions Tamoxifen (all women), at least 1 tamoxifen prescription started 
within 1 year of diagnosis. 
Cumulus percent density. 
Density reduction more than 8.7% vs. less than 0.5% at 3-26 
month follow-up mammogram. 
Outcomes Breast cancer mortality (time to death caused by breast cancer). 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate risk No information on source population or key 
characteristics in women included vs. not included 
from source population. 
Study attrition Low risk Follow-up information from population registry, 
reasons for censoring discussed. 
Prognostic factor 
measurement 
Low risk Valid and reliable density and density change 
measures (based on tertiles). 
Outcome measurement Low risk From population registry, clear definitions of start 
of follow-up and reasons for censoring. 
Study confounding Low risk Adequate adjustment. 
Statistical analysis and 
reporting 
Low risk 
Adequate analysis. 
 
Sandberg 2013 
Methods Case-control (matched on age and calendar period of first breast 
cancer diagnosis, adjuvant therapy and follow-up time), non-
randomised. 
Initial breast cancer diagnosis 1976-2005. 
Follow-up mean 8 years. 
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Prognostic biomarker. 
Treatment setting. 
Participants Sweden. 
211 cases and 211 controls. 
Age at first diagnosis: ≤45 years (n cases =37, n controls=37), 45-
55 years (n cases=68, n controls=68), 55-65 years (n cases=56, n 
controls=56) and ≥65 years (n cases =50, n controls=50). 
Premenopausal and postmenopausal women. 
All invasive at first diagnosis. 
Interventions Endocrine therapy (n cases=87, n controls=87), but specific 
treatments not reported. 
Fully-automated area-based method measuring percentage density. 
Density reduction 10% or more vs. stable density (<10% increase 
to <10% reduction) at 1-5 year follow-up mammogram. 
Outcomes Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast). 
Notes   
Item 
Authors' 
judgement 
Support for judgement 
Study participation Moderate 
risk 
No information on source population but comparisons 
conducted on key characteristics between women 
included vs. not included from source population. 
Study attrition Moderate 
risk 
Follow-up information from population registry, but 
no information on reasons for censoring or loss to 
follow-up. 
Prognostic factor 
measurement 
Moderate 
risk 
Large variability in time between baseline and follow-
up mammograms (follow-up mammogram 1-5 years 
after first breast cancer diagnosis), 66 women 
excluded if baseline percent density <10% or >90% 
because they could not undergo some of the defined 
density changes but these numbers were unknown for 
the subgroup of women on endocrine therapy. 
Outcome measurement Low risk From population registry. 
Study confounding Moderate 
risk 
Adjusted for age through matching, but other 
adjustments are unclear in the subgroup of women on 
endocrine therapy. 
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Statistical analysis and 
reporting 
Moderate 
risk 
Appropriate analysis for the study's primary objective, 
but the analysis in the subgroup of women on 
endocrine therapy was a secondary objective. 
Numbers unknown and unclear adjustments for the 
subgroup of women on endocrine therapy, cannot 
separate out endocrine therapies. 
 
van Nes 2015 
Methods Retrospective sub-cohort within a multi-centre randomised 
controlled trial (TEAM). 
Start of TEAM trial enrolment in 2001, but unknown time period 
of sub-cohort study. 
Follow-up median 6 years. 
Prognostic biomarker. 
Treatment setting. 
Participants The Netherlands. 
378 women. 
Age 45-91 years at baseline. 
Postmenopausal women. 
All invasive at first diagnosis. 
Interventions Exemestane 25mg daily for 5 years (n=197), tamoxifen 20mg daily 
for 2-3 years followed by 3-2 years of exemestane (totalling 5 
years) (n=181). 
Visually-assessed percent density in 20% bands (Boyd categories). 
Unclear comparison: "change in breast density". 
Outcomes Recurrence and incidence of a secondary primary breast cancer 
(e.g. in the contralateral breast) combined (loco-regional 
recurrence, distance recurrence or contralateral breast cancer). 
Notes Cannot include as a prognostic biomarker because there were no 
results to extract. 
Item 
Authors' 
judgement 
Support for judgement 
Study participation Low risk Source population not described but referenced (375), 
comparisons conducted between women included vs. 
not included from source population. 
Study attrition Moderate No information on participant drop-out, loss to 
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risk follow-up or reasons for censoring. 
Prognostic factor 
measurement 
Low risk Valid and reliable density and density change 
measures, although no information on which follow-
up mammograms were used for the density change 
measure (therefore no information on time between 
baseline and follow-up mammogram). 
Outcome measurement Low risk From trial database, clear definition of start of 
follow-up but unclear reasons for censoring (per 
protocol analysis so women were censored when they 
stopped treatment but no information on other 
reasons). 
Study confounding Moderate 
risk 
Unclear adjustments (if any). 
Statistical analysis and 
reporting 
High risk Insufficient presentation of data, adjustments and 
results for density change, both treatment arms 
combined so unable to separate out endocrine 
therapies. 
 
4.4.1.3 Excluded studies  
 
Seventy-nine studies were excluded after reading their full-text articles. Reasons for exclusion 
included wrong outcome (mammographic density change was modelled as the outcome), wrong 
study design (study was not designed to address the review question) and reviews (discussion 
regarding density change as a potential biomarker for endocrine therapy, but without any novel 
data). Abstracts from conference presentations were excluded because these had not undergone 
peer-review to be published as full-texts. For further details, see PRISMA flow diagram (Figure 
4.3) and ‘Characteristics of excluded studies’ table (Table 4.2) which highlights some 
potentially relevant records that were excluded and the reasons for exclusions.  
 
Table 4.2: Characteristics of excluded studies 
AllianceforClinicalTrialsinOncology 2006 (376) 
Reason for exclusion No results posted 
AllianceforClinicalTrialsinOncology 2007 (377) 
Reason for exclusion Wrong outcomes 
Andersson 2017 (331) 
Reason for exclusion Density change not measured (not defined as a measure between a 
140 
 
baseline and a follow-up mammogram) 
Atkinson 1999 (205) 
Reason for exclusion Wrong outcomes 
Becker 2009 (378) 
Reason for exclusion Review 
Boyd 2001 (78) 
Reason for exclusion Wrong study design 
Boyd 2011 (379) 
Reason for exclusion Wrong study design 
CaseComprehensiveCancer 2007 (380) 
Reason for exclusion Still recruiting 
Chlebowski 2003 (381) 
Reason for exclusion Wrong study design 
Cosmacini 1993 (382) 
Reason for exclusion Abstract only - not peer-reviewed, not enough information 
Cuzick 2012 (383) 
Reason for exclusion Wrong study design 
Decensi 2004 (384) 
Reason for exclusion Abstract only - not peer-reviewed, not enough information 
Decensi 2009 (385) 
Reason for exclusion Density change not measured (not defined as a measure between a 
baseline and a follow-up mammogram because repeated measures 
ANOVA was used, additionally digital density was calibrated by 
adjusting for different variables at different time points so the 
density measure was not the same at baseline and at follow-up 
mammogram) 
 
Ekpo 2016 (296) 
Reason for exclusion Wrong outcomes 
Engmann 2017 (271) 
Reason for exclusion Wrong outcomes 
Fabian 2006 (386) 
Reason for exclusion Wrong study design 
Fabian 2007 (387) 
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Reason for exclusion Wrong study design 
Fabian 2016 (388) 
Reason for exclusion Review 
Ghosh 2010 (389) 
Reason for exclusion Wrong study design 
Kim 2014 (390) 
Reason for exclusion Association between MRI density method and breast cancer risk 
not validated 
Kmietowicz 2013 (391) 
Reason for exclusion Editorial about another paper / not primary research data 
Macis 2011 (392) 
Reason for exclusion No results posted 
Martin 2009 (339) 
Reason for exclusion Wrong study design 
Martin 2016 (393) 
Reason for exclusion Abstract only - not peer-reviewed, not enough information 
Mullooly 2016 (348) 
Reason for exclusion Review 
NCICClinicalTrialsGroup 2000 (394) 
Reason for exclusion Wrong study design 
NCICClinicalTrialsGroup 2001 (395) 
Reason for exclusion Wrong study design 
NorthwesternUniversity 2003 (396) 
Reason for exclusion Wrong outcomes 
Ozhand 2013 (397) 
Reason for exclusion Abstract only - not peer-reviewed, not enough information 
 
Redfern 2016a (398) 
Reason for exclusion Wrong study design 
Redfern 2016b (399) 
Reason for exclusion Abstract only - not peer-reviewed, not enough information 
SeoulNationalUniversityHospital 2013 (400) 
Reason for exclusion Still recruiting 
SeoulNationalUniversityHospital 2018 (401) 
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Reason for exclusion Data collection not complete 
Shawky 2017 (345) 
Reason for exclusion Review 
UniversityofCalifornia 2013 (402) 
Reason for exclusion Withdrawn 
UniversityofVirginia 2004 (403) 
Reason for exclusion Wrong study design 
Ursin 1996 (404) 
Reason for exclusion Wrong outcomes 
Vachon 2013a (123) 
Reason for exclusion Wrong study design 
Vachon 2013b (267) 
Reason for exclusion Wrong outcomes 
Whitman 2000 (405) 
Reason for exclusion Review 
 
4.4.2 Risk of bias in included studies  
 
Study participation 
The risk of bias for study participation was moderate for most studies because the source 
populations were not adequately described. The two sub-studies within clinical trials (19, 374) 
were the only studies to give an indication of key characteristics of the source population, either 
in the text or through another referenced study. Four studies (19, 372-374) conducted an 
analysis to test the difference in key characteristics between women in the source population 
and women included in the study sample. The two sub-studies within clinical trials included 
information on both of these criteria and were rated low risk. 
 
 
Study attrition 
The risk of bias for study attrition was mixed across studies. Four studies were rated moderate 
risk because of a lack of information on participant drop-out, loss to follow-up or reasons for 
censoring. One study (372) required women to still be alive at the time of interview for the 
study, therefore it lacked information on women who had died before recruitment. Women who 
had a later breast cancer diagnosis were also more likely to be in the study, leading to a potential 
survival bias. This study was therefore given a high risk of bias for study attrition. 
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Prognostic factor measurement 
The risk of bias for the measurement of mammographic density was moderate or low. Studies 
were deemed to be at a higher risk of bias if they did not provide information on the experience 
of the reader(s), the time between baseline and follow-up mammogram, blinding to treatment (if 
the sample of women could be on more than one drug) or case-control status, reliability of 
measurements, number of women who had density measured, or reasons for missing density 
data. Two studies (19, 265) were given a moderate rating for risk of bias for the prognostic 
factor measurement because the density reduction cut-point was determined by the data (19) or 
an ‘a priori’ definition that was not justified (31). 
 
Outcome measurement 
The risk of bias for the outcome measurement was the domain considered to be at the lowest 
risk of bias. The two studies (263, 264) rated moderate risk conducted a survival analysis but 
did not define a start of follow-up or reasons for censoring, and there was no indication of 
women lost to follow-up. It is essential to determine these factors when conducting a survival 
analysis. The other studies to not report reasons for censoring or loss to follow-up were deemed 
to be low risk because they were linked to population registries or clinical trials. 
 
Study confounding 
The risk of bias for study confounding was mixed across studies. Two studies did not give clear 
definitions for age (263, 264), adjustments were unclear in three studies (264, 373, 374) and one 
study was potentially affected by recall bias since women recalled their confounding risk factors 
over telephone (372). One study (263) did not adjust for the confounding factor, chemotherapy, 
even though this was shown to have an effect on density reduction. Chemotherapy can induce 
menopause in premenopausal women, causing an oestrogen deprivation and reduction in density 
as well as recurrence. Therefore, adjustments should be made for chemotherapy in adjuvant 
studies where necessary. 
 
 
 
Statistical analysis and reporting 
The risk of bias for statistical analysis and reporting was considered to be the highest risk 
domain. The statistical methods for survival analysis were not adequately defined in two studies 
(263, 264) and the subgroup analysis of interest in one study (373) was not described in detail. 
The study by Knight et al. was not designed to look at women on endocrine therapy specifically 
and hence the analysis was adjusted for tamoxifen use, making the results ineligible for the 
prognostic or predictive biomarker review (372). Additionally, the results for van Nes et al. 
were not reported, so this study was given a high risk of bias for reporting (374). 
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The risk of bias in each domain and by each study is outlined in Figure 4.4. A detailed 
description of the risk of bias judgements can be found in appendix B.VII. 
 
 
 
Figure 4.4: Risk of bias plot (red: high risk, yellow: moderate risk, green: low risk). 
 
 
4.4.3 Effects of interventions 
 
The different classes of drugs, outcomes, mammographic density measures and effect measures 
(for instance, the cut-points used) of the included studies were deemed too heterogeneous to be 
able to conduct a meaningful meta-analysis. Instead, the results of each study were reported in 
the ‘Summary of findings’ tables (Table 4.3 and Table 4.4). The study by Knight et al. (372) 
could not be included in the prognostic or predictive biomarker review due to the adjustment for 
endocrine therapy, and the study by van Nes et al. (374) was not included in the prognostic 
biomarker review because of a lack of reported results. 
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In the prognostic biomarker review (prevention), Cuzick et al. reported a 68% reduction in 
breast cancer risk with prophylactic tamoxifen for women who had a 12-18 month visually-
assessed percent density reduction ≥10% compared with no change (OR=0.32 (95% CI, 0.14 to 
0.72)) (19). For the prognostic biomarker review in the treatment setting, Kim et al. reported 
HRs of 0.66 (95% CI, 0.40 to 1.09) and 0.14 (95% CI, 0.02 to 1.11) for risk of recurrence with 
an 8-20 month Cumulus-assessed percent density reduction ≥5% compared with <5% whilst on 
tamoxifen or AIs, respectively (264). Similarly, in the prognostic biomarker review (treatment), 
Ko et al. reported a 65% reduction in risk of recurrence for women with a 10-34 month 
tamoxifen-induced reduction in BI-RADS density compared with no reduction (HR=0.35 (95% 
CI, 0.17 to 0.68)) (263). For mortality (treatment) in the prognostic biomarker review, Li et al. 
reported a 50% reduction in risk of breast cancer death with 6-36 month tamoxifen-induced 
relative reduction in dense area (machine learning area-based method) >20% compared with 
little change (≤9% increase to ≤10% reduction) (HR=0.50 (95% CI, 0.27 to 0.93)) ((265)). In 
another prognostic biomarker review study (treatment), Nyante et al. reported a 56% decreased 
risk of breast cancer death with a 3-26 month tamoxifen-induced reduction in Cumulus-assessed 
percent density of >8.7% compared with <0.5% (OR=0.44 (95% CI, 0.22 to 0.88)) (266). The 
final prognostic biomarker study (treatment) reported an OR of 0.52 (95% CI, 0.18 to 1.51) for 
risk of contralateral breast cancer with a 1-5 year reduction in percent density (machine learning 
area-based method) of ≥10% compared with little change (<10% reduction to <10% increase) 
whilst on endocrine therapy (373). In the predictive biomarker review (prevention), the OR of 
risk of breast cancer for an interaction between prophylactic tamoxifen and 12-18 month 
visually-assessed percent density reduction (≥10% or <10%) was not reported, but it was 
calculated as 0.53 (95% CI (0.21 to 1.32)) from raw data provided by the study authors (19). 
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Table 4.3: Endocrine therapy-induced mammographic density reduction vs. No endocrine therapy-
induced mammographic density reduction as a prognostic biomarker 
 
Endocrine therapy-induced mammographic density reduction vs. No endocrine therapy-
induced mammographic density reduction as a prognostic biomarker 
Patient or population: Women on endocrine therapy (SERMs or AIs) 
Setting: Prevention or Treatment 
Intervention: Endocrine therapy-induced mammographic density reduction 
Comparison: No endocrine therapy-induced mammographic density reduction 
Outcomes Impact № of 
participants 
(studies) 
Certainty 
of the 
evidence 
(GRADE) 
Incidence of 
invasive breast 
cancer and DCIS: 
Prevention, 
Tamoxifen 
One study reported an OR of 0.32 (95% CI, 
0.14 to 0.72) for 12-18 month visually-assessed 
percent density reduction ≥10% compared with 
no density change. 
51 cases 456 
controls 
(1 
observational 
study) 
⊕⊕⊝⊝ 
LOW 
Recurrence: 
Treatment, 
Tamoxifen 
One study reported an HR of 0.66 (95% CI, 
0.40 to 1.09) for 8-20 month Cumulus-assessed 
percent density reduction ≥5% compared with 
<5%. Another study reported an HR of 0.35 
(95% CI, 0.17 to 0.68) for 10-34 month 
reduction in BI-RADS density compared with 
no reduction (or increase). 
1956 
(2 
observational 
studies) 
⊕⊝⊝⊝ 
VERY 
LOW 1 2 
Recurrence: 
Treatment, AIs 
One study reported an HR of 0.14 (95% CI, 
0.02 to 1.11) for 8-20 month Cumulus-assessed 
percent density reduction ≥5% compared with 
<5%. 
175 
(1 
observational 
study) 
⊕⊝⊝⊝ 
VERY 
LOW 3 4 
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Table 4.3 continued 
Breast cancer 
mortality: Treatment, 
Tamoxifen 
One study reported an OR=0.44 (95% CI, 
0.22 to 0.88) for 3-26 month Cumulus-
assessed percent density reduction >8.7% 
compared with <0.5%. Another study 
reported an HR of 0.50 (95% CI, 0.27 to 
0.93) for 6-36 month relative reduction in 
dense area (machine learning area-based 
method) >20% compared with stable 
density (≤9% increase to ≤10% 
reduction). 
1st study: 97 cases 
252 controls; 2nd 
study: 26 
events/217 exposed, 
49 events/257 
unexposed 
(2 observational 
studies) 
⊕⊕⊝⊝ 
LOW 
Incidence of a 
secondary primary 
breast cancer (e.g. in 
the contralateral 
breast): Treatment, 
unknown endocrine 
therapy 
One study reported an OR of 0.52 (95% 
CI, 0.18 to 1.51) for 1-5 year reduction in 
percent density (machine learning area-
based method) ≥10% compared with 
stable density (<10% increase to <10% 
reduction). 
87 cases 87 controls 
(1 observational 
study) 
⊕⊝⊝⊝ 
VERY 
LOW 5 6 
CI: Confidence interval; HR: Hazard ratio; OR: Odds ratio 
GRADE Working Group grades of evidence  
High certainty: We are very confident that the true effect lies close to that of the estimate of the 
effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is 
likely to be substantially different from the estimate of effect 
 
1 Little information about study participation and attrition, no information on start of follow -up or 
reasons for censoring, unclear if adjustments made in one study and no adjustment for important 
confounding factors such as chemotherapy in another study, there may have been switching of endocrine 
therapy between baseline and follow-up mammogram in one study, density assessment may have been 
made on the ipsilateral breast in one study without an assessment of reliability of the density measure.  
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2 Confidence interval includes the null effect for one study, no more than 147 events (one study does not 
give the number of events in the tamoxifen subgroup, but there are 80 events in the study overall + 67 
events in the other study). 
3 Little information about study participation and attrition, no information on start of follow -up or 
reasons for censoring, unclear if adjustments made, there may have been switching of endocrine therapy 
between baseline and follow-up mammogram. 
4 Confidence interval includes the null effect, no more than 80 events (study does not give the number of 
events in the AIs subgroup, but there are 80 events in the study overall). 
5 The analysis in the subgroup of women on endocrine therapy was only a secondary objective of the 
study, therefore the data for the women included in the subgroup analysis are not reported and the 
individual endocrine therapies cannot be separated. 
6 Confidence interval includes the null effect, no more than 87 events (study does not give the number of 
events in the endocrine therapy subgroup analysis, but there are 87 cases on endocrine therapy in the 
study overall), large range of 1-5 years between diagnosis and follow-up mammogram might capture an 
effect on density change other than endocrine therapy, for example, weight change (adjustment for 
change in adiposity between mammograms was not considered). 
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Table 4.4: Effect of mammographic density reduction in endocrine therapy group vs. Effect of 
mammographic density reduction in control group as a predictive biomarker 
 
Effect of mammographic density reduction in endocrine therapy group vs. Effect of 
mammographic density reduction in control group as a predictive biomarker 
Patient or population: Women on endocrine therapy (SERMs or AIs) or a control group 
Setting: Prevention or Treatment 
Intervention: Effect of mammographic density reduction in endocrine therapy group 
Comparison: Effect of mammographic density reduction in control group 
Outcomes Impact № of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Incidence of invasive 
breast cancer and 
DCIS: Prevention, 
Tamoxifen 
One study reported an OR of 0.53 (95% CI, 
0.21 to 1.32) for an interaction between 
prophylactic tamoxifen and 12-18 month 
visually-assessed percent density reduction 
(≥10% or <10%). 
123 cases 942 
controls 
(1 
observational 
study) 
⊕⊕⊝⊝ 
LOW 1 2 
CI: Confidence interval; OR: Odds ratio 
GRADE Working Group grades of evidence  
High certainty: We are very confident that the true effect lies close to that of the estimate of the 
effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is 
likely to be substantially different from the estimate of effect 
 
1 This is the only study found to investigate whether density change can be used as a predictive biomarker 
for women on endocrine therapy. 
2 Confidence interval includes the null effect, 123 cases provides small power t o detect an interaction 
effect. 
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4.5 Discussion 
 
4.5.1 Summary of main results 
 
This review demonstrated a potential use of mammographic density as a prognostic or 
predictive biomarker for endocrine therapy, but the evidence was limited by some quality issues 
in the included studies.  
 
All studies included in the quantitative synthesis were observational and the number of studies 
testing each outcome was considerably small, with no more than two studies contributing to an 
outcome. Most of the studies focused on the mammographic density biomarker whilst on 
tamoxifen, and only one study provided results for the density change biomarker for treatment 
with AIs (264). One study included women on ‘endocrine therapy’ but did not stipulate a 
particular drug (373). Only one study contributed to the predictive biomarker review (19), 
whereas six studies were included in the prognostic biomarker review (19, 263-266, 373). 
Similarly, only one study was in the preventive setting (19), whilst five studies were in the 
adjuvant setting (263-266, 373).  
 
There was a great deal of variation between studies. Density measurements included visual 
percentage score, BI-RADS categorical assessment, Cumulus semi-automated percentage score 
and machine-learned fully-automated percentage and absolute scores. Multiple cut-points for 
density reduction were tested, including 5%, 10% or tertile cut-points (absolute percentage 
density reduction), a 20% cut-point (relative dense area reduction), and BI-RADS categories. 
The characteristics of participants also varied. Studies were conducted in European, North 
American and Asian populations of premenopausal and postmenopausal women, with different 
disease status at first diagnosis in treatment studies. 
 
As seen in the ‘Summary of findings’ tables, the GRADE certainty of evidence for outcomes 
was either low or very low, which was mainly driven by all studies starting at a low level of 
certainty due to their observational design. Additionally, some studies were downgraded 
because of high risk of bias or indirectness whereby studies were not designed to address the 
objectives of this review. 
 
4.5.2 Overall completeness and applicability of evidence 
 
The evidence in this review is reasonably limited and more studies are required to improve the 
certainty of evidence for mammographic density to be used as a biomarker for endocrine 
therapy. The findings of this review suggest that a mammographic density biomarker is 
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currently applicable to further research, but is not yet reliable enough to be applied to clinical 
practice. More research is needed on the use of mammographic density as a biomarker in 
response to other SERMs beyond tamoxifen as well as AIs. 
 
4.5.3 Quality of the evidence 
 
There was a large amount of heterogeneity across studies and the amount of evidence was low, 
with only six studies included in the quantitative synthesis (19, 263-266, 373). There was very 
low certainty of evidence for the recurrence and contralateral breast cancer outcomes which was 
driven by high risk of bias and indirectness, respectively. Additionally, the recurrence outcome 
on AI treatment and contralateral breast cancer incidence outcome (with a mixture of endocrine 
therapies) had evidence from only one study each (264, 373). There was a low certainty of 
evidence for the ‘Incidence of invasive breast cancer and DCIS’ outcome and the ‘Breast cancer 
mortality’ outcome. The influence of bias was relatively low for these outcomes, but this was 
counterbalanced by the small number of contributing studies. Breast cancer incidence was 
assessed in only one study (prognostic and predictive) (19) and breast cancer specific mortality 
was assessed in two studies (265, 266); perhaps making the latter the outcome with the highest 
certainty of evidence. For the predictive biomarker review, the addition of the ROBINS-I tool in 
assessment of risk of bias up-weighted the quality of evidence of the observational study from 
low to high because the placebo comparison group gave more support for the effect being 
treatment-induced. Nonetheless, this was downgraded again because there was only one 
contributing study that reported an imprecise effect with a confidence interval covering the null 
effect (19). 
 
4.5.4 Potential biases in the review process  
 
A potential bias of the review process is the exclusion of grey literature which included five 
conference abstracts (382, 384, 393, 397, 399). These were regarded as ineligible because they 
had not been peer-reviewed and the abstracts were limited in the amount of information they 
could report, such as full statistical methodology, justification for chosen techniques, and 
number of women with density reductions by outcome. These studies may be eligible for 
inclusion in a subsequent updated version of this review once they are reported as peer-reviewed 
full texts. Similarly, there were two studies without reported results (376, 392), two studies still 
recruiting (380, 400) and one study still collecting data (401), which may also be eligible for 
inclusion in an updated review once results are published as peer-reviewed full texts. One study 
used a non-validated MRI density method (390), which may be eligible in an updated review if 
more than one study (outside of the review studies) can show an association between the density 
method and breast cancer risk. 
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4.5.5 Agreements and disagreements with other studies or reviews 
 
A systematic review by Shawky et al. entitled “Mammographic density: a potential monitoring 
biomarker for adjuvant and preventative breast cancer endocrine therapies” (345) reported 
findings similar to this review, although an assessment of quality was not included in their 
paper. Shawky et al.’s review included a study that was excluded from this review because it 
was a conference abstract (399). The study by Knight et al. that was included in this review was 
published after Shawky et al.’s paper and was hence not included in their list of studies. A 
recent systematic review by Kanbayti et al. (346) reported similar findings to this review, 
although their review assessed the relationship between mammographic density reduction and 
patient outcomes in women receiving any type of breast cancer treatment, therefore the focus 
was not specific to endocrine therapy. Furthermore, the review included two studies that were 
excluded at the full text screening stage of this review (331, 390). This is due to differences in 
the inclusion criteria: Kanbayti’s study did not specify that the density measurement was to 
have been validated as a breast cancer risk factor in more than one study (outside of the review 
studies), and the density biomarker did not have to be derived from a baseline and a follow-up 
mammogram as was stipulated in this review. Moreover, Kanbayti et al. did not include the 
study by Cuzick et al. (19) because their population of interest was breast cancer patients treated 
in the adjuvant setting only.  
 
4.6 Conclusions 
  
4.6.1 Implications for practice 
 
If mammographic density is determined to be a prognostic or predictive biomarker for 
endocrine therapy, it may be useful as a tool for measuring a woman’s response to treatment. 
Currently, women have to rely on a ‘wait-and-see’ approach to assess if a course of endocrine 
therapy is working for them or not, but a density biomarker would provide an early indication of 
response. Knowing this information would allow women to make more informed decisions 
about whether to stay on an initial course of endocrine therapy or to change to another form of 
treatment. This would be particularly useful for those experiencing side effects of treatment, 
who may wish to balance the benefits and harms of continuing on the drug, which provides a 
more personalised approach for adjuvant or chemo-preventive care. 
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4.6.2 Implications for research 
 
This review highlighted the need for more studies on density as a biomarker for endocrine 
therapy, to provide sufficient evidence before implementation of the biomarker into clinical 
practice. Some important points for consideration in future studies also arose as a result of the 
review. These are discussed in detail below: 
 
 As described in Shawky et al. (345), it is important to establish the best density change 
predictor (qualitative vs. quantitative, area vs. volume, percent density vs. absolute density 
etc.), the best density change measurement method (manual vs. semi-automated vs. fully-
automated etc.), the best density change cut-point, and whether absolute or relative density 
change is the better predictor of breast cancer risk and mortality.  
 Compliance may have a confounding effect on the relationship between endocrine therapy-
induced density change and breast cancer outcome. A lower compliance means less 
treatment is administered, hence a lower potential for density to reduce as well as a greater 
increase in risk and mortality. However, a lower compliance may be due to side effects of 
the treatment, which have been linked to a lower risk of recurrence (406, 407). Therefore, 
low compliance (as a result of side effects on endocrine therapy) might be a marker of 
treatment efficacy, and efforts should be made to test and control for the confounding effect 
of compliance in future studies. 
 Another factor to consider is the negative confounding effect on results caused by masking. 
Women who experience a decrease in density whilst on treatment have a lower masking 
effect compared with women who do not have a reduction in density (provided all women 
have a similar starting density), so it is more likely that a cancer will be found on the 
follow-up mammograms of women who experience a treatment-induced density reduction. 
This would therefore cause an attenuation of the true effect on risk, recurrence and 
contralateral disease, suggesting that the association of treatment-induced density reduction 
on these breast cancer outcomes may in fact be stronger than what is typically found. It is 
therefore essential to allow for a long enough follow-up to avoid masking bias and to ensure 
that cancers occurring after measuring density change are adequately recorded. Nonetheless, 
follow-up should not be so long as to capture a possible increase in density after treatment 
cessation (350, 351) which could further influence the association between treatment-
induced density change and breast cancer outcome. 
 Efforts should be made to ensure there has been no previous treatment with SERMs or AIs 
before women enter the study (for example, for DCIS or prevention). This is important 
because residual effects of these previous treatments might influence density change and 
outcome during the study. For instance, the prolonged benefit of tamoxifen (200) may 
confound results if the number of women with residual effects is imbalanced between the 
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new treatment groups (predictive biomarker). Additionally, women previously treated with 
an endocrine drug may have already experienced a density decrease which cannot decrease 
further. However, they may simultaneously experience the benefit of treatment, thereby 
attenuating the relationship between density reduction and breast cancer outcome in the 
study. 
 For studies of density change as a predictive biomarker, a suitable control group must be 
defined. Control groups defined as ‘no tamoxifen’ (as in Li et al. (265)) may have been 
treated with another SERM or AI, therefore changing the comparison group definition. 
Furthermore, women may have not received endocrine therapy because they had ER- breast 
cancers, which would be problematic if comparing groups of women with different starting 
prognoses. 
 Finally, studies assessing density change and breast cancer outcome need to have clear 
definitions of start of follow-up to avoid a potential immortal time bias. This occurs when 
patients are defined as having a longer follow-up time than they actual received because 
they were not truly at-risk for all of the follow-up time. For instance, women have to be 
alive in order to undergo follow-up mammography, so a breast cancer death event cannot 
occur before a follow-up mammogram by definition of the study design. Therefore, women 
are only at-risk of death from follow-up mammogram. Only one study (265) accounted for 
this by starting follow-up at the follow-up mammogram. Incorrect follow-up times can be 
problematic if the ‘immortal time’ differs between women exposed to and not exposed to 
the predictor. Additionally, studies should ideally only include women who are still at-risk 
between mammograms so that the prognostic biomarker occurs before the event. Therefore 
(by definition) follow-up has to start at follow-up mammogram. If a study stipulates that 
women have to be on treatment for a certain amount of time (for example, 1 year), then 
women are only at-risk from the latter of 1 year from start of treatment or follow-up 
mammogram, and follow-up should start from that point in time. These timing issues are 
mainly relevant for cohort studies assessing time-to-event, but they can also be applicable to 
case-control studies that match on follow-up time. For example, if follow-up is started when 
treatment begins and the time between start of treatment and follow-up mammogram differs 
between cases and controls, then they may not be matched correctly on follow-up time. 
 
The points outlined above indicate the implications for research derived from this review, and 
they are important considerations when designing future studies of mammographic density, 
endocrine therapy and breast cancer outcome. 
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Chapter 5: Anastrozole and mammographic density reduction in women at 
increased risk of breast cancer 
 
5.1 Introduction 
 
As mentioned in Chapter 4, SERMs and AIs are effective endocrine therapies for preventing 
and treating ER+ breast cancers. A particular selective oestrogen receptor modulator, tamoxifen, 
is a well-established drug used for preventing recurrence and reducing mortality in women with 
early stage ER+ breast cancer (408). As early as 1985, Cuzick and Baum also showed the 
benefit of tamoxifen in preventing new contralateral breast cancers (409), and in 2007, the IBIS-
I trial showed that prophylactic tamoxifen reduced the risk of ER+ breast cancer in women at an 
increased risk of breast cancer by 30-40% (410). Further still, the benefit of chemoprevention 
with tamoxifen can be seen at least 10 years after an initial course of treatment (200). 
 
However, AIs, including anastrozole, have been shown to be more effective in reducing the 
recurrence of early-stage ER+ disease than tamoxifen (349); and in 2014, analysis from IBIS-II 
showed that anastrozole reduced the risk of ER+ breast cancer in high-risk postmenopausal 
women by 60% (208). AIs have a low toxicity profile and tend to be well tolerated with fewer 
side effects than tamoxifen (411), making them a promising endocrine therapy for routine 
chemoprevention in postmenopausal women at increased risk of breast cancer. 
 
It has been shown in numerous studies that tamoxifen reduces density in the preventive and 
adjuvant setting (203-206, 336), and most importantly, a reduction in density may be a marker 
of concurrent reduction in risk. The IBIS-I trial showed that high-risk women who experienced 
≥10% density reduction after 12-18 months of prophylactic tamoxifen had approximately 63% 
lower risk of developing breast cancer compared with women on placebo, whilst women who 
experienced <10% density reduction on tamoxifen had a similar risk to women on placebo (19) 
(Figure 5.1). However, studies looking into the relationship between preventive AIs and density 
have so far shown modest or insignificant results (268-270), which is perhaps due to their small 
sample size; and larger studies looking into this association are in the adjuvant setting only 
(267, 271, 337). It is still unknown whether, like tamoxifen, preventive anastrozole treatment 
reduces density, and whether this is more than the natural decline occurring with age.  
 
This study aims to compare mammographic density changes between the placebo and 
anastrozole arms of the IBIS-II Prevention trial to determine whether women on anastrozole 
experience different density changes (between baseline and first follow-up mammogram, and 
baseline and final follow-up mammogram) to women on placebo. Then, in Chapter 6, the effect 
of this treatment-induced density change will be assessed on breast cancer risk. 
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a)                                                            b) 
 
 
Figure 5.1: Visually assessed density change between baseline and follow-up mammogram (12-18 
months after randomisation) in two women from the IBIS-I trial treated with tamoxifen. 
a) No density change for one woman (left: baseline, right: 12-18 month follow-up mammogram), b) 15% 
reduction in density for another woman (left: baseline, right: 12-18 month follow-up mammogram). A 
density change similar to b) was associated with a concurrent approximately 63% reduction in breast 
cancer risk relative to women on placebo, whilst no density change, such as a), had a breast cancer risk 
similar to women on placebo. 
 
A detailed description of the primary hypothesis and secondary hypotheses is outlined below: 
 
Primary hypothesis 
 H0: There is no difference in age-adjusted change in density from baseline to first follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm 
(continuous effect is primary). 
 H1: Age-adjusted change in density from baseline to first follow-up mammogram is 
different between patients in the anastrozole arm and patients in the placebo arm 
(continuous effect is primary). 
 
Secondary hypothesis I 
 H0: There is no difference in change in density from baseline to first follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm, after 
adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, image 
type, and time between baseline and first follow-up mammogram. 
 H1: Change in density from baseline to first follow-up mammogram is different between 
patients in the anastrozole arm and patients in the placebo arm, after adjustment for age at 
randomisation, body mass index at randomisation, hormone replacement therapy use up to 
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12 months before randomisation, age at menopause, image type, and time between baseline 
and first follow-up mammogram. 
 
Secondary hypothesis II 
 H0: There is no difference in age-adjusted change in density from baseline to final follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm. 
 H1: Age-adjusted change in density from baseline to final follow-up mammogram is 
different between patients in the anastrozole arm and patients in the placebo arm. 
 
Secondary hypothesis III 
 H0: There is no difference in change in density from baseline to final follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm, after 
adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, image 
type, and time between baseline and final follow-up mammogram. 
 H1: Change in density from baseline to final follow-up mammogram is different between 
patients in the anastrozole arm and patients in the placebo arm, after adjustment for age at 
randomisation, body mass index at randomisation, hormone replacement therapy use up to 
12 months before randomisation, age at menopause, image type, and time between baseline 
and final follow-up mammogram. 
 
Secondary hypothesis IV 
 H0: There is no difference in age-adjusted anastrozole-induced change in density from 
baseline to first follow-up mammogram between subgroups of covariates (age at 
randomisation, body mass index at randomisation, age at menarche, age at menopause, 
Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral contraception use, 
hormone replacement therapy use up to 12 months before randomisation, smoking status, 
history of atypical hyperplasia or LCIS, image type, and time between baseline and first 
follow-up mammogram). 
 H1: Age-adjusted anastrozole-induced change in density from baseline to first follow-up 
mammogram is different between subgroups of covariates (age at randomisation, body mass 
index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 10-year risk, 
baseline density, age at first birth, oral contraception use, hormone replacement therapy use 
up to 12 months before randomisation, smoking status, history of atypical hyperplasia or 
LCIS, image type, and time between baseline and first follow-up mammogram). 
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Secondary hypothesis V 
 H0: There is no difference in age-adjusted anastrozole-induced change in density from 
baseline to final follow-up mammogram between subgroups of covariates (age at 
randomisation, body mass index at randomisation, age at menarche, age at menopause, 
Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral contraception use, 
hormone replacement therapy use up to 12 months before randomisation, smoking status, 
history of atypical hyperplasia or LCIS, image type, and time between baseline and final 
follow-up mammogram). 
 H1: Age-adjusted anastrozole-induced change in density from baseline to final follow-up 
mammogram is different between subgroups of covariates (age at randomisation, body mass 
index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 10-year risk, 
baseline density, age at first birth, oral contraception use, hormone replacement therapy use 
up to 12 months before randomisation, smoking status, history of atypical hyperplasia or 
LCIS, image type, and time between baseline and final follow-up mammogram). 
 
5.2 Methods 
 
5.2.1 Study design 
 
This study uses mammograms collected as part of a case-control study from the IBIS-II trial; a 
double-blind multicentre randomised placebo-controlled trial of 3864 postmenopausal women 
aged 40-70yr at an increased risk of breast cancer, aimed at determining whether 
chemoprevention of breast cancer with anastrozole is beneficial in this population of women. In 
brief, increased risk was determined by family history, previous benign disease with 
proliferation, nulliparity, LCIS, atypical hyperplasia (ductal or lobular), DCIS, and 
mammographic density ≥50% without use of HRT in the previous 3 months. Women were 
breast cancer-free at randomisation, and had not had a cancer in the previous 5 years (except 
non-melanoma skin cancer or in situ cancer of the cervix). Women were ineligible if they had 
taken SERMs for more than 6 months previously (unless they were taken as part of the IBIS-I 
trial and treatment had been completed at least 5 years prior to study entry), and women were 
not allowed to take a concurrent SERM or HRT whilst enrolled on the trial. Women were also 
excluded due to: premenopausal status, a prophylactic mastectomy, evidence of severe 
osteoporosis, concomitant disease, life expectancy <10 years, psychiatric or physical co-
morbidities that could affect their ability to take part in the trial, and treatment with non-
approved drugs up to 3 months before randomisation. Postmenopausal status was defined as 
meeting at least one of the following criteria: bilateral oophorectomy, aged over 60yr, aged 
≤60yr with a uterus and amenorrhoea for at least 12 months, or aged ≤60yr without a uterus and 
FSH >30 IU/L. Eligible women were recruited between 2nd Feb 2003 and 31st Jan 2012 from 18 
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countries and were randomly assigned to a treatment arm on a 1:1 basis by central computer 
allocation. Women either received 1mg of orally-consumed anastrozole or a placebo alternative, 
to be taken every day for 5 years (n=1914 anastrozole and 1937 placebo). The primary endpoint 
was histologically confirmed breast cancer (invasive or non-invasive including ductal carcinoma 
in situ). A baseline questionnaire was completed by participants at recruitment to enable 
collection of information on confounding factors for risk of breast cancer. A mammogram was 
taken at baseline (after enrolment but before randomisation) and screening mammograms were 
taken at intervals as decided by the local co-ordinating centres, but at least every 2 years. These 
mammograms were subsequently sent to the trial co-ordinating centre. 
 
For this nested case-control study, a cohort at the start of follow-up was defined, from which 
cases and controls were chosen. This study was designed such that the defined cohort was all 
randomised women who had participated in the IBIS-II main trial and had at least one available 
baseline MLO mammogram and at least one available first follow-up MLO mammogram 
collected as of May 2017 (n=1,274: 43 cases and 1,231 controls). Baseline mammograms were 
defined to be ≥0 months to <12.5 months prior to date of randomisation, first follow-up 
mammograms were ≥8.5 months to <38.5 months after date of randomisation, and final follow-
up mammograms (if available) were ≥47.5 months to <60.5 months after date of randomisation. 
These time frames were chosen to mirror those used in IBIS-I (19) and in accordance with 
standard operating procedures for the local IBIS-II co-ordinating centres. Only MLO views 
were included to emulate the IBIS-I study (19) and because MLO views were predominantly 
collected during the trial. Follow-up began at each woman’s first follow-up mammogram (not 
including the actual time of first follow-up mammogram) and ended at the earliest of: date of 
diagnosis (cases) or May 2017 if disease-free at this time (controls). This was done so that 
breast cancer events happened only after the density change predictor had occurred. Starting 
follow-up at first follow-up instead of treatment initiation prevented an immortal time bias 
(4.6.2) whereby the section of follow-up that was not truly ‘at-risk’ was excluded. Later in the 
chapter, cases are excluded if their event occurred before or at first follow-up mammogram, so 
(by definition) all women were breast cancer-free at first follow-up mammogram and the clock 
should start from this point. This bias is most relevant when conducting time-to-event analyses 
and is therefore not applicable in this study, but for completeness and to plan for potential 
further analyses, this was considered. 
 
Cases were defined as women who developed breast cancer (invasive or non-invasive including 
DCIS) anytime throughout follow-up until (and including) May 2017 and controls were a 
random sample of the defined cohort who were breast cancer-free as of May 2017. 
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5.2.2 Power calculation 
 
Density change for postmenopausal women in the IBIS-I nested study (19) was weighted based 
on age at randomisation of the IBIS-II cohort, to estimate the expected density change in a 
sample of women with the same age structure as IBIS-II. This was done separately for controls 
on placebo, controls on tamoxifen, cases on placebo and cases on tamoxifen (appendix C.I-
C.IV). Different effect sizes (1/2 and 3/4) for tamoxifen were also tested by taking a weighting 
of the placebo and tamoxifen density change distributions corresponding to the proposed effect 
size (appendix C.V). This was done to allow anastrozole to have a weaker effect on density 
change than tamoxifen. For example, 1.11% of placebo controls and 0.23% of anastrozole 
controls were predicted to have a 30% reduction. If anastrozole was 3/4 as effective as 
tamoxifen at reducing density compared with placebo: 1.11% - (3/4)*(1.11%-0.23%) = 0.45% 
of anastrozole controls were predicted to have a 30% reduction. So, the proportions in each 
treatment arm became more similar as anastrozole became less effective. Then, an overall 
density change distribution for each treatment arm was formulated by weighting the density 
change distributions according to the distribution of cases and controls by treatment arm in 
IBIS-II (appendix C.VI-C.VII). The empirical cumulative distribution of density change in each 
treatment arm was then modelled, and two uniformly distributed random numbers were 
generated between (0,1) to find the inverse of the empirical cumulative distribution functions 
and simulate a density change value for placebo and anastrozole expected under the alternative 
hypothesis. This was repeated a number of times corresponding to the sample size in each 
treatment arm: sample sizes between 400 and 600 women per treatment arm were tested. Next, a 
linear regression model tested density change on treatment arm using the simulated data, and the 
simulation was recorded as a ‘pass’ if the (t-test) p-value for the treatment effect was <0.05 
(based on a test of superiority). Simulations were repeated 10,000 times and the percentage of 
passes was counted to give the power. This was also done for dichotomised density change 
(≥10% reduction and <10% reduction), using a logistic regression model with treatment arm as 
the predictor. Results for different sample sizes can be found in appendix C.VIII. 
 
Power was calculated to be 76%-94% for an anastrozole effect size 3/4 to 1 times that of 
tamoxifen, with 600 women per arm, to show a difference in density change (≥10% reduction 
and <10% reduction) from baseline to first follow-up mammogram between the two treatment 
arms at the 5% type-I error level (appendix C.IX). A proportion of women were also added to 
the required sample size to account for women with baseline density <10% that would later be 
excluded (based on the number of postmenopausal women with baseline density <10% in IBIS-
I) (appendix C.X). In total, 1473 controls and 44 cases were required. A sample size larger than 
this was impracticable given the resources and number of mammograms received. 
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5.2.3 Data collection 
 
An active effort was made to collect baseline and first follow-up mammograms for all IBIS-II 
participants. This was an attempt to include as many cases as possible in order to maximise 
statistical power. All national and international centres were emailed to request mammograms 
that had not yet been received by the co-ordinating centre. Response was greatest from the UK 
centres, ANZ centres (Australia and New Zealand), Belgium, Denmark, Italy and Finland, 
although the availability of case mammograms was somewhat disappointing. Many case 
mammograms were missing (lost, archived or destroyed in accordance with the local archiving 
policy) or had not been recorded at a participating site because the patient had moved address. 
 
The multicentre aspect of the trial also caused unavoidable variation in the types of 
mammograms sent to the trial co-ordinating centre. Mammograms were taken using different 
machines and different image sizes. Mammograms could come in hardcopy form (viewed on a 
light box) or softcopy form (viewed on a computer screen). Film mammograms received by the 
trial co-ordinating centre mainly came in the form of original hardcopy or digitised softcopy 
images, but a handful (either hardcopy or softcopy) had gone through a number of iterations of 
conversion. Digital mammograms were mainly received in the form of original DICOM images 
(softcopy), however, as with film mammograms, some had been through various conversions 
before being sent to the trial co-ordinating centre. This created variability in image quality (for 
instance, different scanners at different sites). There was also a change of scanner at the trial co-
ordinating centre throughout the trial, meaning that film mammograms received early on in the 
trial were scanned using a Vidar digitiser and saved as TIFF files, whilst films received later in 
the trial were digitised using an Array 2905 digitiser and saved as DICOM files. 
 
5.2.4 Updating the Standard Operating Procedures 
 
A number of issues were discovered in the standard operating procedure (SOP) outlining 
instructions for the IBIS-II members of staff to process, store and batch mammograms. 
Consequently, the SOP was updated by the author of this thesis (Emma Atakpa) and Dr 
Brentnall to rectify these issues. The main issues and implemented solutions are described 
below: 
 
 Mammograms had a ‘levels’ conversion applied to them to try to standardise images. The 
‘levels’ conversion was initially intended for film mammograms, however, its application to 
FFDM images was potentially detrimental to image quality since FFDM undergo their own 
optimisation when they are processed from raw to ‘for-presentation’. Additionally, on 
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inspection of the mammograms, it was apparent that this conversion had not been applied to 
all of the mammograms. 
 Mammograms no longer underwent the ‘levels’ conversion. It was left to the radiologist (Dr 
Linda Metaxa) to edit contrast and brightness settings on a DICOM viewer to an optimum 
level for visual assessment. 
 
 All mammograms were opened in Photoshop and had a black box placed over any patient 
identifiable information (PII) including name, date of birth and address. The image header 
was also anonymised if any PII was contained within it. All images were then saved as 
DICOM images. Whilst this was reasonable for film mammograms, this lost header 
information in FFDM images, which contained potentially useful imaging factors. 
 FFDM were no longer opened in Photoshop, but were instead copied directly from the file 
directory and headers were anonymised automatically using anonymisation software 
provided by Volpara (no PII was contained on the FFDM images themselves). Raw images 
were also saved (although they were not included in this study, but were saved for potential 
future studies). This ensured that the original high quality DICOM image was intact and it 
also increased efficiency by reducing manual processing workload. 
 
 Some images were of a very low resolution because they had been saved as JPEG images 
instead of TIFF or DICOM images. This appeared to be the case after digital mammograms 
had been opened in various DICOM viewers provided by the local sites that did not provide 
an option to save the image as a DICOM file. JPEG files compress images and remove 
some of the image information to make them more portable (412), and hence they can 
change the quality of the original mammogram.  
 FFDM images were no longer opened in DICOM viewers, but were instead copied directly 
from the file directory, and hence they were saved in their original DICOM format. Film 
mammograms were to continue being saved in DICOM format after anonymisation. 
 
It was decided that mammograms should undergo two stages of quality control (one by the 
thesis author (Emma Atakpa) at the batching stage and another by the radiologist, Dr Metaxa, at 
the density scoring stage) to reduce the remaining variation caused by differing mammogram 
types and quality. 
 
After implementation of the updated SOP, IBIS-II bio-specimen staff were trained by the thesis 
author (Emma Atakpa) to request, process and store mammograms using this new process. With 
the IBIS-II staff and the thesis author (Emma Atakpa) requesting outstanding images and 
working through a backlog of retrieved deliveries, the number of women with at least one 
available MLO baseline and at least one available MLO first follow-up mammogram reached 
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1,274 as of May 2017. These 1,274 women made up the defined cohort which consisted of 43 
cases and 1,231 controls. 
 
5.2.5 Exclusions 
 
Contralateral mammograms were kept for cases and mammograms from a randomly selected 
breast side (chosen using a random number generator) were kept for breast cancer-free controls 
to ensure that no cancers were present on the mammograms which could be misinterpreted as 
dense tissue. Women without information on diagnostic breast side or with bilateral breast 
cancer were excluded because it could not be guaranteed that either breast was breast cancer-
free at the time of follow-up mammogram. 
 
Duplicate mammograms were deleted so that each woman had only one mammogram per time 
point. Judgement of the best quality image was made by the thesis author (Emma Atakpa). 
 
To ensure that density change from baseline to first follow-up mammogram could be used as a 
predictor of breast cancer risk, breast cancer events had to occur after the first follow-up 
mammogram. Therefore, women with an event before or at first follow-up mammogram were 
excluded. If cases had an incomplete diagnosis date that could not be reasonably rounded to the 
1st day of the month, or if no diagnosis date had been entered, they were excluded. Final follow-
up mammograms at or after the event were also removed to ensure that all women were breast 
cancer-free at all mammograms. 
 
5.2.6 Exclusions – quality control (1) 
 
The method for anonymisation at the processing stage was subject to human error (placing a 
black box around PII on the image and deleting sensitive information in DICOM headers), and a 
number of FFDM images produced an error after Volpara-provided anonymisation software. 
Therefore, further checks were conducted to ensure sufficient anonymisation before batching to 
send to the radiologist. Dr Brentnall ran Python code on all images to remove sensitive PII that 
was still contained in the DICOM headers. The mammograms were checked over by the thesis 
author (Emma Atakpa) to find any PII still contained on the image itself. If sensitive PII 
remained, these were anonymised following the method outlined in the updated SOP (open 
mammogram in Photoshop, place a black box over the PII and save as a DICOM file). 
 
The mammograms were pseudo-anonymised using a random ID and suffix a, b or c for a 
woman’s baseline, first and final follow-up mammograms, respectively. These new identifiers 
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were then burned onto the bottom centre of the mammograms using Python code written by Dr 
Brentnall to aid Dr Metaxa’s analysis of density. 
 
Image quality was then assessed by the thesis author (Emma Atakpa) and any mammograms 
that were judged to be below an expected standard for density assessment were removed. 
Reasons for exclusion were: 
 
 Low resolution (JPEG images). 
 Mammograms were too dark or light and could not be adequately seen after adjustment of 
brightness or contrast. 
 Mammograms were too grainy. 
 Incorrect mammographic view or breast side. 
 Digital breast tomosynthesis slice – not the same imaging technique as the other 
mammograms i.e. 2D mammography. 
 Writing pre-burned onto the mammogram (by study centres and hospitals) that covered the 
breast and affected density assessment. 
 Wire localisation (this is an indicator of an abnormality possibly requiring a surgical 
biopsy) that affected the density assessment. 
 Breast implant – breast tissue removed for insertion. 
 Staples in the breast – indication of previous surgery which may have affected breast tissue 
composition. 
 
After exclusions, there were 973 women (35 cases and 938 controls) with one MLO baseline 
and one MLO first follow-up mammogram. 
 
5.2.7 Batching 
 
All images were sent to Dr Metaxa in one batch using the IBIS-II secure file transfer protocol. 
Dr Metaxa viewed the mammograms using the DICOM viewer ‘Sante DICOM Editor’ (413) on 
a workstation used to view mammograms for detection. After initial testing, it was noted that 
some DICOM files produced an error on opening. Therefore, all mammograms were converted 
to TIFF format to allow easier reading of the mammograms. A Python code was used by Dr 
Brentnall to convert DICOM images to TIFF format, and for those files that produced an error, 
the thesis author (Emma Atakpa) used the ‘Sante DICOM Editor’ program (413) to convert the 
images manually. The TIFF and DICOM files produced the same image (no processing when 
converting the files). 
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5.2.8 Mammographic density scoring 
 
Density was measured using visual assessment by an experienced radiologist (Dr Metaxa), who 
also made a judgement on whether she believed the original mammogram format to be film or 
digital. 
 
Before undertaking the readings, an assessment was made on inter-reader reliability of VAS 
between Dr Metaxa and Dr Ruth Warren (expert radiologist who read the mammograms for 
IBIS-I). A test set of 100 IBIS-I mammograms had been previously scored by Dr Warren and 
were compared with Dr Metaxa’s scores (Figure 5.2 and Figure 5.3). Correlation between the 
two readers was very good (Pearson correlation coefficient = 0.99, p<0.001, Spearman 
correlation coefficient = 0.98, p<0.001). 
 
 
Figure 5.2: Correlation between Dr Ruth Warren’s scores and Dr Linda Metaxa’s scores. 
 
Figure 5.3: Bland Altman plots of concordance (359) between Dr Ruth Warren’s scores and Dr Linda 
Metaxa’s scores. 
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Each mammogram was scored in 5% increments (on a 21 point scale from 0 to 100%), 
following the same method as in IBIS-I (19, 203). Mammograms were read on a per-woman 
basis and each mammogram was read sequentially, in date order, in comparison with the 
previous mammograms for that woman, i.e. baseline first, followed by first follow-up 
mammogram (compared with baseline mammogram) and finally, final follow-up mammogram 
(compared with both baseline and first follow-up mammograms). Dr Metaxa was blinded to 
treatment group, case status and other information including risk factors. 
 
5.2.9 Quality control (2) 
 
After assessment by Dr Metaxa, mammograms were removed for the following reasons: 
 
 Image quality was too low to reliably assess density. 
 Incorrect breast side or mammographic view (for example, medio-lateral (ML) view instead 
of MLO view). 
 Scarring indicating surgery (for example, a vacuum biopsy for a benign condition) which 
affected density assessment. 
 Breast partially cut off as it was too big for the compression plate which affected the ability 
to assess density. 
 Mammograms per-woman were of a different type (film or digital) – if baseline and first 
follow-up mammograms differed, the woman was excluded; if final follow-up mammogram 
differed from baseline and first follow-up mammogram, this mammogram was removed. 
These were excluded because digital mammograms tend to be darker than film 
mammograms and may therefore look less dense than if the breast had been imaged onto a 
film. 
 Digital mammograms per-woman were processed using different machines (e.g. Fuji, 
Philips, Siemens) – if baseline and first follow-up mammograms differed (and this was 
deemed to affect the true measure of density change), the woman was excluded; if final 
follow-up mammogram differed from baseline and first follow-up mammogram, this 
mammogram was removed. 
 Mammograms per-woman had substantially different radiographer techniques (e.g. different 
orientation of the breast positioning) which affected the spread of tissue and hence affected 
the true measure of density change – if baseline and first follow-up mammograms differed, 
the woman was excluded; if final follow-up mammogram differed from baseline and first 
follow-up mammogram, this mammogram was removed. 
 
The resulting number of women with a baseline and a first follow-up mammogram was 842 (31 
cases and 811 controls). 
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5.2.10 Baseline mammographic density at least 10% 
 
First and final density change were defined as the difference between baseline density and first 
or final follow-up mammogram density, respectively. This was measured continuously and 
dichotomised into <10% or ≥10% absolute reduction (and <5% or ≥5% absolute reduction). To 
be able to lose 10% density, women had to start with at least 10% density at baseline. Therefore, 
women with a baseline density <10% were excluded. 
 
The resulting number of women was 576 (19 cases and 557 controls) who had one available 
MLO baseline mammogram and one available MLO first follow-up mammogram. 
 
 
 
Figure 5.4: Flow diagram of study sample; QC=quality control. 
 
Case status was updated (October 2018), to reassign women who were initially recorded as 
controls to now be cases. New cases whose ipsilateral breast had been assessed were excluded; 
as were new cases with diagnosis before or at first follow-up mammogram (i.e. there was a 
delay in reporting their diagnosis to the trials unit after mammograms had been sent to the 
radiologist). Final follow-up mammograms at or after diagnosis were removed for these new 
cases. 
 
Defined cohort:
43 cases and 1,231 controls
No contralateral mammogram, breast cancer event before or at 1st follow-up 
mammogram, QC1:
8 cases and 293 controls excluded
QC2:
4 cases and 127 controls excluded
Baseline density <10%:
12 cases and 254 controls excluded
Rechecking case status:
1 control excluded (3 controls now cases)
Final sample:
22 cases and 553 controls
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The new definition for cases was therefore described as women who had been diagnosed with 
breast cancer as of October 2018, and breast cancer-free controls were defined as women who 
had not been diagnosed with breast cancer as of October 2018. 
 
The final number of women with one available MLO baseline mammogram and one available 
MLO first follow-up mammogram was 575 (22 cases and 553 controls). These women 
contributed mammograms from 46 participating centres across 6 countries: the UK, Italy, 
Finland, Denmark, Ireland and ANZ (Australia and New Zealand were grouped into one co-
ordinating centre). 
 
5.2.11 Statistical methods 
 
A statistical analysis plan was developed for the study (appendix C.XXIII). All statistical 
analysis was conducted using Stata (316), and tests were two-sided with a significance level of 
5%. The study used an intention-to-treat analysis (so the study design was based on the initial 
treatment intent, not the treatment that was eventually administered); therefore time on 
treatment was not included in adjustments. Only the trial statistician (Dr Ivana Sestak) was un-
blinded to treatment allocation, therefore a set of Stata code was sent to Dr Sestak to run on the 
un-blinded data. A proforma was developed and sent to the IBIS-II Trial Steering Committee, 
who approved the study (appendix C.XXIV). 
 
5.2.11.1 Baseline characteristics 
 
Baseline covariates (collected via questionnaires as part of the IBIS-II trial) were: age at 
randomisation (years), body mass index (BMI) at randomisation (kg/m2), age at menarche 
(years), age at menopause (years), Tyrer-Cuzick 10-year risk (%; version 7 excluding breast 
density), baseline density (%), age at first birth (nulliparous/>27/21-27/≤20), oral contraception 
use (never/previously/currently), hormone replacement therapy use up to 12 months before 
randomisation (no/yes; categorised in line with the IBIS-II main study (208); since HRT was 
not allowed during the trial, its use up to 12m before randomisation was considered to be a 
confounding factor which could have increased baseline density), smoking status 
(never/former/current), history of atypical hyperplasia or LCIS (no/yes) and image type 
(film/digital). Baseline covariates were summarised overall and by treatment arm using 
frequency tables. Frequency counts and percentages were provided for categorical data and 
means (standard deviation, SD) and medians (interquartile range, IQR) were provided for 
continuous data. Two-sample t-tests (for mean difference) and Wilcoxon rank sum tests (for 
median difference) were applied between treatment arms for continuous data and Pearson chi-
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squared tests (Fisher’s exact tests if cell size <5) tested independence between treatment arms in 
categorical data. 
 
5.2.11.2 Effect of covariates on baseline mammographic density 
 
An exploratory analysis assessed the effect of baseline covariates on baseline density using 
multivariable linear and logistic (baseline density dichotomised into <50% or ≥50%) regression 
models; adjusted for age at randomisation only and again for all covariates (except baseline 
density). Non-parametric empirical bootstrap 95% confidence intervals were used in linear 
regression models with continuous density outcome (2.2.4.3). 
 
5.2.11.3 Change in mammographic density 
 
There was a left skew on the density change data because density was assessed in comparison 
with previous mammograms and was more likely to decrease or stay the same than to increase 
(appendix C.XI-C.XXII), giving a small variance in per-woman readings (414). Therefore, 
density change did not follow a normal distribution, hence non-parametric methods (medians 
(interquartile range), Wilcoxon rank sum tests, and empirical bootstrap 95% confidence 
intervals in linear regression models (2.2.4.3)) were used as well as parametric methods (means 
(standard deviations) and two-sided t-tests). Furthermore, density change was assessed as a 
dichotomous variable (<10% absolute reduction or ≥10% absolute reduction, and <5% absolute 
reduction or ≥5% absolute reduction). The 5% cut-point was chosen because density was 
measured in 5% increments and the 10% cut-point was chosen because it was the minimum 
change that could be reproducibly detected in IBIS-I (19). 
 
5.2.11.4 Change in mammographic density – Boyd categories 
 
A cross tabulation was used to show the number of women in each Boyd category (0%, 1-10%, 
11-25%, 26-50%, 51-75%, 76-100%) at baseline and first and final follow-up, overall and by 
treatment.  
 
5.2.11.5 Change in mammographic density – unadjusted tests 
 
Two-sample t-tests (for mean difference) and Wilcoxon rank sum tests (for median difference) 
assessed whether there was a difference in first and final follow-up density change between 
treatment arms, and Pearson chi-squared tests (Fisher’s exact tests if cell size <5) tested whether 
there was independence in dichotomous first and final follow-up density change between 
treatment arms. 
 
170 
 
5.2.11.6 Change in mammographic density – adjusted regression models 
 
The primary analysis used linear (continuous density change) regression models to examine the 
association between treatment arm and change in density from baseline mammogram to first 
follow-up mammogram, adjusted for age at randomisation (years). This was also assessed using 
logistic regression models for dichotomous density change. The secondary analysis (I) repeated 
the primary analysis with adjustment for age at randomisation (years), body mass index at 
randomisation (kg/m2), hormone replacement therapy use up to 12 months before randomisation 
(no/yes), age at menopause (years), image type (film/digital) and time between baseline and 
follow-up mammogram (years). As an exploratory analysis, models were also adjusted for 
baseline density (%) and age at randomisation (years) only, and baseline density (%) and all 
other adjusting factors. The secondary analysis (II) repeated the primary analysis and the 
secondary analysis (III) repeated the secondary analysis (I) (including exploratory adjustments) 
but for final follow-up density change, in a subgroup of women who had an available final 
mammogram density score.  
 
The adjusting covariates for regression models were chosen based on literature which suggests 
that they have a confounding effect on density change, including those shown to be significant 
in the IBIS-I trial (203). Age at randomisation was retained in all regression models, regardless 
of significance, because age is a strong confounder of density and density change. To aid 
interpretation, continuous adjusting variables were centred about their median in regression 
models. 
 
5.2.11.7 Change in mammographic density – subgroup analyses 
 
The secondary analyses (IV) and (V) used two-sided t-tests and Wilcoxon rank-sum tests (2 
subgroups) or ANOVA F-tests and non-parametric Cuzick trend tests (>2 ordered subgroups) to 
assess heterogeneity, namely whether the effect of anastrozole on first and final density change 
varied between different covariate subgroups. Univariate logistic regression models were also 
used to assess the odds of a high density reduction (≥10% or ≥5% absolute reduction) in one 
subgroup relative to another subgroup, in anastrozole treated patients only. The covariates 
assessed in this subgroup analysis were the same as those at baseline, plus time between 
baseline and follow-up mammograms (years). Continuous variables were separated into 
subgroups by their median value. 
 
5.2.11.8 Change in mammographic density – sensitivity analyses 
 
As a sensitivity analysis, all analyses of density change at first follow-up mammogram were 
repeated in the subgroup of women with an available final mammogram. 
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5.3 Results 
 
Table 5.1: Baseline characteristics overall and by treatment arm. 
Variable n 
Overall 
n 
Placebo 
n 
Anastrozole 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Age at randomisation 
(yr) 
566 
58.9 
(5.5) 
59 (55-
63) 
271 
58.9 
(5.7) 
59 (55-
63) 
295 
58.9 
(5.4) 
59 (54-
63) 
P*  0.91, 0.77 
Body Mass Index 
(kg/m2) 
562 
27.1 
(4.6) 
26.5 
(23.8-
29.7) 
268 
27.0 
(4.8) 
26.5 
(23.8-
29.5) 
294 
27.1 
(4.4) 
26.5 
(23.8-
29.9) 
P*  0.77, 0.57 
Age at menarche (yr) 562 
12.9 
(1.6) 
13 (12-
14) 
269 
12.9 
(1.6) 
13 (12-
14) 
293 
12.8 
(1.7) 
13 (12-
14) 
P*  0.84, 0.69 
Age at menopause (yr) 563 
48.3 
(6.2) 
50 (46-
52) 
268 
48.4 
(6.0) 
50 (46-
52) 
294 
48.4 
(5.7) 
50 (45-
52) 
P*  0.97, 0.91 
Tyrer-Cuzick 10-year 
risk (%) 
568 
8.6 
(4.2) 
7.8 (6.1-
10.1) 
273 
8.7 
(3.8) 
7.9 (6.3-
10.6) 
295 
8.6 
(4.5) 
7.6 (5.9-
9.7) 
P*  0.72, 0.15 
Baseline density (%) 575 
43.5 
(24.8) 
45 (20-
65) 
276 
44.3 
(24.9) 
45 (20-
65) 
299 
42.7 
(24.8) 
40 (20-
65) 
P*  0.45, 0.45 
  n %  n %  n % 
Age at first birth (yr)  
Nulliparous 
566 
98 17.3 
271 
54 19.9 
295 
44 14.9 
>27 121 21.4 57 21.0 64 21.7 
21-27 245 43.3 110 40.6 135 45.8 
≤20 102 18.0 50 18.5 52 17.6 
P**  0.39 
Oral contraception 
use 
 
Never 
565 
120 21.4 
270 
65 24.1 
295 
55 18.6 
Previously 441 78.1 205 75.9 236 80.0 
Currently 4 0.7 0 0.0 4 1.4 
P**  0.04# 
HRT use < 12 months 
before randomisation 
 
No 
566 
534 94.4 
271 
253 93.4 
295 
281 95.3 
Yes 32 5.7 18 6.6 14 4.8 
P**  0.33 
Smoking status  
Never  317 56.1  156 57.6 
294 
161 54.8 
Former 565 73 12.9 271 32 11.8 41 14.0 
Current  175 31.0  83 30.6 92 31.3 
P**  0.70 
History of Atypical 
Hyperplasia or LCIS  
 
No 
566 
519 91.7 
271 
249 91.9 
295 
270 91.5 
Yes 47 8.3 22 8.1 25 8.5 
P**  0.88 
Image type  
Film 
575 
190 33.0 
276 
83 30.1 
299 
107 35.8 
Digital 385 67.0 193 69.9 192 64.2 
P**  0.15 
*P-value from two-sample t-test (for means) and Wilcoxon rank sum test (for medians), respectively, for 
continuous variables by treatment arm; **P-value from Pearson chi-squared test (# Fisher’s exact test if 
cell size <5) for variable categories by treatment arm; interquartile range (IQR), standard deviation 
(SD). 
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5.3.1 Baseline characteristics 
 
Baseline characteristics were well balanced between treatment arms for all women (Table 5.1). 
Women who had used or were currently using oral contraception were slightly more likely to be 
in the anastrozole group, but the difference in numbers was small. Nine women transferred to a 
different participating centre where their study number changed. Therefore, some covariates, 
such as age, could not be matched to the study number and were missing for these women.  
 
5.3.2 Timings of mammograms 
 
The median (IQR) and range of time between baseline mammogram and randomisation was 0.2 
years (0.1 years-0.4 years) and 0.0 years-1.0 years (i.e. 2.4 months (1.1 months-5.2 months) and 
0 months-12.2 months). The median (IQR) and range of time between randomisation and first 
follow-up mammogram was 2.0 years (1.4 years-2.2 years) and 0.7 years-3.2 years, and the 
median (IQR) and range of time between randomisation and final follow-up mammogram was 
4.4 years (4.1 years-4.8 years) and 4.0 years-5.0 years. The median (IQR) and range of time 
between baseline mammogram and first follow-up mammogram was 2.1 years (1.6 years-2.8 
years) and 0.9 years-3.9 years. The median (IQR) and range of time between baseline 
mammogram and final follow-up mammogram was 4.6 years (4.4 years-5.0 years) and 4.0 
years-5.9 years. 
 
5.3.3 Effect of covariates on baseline mammographic density 
 
Results from the age-adjusted and multivariable linear and logistic regression models for breast 
density at baseline are summarized in Table 5.2. Older age at randomisation was associated with 
reduced breast density (-0.45% (95% CI, -0.82 to -0.09) per year increase in age), but less so in 
multivariable models (-0.26% (95% CI, -0.64 to 0.11) per year increase in age). Higher body 
mass index was associated with a reduction in breast density in both age-adjusted (-1.69% (95% 
CI, -2.13 to -1.26) per kg/m2 increase) and multivariable (-1.73% (95% CI, -2.17 to -1.31) per 
kg/m2 increase) models. Age at first birth was another predictor of breast density in both age-
adjusted and multivariable models. Compared with nulliparous women (n=98), women who had 
their first full-term birth below the age of 20 years (n=102) had approximately 15% lower 
absolute breast density. The other statistically significant variable was image type, which 
showed lower density for digital images. This is expected since digital mammograms appear 
darker and thus less dense than film mammograms. 
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Table 5.2: Association between baseline covariates and baseline breast density (continuous (%) and dichotomised into <50% or ≥50%) in age-adjusted and multivariable linear and  
logistic regression models. 
Variable n+ 
Age-adjusted linear 
regression 
Multivariable linear 
regression 
Age-adjusted logistic 
regression 
Multivariable logistic 
regression 
β-coefficient 
(95%  CI)# 
P-value## 
β-coefficient 
(95%  CI)# 
P-value## 
OR 
(95%  CI)### 
P-value### 
OR 
(95%  CI)### 
P-value### 
Age at randomisation 
(yr)* 
566/553 
-0.45 
(-0.82,-0.09) 
0.01 
-0.26 
(-0.64,0.11) 
0.18 
0.97 
(0.94,1.00) 
0.04 
0.98 
(0.94,1.02) 
0.27 
Body Mass Index 
(kg/m2)* 
562/553 
-1.69 
(-2.13,-1.26) 
<0.01 
-1.73 
(-2.17,-1.31) 
<0.01 
0.87 
(0.83,0.91) 
<0.01 
0.86 
(0.82,0.90) 
<0.01 
Age at menarche (yr)* 562/553 
0.55 
(-0.73,1.84) 
0.41 
0.18 
(-0.99,1.39) 
0.77 
1.04 
(0.93,1.15) 
0.50 
1.02 
(0.90,1.14) 
0.79 
Age at menopause (yr)* 562/553 
0.11 
(-0.23,0.46) 
0.51 
0.03 
(-0.29,0.36) 
0.86 
1.00 
(0.97,1.03) 
0.99 
0.99 
(0.96,1.03) 
0.61 
Tyrer-Cuzick 10-year 
risk (% )* 
564/553 
0.45 
(-0.05,0.94) 
0.08 
0.47 
(-0.22,1.19) 
0.19 
1.03 
(0.99,1.08) 
0.11 
1.02 
(0.96,1.10) 
0.48 
Age at first birth (yr)**  
Nulliparous 
566/553 
Ref - Ref - Ref - Ref - 
>27 
-7.67 
(-14.50,-0.78) 
0.03 
-9.82 
(-16.61,-2.79) 
0.01 
0.74 
(0.43,1.27) 
0.28 
0.64 
(0.35,1.15) 
0.13 
21-27 
-8.97 
(-15.00,-2.91) 
<0.01 
-9.92 
(-16.04,-3.48) 
<0.01 
0.57 
(0.35,0.91) 
0.02 
0.52 
(0.30,0.89) 
0.02 
≤20 
-15.72 
(-22.48,-8.68) 
<0.01 
-15.40 
(-22.30,-8.09) 
<0.01 
0.33 
(0.19,0.60) 
<0.01 
0.31 
(0.16,0.61) 
<0.01 
Oral contraception use**  
Never 
565/553 
Ref - Ref - Ref - Ref - 
Previously 
-1.51 
(-6.47,3.49) 
0.55 
1.39 
(-3.30,6.18) 
0.57 
0.83 
(0.54,1.27) 
0.39 
1.04 
(0.66,1.66) 
0.86 
Currently 
-11.27 
(-32.00,36.28) 
0.50 
-2.95 
(-28.48,42.58) 
0.88 
0.47 
(0.05,4.65) 
0.52 
1.15 
(0.10,13.3) 
0.91 
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Table 5.2 continued 
 
HRT use up to 12 months 
before randomisation** 
 
No 
566/553 
Ref - Ref - Ref - Ref - 
Yes 
3.83 
(-5.38,13.18) 
0.42 
3.23 
(-5.80,12.83) 
0.50 
1.16 
(0.56,2.39) 
0.69 
1.16 
(0.51,2.62) 
0.72 
Smoking status**  
Never 
565/553 
Ref - Ref - Ref - Ref - 
Former 
4.01 
(-2.83,10.86) 
0.25 
1.74 
(-4.29,7.72) 
0.57 
1.19 
(0.71,2.00) 
0.51 
0.94 
(0.53,1.68) 
0.84 
Current 
2.55 
(-1.98,7.06) 
0.27 
3.72 
(-0.92,8.05) 
0.10 
1.08 
(0.74,1.57) 
0.69 
1.17 
(0.77,1.78) 
0.47 
History of Atypical 
Hyperplasia or LCIS** 
 
No 
566/553 
Ref - Ref - Ref - Ref - 
Yes 
4.83 
(-3.19,12.89) 
0.24 
2.46 
(-7.41,12.31) 
0.63 
1.60 
(0.88,2.92) 
0.13 
1.66 
(0.63,4.35) 
0.30 
Image type**  
Film 
566/553 
Ref - Ref - Ref - Ref - 
Digital 
-4.94 
(-9.15,-0.67) 
0.02 
-7.59 
(-11.61,-3.24) 
<0.01 
0.72 
(0.51,1.03) 
0.07 
0.57 
(0.38,0.84) 
0.01 
 
All covariates adjusted for age at randomisation (yr) in age-adjusted models (except for age at randomisation (yr)), all covariates included in multivariable models; continuous 
variables centred about their median (see Table 5.1 overall column); * β-coefficient represents effect on baseline density per unit increase in covariate, odds ratio (OR) represents 
odds of having ≥50% baseline density per unit increase in covariate; ** β-coefficient represents difference in baseline density from reference category, OR represents odds of having 
≥50% baseline density relative to the reference category; #empirical bootstrap 95% CI;  ##P-value from z-test with known sample mean and standard deviation (the population is to  
the sample as the sample is to the bootstrap sample); ###95% CI and P-value from a Wald test; +number in age-adjusted model/number in multivariable model. 
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Table 5.3: Cross tabulation of number of women in each Boyd category at entry to the study with category at first and final follow-up. 
Boyd category at 
entry 
Number of women 
Boyd category at first follow-up 
Total 
Boyd category at first follow-up (women with a final 
mammogram) Total 
0%  1-10%  11-25%  26-50%  51-75%  76-100% 0%  1-10%  11-25%  26-50%  51-75%  76-100%  
0%  - - - - - - 0(0/0) - - - - - - 0(0/0) 
1-10%  - 49(22/27) 1(1/0) - - - 50(23/27) - 14(9/5) - - - - 14(9/5) 
11-25%  - 13(7/6) 147(65/82) - - - 160(72/88) - 3(2/1) 37(18/19) - - - 40(20/20) 
26-50%  - - 5(2/3) 134(69/65) 1(0/1) - 140(71/69) - - 2(1/1) 35(20/15) - - 37(21/16) 
51-75%  - - - 6(1/5) 153(78/75) - 159(79/80) - - - 3(0/3) 41(20/21)  44(20/24) 
76-100%  - - - - 8(4/4) 58(27/31) 66(31/35) - - - - 2(2/0) 14(7/7) 16(9/7) 
Total 0(0/0) 62(29/33) 153(68/85) 140(70/70) 162(82/80) 58(27/31) 575(276/299) 0(0/0) 17(11/6) 39(19/20) 38(20/18) 43(22/21) 14(7/7) 151(79/72) 
 
Boyd category at 
entry 
Number of women 
Boyd category at final follow-up 
Total 
0%  1-10%  11-25%  26-50%  51-75%  76-100%  
0%  - - - - - - 0(0/0) 
1-10%  - 14(9/5) - - - - 14(9/5) 
11-25%  - 4(3/1) 36(17/19) - - - 40(20/20) 
26-50%  - - 2(1/1) 35(20/15) - - 37(21/16) 
51-75%  - - - 3(1/2) 41(19/22) - 44(20/24) 
76-100%  - - - - 2(2/0) 14(7/7) 16(9/7) 
Total 0(0/0) 18(12/6) 38(18/20) 38(21/17) 43(21/22) 14(7/7) 151(79/72) 
 
The first number in each cell is the total number of subjects; numbers in parentheses are the placebo and anastrozole groups,  respectively; ‘-‘ indicates no entries. 
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Table 5.4: Continuous change in density (%) by treatment arm. 
 
 n 
Mean (95% 
CI) 
Standard 
deviation 
P-value* Median IQR 
P-
value** 
First follow-up  
Placebo 276 
-0.82 
(-1.12, -0.51) 
2.59 
0.28 
0 (0,0) 
0.13 
Anastrozole 299 
-1.05 
(-1.36, -0.75) 
2.65 0 (0,0) 
First follow-up 
(women with a final 
mammogram) 
 
Placebo 79 
-1.08 
(-1.71, -0.44) 
2.85 
0.94 
0 (0,0) 
0.58 
Anastrozole 72 
-1.04 
(-1.56, -0.52) 
2.21 0 (0,0) 
Final follow-up  
Placebo 79 
-2.15 
(-3.01, -1.30) 
3.81 
0.47 
0 (-5,0) 
0.43 
Anastrozole 72 
-1.74 
(-2.48, -0.99) 
3.16 0 (-5,0) 
 
*P-value from two-sided t-test (for means); **P-value from Wilcoxon rank sum test (for medians); 
interquartile range (IQR), 95% confidence interval (95% CI). 
 
 
Table 5.5: Dichotomised change in density (%) by treatment arm. 
 
 n (% of follow-up) 
P-
value 
n (% of follow-up) 
P-
value  
<10% 
reduction 
≥10% 
reduction 
<5% 
reduction 
≥5% 
reduction 
First follow-up  
Placebo 268 (97.1%) 8 (2.9%) 
0.49 
236 (85.5%) 40 (14.5%) 
0.14 
Anastrozole 293 (98.0%) 6 (2.0%) 242 (80.9%) 57 (19.1%) 
First follow-up 
(women with a final 
mammogram) 
 
Placebo 75 (94.9%) 4 (5.1%) 
0.37# 
67 (84.8%) 12 (15.2%) 
0.49 
Anastrozole 71 (98.6%) 1 (1.4%) 58 (80.6%) 14 (19.4%) 
Final follow-up  
Placebo 75 (94.9%) 4 (5.1%) 
1.00# 
50 (63.3%) 29 (36.7%) 
0.43 
Anastrozole 69 (95.8%) 3 (4.2%) 50 (69.4%) 22 (30.6%) 
 
P-value from Pearson chi-squared test (#Fisher’s exact test if cell size <5).  
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5.3.4 Change in mammographic density – Boyd categories 
 
Change in density was summarised in terms of the number of women in each treatment group 
by Boyd scale at baseline and at first and final follow-up mammogram (Table 5.3). Movement 
between Boyd categories was minimal, and women who had a decrease in density moved by no 
more than one category below their baseline category. A similar percentage of women on 
placebo and anastrozole moved to a lower Boyd category at first follow-up mammogram 
(14/276=5% and 18/299=6%, respectively), with slightly more women moving down a category 
on placebo than anastrozole at final follow-up mammogram (7/79=9% and 4/72=6%, 
respectively). Increases in breast density were rare, and the two women (1 anastrozole control 
and 1 placebo control) who had increased density at first follow-up mammogram moved up by 
no more than one category. On inspection of the mammograms for these two women, both 
appeared to be caused by increases in dense tissue as opposed to weight-loss (decrease in breast 
fat), but the reason for the increase is unclear. These two women were not on HRT throughout 
the trial and they did not go on to develop breast cancer. 
 
5.3.5 Change in mammographic density – first follow-up mammogram 
 
At baseline, the mean breast density was 44.3% (95% CI, 41.4% to 47.3%) for the placebo 
group and 42.7% (95% CI, 39.9% to 45.6%) for the anastrozole group (p=0.45 from two-sample 
t-test and Wilcoxon rank sum test). By the first follow-up mammogram, breast density had 
fallen to an average 43.5% (95% CI, 40.5% to 46.4%) in the placebo group, with a change from 
baseline of -0.82% (95% CI, -1.12% to -0.51%) (Table 5.4). By the first follow-up 
mammogram, breast density had fallen to an average 41.7% (95% CI, 38.9% to 44.5%) in the 
anastrozole group, with a change from baseline of -1.05% (95% CI, -1.36% to -0.75%). The 
difference in density change at first follow-up mammogram between treatment arms 
(anastrozole minus placebo) was not significant (mean 0.24%, 95% CI, -0.19% to 0.67%, 
p=0.28 from two-sample t-test and p=0.13 from Wilcoxon rank sum test).  
 
5.3.6 Change in mammographic density – final follow-up mammogram 
 
By the final follow-up mammogram, breast density had fallen to an average 41.5% (95% CI, 
35.8% to 47.3%) in the placebo group, with a change from baseline of -2.15% (95% CI, -3.01% 
to -1.30%). For anastrozole, breast density had fallen to an average of 42.5% (95% CI, 36.7% to 
48.3%), with a change from baseline of -1.74% (95% CI, -2.48% to -0.99%). The difference in 
density change at final follow-up mammogram between treatment arms (anastrozole minus 
placebo) was not significant (mean -0.42%, 95% CI, -1.55% to 0.72%, p=0.47 from two-sample 
t-test and p=0.43 from Wilcoxon rank sum test) Table 5.4. 
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At first glance, anastrozole appeared to decrease more than placebo at first follow-up 
mammogram (-1.05% vs. -0.82%), but less than placebo at final follow-up mammogram (-
1.74% vs. -2.15%), suggesting a possible slowing down of anastrozole-induced rate of change 
in the latter stages of follow-up. However, when assessing the subgroup of women with an 
available final follow-up mammogram, anastrozole-treated women had less of a density 
reduction than those on placebo at both first and final follow-up mammogram (-1.04% vs. -
1.08% and -1.74% vs. -2.15%, respectively). Therefore, the effects seen at final follow-up 
mammogram may have been specific to this subgroup of women only.  
 
Results were similar for dichotomised density, where tests for differences in density change 
between treatment arms were non-significant (Table 5.5). The number of women losing at least 
10% density at first and final follow-up mammograms was small in both treatment arms, but 
numbers were larger for at least 5% density reduction. Although not significant, there was some 
suggestion that more women lost at least 5% density on anastrozole than placebo at first follow-
up mammogram (19.1% vs. 14.5%), but this was not the case at final follow-up mammogram. 
Overall, breast density fell over the course of the study for both anastrozole and placebo, but 
changes were not significantly different between treatment arms. 
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Table 5.6: Association between treatment arm and change in density (continuous (%), <10%/≥10% 
reduction and <5%/≥5% reduction) in adjusted linear and logistic regression models. 
 
Treatment Continuous# 
First follow-up 
 
Age-adjusted (n=566) 
Adjusted1 
(n=559) 
Adjusted2 
(n=566) 
Adjusted3 
(n=559) 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
-0.17 
(-0.59,0.26) 
0.43 
-0.27 
(-0.69,0.13) 
0.19 
-0.18 
(-0.60,0.26) 
0.41 
-0.29 
(-0.70,0.13) 
0.18 
First follow-up (women with a final mammogram) 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.01 
(-0.77,0.81) 
0.98 
-0.07 
(-0.87,0.72) 
0.86 
0.01 
(-0.78,0.81) 
0.98 
-0.08 
(-0.87,0.73) 
0.84 
Final follow-up 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
β-coefficient 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.39 
(-0.71,1.46) 
0.48 
0.27 
(-0.81,1.30) 
0.61 
0.39 
(-0.70,1.46) 
0.48 
0.26 
(-0.84,1.31) 
0.63 
 
Treatment ≥10% reduction* 
First follow-up 
 
Age-adjusted (n=566) 
Adjusted1 
(n=559) 
Adjusted2 
(n=566) 
Adjusted3 
(n=559) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.57 
(0.18,1.77) 
0.33 
0.82 
(0.25,2.73) 
0.75 
0.59 
(0.19,1.83) 
0.36 
0.84 
(0.25,2.79) 
0.77 
First follow-up (women with a final mammogram) 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.27 
(0.03,2.44) 
0.24 
0.37 
(0.04,3.83) 
0.40 
0.26 
(0.03,2.43) 
0.24 
0.36 
(0.03,3.77) 
0.40 
Final follow-up 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.83 
(0.18,3.91) 
0.82 
1.06 
(0.20,5.62) 
0.95 
0.82 
(0.17,3.92) 
0.81 
1.04 
(0.19,5.61) 
0.96 
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Table 5.6 continued 
 
Treatment ≥5% reduction** 
First follow-up 
 
Age-adjusted (n=566) 
Adjusted1 
(n=559) 
Adjusted2 
(n=566) 
Adjusted3 
(n=559) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
1.33 
(0.85,2.09) 
0.21 
1.51 
(0.95,2.40) 
0.08 
1.33 
(0.85,2.09) 
0.21 
1.51 
(0.95,2.41) 
0.08 
First follow-up (women with a final mammogram) 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
1.40 
(0.58,3.38) 
0.45 
1.76 
(0.68,4.51) 
0.24 
1.40 
(0.58,3.37) 
0.45 
1.75 
(0.68,4.49) 
0.25 
Final follow-up 
 
Age-adjusted (n=150) 
Adjusted1 
(n=148) 
Adjusted2 
(n=150) 
Adjusted3 
(n=148) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Placebo Ref - Ref - Ref - Ref - 
Anastrozole 
0.75 
(0.38,1.51) 
0.42 
0.87 
(0.41,1.82) 
0.71 
0.75 
(0.37,1.51) 
0.42 
0.87 
(0.41,1.82) 
0.71 
 
Treatment adjusted for age at randomisation (yr) in age-adjusted models; 1treatment adjusted for age at 
randomisation (yr), body mass index at randomisation (kg/m2), hormone replacement therapy use up to 
12 months before randomisation (no/yes), age at menopause ( yr), image type (film/digital) and time 
between baseline and follow-up mammogram (yr); 2treatment adjusted for age at randomisation (yr) and  
baseline density (%); 3treatment adjusted for age at randomisation (yr), body mass index at 
randomisation (kg/m2), hormone replacement therapy use up to 12 months before randomisation (no/yes), 
age at menopause (yr), image type (film/digital), time between baseline and follow-up mammogram (yr) 
and baseline density (%); # β-coefficient represents difference in density change from placebo, empirical 
bootstrap 95% CI, P-value from z-test with known sample mean and standard deviation (the population is 
to the sample as the sample is to the bootstrap sample); * odds ratio (OR) represents odds of ≥10% 
density reduction relative to placebo, 95% confidence interval (95% CI) and P-value from a Wald test; ** 
OR represents odds of ≥5% density reduction relative to placebo, 95% CI and P-value from a Wald test. 
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Table 5.7: Change in density (continuous, %) and odds ratios of relative risk of high density reduction (≥10% and ≥5%) by subgroups of covariates in the anastrozole arm only . 
Variable 
First follow-up First follow-up (women with a final mammogram) Final follow-up 
n 
Continuous ≥10% reduction# ≥5% reduction## 
n 
Continuous 
≥10% 
reduction# 
≥5% reduction## 
n 
Continuous ≥10% reduction# ≥5% reduction## 
Mean 
(SD) 
Median 
(IQR) 
OR 
(95% CI) 
P 
OR 
(95% CI) 
P 
Mean 
(SD) 
Median 
(IQR) 
OR 
(95% 
CI) 
P 
OR 
(95% CI) 
P 
Mean 
(SD) 
Median 
(IQR) 
OR 
(95% CI) 
P 
OR 
(95% CI) 
P 
Age at 
randomisation 
(yr)* 
 
<59 yr 145 
-1.07 
(2.84) 
0 (0,0) Ref - Ref - 33 
-1.21 
(2.18) 
0 (0,0) Ref - Ref - 33 
-2.12 
(3.54) 
0 (-5,0) Ref - Ref - 
≥59 yr 150 
-0.93 
(2.20) 
0 (0,0) 
1.46 
(0.24,8.86) 
0.68 
0.77 
(0.43,1.38) 
0.38 39 
-0.90 
(2.26) 
0 (0,0) n/a n/a 
0.57 
(0.17,1.85) 
0.35 39 
-1.41 
(2.80) 
0 (-5,0) 
0.41 
(0.04,4.71) 
0.47 
0.79 
(0.29,2.15) 
0.64 
P**  0.65 0.56  0.55 0.38  0.35 0.49  
Body Mass 
Index (kg/m2)* 
 
<26.5 kg/m2 146 
-1.03 
(2.19) 
0 (0,0) Ref - Ref - 38 
-0.92 
(1.96) 
0 (0,0) Ref - Ref - 38 
-1.71 
(3.14) 
0 (-5,0) Ref - Ref - 
≥26.5 kg/m2 148 
-0.98 
(2.84) 
0 (0,0) 
1.49 
(0.25,9.05) 
0.67 
0.94 
(0.52,1.69) 
0.84 34 
-1.18 
(2.48) 
0 (0,0) n/a n/a 
1.15 
(0.36,3.69) 
0.82 34 
-1.76 
(3.23) 
0 (-5,0) 
2.31 
(0.20,26.71) 
0.50 
1.17 
(0.43,3.20) 
0.75 
P**  0.87 0.69  0.63 0.77  0.94 0.86  
Age at menarche 
(yr)* 
 
<13 yr 126 
-1.19 
(2.93) 
0 (0,0) Ref - Ref - 33 
-0.91 
(1.96) 
0 (0,0) Ref - Ref - 33 
-1.36 
(2.87) 
0 (-5,0) Ref - Ref - 
≥13 yr 167 
-0.87 
(2.19) 
0 (0,0) 
1.13 
(0.19,6.89) 
0.89 
0.68 
(0.37,1.22) 
0.19 38 
-1.18 
(2.45) 
0 (0,0) n/a n/a 
1.20 
(0.37,3.90) 
0.76 38 
-2.11 
(3.42) 
0 (-5,0) 
1.78 
(0.15,20.54) 
0.65 
1.39 
(0.50,3.84) 
0.53 
P**  0.28 0.22  0.61 0.73  0.33 0.41  
Age at 
menopause (yr)* 
 
<50 yr 138 
-1.05 
(2.86) 
0 (0,0) Ref - Ref - 39 
-1.28 
(2.49) 
0 (0,0) Ref - Ref - 39 
-1.92 
(3.74) 
0 (-5,0) Ref - Ref - 
≥50 yr 156 
-0.96 
(2.21) 
0 (0,0) 
1.33 
(0.22,8.10) 
0.76 
0.82 
(0.46,1.48) 
0.51 32 
-0.78 
(1.84) 
0 (0,0) n/a n/a 
0.62 
(0.18,2.07) 
0.44 32 
-1.56 
(2.35) 
0 (-5,0) n/a n/a 
1.02 
(0.37,2.81) 
0.97 
P**  0.76 0.72  0.35 0.41  0.64 0.99  
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Table 5.7 continued 
 
Tyrer-Cuzick 10-year 
risk (%)* 
 
<7.8% 154 
-0.94 
(2.61) 
0 
(0,0) 
Ref - Ref - 43 
-0.93 
(2.25) 
0 
(0,0) 
Ref - Ref - 43 
-1.86 
(3.62) 
0 (-
5,0) 
Ref - Ref - 
≥7.8% 141 
-1.13 
(2.70) 
0 
(0,0) 
1.09 
(0.22,5.51) 
0.91 
1.07 
(0.59,1.92) 
0.83 28 
-1.07 
(2.09) 
0 
(0,0) 
n/a n/a 
1.40 
(0.42,4.72) 
0.58 28 
-1.43 
(2.30) 
0 (-
5,0) 
n/a n/a 
0.92 
(0.32,2.63) 
0.88 
P**  0.53 0.66  0.79 0.62  0.58 0.86  
Baseline density (%)*  
<45% 151 
-0.86 
(1.98) 
0 
(0,0) 
Ref - Ref - 35 
-0.86 
(1.91) 
0 
(0,0) 
Ref - Ref - 35 
-1.57 
(2.36) 
0 (-
5,0) 
Ref - Ref - 
≥45% 148 
-1.25 
(3.19) 
0 
(0,0) 
n/a n/a 
1.17 
(0.66,2.08) 
0.60 37 
-1.22 
(2.47) 
0 
(0,0) 
n/a n/a 
1.33 
(0.41,4.33) 
0.63 37 
-1.89 
(3.79) 
0 (-
5,0) 
n/a n/a 
0.92 
(0.34,2.52) 
0.88 
P**  0.21 0.51  0.50 0.60  0.67 0.93  
Age at first birth (yr)  
Nulliparous 44 
-0.91 
(2.23) 
0 
(0,0) 
Ref - Ref - 9 
-1.11 
(3.33) 
0 
(0,0) 
Ref - Ref - 9 
-1.11 
(3.33) 
0 
(0,0) 
Ref - Ref - 
>27 64 
-0.86 
(2.10) 
0 
(0,0) 
n/a n/a 
1.22 
(0.44,3.39) 
0.70 18 
-1.39 
(2.30) 
0 (-
5,0) 
n/a n/a 
3.08 
(0.30,31.33) 
0.34 18 
-2.22 
(2.56) 
0 (-
5,0) 
n/a n/a 
6.40 
(0.66,62.40) 
0.11 
21-27 135 
-1.19 
(2.81) 
0 
(0,0) 
1.31 
(0.14,12.07) 
0.81 
1.26 
(0.51,3.15) 
0.62 35 
-0.86 
(1.91) 
0 
(0,0) 
n/a n/a 
1.66 
(0.17,15.82) 
0.66 35 
-1.43 
(3.55) 
0 
(0,0) 
0.48 
(0.04,6.04) 
0.57 
2.37 
(0.26,21.90) 
0.45 
≤20 52 
-0.77 
(2.50) 
0 
(0,0) 
n/a n/a 
1.26 
(0.44,3.64) 
0.67 10 
-1.00 
(2.11) 
0 
(0,0) 
n/a n/a 
2.00 
(0.15,26.73) 
0.60 10 
-2.50 
(2.64) 
-2.5 
(-5,0) 
n/a n/a 
8.00 
(0.71,90.00) 
0.09 
P**  0.71 0.76  0.88 0.93  0.65 0.52  
Oral contraception use  
Never 55 
-1.27 
(2.59) 
0 
(0,0) 
Ref - Ref - 10 
-1.00 
(2.11) 
0 
(0,0) 
Ref - Ref - 10 
0.00 
(2.36) 
0 
(0,0) 
Ref - Ref - 
Previously 236 
-0.95 
(2.54) 
0 
(0,0) 
0.34 
(0.06,2.09) 
0.25 
0.80 
(0.39,1.64) 
0.54 62 
-1.05 
(2.24) 
0 
(0,0) 
-0.05 
(-
1.56,1.46) 
0.95 n/a n/a 62 
-2.02 
(3.20) 
0 (-
5,0) 
n/a n/a 
4.61 
(0.55,38.86) 
0.16 
Currently 4 
0.00 
(0.00) 
0 
(0,0) 
n/a n/a n/a n/a 0 - - - - - - 0 - - - - - - 
P**  0.51 0.30  0.95 0.98  0.06 0.06  
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Table 5.7 continued 
 
HRT use up to 12 months 
before randomisation 
 
No 281 
-0.98 
(2.54) 
0 
(0,0) 
Ref - Ref - 67 
-0.97 
(2.17) 
0 
(0,0) 
Ref - Ref - 67 
-1.64 
(3.18) 
0 (-
5,0) 
Ref - Ref - 
Yes 14 
-1.43 
(2.34) 
0 (-
5,0) 
n/a n/a 
1.80 
(0.54,5.98) 
0.34 5 
-2.00 
(2.74) 
0 (-
5,0) 
n/a n/a 
3.06 
(0.46,20.33) 
0.25 5 
-3.00 
(2.74) 
0 (-
5,0) 
n/a n/a 
3.79 
(0.59,24.50) 
0.16 
P**  0.52 0.34  0.32 0.25  0.36 0.18  
Smoking status  
Never 161 
-1.02 
(2.80) 
0 
(0,0) 
Ref - Ref - 34 
-1.18 
(2.48) 
0 
(0,0) 
Ref - Ref - 34 
-1.47 
(2.89) 
0 (-
5,0) 
Ref - Ref - 
Former 41 
-0.61 
(1.66) 
0 
(0,0) 
n/a n/a 
0.58 
(0.21,1.61) 
0.30 14 
-1.07 
(2.13) 
0 
(0,0) 
n/a n/a 
1.05 
(0.23,4.83) 
0.95 14 
-2.14 
(3.23) 
0 (-
5,0) 
2.54 
(0.15,43.67) 
0.52 
1.33 
(0.36,4.99) 
0.67 
Current 92 
-1.14 
(2.36) 
0 
(0,0) 
1.17 
(0.19,7.14) 
0.87 
1.09 
(0.58,2.07) 
0.79 24 
-0.83 
(1.90) 
0 
(0,0) 
n/a n/a 
0.77 
(0.20,3.00) 
0.71 24 
-1.88 
(3.55) 
0 (-
5,0) 
1.43 
(0.09,24.13) 
0.80 
0.99 
(0.31,3.12) 
0.98 
P**  0.53 0.73  0.85 0.69  0.78 0.82  
History of Atypical 
Hyperplasia or LCIS 
 
No 270 
-0.94 
(2.50) 
0 
(0,0) 
Ref - Ref - 66 
-0.98 
(2.19) 
0 
(0,0) 
Ref - Ref - 66 
-1.74 
(3.22) 
0 (-
5,0) 
Ref - Ref - 
Yes 25 
-1.60 
(2.78) 
0 (-
5,0) 
2.77 
(0.30,25.79) 
0.37 
1.80 
(0.71,4.55) 
0.22 6 
-1.67 
(2.58) 
0 (-
5,0) 
n/a n/a 
2.25 
(0.37,13.73) 
0.38 6 
-1.67 
(2.58) 
0 (-
5,0) 
n/a n/a 
1.15 
(0.19,6.80) 
0.88 
P**  0.22 0.18  0.47 0.39  0.96 0.90  
Image type  
Film 107 
-0.89 
(2.82) 
0 
(0,0) 
Ref - Ref - 19 
-1.05 
(2.09) 
0 
(0,0) 
Ref - Ref - 19 
-1.58 
(4.10) 
0 (-
5,0) 
Ref - Ref - 
Digital 192 
-1.15 
(2.56) 
0 
(0,0) 
2.83 
(0.33,24.58) 
0.35 
1.26 
(0.68,2.33) 
0.46 53 
-1.04 
(2.27) 
0 
(0,0) 
n/a n/a 
0.87 
(0.24,3.20) 
0.84 53 
-1.79 
(2.79) 
0 (-
5,0) 
0.71 
(0.06,8.26) 
0.78 
1.32 
(0.41,4.27) 
0.64 
P**  0.42 0.40  0.98 0.87  0.80 0.51  
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Table 5.7 continued 
 
Time between baseline and first follow-
up mammogram (yr)* 
 
<2.1 years 151 
-1.03 
(2.73) 
0 
(0,0) 
Ref - Ref - 29 
-0.86 
(2.34) 
0 
(0,0) 
Ref - Ref - - - - - - - - 
≥2.1 years 148 
-1.08 
(2.58) 
0 
(0,0) 
0.50 
(0.09,2.79) 
0.43 
0.98 
(0.55,1.75) 
0.95 43 
-1.16 
(2.14) 
0 
(0,0) 
n/a n/a 
1.89 
(0.53,6.75) 
0.33 - - - - - - - 
P**  0.86 0.90  0.58 0.37  - -  
Time between baseline and final 
follow-up mammogram (yr)* 
 
<4.6 years - - - - - - - - - - - - - 40 
-2.13 
(3.38) 
Ref - Ref - 
≥4.6 years - - - - - - - - - - - - - 32 
-1.25 
(2.84) 
0.61 
(0.05,7.08) 
0.70 
0.62 
(0.22,1.74) 
0.36 
P**  - -  - -  0.25 0.28  
 
*Continuous variables dichotomised by their median (Table 5.1: median time between baseline and first follow-up mammogram=2.1 years, median time between baseline and  fina l  
follow-up mammogram=4.6 years); ** P-value from two-sample t-test (corresponding to mean column) or Wilcoxon rank sum test (corresponding to median column) for covaria tes 
with 2 subgroups, P-value from ANOVA F-test (corresponding to mean column) or Cuzick’s trend test (corresponding to median column) for covariates with >2 ordered su bgroups; 
# odds ratio (OR) represents odds of ≥10% density reduction relative to the reference category, adjusted for age at randomisation ( yr) (except for age at randomisation (yr)), 95% 
confidence interval (95% CI) and P-value from a Wald test; ## OR represents odds of ≥5% density reduction relative to the reference category, adjusted for age a t randomisation 
(yr) (except for age at randomisation (yr)), 95% CI and P-value from a Wald test; n/a represents no results since subgroups perfectly predicted dichotomous density change; 
interquartile range (IQR); standard deviation (SD). 
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5.3.7 Adjusted change in mammographic density – first follow-up mammogram 
(primary analysis) 
 
Results from the linear and logistic regression models examining the adjusted associations 
between treatment arm and change in breast density are given in Table 5.6. The more negative 
the coefficient for continuous density change, the greater the effect of anastrozole on decreasing 
breast density from baseline mammogram than placebo. The primary analysis at first follow-up 
mammogram found that anastrozole had a mean -0.17% (95% CI, -0.59% to 0.26%, p=0.43) 
decrease in density compared with placebo after adjustment for age at baseline. This changed to 
a mean -0.27% (95% CI, -0.69% to 0.13%, p=0.19) decrease in the fully adjusted linear model. 
Accounting for baseline density only slightly strengthened the effect in both adjusted models. 
Baseline density was only marginally (non-significantly) associated with density change (mean 
density change per 10% increase in baseline density: -0.06% (95% CI, -0.14 to 0.03), p=0.21). 
If anything, it was suggestive that women on anastrozole were less likely to see a reduction in 
density of at least 10% at first follow-up mammogram than women on placebo (OR for 
anastrozole relative to placebo=0.57, 95% CI, 0.18 to 1.77, p=0.33 (age-adjusted), OR for 
anastrozole relative to placebo=0.82, 95% CI, 0.25 to 2.73, p=0.75 (fully-adjusted)), although 
the number of women experiencing at least 10% density reduction was small. Secondary 
analyses also assessed density change when dichotomised by a 5% reduction. In the age-
adjusted model, there was some suggestion that women on anastrozole were more likely to see a 
density reduction of at least 5% at first follow-up mammogram than placebo (OR for 
anastrozole relative to placebo=1.33, 95% CI, 0.85 to 2.09, p=0.21). This changed to an OR of 
1.51 (95% CI, 0.95 to 2.40, p=0.08) for anastrozole relative to placebo when adjusted for other 
factors in the fully-adjusted model. 
 
The study was underpowered to find a difference in density change at first follow-up 
mammogram between anastrozole and placebo. With 575 women (22 cases, 553 controls), the 
power to detect a difference in density change (continuous) from baseline to first follow-up 
mammogram between the two treatment arms at the 5% type-I error level was only 8%. The 
power to detect a difference in density change (≥10% reduction and <10% reduction) from 
baseline to first follow-up mammogram between the two treatment arms at the 5% type-I error 
level was 11% (6.2.1). The power to detect a difference in density change (≥5% reduction and 
<5% reduction) from baseline to first follow-up mammogram between the two treatment arms at 
the 5% type-I error level was 32% (6.2.1). 
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5.3.8 Adjusted change in mammographic density – final follow-up mammogram 
 
At final follow-up mammogram, anastrozole had a mean 0.39% (95% CI, -0.71% to 1.46%, 
p=0.48) increase in density compared with placebo after adjustment for age at baseline, which 
changed to 0.27% (95% CI, -0.81% to 1.30%, p=0.61) in the fully adjusted linear model (Table 
5.6). Accounting for baseline density, again, had little effect. There was no clear difference in 
the odds of at least a 10% density reduction at final follow-up mammogram between placebo 
and anastrozole (OR for anastrozole relative to placebo=0.83, 95% CI, 0.18 to 3.91, p=0.82 
(age-adjusted), OR for anastrozole relative to placebo=1.06, 95% CI, 0.20 to 5.62, p=0.95 
(fully-adjusted)). When dichotomised by a 5% reduction and adjusted for age at baseline, 
women on anastrozole had an odds ratio of experiencing a density reduction of at least 5% at 
final follow-up mammogram (relative to placebo) of 0.75 (95% CI, 0.38 to 1.51, p=0.42). When 
adjusted for other covariates, the odds ratio relative to placebo changed to 0.87 (95% CI, 0.41 to 
1.82, p=0.71). 
 
5.3.9 Missing covariate data 
 
As a sensitivity analysis, the age-adjusted regression models (n=566) were run in the subgroup 
of women with non-missing data for all adjusting variables (i.e. the subgroup included in fully-
adjusted multivariable regression models, n=559), to test whether adjusted results were robust to 
missing data. There was only a small amount of missing data for adjusting covariates and the 
results of these sensitivity models were similar to those in the main analysis (results not 
reported); hence the analysis was robust to missing data. 
 
5.3.10 Subgroup analysis 
 
Table 5.7 shows the effect of anastrozole on density change by different subgroups of covariates 
in the anastrozole arm only. Continuous covariates were dichotomised by their medians in all 
women since there were no differences by treatment arm (Table 5.1). There was no discernible 
difference in the effect of anastrozole on density change compared to placebo in these 
subgroups. 
 
5.3.11 Potential impact of compliance 
 
To test the impact of compliance, Kaplan–Meier curves and log rank tests were conducted in 
cases (censored 3 months before cancer diagnosis) and controls, to assess the difference in time 
to stopping treatment between: anastrozole cases with ≥5% vs. <5% reduction in density (no 
cases had ≥10% reduction in density), placebo cases with ≥5% vs. <5% reduction in density (no 
cases had ≥10% reduction in density), anastrozole controls with ≥5% vs. <5% and ≥10% vs. 
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<10% reduction in density, and placebo controls with ≥5% vs. <5% and ≥10% vs. <10% 
reduction in density. Better compliance may have been associated with a decrease in density 
since more treatment would have been administered. Figure 5.5 shows the results for 
anastrozole cases (log-rank p=0.15), Figure 5.6 shows the results for placebo cases (log-rank 
p=0.53), Figure 5.7 (log-rank p=0.13) and Figure 5.8 (log-rank p= 0.43) show the results for 
anastrozole controls with 10% and 5% cut-points, respectively, and Figure 5.9 (log-rank p= 
0.75) and Figure 5.10 (log-rank p= 0.48) show the results for placebo controls with 10% and 5% 
cut-points, respectively. There did not appear to be a difference in compliance between the two 
treatment arms (by case-control status). 
 
 
Figure 5.5: Kaplan-Meier graph for anastrozole cases (5% cut-point). 
 
Figure 5.6: Kaplan-Meier graph for placebo cases (5% cut-point). 
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Figure 5.7: Kaplan-Meier graph for anastrozole controls (10% cut-point). 
 
Figure 5.8: Kaplan-Meier graph for anastrozole controls (5% cut-point). 
 
Figure 5.9: Kaplan-Meier graph for placebo controls (10% cut-point). 
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Figure 5.10: Kaplan-Meier graph for placebo controls (5% cut-point). 
 
5.3.12 Missing mammograms 
 
Since the sampling frame for this study is based on the availability of mammograms at the time 
of study design, the nested sample may not have truly represented the source population (IBIS-
II main cohort). To test this, comparisons were made between cases that were included in this 
study and those from the main IBIS-II study who were not included, and between controls that 
were included in this study and those from the main IBIS-II study who were not included (Table 
5.8). Included and non-included controls were similar in terms of age, Tyrer-Cuzick 10-year risk 
and HRT use, whilst included and non-included cases were similar in terms of age, BMI and 
HRT use. However, there was a significant difference in BMI between included and non-
included controls, with the latter being somewhat heavier (mean non-included=28.4kg/m2; mean 
included=27.0kg/m2, p<0.01). When this was separated by country, the difference in BMI 
appeared to be driven by the UK centres. There was also a marginally significant difference in 
Tyrer-Cuzick 10-year risk between included and non-included cases, with the latter having a 
lower risk (mean non-included=9.2%; mean included=11.5%, p=0.06). There was also some 
indication that non-included controls had a slightly lower risk than included controls for the UK 
centres (mean non-included=8.2%; mean included=8.6%, p=0.05). The difference in HRT use 
between included and non-included controls in Ireland was driven by only 1 woman, and there 
did not appear to be a difference in any other country. 
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Table 5.8: Comparison of main confounding variables between women included in this study and women in the main IBIS-II study who were not included, overall and by country o f 
the included women 
Country of included 
controls 
Controls 
N Age at randomisation (yr) Body Mass Index (kg/m2) Tyrer-Cuzick 10-year risk (%) 
HRT use up to 12 months 
before randomisation 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statisti
c 
Include
d 
Not 
included 
All 553 3165 
Mean 
(SD) 
58.9 
(5.6) 
58.7 (5.8) 
Mean 
(SD) 
27.0 
(4.6) 
28.4 (5.8) 
Mean 
(SD) 
8.5 (4.1) 8.3 (4.2) no/yes 513/31 2870/237 
P* 0.38 P* <0.01 P* 0.41 P** 0.11 
Australia and New 
Zealand 
24 782 
Mean 
(SD) 
59.8 
(4.7) 
59.8 (5.7) 
Mean 
(SD) 
28.3 
(5.0) 
29.0 (5.7) 
Mean 
(SD) 
7.6 (5.0) 8.4 (3.4) no/yes 19/2 678/73 
P* 0.99 P* 0.58 P* 0.29 P** 1.00# 
Denmark 5 47 
Mean 
(SD) 
54.4 
(4.2) 
55.7 (6.2) 
Mean 
(SD) 
26.3 
(4.3) 
25.3 (4.2) 
Mean 
(SD) 
10.0 
(6.1) 
8.5 (4.6) no/yes 5/0 42/5 
P* 0.64 P* 0.62 P* 0.52 P** 1.00# 
Finland 24 100 
Mean 
(SD) 
61.9 
(5.8) 
60.3 (5.0) 
Mean 
(SD) 
28.1 
(4.1) 
27.9 (5.5) 
Mean 
(SD) 
7.0 (2.8) 7.7 (3.0) no/yes 23/1 89/11 
P* 0.18 P* 0.88 P* 0.32 P** 0.46# 
Ireland 1 63 
Mean 
(SD) 
52 (-) 56.8 (5.6) 
Mean 
(SD) 
27 (-) 29.3 (5.7) 
Mean 
(SD) 
5.6 (-) 9.3 (4.2) no/yes 0/1 60/1 
P* - P* - P* - P** 0.03# 
Italy 58 135 
Mean 
(SD) 
58.6 
(6.1) 
58.7 (5.5) 
Mean 
(SD) 
24.9 
(4.0) 
25.9 (4.7) 
Mean 
(SD) 
8.4 (4.1) 8.7 (5.7) no/yes 55/3 129/5 
P* 0.93 P* 0.15 P* 0.66 P** 0.70# 
UK 441 1663 
Mean 
(SD) 
58.8 
(5.5) 
58.7 (5.7) 
Mean 
(SD) 
27.2 
(4.6) 
28.6 (5.9) 
Mean 
(SD) 
8.6 (4.0) 8.2 (3.9) no/yes 411/24 1535/110 
P* 0.68 P* <0.01 P* 0.05 P** 0.38 
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Table 5.8 continued 
Country of included 
cases 
Cases 
N Age at randomisation (yr) Body Mass Index (kg/m2) Tyrer-Cuzick 10-year risk (%) 
HRT use up to 12 months 
before randomisation 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statistic 
Include
d 
Not 
included 
Statisti
c 
Include
d 
Not 
included 
All 22 225 
Mean 
(SD) 
57.8 
(4.5) 
58.9 (5.6) 
Mean 
(SD) 
28.6 
(5.1) 
29.5 (6.7) 
Mean 
(SD) 
11.5 
(5.5) 
9.2 (5.4) no/yes 21/1 206/18 
P* 0.36 P* 0.50 P* 0.06 P** 1.00# 
Australia and New 
Zealand 
1 43 
Mean 
(SD) 
61.0 (-) 59.8 (5.7) 
Mean 
(SD) 
31.8 (-) 29.6 (6.5) 
Mean 
(SD) 
15.4 (-) 8.4 (3.1) no/yes 1/0 38/5 
P* - P* - P* - P** 1.00# 
Denmark 1 3 
Mean 
(SD) 
59.0 (-) 54.3 (3.1) 
Mean 
(SD) 
26.8 (-) 28.5 (7.3) 
Mean 
(SD) 
12.7 (-) 13.9 (9.2) no/yes 1/0 3/0 
P* - P* - P* - P** - 
Finland 1 3 
Mean 
(SD) 
58.0 (-) 57.7 (7.4) 
Mean 
(SD) 
25.5 (-) 31.9 (1.9) 
Mean 
(SD) 
13.5 (-) 7.8 (4.5) no/yes 1/0 3/0 
P* - P* - P* - P** - 
Italy 1 17 
Mean 
(SD) 
49.0 (-) 60.7 (5.3) 
Mean 
(SD) 
22.9 (-) 27.8 (4.0) 
Mean 
(SD) 
20.1 (-) 11.3 (8.6) no/yes 1/0 17/0 
P* - P* - P* - P** - 
UK 18 132 
Mean 
(SD) 
58.0 
(4.4) 
58.9 (5.3) 
Mean 
(SD) 
29.0 
(5.4) 
30.2 (7.4) 
Mean 
(SD) 
10.7 
(5.5) 
9.4 (5.2) no/yes 17/1 121/10 
P* 0.52 P* 0.49 P* 0.32 P** 1.00# 
 
*P-value from two-sided t-test; **P-value from Pearson chi-squared test (#Fisher’s exact test if cell size <5); ‘-‘ indicates that value could not be calculated due to small numbers; 
standard deviation (SD). 
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5.4 Discussion 
 
In this study, breast density was shown to decrease with anastrozole in the first 2 years of 
therapy, but this effect was not significantly different from the density decreases seen in women 
on placebo. It might be that the early anastrozole-induced density reduction seen in this study 
was only attributable to aging; or perhaps it was a true but small effect, however there was 
limited power to detect it. Only 8% power was obtained to detect a continuous difference in 
density change between treatment arms, even with a reasonable number of women (n=575). 
This further suggests that the effect size of anastrozole-induced density reduction is very small. 
 
The results for this study are consistent with previous findings that show modest reductions in 
density with use of aromatase inhibitors (compared with a control group). In 2007, Vachon et al. 
(2007) conducted a study of 9-15 month change in Cumulus percent density with letrozole in 
women with early-onset breast cancer who had previously undergone 5 years of tamoxifen 
treatment (270). They found no difference in density reduction relative to placebo (mean percent 
density reduction of 0.8% in letrozole and 0.6% in placebo (p=0.76)). In the preventive setting, 
Ciglar et al. (2010) showed similar results in their analysis of healthy postmenopausal women 
with or without a history of breast cancer, but with a baseline density greater than 25% from the 
NCIC CTG MAP.1 trial. After 12 months, Cumulus percent density was similar between 
women treated with letrozole or placebo (mean percent density reduction of 1.74% on letrozole 
and 0.24% on placebo (p=0.67)) (268). A similar trial by Ciglar et al. in 2011 (the NCIC CTG 
MAP.2 trial) reported a mean Cumulus percent density increase of 0.56% on exemestane and 
0.58% on placebo (p=0.91) after 12 months of treatment (269). In both studies by Ciglar et al., 
density change was similar in both treatment arms even after 24 months of treatment. However, 
this potentially weak effect is not always seen. An aromatase inhibitor-induced density 
reduction was reported in a small cohort study by Mousa et al. who assessed density in 40 
women on either HRT alone or HRT plus AIs (415). However, it should be noted that the 
chosen method of density assessment (integrated pixel intensity) is not a common or verified 
density measurement technique. It could be that this method of assessment is measuring a 
mammographic feature other than density (for example, a textural feature) so these results 
would require validation with an established density measurement technique.  
 
One reason why these studies may not have seen an effect of AIs on density reduction is their 
lack of statistical power due to their small sample sizes. Density change after approximately 12 
months of treatment was assessed in only 68 women in Vachon et al. (2007), 49 women in 
Ciglar et al. (2010) and 65 women in Ciglar et al. (2011). A large amount of starting density is 
required to see a substantial absolute density reduction in postmenopausal women. Whilst 
studies such as Ciglar et al. (2010) included women with at least 25% starting density and still 
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found little effect, women were also eligible to enter the trial if they had taken tamoxifen up to 
3-months prior to recruitment, which has been shown to have anti-estrogenic effects for more 
than 10 years after treatment cessation (200). This may also extend to a prolonged effect on 
density, which would be particularly relevant if more placebo subjects were previously on 
tamoxifen, hence attenuating the effect of the AI. Most other studies looking into the effect of 
aromatase inhibitors on density do not have a placebo or ‘no treatment’ control group to assess 
its effect beyond that of aging (296). 
 
A recent study by Engmann et al. did find a difference in density change between women on 
AIs and women not on endocrine treatment. They showed that 403 breast cancer cases on AIs 
experienced, on average, 0.3% greater 2-3 year reduction in Volpara percent density and 0.6% 
greater 2-3 year reduction in Quantra percent density than 1,618 breast cancer-free controls. 
These results were also statistically significant (Volpara p=0.02, Quantra p=0.03) (271). This is 
one of only a few studies to assess the effect of aromatase inhibitors on density in a 
considerably large sample of women. Another study by Vachon et al. in 2013, investigated the 
difference in Cumulus percent density 10 month change between 369 early-stage 
postmenopausal breast cancer cases on adjuvant anastrozole and 369 matched breast cancer-free 
controls. Unlike Engmann et al., they found modest and non-significant results, with the cases 
experiencing a median density reduction that was only 0.1% lower than their matched controls 
(p=0.51) (267). In a more recent study in 355 postmenopausal breast cancer patients, Eriksson et 
al. again showed little association between AIs and density change (OR for a density reduction 
greater than 15% in women treated with an AI relative to those not treated with any endocrine 
therapy=0.91 (95% CI, 0.65 to 1.26)) (337). 
 
One explanation for these dissimilar findings could be the difference in measurement 
techniques. Vachon et al. measured 2-dimensional density using Cumulus and Eriksson 
measured 2-dimensional density using the ‘STRATUS’ tool which aligns mammograms to 
reduce measurement error between sequential mammograms (416); whereas Engmann used 3-
dimensional Volpara and Quantra. It may be that small changes in density with use of AIs are 
best measured using volumetric methods. 
 
Several strengths of this study are listed below: 
 This is the largest known study to date to assess the effect of an aromatase inhibitor on 
density in the preventive setting. 
 Inclusion of a placebo control group enabled a comparison between reductions in density 
whilst on treatment and reductions that would occur naturally with age. 
 Including a first and final follow-up mammogram allowed for assessment of density 
changes throughout the course of anastrozole treatment. 
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 The study is nested within a double-blind placebo-controlled randomised trial which is 
subject to minimal bias. 
 The multicentre aspect of the study enabled recruitment of women from different countries 
and ethnicities, increasing generalisability of results. 
 Exclusion of women with bilateral breast cancer, implants or preventive mastectomies, and 
assessment of the contralateral breast in cases ensured density estimates were not affected 
by these confounding factors. Since women were not allowed to take HRT during the trial, 
potential confounding from HRT was also reduced. 
 There was no switching of treatment throughout the trial, ensuring that the recorded effects 
were as a result of anastrozole treatment only. 
 Questionnaire data was collected for all women, allowing for adjustment of age and other 
density change confounding variables such as BMI, reproductive factors, HRT use and a 
history of benign disease. 
 There was a high inter-reader correlation between Dr Metaxa and the radiologist for IBIS-I 
(Dr Ruth Warren). 
 Dr Metaxa was blinded to treatment, case status and other risk factors, reducing bias from 
these factors in the measurement of density and density change. 
 
Several limitations of this study are listed below: 
 There was limited power to detect a change in density between treatment arms. However, 
the sample size in this study was similar to or larger than other studies assessing density 
change on AIs (as outlined in the discussion). 
 The multicentre aspect of the study resulted in different imaging modalities, imaging 
technologies and scanning techniques. This may have introduced variability in the density 
measurements, therefore making the signal of an anastrozole effect on density change 
harder to detect through added noise. 
 The measurement of covariates (such as BMI) would have been more reliable if measured 
using accurate measuring devices instead of questionnaires as used in this study. 
 Use of a volumetric measurement method such as Volpara or Quantra may have been better 
at detecting small changes in density than the 2-dimensional visual assessment method used 
in this study. However, since the study included both digital and film mammograms, not all 
images could be measured using these methods which require raw images from digital 
mammography. 
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5.5 Conclusion 
 
Findings of this study indicate that visually-assessed percent breast density may be marginally 
reduced by prophylactic anastrozole treatment, but that this reduction is likely to be minimal. 
However, use of different density measurement techniques that measure density change to a 
finer grain of detail (for instance, volumetric methods) may be useful for assessing the effect of 
anastrozole on density change, hence further examination is required on this topic. Nonetheless, 
these results suggest that the risk reduction from anastrozole observed in IBIS-II is unlikely to 
be fully mediated through density, as was suggested with tamoxifen in IBIS-I. 
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Chapter 6: Anastrozole-induced reduction in mammographic density and 
breast cancer risk reduction: a case-control study 
 
6.1 Introduction 
 
As described in Chapters 4 and 5, the SERM, tamoxifen, decreases risk (410) as well as density 
(203-206, 336). This reduction in density might be a marker of concurrent reduction in breast 
cancer risk, making endocrine therapy-induced density reduction a potential biomarker for risk 
reduction. It is not yet known whether anastrozole-induced density reduction can similarly be 
used as a biomarker for risk reduction, whereby an early anastrozole-induced density reduction 
of at least 10% would be associated with a lower risk of breast cancer compared with <10% 
anastrozole-induced density reduction. There is some suggestion of this biomarker effect with 
adjuvant aromatase inhibitors (264), but no study has so far examined the effect with preventive 
anastrozole therapy. Validation of aromatase inhibitor-induced density reduction would be 
useful as a biomarker for risk reduction in postmenopausal women whose risk may be lowered 
more than that with tamoxifen (349), and who may experience fewer adverse effects and better 
tolerance of symptoms than if treated with tamoxifen (348, 411). This study aims to assess early 
anastrozole-induced change in density as a biomarker for breast cancer risk reduction in patients 
from the IBIS-II Prevention trial. A detailed description of the primary and secondary 
hypotheses is described below: 
 
Primary hypothesis (Prognostic biomarker) 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥10% reduction in density at first follow-up mammogram and 
anastrozole-treated patients who experience a <10% reduction in density at first follow-up 
mammogram 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a 
≥10% reduction in density at first follow-up mammogram is different to age-adjusted risk of 
breast cancer in anastrozole-treated patients who experience a <10% reduction in density at 
first follow-up mammogram 
 
Secondary hypothesis I (Prognostic biomarker) 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥5% reduction in density at first follow-up mammogram and 
anastrozole-treated patients who experience a <5% reduction in density at first follow-up 
mammogram 
 
197 
 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a ≥5% 
reduction in density at first follow-up mammogram is different to age-adjusted risk of breast 
cancer in anastrozole-treated patients who experience a <5% reduction in density at first 
follow-up mammogram 
 
Secondary hypothesis II (Prognostic biomarker) 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥10% reduction in density at first follow-up mammogram and anastrozole-
treated patients who experience a <10% reduction in density at first follow-up 
mammogram, after adjustment for age at randomisation, body mass index at randomisation, 
baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥10% reduction 
in density at first follow-up mammogram is different to risk of breast cancer in anastrozole-
treated patients who experience a <10% reduction in density at first follow-up 
mammogram, after adjustment for age at randomisation, body mass index at randomisation, 
baseline density, and Tyrer-Cuzick 10-year risk. 
 
Secondary hypothesis III (Prognostic biomarker) 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥5% reduction in density at first follow-up mammogram and anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram, 
after adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥5% reduction in 
density at first follow-up mammogram is different to risk of breast cancer in anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram, 
after adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 
Secondary hypothesis IV (Predictive biomarker I) 
 H0: (1) There is no difference in age-adjusted risk of breast cancer between anastrozole-
treated patients who experience a ≥10% reduction in density at first follow-up mammogram 
and placebo-treated patients, (2) there is no difference in age-adjusted risk of breast cancer 
between anastrozole-treated patients who experience a <10% reduction in density at first 
follow-up mammogram and placebo-treated patients. 
 H1: (1) Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a 
≥10% reduction in density at first follow-up mammogram is different to age-adjusted risk of 
breast cancer in placebo-treated patients, (2) age-adjusted risk of breast cancer in 
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anastrozole-treated patients who experience a <10% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in placebo-treated patients. 
 
Secondary hypothesis V (Predictive biomarker I) 
 H0: (1) There is no difference in age-adjusted risk of breast cancer between anastrozole-
treated patients who experience a ≥5% reduction in density at first follow-up mammogram 
and placebo-treated patients, (2) there is no difference in age-adjusted risk of breast cancer 
between anastrozole-treated patients who experience a <5% reduction in density at first 
follow-up mammogram and placebo-treated patients 
 H1: (1) Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a 
≥5% reduction in density at first follow-up mammogram is different to age-adjusted risk of 
breast cancer in placebo-treated patients, (2) age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a <5% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in placebo-treated patients. 
 
Secondary hypothesis VI (Predictive biomarker I) 
 H0: (1) There is no difference in risk of breast cancer between anastrozole-treated patients 
who experience a ≥10% reduction in density at first follow-up mammogram and placebo-
treated patients and (2) there is no difference in risk of breast cancer between anastrozole-
treated patients who experience a <10% reduction in density at first follow-up mammogram 
and placebo-treated patients, both after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: (1) Risk of breast cancer in anastrozole-treated patients who experience a ≥10% 
reduction in density at first follow-up mammogram is different to risk of breast cancer in 
placebo-treated patients and (2) risk of breast cancer in anastrozole-treated patients who 
experience a <10% reduction in density at first follow-up mammogram is different to risk of 
breast cancer in placebo-treated patients, both after adjustment for age at randomisation, 
body mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
Secondary hypothesis VII (Predictive biomarker I) 
 H0: (1) There is no difference in risk of breast cancer between anastrozole-treated patients 
who experience a ≥5% reduction in density at first follow-up mammogram and placebo-
treated patients and (2) there is no difference in risk of breast cancer between anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram 
and placebo-treated patients, both after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: (1) Risk of breast cancer in anastrozole-treated patients who experience a ≥5% 
reduction in density at first follow-up mammogram is different to risk of breast cancer in 
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placebo-treated patients and (2) risk of breast cancer in anastrozole-treated patients who 
experience a <5% reduction in density at first follow-up mammogram is different to risk of 
breast cancer in placebo-treated patients, both after adjustment for age at randomisation, 
body mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
Secondary hypothesis VIII (Predictive biomarker II) 
 H0: There is no difference in the age-adjusted effect of ≥10% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <10% reduction) between 
anastrozole-treated patients and placebo-treated patients (interaction between treatment and 
density change). 
 H1: The age-adjusted effect of ≥10% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <10% reduction) in anastrozole-treated patients is different to 
the age-adjusted effect of ≥10% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <10% reduction) in placebo-treated patients (interaction 
between treatment and density change). 
 
Secondary hypothesis IX (Predictive biomarker II) 
 H0: There is no difference in the age-adjusted effect of ≥5% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <5% reduction) between 
anastrozole-treated patients and placebo-treated patients (interaction between treatment and 
density change). 
 H1: The age-adjusted effect of ≥5% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <5% reduction) in anastrozole-treated patients is different to 
the age-adjusted effect of ≥5% reduction in density at first follow-up mammogram on breast 
cancer risk (relative to <5% reduction) in placebo-treated patients (interaction between 
treatment and density change). 
 
Secondary hypothesis X (Predictive biomarker II) 
 H0: There is no difference in the effect of ≥10% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <10% reduction) between anastrozole-treated 
patients and placebo-treated patients, after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk (interaction 
between treatment and density change). 
 H1: The effect of ≥10% reduction in density at first follow-up mammogram on breast cancer 
risk (relative to <10% reduction) in anastrozole-treated patients is different to the effect of 
≥10% reduction in density at first follow-up mammogram on breast cancer risk (relative to 
<10% reduction) in placebo-treated patients, after adjustment for age at randomisation, 
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body mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk 
(interaction between treatment and density change). 
 
Secondary hypothesis XI (Predictive biomarker II) 
 H0: There is no difference in the effect of ≥5% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <5% reduction) between anastrozole-treated 
patients and placebo-treated patients, after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk  (interaction 
between treatment and density change). 
 H1: The effect of ≥5% reduction in density at first follow-up mammogram on breast cancer 
risk (relative to <5% reduction) in anastrozole-treated patients is different to the effect of 
≥5% reduction in density at first follow-up mammogram on breast cancer risk (relative to 
<5% reduction) in placebo-treated patients, after adjustment for age at randomisation, body 
mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk (interaction 
between treatment and density change). 
 
Secondary hypothesis XII (Prognostic and Predictive biomarker I) 
 H0: There is no difference in age-adjusted breast cancer risk between subgroups of 
covariates (tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement therapy use 
up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time 
between baseline mammogram and first follow-up mammogram) in women who experience 
an anastrozole-induced ≥10% reduction in density from baseline to first follow-up 
mammogram. 
 H1: Age-adjusted breast cancer risk in women who experience an anastrozole-induced 
≥10% reduction in density from baseline to first follow-up mammogram is different 
between subgroups of covariates (tumour ER status, age at randomisation, body mass index 
at randomisation, baseline density, history of atypical hyperplasia or LCIS, hormone 
replacement therapy use up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, 
image type, and time between baseline mammogram and first follow-up mammogram). 
 
Secondary hypothesis XIII (Prognostic and Predictive biomarker I) 
 H0: There is no difference in age-adjusted breast cancer risk between subgroups of 
covariates (tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement therapy use 
up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time 
between baseline mammogram and first follow-up mammogram) in women who experience 
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an anastrozole-induced ≥5% reduction in density from baseline to first follow-up 
mammogram. 
 H1: Age-adjusted breast cancer risk in women who experience an anastrozole-induced ≥5% 
reduction in density from baseline to first follow-up mammogram is different between 
subgroups of covariates (tumour ER status, age at randomisation, body mass index at 
randomisation, baseline density, history of atypical hyperplasia or LCIS, hormone 
replacement therapy use up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, 
image type, and time between baseline mammogram and first follow-up mammogram). 
 
6.2 Methods 
 
The ‘Study design’, ‘Data collection’, ‘Updating the Standard Operating Procedures’, 
‘Exclusions’,  ‘Exclusions - quality control (1)’, ‘Batching’, ‘Mammographic density scoring’, 
‘Quality control (2)’ and ‘Baseline mammographic density at least 10%’ sections are described 
in Chapter 5 (5.2). 
 
6.2.1 Power calculation 
 
The estimated distribution of IBIS-II cases and controls with <10% and ≥10% density reduction 
per treatment arm was calculated by weighting the distributions that were observed in IBIS-I 
(19) with hazard ratios relative to placebo from IBIS-I (HR=0.7) (200) and IBIS-II (HR=0.5) 
(208). The numbers in the table below relate to the distribution of the 123 cases in IBIS-I, 
whereby 57 cases on placebo lost less than 10% density, 15 cases on placebo lost at least 10% 
density, 36 cases on tamoxifen lost less than 10% density and 15 cases on tamoxifen lost at least 
10% density. Since fewer women on anastrozole in IBIS-II developed breast cancer than women 
on tamoxifen in IBIS-I, some cases were removed from the anastrozole row. The parameters  𝑥1 
and 𝑥2 were the number of cases needed to add to the placebo row (from the anastrozole row) to 
ensure that the 2x2 table equalled 123 (total number of cases in IBIS-I density study). The 
expected case distribution was: 
 
 <10% reduction ≥10% reduction 
Placebo 57 + 𝑥1 15 + 𝑥2 
Anastrozole 
36 (
0.5
0.7
) 15 (
0.5
0.7
) 
 
There were therefore 36 (
0.2
0.7
)  + 15 (
0.2
0.7
)  fewer cases on anastrozole who needed to go into the 
placebo group. Thus, 𝑥1 =
57
(57+15)
 
(36+15) 0.2
0.7
  and 𝑥2 =
15
(57+15)
 
(36+15) 0.2
0.7
 .  
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The expected case distribution for anastrozole was therefore estimated to be: 
 
 <10% reduction ≥10% reduction  
Placebo 68 18  
Anastrozole 26 11 Ʃ = 123 
   
For 3 controls per 1 case, the number of controls needed was 3x123=369. In IBIS-I, there were 
361 controls on placebo who lost less than 10% density, 125 controls on placebo who lost at 
least 10% density, 239 controls on tamoxifen who lost less than 10% density and 217 controls 
on tamoxifen lost at least 10% density, totalling 942 controls. Reweighting this distribution to 
have a total of 369 gave an expected control distribution of:  
 
 <10% reduction ≥10% reduction  
Placebo 369 (
361
942
) = 141 369 (
125
942
) = 49  
Anastrozole 369 (
239
942
) = 94 369 (
217
942
) = 85 Ʃ = 369 
 
Therefore, the proportion of expected breast cancer events was: 
 
 <10% reduction ≥10% reduction 
Placebo 
68
68 + 141
= 0.33 
18
18 + 49
= 0.27 
Anastrozole 
26
26 + 94
= 0.22 
11
11 + 85
= 0.11 
 
These distributions were then weighted using chosen multipliers to obtain sample sizes for 50, 
100, 150 and 200 cases, with 3 controls per 1 case. A difference of proportions power 
calculation was then estimated (superiority test) (417). 
 
The power for different sample sizes (3 controls per 1 case) was therefore: 
 
Sample size 200 (50 cases) 400 (100 cases) 600 (150 cases) 800 (200 cases) 
Power 0.295 0.516 0.688 0.808 
 
As a result, there was 81% power with 247 cases and 1013 controls to show a difference in risk 
between anastrozole-treated patients experiencing ≥10% density change and anastrozole-treated 
patients experiencing <10% density change from baseline to first follow-up mammogram at the 
5% type-I error level. This number also accounted for exclusions with baseline density <10% 
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based on the number of postmenopausal women with baseline density <10% in IBIS-I. A 
sample size larger than this was impracticable given the resources, number of mammograms 
received and number of breast cancer cases in the entire IBIS-II trial (n=approximately 200 at 
the time of study design). Assuming anastrozole to be 1/2 or 3/4 the effect size of tamoxifen 
would have made the power smaller. There was therefore not enough power to complete the 
primary objective. However, Kim et al.’s suggestion of increased risk of recurrence in ER+ 
breast cancer cases on AIs who lost <5% density after 8-20 months of treatment relative to 
similarly treated women who lost ≥5% density (HR=7.11, 95% CI, 0.90 to 56.37, p=0.06) (264) 
indicated that this study possibly had adequate power. The number of recurrences on AIs was 
not reported in Kim et al. but it was estimated to be 13 from other numbers reported in the 
paper. Assuming 32% of the 35 cases in this study that were sent to Dr Metaxa were on 
anastrozole (40 anastrozole cases/125 cases in Cuzick et al. (208)) it was estimated that there 
would be approximately 11 anastrozole cases in this study. Therefore, there was potentially 
enough power to detect an effect if density change was dichotomised into <5% and ≥5% 
reduction (secondary objectives). 
 
6.2.2 Statistical methods 
 
As in Chapter 5, a statistical analysis plan was developed for the study (appendix C.XXV). All 
statistical analysis was conducted using Stata (316), and tests were two-sided with a 
significance level of 5%. Time on treatment was not included in adjustments (intention-to-treat 
analysis). A set of Stata code was sent to Dr Sestak to run on un-blinded data and a proforma 
was developed and sent to the IBIS-II Trial Steering committee, who approved the study 
(appendix C.XXVI). 
 
6.2.2.1 Baseline characteristics 
 
Baseline covariates were summarised using frequency tables (as described in 5.2.11.1) by 
treatment arm and case status.  
 
6.2.2.2 Change in mammographic density 
 
Density change was assessed as a dichotomous variable (<10% absolute reduction or ≥10% 
absolute reduction, and <5% absolute reduction or ≥5% absolute reduction), where cut-points 
were chosen to emulate previous studies reporting that dichotomous density change is a useful 
biomarker for breast cancer risk (Chapter 4).  
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6.2.2.3 Change in mammographic density – Boyd categories 
 
A cross tabulation of Boyd categories was used as in Chapter 5, but with the primary interest in 
case-control status and density change between baseline and first follow-up mammogram only. 
 
6.2.2.4 Change in mammographic density – unadjusted tests 
 
Two-sample t-tests, Wilcoxon rank sum tests and Pearson chi-squared tests (Fisher’s exact tests 
if cell size <5) were used as in 5.2.11.5, but with the primary interest in case-control status and 
density change between baseline and first follow-up mammogram only. 
 
6.2.2.5 Change in mammographic density – adjusted regression models 
 
Age at randomisation was retained in all regression models, regardless of significance, because 
age is a strong confounder of density change and breast cancer risk. Continuous adjusting 
variables were centred about their median in regression models. The adjusting covariates for 
regression models were chosen based on literature which suggests that they have a confounding 
effect on breast cancer risk and density change, including those shown to be significant in the 
IBIS-I trial (19).  
 
The primary analysis used logistic regression models to examine the association between risk of 
breast cancer and change in density from baseline mammogram to first follow-up mammogram 
(dichotomised into <10% absolute reduction and ≥10% absolute reduction, reference category: 
<10% absolute reduction), adjusted for age at randomisation (years), in anastrozole-treated 
patients only. The secondary analysis (I) repeated the primary analysis for density change 
dichotomised into <5% absolute reduction and ≥5% absolute reduction (reference category: 
<5% absolute reduction). The secondary analysis (II) repeated the primary analysis with 
adjustment for age at randomisation (years), body mass index at randomisation (kg/m2), baseline 
density (%) and Tyrer-Cuzick 10-year risk (%, version 7 excluding breast density). The 
secondary analysis (III) repeated the secondary analysis (II) for density change dichotomised 
into <5% absolute reduction and ≥5% absolute reduction (reference category: <5% absolute 
reduction). 
 
The secondary analysis (IV) used logistic regression models to examine the association between 
risk of breast cancer and a factor variable for change in density and treatment (categories: <10% 
anastrozole-induced absolute reduction in density from baseline mammogram to first follow-up 
mammogram, ≥10% anastrozole-induced absolute reduction in density from baseline 
mammogram to first follow-up mammogram, and placebo, reference category: placebo) in all 
women, adjusted for age at randomisation (years). The secondary analysis (V) repeated the 
 
205 
 
secondary analysis (IV) for density change dichotomised into <5% absolute reduction and ≥5% 
absolute reduction. The secondary analysis (VI) repeated the secondary analysis (IV) with 
adjustment for age at randomisation (years), body mass index at randomisation (kg/m2), baseline 
density (%) and Tyrer-Cuzick 10-year risk (%, version 7 excluding breast density). The 
secondary analysis (VII) repeated the secondary analysis (IV) for density change dichotomised 
into <5% absolute reduction and ≥5% absolute reduction, with adjustment for age at 
randomisation (years), body mass index at randomisation (kg/m2), baseline density (%) and 
Tyrer-Cuzick 10-year risk (%, version 7 excluding breast density). 
 
The secondary analysis (VIII) used logistic regression models to examine the association 
between risk of breast cancer and change in density from baseline mammogram to first follow-
up mammogram (dichotomised into <10% absolute reduction and ≥10% absolute reduction, 
reference category: <10% absolute reduction), treatment arm (placebo or anastrozole, reference 
category: placebo), and an interaction between density change and treatment, in all women, 
adjusted for age at randomisation (years). The secondary analysis (IX) repeated the secondary 
analysis (VIII) for density change dichotomised into <5% absolute reduction and ≥5% absolute 
reduction (reference category: <5% absolute reduction). The secondary analysis (X) repeated 
the secondary analysis (VIII) with adjustment for age at randomisation (years), body mass index 
at randomisation (kg/m2), baseline density (%) and Tyrer-Cuzick 10-year risk (%, version 7 
excluding breast density). The secondary analysis (XI) repeated the secondary analysis (VIII) 
for density change dichotomised into <5% absolute reduction and ≥5%  absolute reduction 
(reference category: <5% absolute reduction), with adjustment for age at randomisation (years), 
body mass index at randomisation (kg/m2), baseline density (%) and Tyrer-Cuzick 10-year risk 
(%, version 7 excluding breast density). 
 
6.2.2.6 Change in mammographic density – subgroup analyses 
 
The secondary analysis (XII) used logistic regression to examine the association between risk of 
breast cancer and change in density from baseline mammogram to first follow-up mammogram 
(dichotomised into <10% absolute reduction and ≥10% absolute reduction, reference category: 
<10% absolute reduction), adjusted for age at randomisation (years), in anastrozole-treated 
patients only, in different covariate subgroups. Logistic regression models were also used to 
examine the association between risk of breast cancer and a factor variable for change in density 
and treatment (categories: <10% absolute anastrozole-induced reduction in density from 
baseline mammogram to first follow-up mammogram, ≥10% absolute anastrozole-induced 
reduction in density from baseline mammogram to first follow-up mammogram, and placebo, 
reference category: placebo) in all women, adjusted for age at randomisation (years), in 
different covariate subgroups. The secondary analysis (XIII) repeated the secondary analysis 
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(XII) for density change dichotomised into <5% absolute reduction and ≥5% absolute reduction. 
Covariate subgroups were: tumour ER status (negative/positive), age at randomisation (years), 
body mass index (BMI) at randomisation (kg/m2), baseline density (%), history of atypical 
hyperplasia or LCIS (no/yes), hormone replacement therapy use up to 12 months before 
randomisation (no/yes), Tyrer-Cuzick 10-year risk (%, version 7 excluding breast density), 
image type (film/digital) and time between baseline mammogram and first follow-up 
mammogram (years). Continuous variables were separated into subgroups by their median 
value. 
 
6.3 Results 
 
6.3.1 Baseline characteristics 
 
The distribution of baseline characteristics differed between cases and controls (Table 6.1). 
There was a significant difference between cases and controls in terms of Tyrer-Cuzick 10-year 
risk and history of atypical hyperplasia or LCIS, which was only apparent in the placebo arm 
and not the anastrozole arm. 
 
Mean baseline density was 47% in cases and 43% in controls (mean difference cases minus 
controls=3.4%, 95% CI, -7.1% to 14.1%, two-sample t-test p=0.52); which was 47% in case 
subjects and 44% in control subjects of the placebo arm (mean difference cases minus 
controls=3.1%, 95% CI, -10.8% to 17.1%, two-sample t-test p=0.66), and 46% in case subjects 
and 43% in control subjects of the anastrozole arm (mean difference cases minus 
controls=3.5%, 95% CI, -13.1% to 20.0%, two-sample t-test p=0.68). The association between 
baseline density (continuous) and risk of developing breast cancer was not significant overall 
(OR=1.06 per 10% increase in baseline density (95% CI, 0.89 to 1.25), p=0.52). The suggested 
relative reduction in breast cancer risk associated with anastrozole in this study was 37% (OR 
relative to placebo=0.63 (95% CI, 0.26 to 1.49), p=0.29), which was consistent with the IBIS-II 
main study finding of 53% relative risk reduction (208). 
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Table 6.1: Baseline characteristics overall and by treatment, separated by case status 
 
Variable 
Overall Placebo Anastrozole 
Cases Controls Cases Controls Cases Controls 
n 
Mean 
(SD) 
Median 
(IQR) 
n 
Mean 
(SD) 
Median 
(IQR) 
n 
Mean 
(SD) 
Median 
(IQR) 
n 
Mean 
(SD) 
Median 
(IQR) 
n 
Mean 
(SD) 
Median 
(IQR) 
n 
Mean 
(SD) 
Median 
(IQR) 
Age at 
randomisation (yr) 
22 
57.8 
(4.5) 
58 (54-
61) 
544 
58.9 
(5.6) 
59 (55-
63) 
13 
57.8 
(4.6) 
58 (56-
61) 
258 
58.9 
(5.7) 
59 (55-
63) 
9 
57.8 
(4.5) 
59 (54-
60) 
286 
59.0 
(5.4) 
59 (54-
63) 
P* 0.33, 0.33 0.48, 0.40 0.52, 0.57 
Body Mass Index 
(kg/m2) 
22 
28.6 
(5.1) 
29.3 
(23.8-
32.0) 
540 
27.0 
(4.6) 
26.4 
(23.8-
29.5) 
13 
28.1 
(5.1) 
27.8 
(25.5-
31.8) 
255 
26.9 
(4.8) 
26.4 
(23.8-
29.4) 
9 
29.1 
(5.4) 
30.1 
(23.8-
34.2) 
285 
27.1 
(4.4) 
26.4 
(23.9-
29.7) 
P* 0.12, 0.11 0.38, 0.27 0.17, 0.23 
Age at menarche 
(yr) 
22 
12.8 
(1.8) 
13 (11-
14) 
540 
12.9 
(1.6) 
13 (12-
14) 
13 
12.4 
(1.7) 
12 (11-
13) 
256 
12.9 
(1.6) 
13 (12-
14) 
9 
13.3 
(1.9) 
13 (12-
14) 
284 
12.8 
(1.7) 
13 (12-
14) 
P* 0.79, 0.63 0.244, 0.202 0.38, 0.48 
Age at menopause 
(yr) 
22 
49.2 
(6.8) 
50 (48-
54) 
541 
48.3 
(6.2) 
50 (46-
52) 
13 
49.8 
(5.5) 
50 (48-
53) 
255 
48.3 
(6.1) 
50 (46-
52) 
9 
48.3 
(8.8) 
50 (42-
55) 
285 
48.4 
(5.6) 
50 (45-
52) 
P* 0.51, 0.31 0.39, 0.35 0.98, 0.67 
Tyrer-Cuzick 10-
year risk (%) 
22 
11.5 
(5.5) 
10.2 
(7.7-14.6) 
546 
8.5 
(4.1) 
7.7 
(6.0-10.0) 
13 
12.1 
(4.0) 
12.7 
(9.4-14.6) 
260 
8.5 
(3.7) 
7.8 
(6.2-10.5) 
9 
10.8 
(7.3) 
7.7 
(7.3-10.8) 
286 
8.5 
(4.4) 
7.5 
(5.9-9.7) 
P* <0.01, <0.01 <0.01, <0.01 0.14, 0.36 
Baseline density 
(%) 
22 
46.8 
(27.8) 
50 (20-
70) 
553 
43.4 
(24.7) 
45 (20-
65) 
13 
47.3 
(31.1) 
30 (20-
80) 
263 
44.2 
(24.6) 
45 (20-
65) 
9 
46.1 
(24.1) 
55 (30-
65) 
290 
42.6 
(24.9) 
40 (20-
65) 
P* 0.52, 0.58 0.66, 0.71 0.68, 0.70 
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Table 6.1 continued 
 
Variable 
Overall Placebo Anastrozole 
Cases Controls Cases Controls Cases Controls 
Total n % Total n % Total n % Total n % Total n % Total n % 
Age at first birth (yr)  
Nulliparous 
22 
2 9.1 
544 
96 17.7 
13 
2 15.4 
258 
52 20.2 
9 
0 0.0 
286 
44 15.4 
>27 7 31.8 114 21.0 4 30.8 53 20.5 3 33.3 61 21.3 
21-27 11 50.0 234 43.0 6 46.2 104 40.3 5 55.6 130 45.5 
≤20 2 9.1 100 18.4 1 7.7 49 19.0 1 11.1 51 17.8 
P** 0.40# 0.70# 0.60# 
Oral contraception use  
Never 
22 
4 18.2 
543 
116 21.4 
13 
3 23.1 
257 
62 24.1 
9 
1 11.1 
286 
54 18.9 
Previously 18 81.8 423 77.9 10 76.9 195 75.9 8 88.9 228 79.7 
Currently 0 0.0 4 0.7 0 0.0 0 0.0 0 0.0 4 1.4 
P** 1.00# 1.00# 1.00# 
HRT use up to 12 months before 
randomisation 
 
No 
22 
22 100.0 
544 
512 94.1 
13 
13 100.0 
258 
240 93.0 
9 
9 100.0 
286 
272 95.1 
Yes 0 0.0 32 5.9 0 0.0 18 7.0 0 0.0 14 4.9 
P** 0.63# 1.00# 1.00# 
Smoking status  
Never 
22 
11 50.0 
543 
306 56.4 
13 
6 46.2 
258 
150 58.1 
9 
5 55.6 
285 
156 54.7 
Former 2 9.1 71 13.1 2 15.4 30 11.6 0 0.0 41 14.4 
Current 9 40.9 166 30.6 5 38.5 78 30.2 4 44.4 88 30.9 
P** 0.64# 0.64# 0.51# 
History of Atypical Hyperplasia or LCIS   
No 
22 
15 68.2 
544 
504 92.7 
13 
8 61.5 
258 
241 93.4 
9 
7 77.8 
286 
263 92.0 
Yes 7 31.8 40 7.4 5 38.5 17 6.6 2 22.2 23 8.0 
P** <0.01 <0.01 0.17# 
Image type  
Film 
22 
11 50.0 
553 
179 32.4 
13 
6 46.2 
263 
77 29.3 
9 
5 55.6 
290 
102 35.2 
Digital 11 50.0 374 67.6 7 53.9 186 70.7 4 44.4 188 64.8 
P** 0.09 0.20 0.29# 
 
*P-value from two-sample t-test (for means) and Wilcoxon rank sum test (for medians), respectively, for continuous variables by case status; **P-value from Pearson chi-squared 
test (# Fisher’s exact test if cell size <5) for variable categories by case status; interquartile range (IQR), standard deviation (SD). 
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Table 6.2: Cross tabulation of number of women in each Boyd category at entry to the study with category at first follow -up, by case status 
 Number of women 
Boyd 
category at 
entry 
Boyd category at first follow-up: Cases Total Boyd category at first follow-up: Controls Total 
 0%  
1-
10%  
11-
25%  
26-
50%  
51-
75%  
76-
100%  
 0%  1-10%  11-25%  26-50%  51-75%  76-100%   
0%  - - - - - - 0(0/0) - - - - - - 0(0/0) 
1-10%  - 2(0/2) - - - - 2(0/2) - 47(22/25) 1(1/0) - - - 48(23/25) 
11-25%  - 1(1/0) 4(4/0) - - - 5(5/0) - 12(6/6) 143(61/82) - - - 155(67/88) 
26-50%  - - - 4(2/2) - - 4(2/2) - - 5(2/3) 130(67/63) 1(0/1) - 136(69/67) 
51-75%  - - - - 7(2/5) - 7(2/5) - - - 6(1/5) 146(76/70) - 152(77/75) 
76-100%  - - - - - 4(4/0) 4(4/0) - - - - 8(4/4) 54(23/31) 62(27/35) 
Total 0(0/0) 3(1/2) 4(4/0) 4(2/2) 7(2/5) 4(4/0) 22(13/9) 0(0/0) 59(28/31) 149(64/85) 136(68/68) 155(80/75) 54(23/31) 553(263/290) 
 
The first number in each cell is the total number of subjects. Numbers in parentheses are the placebo and anastrozole groups, respectively; ‘-‘ indicates no entries. 
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Table 6.3: First follow-up change in density overall and by treatment, separated by case status 
Change in 
breast 
density (% ) 
Overall Placebo Anastrozole P-value* 
Cases 
(n=22) 
Controls 
(n=553) 
Cases 
(n=13) 
Controls 
(n=263) 
Cases 
(n=9) 
Controls 
(n=290) 
Placebo vs. 
Anastrozole 
Cases vs. 
Controls 
Placebo Cases 
vs. 
Anastrozole 
Cases 
Placebo 
Controls vs. 
Anastrozole 
Controls 
Anastrozole 
Cases vs. 
Anastrozole 
Controls 
Placebo 
Cases vs.  
Placebo 
Controls 
Mean (SD) 
-0.91 
(1.97) 
-0.94 
(2.64) 
-1.15 
(2.19) 
-0.80 
(2.61) 
-0.56 
(1.67) 
-1.07 
(2.68) 
0.28 0.96 0.50 0.23 0.57 0.63 
Median 
(IQR) 
0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 0.13 0.83 0.49 0.09 0.56 0.37 
<10%  
reduction: n 
(%  of 2x2) 
22 
(3.8) 
539 
(93.7) 
13 
(4.7) 
255 
(92.4) 
9 
(3.0) 
284 
(95.0) 
 
≥10%  
reduction:  
n (%  of 
2x2) 
0 
(0.0) 
14 
(2.4) 
0 
(0.0) 
8 
(2.9) 
0 
(0.0) 
6 
(2.0) 
0.49 1.00# n/a 0.47 1.00# 1.00# 
<5%  
reduction:  
n (%  of 
2x2) 
18 
(3.1) 
460 
(80.0) 
10 
(3.6) 
226 
(81.9) 
8 
(2.7) 
234 
(78.3) 
 
≥5%  
reduction:  
n (%  of 
2x2) 
4 
(0.7) 
93 
(16.2) 
3 
(1.1) 
37 
(13.4) 
1 
(0.3) 
56 
(18.7) 
0.14 0.78# 0.62# 0.10 1.00# 0.41# 
P trend** 0.96 0.63 0.56  
 
*P-value from two-sample t-test (corresponding to mean row) and Wilcoxon rank sum test (corresponding to median row) for continuous change in density, o r Pearson chi-squared  
(# Fisher’s exact test if cell size <5) for dichotomised density change (corresponding to ≥10% reduction row and ≥5% reduction row, as appropriate); **P-trend from a Wald test o f 
change in density (continuous) from separate unadjusted logistic regression models of breast cancer risk on change in density  (continuous), overall and in each treatment  arm; n /a  
represents no results since no cases lost  ≥10% density in placebo or anastrozole arm; interquartile range (IQR), standard deviation (SD). 
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6.3.2 Change in mammographic density – Boyd categories 
 
Change in density was shown in terms of the number of women in each treatment group by 
Boyd scale at baseline and first follow-up mammogram in cases and controls (Table 6.2). 
Movement between Boyd categories was minimal, and women who had a decrease in density 
moved by no more than one category below their baseline category. More controls moved to a 
lower Boyd category than cases, with only 1 (placebo) case moving downwards compared with 
31 controls; however in terms of percentages, these numbers were similar between cases and 
controls (1/22=5% of cases, 31/553=6% of controls). Out of the controls moving to a lower 
Boyd category, a similar percentage were on anastrozole (18/290=6%) as placebo (13/263=5%).  
 
6.3.3 Change in mammographic density – unadjusted tests 
 
In Table 6.3, cases and controls lost similar amounts of density overall (controls: mean change 
(%)= -0.94, ≥10% reduction=2.4%, ≥5% reduction=16.2%; cases: mean change (%)= -0.91, 
≥10% reduction=0.0%, ≥5% reduction=0.7%). This was similar in the anastrozole arm 
(controls: mean change (%)= -1.07, ≥5% reduction=18.7%; cases: mean change (%)= -0.56, 
≥5% reduction=0.3%) and placebo arm (controls: mean change (%)= -0.80, ≥5% 
reduction=13.4%; cases: mean change (%)= -1.15, ≥5% reduction=1.1%). The proportions were 
smaller for the 10% density reduction cut-point (anastrozole controls: ≥10% reduction=2.0%; 
anastrozole cases: ≥10% reduction=0.0%; placebo controls: ≥10% reduction=2.9%; placebo 
cases: ≥10% reduction=0.0%). 
 
6.3.4 Change in mammographic density – adjusted regression models 
 
Table 6.4, Table 6.5 and Table 6.6 show the effect of density change in the anastrozole arm only 
(prognostic biomarker), and in all women as a predictive biomarker (compared with the placebo 
arm as a whole and as an interaction effect, respectively). There was no consistent association 
between continuous density reduction and breast cancer risk reduction. There were no case 
subjects who lost ≥10% density in the placebo or anastrozole arm, therefore density change 
dichotomised by 5% reduction was assessed. Density reduction of at least 5% on anastrozole 
(relative to <5% reduction) had an OR of 0.53 (95% CI, 0.06 to 4.31, p=0.55) in the age-
adjusted model and 0.52 (95% CI, 0.06 to 4.26, p=0.54) in the fully-adjusted model (Table 6.4). 
Women in the anastrozole arm who experienced a 5% or greater reduction in breast density 
(relative to women in the placebo arm) had an OR of 0.36 (95% CI, 0.05 to 2.84, p=0.34) in the 
age-adjusted model and 0.34 (95% CI, 0.04 to 2.74, p=0.31) in the fully-adjusted model. 
Women who took anastrozole but experienced less than a 5% reduction in breast density 
(relative to women in the placebo arm) had an OR of 0.69 (95% CI, 0.28 to 1.69, p=0.42) in the 
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age-adjusted model and 0.68 (95% CI, 0.27 to 1.71, p=0.42) in the fully-adjusted model (Table 
6.5). The interaction effect between density reduction (≥5% reduction) and treatment 
(anastrozole) had an OR of 0.32 (95% CI, 0.03 to 3.91, p=0.37) in the age-adjusted model and 
0.23 (95% CI, 0.02 to 2.94, p=0.26) in the fully-adjusted model (Table 6.6). Only 3 women on 
placebo and 1 woman on anastrozole lost at least 5% density and went on to develop breast 
cancer. With 22 cases and 553 controls, the power to detect a difference in risk of breast cancer 
in anastrozole-treated patients who experienced a ≥5% reduction in density at first follow-up 
mammogram relative to anastrozole-treated patients who experienced a <5% reduction in 
density at first follow-up mammogram was only 7% at the 5% type-I error level. 
 
Table 6.4: (Prognostic biomarker): Odds ratios for relative risk of breast cancer on first follow-up 
reduction in density in the anastrozole arm only, from adjusted logistic regression models  
 
Variable 
Age-adjusted 
(n=295) 
Fully-adjusted# 
(n=292) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Density reduction  
Continuous reduction*1 0.92 (0.68,1.25) 0.59 0.92 (0.69,1.22) 0.55 
<10% reduction**2 Ref - Ref - 
≥10% reduction**2 n/a n/a n/a n/a 
<5% reduction**3 Ref - Ref - 
≥5% reduction**3 0.53 (0.06,4.31) 0.55 0.52 (0.06,4.26) 0.54 
 
1 Density reduction modelled as continuous reduction; 2 density reduction modelled as <10%/≥10% 
reduction; 3 density reduction modelled as <5%/≥5% reduction; density reduction adjusted for age at 
randomisation (yr) in age-adjusted models; #density reduction adjusted for age at randomisation (yr), 
body mass index at randomisation (kg/m2), baseline density (%) and Tyrer-Cuzick 10-year risk (%); 
*odds ratio (OR) represents odds of breast cancer per unit decrease in continuous density; **OR 
represents odds of breast cancer relative to the reference category (<10% reduction or <5% reduction, 
as appropriate); 95% confidence intervals (95% CIs) and P-values from Wald tests; n/a represents no 
results since no cases lost  ≥10% density in placebo or anastrozole arm. 
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Table 6.5: (Predictive biomarker I): Odds ratios for relative risk of breast cancer on first follow-up 
reduction in density for the anastrozole arm (relative to the placebo arm) in all women, from adjusted 
logistic regression models 
 
Variable 
Age-adjusted 
(n=566) 
Fully-adjusted# 
(n=560) 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Density reduction  
Continuous reduction*1 1.01 (0.85,1.19) 0.92 1.01 (0.86,1.18) 0.93 
<10% reduction**2 0.64 (0.27,1.52) 0.31 0.64 (0.26,1.55) 0.32 
≥10% reduction**2 n/a n/a n/a n/a 
<5% reduction**3 0.69 (0.28,1.69) 0.42 0.68 (0.27,1.71) 0.42 
≥5% reduction**3 0.36 (0.05,2.84) 0.34 0.34 (0.04,2.74) 0.31 
 
1 Density reduction modelled as continuous reduction; 2 density reduction modelled as a factor variable 
with 3 categories: <10% reduction anastrozole, ≥10% reduction anastrozole and placebo; 3 density 
reduction modelled as a factor variable with 3 categories: <5% reduction anastrozole, ≥5% reduction 
anastrozole and placebo; density reduction adjusted for age at randomisation ( yr) in age-adjusted 
models; # density reduction adjusted for age at randomisation (yr), body mass index at randomisation 
(kg/m2), baseline density (%) and Tyrer-Cuzick 10-year risk (%); *odds ratio (OR) represents odds of 
breast cancer per unit decrease in continuous density; **OR represents odds of breast cancer relative to 
all women in the placebo arm; 95% confidence intervals (CIs) and P-values from Wald tests; n/a 
represents no results since no cases lost  ≥10% density in placebo or anastrozole arm, therefore age -
adjusted model (2) drops 5 anastrozole controls who lost ≥10% density and had  non-missing age, hence 
n=561 and fully-adjusted model (2) drops 5 anastrozole controls who lost ≥10% density and had non -
missing full covariates, hence n=555. 
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Table 6.6: (Predictive biomarker II): Odds ratios for relative risk of breast cancer on first follow-up reduction in density, treatment, and an interaction between density reduction 
and treatment, in all women, from adjusted logistic regression models 
Variable 
Continuous1 <10% /≥10% reduction2 <5% /≥5%  reduction3 
Age-adjusted 
(n=566) 
Fully-adjusted# 
(n=560) 
Age-adjusted 
(n=566) 
Fully-adjusted# 
(n=560) 
Age-adjusted 
(n=566) 
Fully-adjusted# 
(n=560) 
OR 
(95%  CI) 
P-
value 
OR 
(95%  CI) 
P-
value 
OR 
(95%  
CI) 
P-
value 
OR 
(95%  
CI) 
P-
value 
OR 
(95%  CI) 
P-
value 
OR 
(95%  CI) 
P-
value 
Density reduction  
 
 
Continuous 
reduction*1 
1.03 
(0.85,1.25) 
0.73 
1.08 
(0.89,1.30) 
0.44 
<10%  reduction**2 
 
Ref - Ref - 
≥10%  reduction**2 n/a n/a n/a n/a 
<5%  reduction**3 
 
Ref - Ref - 
≥5%  reduction**3 
1.64 
(0.42,6.34) 
0.47 
2.15 
(0.54,8.58) 
0.28 
Treatment  
Placebo*** Ref - Ref - Ref - Ref - Ref - Ref - 
Anastrozole*** 
0.69 
(0.28,1.72) 
0.43 
0.71 
(0.28,1.80) 
0.48 n/a n/a n/a n/a 
0.76 
(0.29,1.95) 
0.56 
0.78 
(0.30,2.05) 
0.61 
Interaction+ 
0.88 
(0.62,1.28) 
0.52 
0.84 
(0.59,1.19) 
0.32 n/a n/a n/a n/a 
0.32 
(0.03,3.91) 
0.37 
0.23 
(0.02,2.94) 
0.26 
1 Density reduction modelled as continuous reduction; 2 density reduction modelled as <10%/≥10% reduction; 3 density reduction modelled as <5%/≥5% reduction; density 
reduction adjusted for age at randomisation (yr) in age-adjusted models; # density reduction adjusted for age at randomisation (yr), body mass index at randomisation (kg/m2), 
baseline density (%) and Tyrer-Cuzick 10-year risk (%); *odds ratio (OR) represents odds of breast cancer per unit decrease in continuous density; **OR represents odds of breast  
cancer relative to the reference category (<10% reduction or <5% reduction, as appropriate); ***OR represents odds of breast cancer relative to placebo; + OR represents odds o f 
an interaction effect between density reduction and treatment arm; 95% confidence intervals (CIs) and P-values from Wald tests; n/a represents no results since no cases lost  ≥10% 
density in placebo or anastrozole arm. 
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Table 6.7: Odds ratios for relative risk of breast cancer on anastrozole-induced first follow-up reduction in density (≥10% reduction and ≥5% reduction) by subgroups of covariates, 
from adjusted logistic regression models 
 
 
 
Variable 
Anastrozole, density 
reduction ≥10% (anastrozole 
arm only) 
P 
Anastrozole, density 
reduction ≥5% 
(anastrozole arm only) 
P 
Anastrozole, density 
reduction ≥10% 
(all women) 
P 
Anastrozole, density 
reduction ≥5% 
(all women) 
P 
No. of anastrozole 
case subjects/total 
number in model 
OR# 
(95% 
CI) 
No. of anastrozole 
case subjects/total 
number in model 
OR## 
(95% CI) 
No. of anastrozole 
case subjects/total 
number in model 
OR+ 
(95% 
CI) 
No. of anastrozole 
case subjects/total 
number in model 
OR++ 
(95% CI) 
Overall 
 
1/295 
0.53 
(0.06,4.31) 
0.55 
 
1/566 
0.36 
(0.05,2.84) 
0.34 
Tumour ER status   
Negative 0/240 n/a n/a 0/271 n/a n/a 
Positive 1/240 n/a n/a 1/271 n/a n/a 
Age at randomisation 
(yr)* 
  
<59 yr 0/265 n/a n/a 0/536 n/a n/a 
≥59 yr 1/265 
1.73 
(0.18,16.61) 
0.64 1/536 
1.13 
(0.13,9.60) 
0.91 
Body Mass Index 
(kg/m2)* 
  
<26.5 kg/m2 0/267 n/a n/a 0/537 n/a n/a 
≥26.5 kg/m2 1/267 
1.15 
(0.14,9.56) 
0.90 1/537 
0.79 
(0.10,6.27) 
0.82 
Baseline density (%)*   
<45% 0/269 n/a n/a 0/540 n/a n/a 
≥45% 1/269 
1.00 
(0.12,8.31) 
1.00 1/540 
0.69 
(0.09,5.49) 
0.73 
History of atypical 
hyperplasia or LCIS  
  
No 1/288 
0.60 
(0.07,4.95) 
0.64 1/559 
0.42 
(0.05,3.27) 
0.41 
Yes 0/288 n/a n/a 0/559 n/a n/a 
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Table 6.7 continued 
 
 
*Continuous variables dichotomised by their median (Table 5.1: overall column, median time between baseline and first follow-up mammogram=2.1 years); #odds ratio (OR) 
represents odds of breast cancer for women with ≥10% density reduction relative to women with<10% density reduction, in diffe rent subgroups, in the anastrozole arm on ly; ##OR 
represents odds of breast cancer for women with ≥5% density reduction relative to women with <5% density reduction, in different subgroups, in the anastrozole arm only; +OR 
represents odds of breast cancer for women with ≥10% density reduction relative to all women in the placebo arm, in different  subgroups; ++OR represents odds of breast cancer 
for women with ≥5% density reduction relative to all women in the placebo arm, in different subgroups; density reduction adju sted for age at randomisation (yr); 95% confidence 
intervals (95% CIs) and P-values from Wald tests; no results for ≥10% reduction since no cases lost  ≥10% density in placebo or anastrozole arm; n/a represents no results since 
subgroup numbers were small and perfectly predicted breast cancer. 
HRT use up to 12 
months before 
randomisation 
 
 
 
 
No 1/291 
0.57 
(0.07, 4.66) 
0.60 1/552 
0.39 
(0.05,3.08) 
0.37 
Yes 0/291 n/a n/a 0/552 n/a n/a 
Tyrer-Cuzick 10-year 
risk (%)* 
  
<7.8% 1/267 
1.07 
(0.13,8.94) 
0.95 1/537 
0.74 
(0.09,5.88) 
0.77 
≥7.8% 0/267 n/a n/a 0/537 n/a n/a 
Image type   
Film 1/258 
1.63 
(0.19,13.87) 
0.66 1/529 
1.13 
(0.14,9.17) 
0.91 
Digital 0/258 n/a n/a 0/529 n/a n/a 
Time between baseline 
mammogram and first 
follow-up 
mammogram (yr)* 
  
<2.1 yr 1/268 
1.07 
(0.13,8.90) 
0.95 1/539 
0.74 
(0.09,5.87) 
0.77 
≥2.1 yr 0/268 n/a n/a 0/539 n/a n/a 
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6.3.5 Subgroup analyses 
 
Table 6.7 shows the estimated effect of anastrozole-induced density reduction as a prognostic 
biomarker (≥10% or ≥5% reduction relative to <10% or <5% reduction, respectively, in the 
anastrozole arm) and a predictive biomarker (≥10% or ≥5% anastrozole-induced density 
reduction relative to placebo in all women), in different subgroups of covariates. Continuous 
covariates were dichotomised by their medians in all women, because there were no differences 
by treatment arm (Table 5.1). There was too little data for the primary analysis, which was even 
smaller when conducting the subgroup analyses. Since there were no case subjects who lost 
≥10% density in the placebo or anastrozole arm, only density change dichotomised by 5% 
reduction could be assessed. However, the number of women in each subgroup for the 5% cut-
point was too small to obtain any useful results since there was only 1 anastrozole case who lost 
at least 5% density, thus the subgroup(s) that she did not belong to contained no anastrozole 
cases with ≥5% reduction and the odds ratios could not be calculated.  
 
6.3.6 Impact of length of time between the baseline and first follow-up mammogram on 
breast cancer risk 
 
The length of time between the baseline and first follow-up mammogram was not associated 
with breast cancer risk (OR per year=1.02 (95% CI, 0.96 to 1.07), p=0.56), and there was no 
statistically significant difference between cases and controls in relation to length of time 
between the baseline and first follow-up mammogram (mean difference cases minus controls = -
1.0 months (95% CI, -4.3 months to 2.4 months), two-sample t-test p=0.56, Wilcoxon rank sum 
test p=0.52). In summary, length of time between baseline and first follow-up mammogram did 
not appear to be associated with risk of breast cancer. 
 
6.3.7 Missing covariate data 
 
As a sensitivity analysis, the age-adjusted regression models (n=295 and n=566) were run in the 
subgroup of women with non-missing data for all adjusting variables (i.e. the subgroup included 
in fully-adjusted multivariable regression models: n=292 and n=560, respectively), to test 
whether adjusted results were robust to missing data. There was only a small amount of missing 
data for adjusting covariates and the results of these sensitivity models were similar to those in 
the main analysis (results not reported); hence the analysis was robust to missing data. 
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6.4 Discussion 
 
The sample size of this study was too small to determine whether anastrozole-induced density 
reduction is a prognostic and predictive biomarker of breast cancer risk reduction, therefore 
results could not be inferred. A larger study with more case subjects is needed to truly test this 
hypothesis. However, given there was little effect of prophylactic anastrozole on density change 
observed in Chapter 5, these data suggest that density change might not be an effective 
prognostic or predictive marker of breast cancer risk reduction with prophylactic anastrozole. 
 
IBIS-I was the first trial to suggest that change in density might be a biomarker of the beneficial 
effect of endocrine therapy. Cuzick et al. found that women who had at least a 10% reduction in 
visually-assessed density in the first 12-18 months of prophylactic tamoxifen treatment had an 
approximate 63% reduction in breast cancer risk compared with women on placebo, whilst 
women who experienced <10% density reduction on tamoxifen had no difference in risk 
compared with women on placebo (19). It was suggested that women who experience the 
greatest density reductions after 12-18 months of tamoxifen may be responding to the drug and 
would perhaps benefit from continuing with their 5 year course of treatment (418). Women who 
see a more modest reduction or increase in density might not be responding to treatment and 
may benefit from alternative therapies such as exercise and dietary interventions to reduce 
weight, or chemoprevention with other SERMs or AIs.  
 
Other studies have since tested Cuzick et al.’s results and provided evidence for density change 
to be used as a biomarker for tamoxifen treatment also in the adjuvant setting (Chapter 4). With 
respect to aromatase inhibitors, a study by Kim et al. found that the hazard ratio for risk of 
recurrence in AI-treated women who lost <5% density compared with women who lost ≥5% 
density after 8-20 months of treatment was 7.11 (95% CI, 0.90 to 56.37, p=0.06). However, as 
discussed in Chapter 4, there were some quality issues with this study, and one should bear this 
in mind when interpreting the results. It is therefore still unclear whether density reduction as a 
result of treatment with aromatase inhibitors can similarly be used as a biomarker for treatment 
efficacy. 
 
As discussed in Chapter 4, low compliance (as a result of side effects of endocrine therapy) in 
the treatment arm might be a marker of treatment efficacy. A test of compliance between 
treatment arms by case-control status was completed in Chapter 5 (5.3.11). This suggested that 
the lower rate of breast cancers in women with larger density reductions was not due to better 
compliance because cases on either anastrozole or placebo had similar compliance regardless of 
density reduction. Nonetheless, the question still remains as to whether the joint association 
between compliance, side effects and density can be used as a biomarker for individual response 
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to treatment. In the Kaplan Meier graphs from Chapter 5 (5.3.11), anastrozole controls who lost 
at least 5% or 10% density were more likely to stop treatment earlier than women who lost less 
than 5% or 10% density, respectively (although log-rank tests were not significant). This effect 
was reversed in cases and placebo controls. This could potentially be a marker that treatment 
was working in these women, causing side effects and hence lower compliance, higher density 
reduction and breast cancer-free ‘control’ status. However, this hypothesis is purely speculative 
and requires validation and further assessment in another study.  
 
There were several strengths of this study. Most of the strengths were outlined in Chapter 5, but 
some additional points relevant to this case-control study are listed below: 
 This is the first known study to examine anastrozole-induced density reduction as a 
biomarker for breast cancer risk reduction in the preventive setting. 
 The inclusion of a placebo arm enabled assessment of density reduction as a predictive 
biomarker. 
 Exclusion of cases with a breast cancer diagnosis before or at first follow-up mammogram 
ensured that timings were appropriate and that the predictor occurred before the event. 
 Measuring density change as both a continuous and dichotomous variable allowed for 
assessment of multiple density change predictors, which found that the 5% cut-point for 
dichotomised density change might be a better threshold than the 10% cut-point for smaller 
density reductions occurring with anastrozole. 
 
There were several limitations of this study. Again, most of the limitations were outlined in 
Chapter 5, but some additional points relevant to this case-control study are listed below: 
 The major limitation of the study is the small number of cases and hence limited power to 
detect an effect of treatment-induced density change on breast cancer risk. The main 
analysis included just one woman from the anastrozole case group who lost at least 5% 
density. Clearly, more women are required to see if this is an effect that may be 
representative of the population. 
 Using an intention to treat analysis has the disadvantage that treatment administered does 
not necessarily mean treatment consumed. However, assessments of compliance showed no 
difference in adherence between cases or controls who did or did not lose density, therefore 
it is unlikely that compliance was a confounding factor. 
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6.5 Conclusion 
 
The sample size of this study was too small to effectively test for an association between 
anastrozole-induced density reduction and breast cancer risk reduction, and therefore 
conclusions could not be drawn. Further assessment in a large sample of women with many 
breast cancer events is essential to investigate this hypothesis with enough statistical power. 
Nonetheless, given there was little effect of anastrozole on density change observed in Chapter 
5, one would not expect density change to be an effective prognostic or predictive biomarker of 
breast cancer risk reduction with prophylactic anastrozole therapy. 
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Chapter 7: Conclusions 
 
7.1 Conclusion of findings 
 
This thesis investigated the association between breast cancer risk and changes in 
mammographic density. The central thesis hypothesis was that repeated measures of 
mammographic density would be valuable for personalised breast cancer prevention. This 
hypothesis was tested over five chapters; each assessing individual study aims centred on the 
evaluation of changes in mammographic density in the assessment of breast cancer risk. An 
introduction and description of study aims, methods, results, discussions and conclusions were 
presented separately for each chapter. In this final chapter, the combined thesis findings are 
summarised and ideas for future research on changes in mammographic density are discussed, 
along with the overall impact of the thesis findings. 
 
Chapter 1 introduced mammographic density and gave an overview of the relevant literature 
relating to changes in mammographic density. The rationale for the thesis was also described as 
well as the study aims for each chapter. 
 
Chapter 2 assessed whether changes in BMI were associated with changes in breast density 
during a one year dietary weight-loss intervention study. The aim was to evaluate whether 
mammographic density acts as a potential mediator for reduction in risk of postmenopausal 
breast cancer with premenopausal weight-loss. Overall, as women lost weight, their breast fat 
decreased but little change was seen in their dense tissue, leading to a higher percentage density. 
This negated the idea that density reduction may be a biomarker for risk reduction with weight-
loss. It is likely that weight-loss-induced reductions in postmenopausal risk are driven by lower 
levels of adipose tissue, which reduce the amount of oestrogen production through 
aromatisation and hence breast cancer risk; but that this pathway is somewhat independent of 
fibroglandular dense tissue. There have been only a few studies to assess the effect of weight-
loss on dense tissue in premenopausal women, with most investigating the effect of bariatric 
surgery and reporting mixed results (252, 253). However, a reduction in dense tissue in 
premenopausal women has been seen previously with a 2 year low-fat, high-carbohydrate diet 
(251), suggesting that certain weight-loss interventions that lower blood levels of estradiol and 
estrone may be required to see such a reduction in dense tissue (296). Density was measured 
using three methods (visual/Cumulus/volumetric ‘Stepwedge’), which allowed for the 
assessment of percentage and absolute density as well as area-based and volumetric density. 
Area and volumetric measures gave similar results for the short-term association between BMI 
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and density: positive relationship with breast fat, inverse relationship with percent density and 
little relationship with dense tissue. 
 
Chapter 3 aimed to assess the benefit of using a woman’s longitudinal history of (BI-RADS) 
density to improve breast cancer risk estimation beyond using a single density measure. 
Longitudinal density was shown to have greater predictive ability and discriminatory accuracy 
than a single measure of most recent density. A quarter more statistical information was gained 
and a small proportion more women were correctly classified as having breast cancer when 
using longitudinal density instead of most recent density. Longitudinal density also predicted a 
six-fold increased risk of breast cancer for women in the highest vs. lowest longitudinal density 
categories, but only a four-fold increased risk was seen between baseline or most recent BI-
RADS density categories 4 and 1. These findings supported the only other known study to 
evaluate predictive ability when using more than one density measure compared with a single 
measure (262). Kerlikowske et al.’s large cohort study reported an AUC for the two-measure 
BI-RADS predictor that was 0.005 units higher than the one-measure predictor, whereas this 
thesis found a slightly greater improvement when including an unlimited number of BI-RADS 
measures (concordance index 0.008 units higher than the most recent BI-RADS density 
measure). The benefit of longitudinal density was driven by shrinkage estimation and a 
reduction in measurement error. There was only a small amount of information gained when 
assessing individual density trajectories, supporting the idea that density has a high amount of 
tracking through time (325, 326). Longitudinal density was also shown to have several potential 
uses in the clinical setting. Predictive accuracy of breast cancer risk models may be improved 
with the addition of longitudinal density; which would be particularly useful for breast cancer 
prevention strategies that aim to stratify screening and standards of care based on risk. 
Additionally, longitudinal density could be easily applied to a screening environment where 
mammography examinations occur at arbitrary points in time. Since longitudinal density is 
predicted using only current and previous density values, its value can be continually updated at 
each woman’s screening appointment. Moreover, risk assessed with longitudinal density would 
lead to more conservative changes between risk groups than most recent BI-RADS density, 
reducing the possibility of a woman receiving a radically different standard of care as a result of 
her moving into a different risk group.  
 
Chapter 4 was a Cochrane systematic review investigating the association between endocrine 
therapy-induced density reduction and breast cancer risk and mortality. Density reduction was 
assessed as both a prognostic and a predictive biomarker, and within each of these, the 
preventive and treatment settings were considered separately, as were the effects of SERMs and 
AIs. A literature search identified 888 potential studies to include in the review. After 
assessment of the titles and abstracts of potential studies, 87 full texts were obtained for further 
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examination. Of these, 8 studies were identified as eligible for the review according to the 
inclusion criteria. One study (19) tested density reduction as a prognostic and predictive 
biomarker for prevention of breast cancer, whilst five studies tested density reduction as a 
prognostic biomarker for the treatment of breast cancer (263-266, 373). One study tested density 
reduction in a sample of women diagnosed with breast cancer, but the analysis adjusted for 
endocrine therapy; hence it could not be classified as either a prognostic or predictive biomarker 
(372). Another study did not report any results that could be extracted so it could not be 
included in the prognostic review (374). The different classes of drugs, outcomes, 
mammographic density measures and effect measures (for instance, the cut-points used) of the 
studies were deemed too heterogeneous to be able to conduct a meaningful meta-analysis. 
Instead, the results of each study were reported in ‘Summary of findings’ tables. In the 
prognostic biomarker review (prevention), one study reported a 68% reduction in breast cancer 
risk with prophylactic tamoxifen for women who had a 12-18 month visually-assessed percent 
density reduction ≥10% compared with no change (OR=0.32 (95% CI, 0.14 to 0.72)) (19). For 
the prognostic biomarker review in the treatment setting, one study indicated an HR of 0.66 
(95% CI, 0.40 to 1.09) for risk of recurrence with an 8-20 month Cumulus-assessed percent 
density reduction ≥5% compared with <5% whilst on tamoxifen (264). For AIs, the HR was 
0.14 (95% CI, 0.02 to 1.11) using the same biomarker (264). Another prognostic biomarker 
review study (treatment) reported a 65% reduction in risk of recurrence for women with a 10-34 
month tamoxifen-induced reduction in BI-RADS density compared with no reduction (HR=0.35 
(95% CI, 0.17 to 0.68)) (263). In terms of mortality, for the prognostic biomarker review 
(treatment), one study reported a 50% reduction in risk of breast cancer death with 6-36 month 
tamoxifen-induced relative reduction in dense area (machine-learned area-based method) >20% 
compared with little change (≤9% increase to ≤10% reduction) (HR=0.50 (95% CI, 0.27 to 
0.93)) (265). Another prognostic biomarker review study (treatment) reported a 56% decreased 
risk of breast cancer death with a 3-26 month tamoxifen-induced reduction in Cumulus-assessed 
percent density of >8.7% compared with <0.5% (OR=0.44 (95% CI, 0.22 to 0.88)) (266). The 
final prognostic biomarker study (treatment) reported an OR of 0.52 (95% CI, 0.18 to 1.51) for 
risk of contralateral breast cancer with a 1-5 year reduction in percent density (machine-learned 
area-based method) of ≥10% compared with little change (<10% reduction to <10% increase) 
whilst on endocrine therapy (373). In the predictive biomarker review (prevention), an 
interaction between prophylactic tamoxifen and 12-18 month visually-assessed percent density 
reduction (≥10% or <10%) had an OR for risk of breast cancer of 0.53 (95% CI, 0.21 to 1.32) 
(19). Overall, there was some evidence to suggest that density reduction may be a prognostic 
and predictive biomarker for reduction in breast cancer risk, and prognostic biomarker for 
reduction in breast cancer risk of recurrence, mortality and contralateral breast cancer with 
tamoxifen. However, the level of evidence for this biomarker was limited by several study 
quality issues. The suggestion of density reduction as a prognostic biomarker for reduction in 
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risk of recurrence whilst on AIs was also limited by study quality issues and requires further 
investigation. 
 
Chapter 5 aimed to assess the effect of prophylactic anastrozole on visually-assessed density 
reduction during the IBIS-II trial. After 2 years of anastrozole treatment, breast density 
decreased by an average of 1.05%, but this was not significantly different from the 0.82% mean 
density reduction on placebo. It is likely that prophylactic anastrozole treatment reduces breast 
density by only a small amount and this was not captured by the study due to limited power. 
However, this is the largest known study to assess the effect of a preventive AI on density, and 
the lack of a significant effect even with a considerable sample size (n=575) further suggests 
only a marginal effect of anastrozole on density. These results were in concordance with 
previous studies reporting a null or very minimal effect of AIs in both the preventive (268-270) 
and adjuvant (267, 337) settings. Whilst a study by Engmann et al. reported a significant 
reduction in volumetric density with adjuvant AIs, the effect was again small with only a 0.3% 
greater reduction in Volpara percent density and 0.6% greater reduction in Quantra percent 
density for breast cancer cases on 2-3 years of AIs compared with breast cancer-free controls on 
no treatment. To see such small changes in density with AI treatment, it may be necessary to use 
volumetric measures that account for overlapping dense tissue within the breast. Use of 
volumetric methods to test the effect of AIs on density requires further exploration. 
 
Chapter 6 aimed to investigate visually-assessed density reduction with prophylactic anastrozole 
as a biomarker for concurrent breast cancer risk reduction using a case-control study from the 
IBIS-II trial. Unfortunately, the number of breast cancer cases was not large enough for the 
study to be adequately powered (n=22), and the number of cases who lost at least 10% or 5% 
density was minimal. Therefore, the sample size was too small to infer an effect and no 
definitive conclusions could be drawn. 
 
Overall, changes in mammographic density were shown to be useful for the assessment of 
breast cancer risk. Repeated measures of density have great potential for use in personalised 
breast cancer prevention. Their use in improving the accuracy of breast cancer risk estimation 
and in indicating response to endocrine treatment could prove to be extremely valuable for 
breast cancer prevention strategies. 
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7.2 Future research: use of changes in mammographic density for breast 
cancer prevention 
 
This thesis revealed two main avenues for further research: (a) further development and 
validation of the longitudinal density measure with the ultimate aim of incorporating it into 
established breast cancer risk models, (b) expanding evidence on mammographic density 
reduction as a biomarker for reduction in risk and mortality with endocrine therapy.  
 
Several approaches can be used to further develop the longitudinal density measure. Firstly, it 
would be useful to test the benefit of applying different weightings to historical density values. 
For instance, more recent values may require up-weighting, whereas earlier mammograms may 
be less informative and require application of ‘forgetting factors’. Secondly, including 
additional confounders of density in the linear mixed model or modelling the mixed effects in a 
multinomial or ordinal logit model may improve the prediction of the longitudinal density 
measure. Thirdly, the ability of longitudinal density to stratify breast cancer risk might be 
improved with the addition of other classical risk factors or a longitudinal measure of BMI in 
the proportional-hazards Cox model. Additionally, estimation of breast cancer risk with 
longitudinal density may be improved with a joint longitudinal-survival model that maximises 
likelihood in both models simultaneously (330, 331). It would then be important to validate the 
longitudinal density measure in other cohorts of women and using different density measures, as 
well as testing the benefit of this measure in established breast cancer risk models such as the 
Tyrer-Cuzick, Gail or BCSC model.  
 
Establishing whether a reduction in density can be used as a biomarker for response to 
endocrine therapy is another priority for future research on changes in mammographic density. 
A meta-analysis of individual participant-level data from the best quality studies identified in 
the Cochrane systematic review would help to overcome some of the quality issues identified as 
well as account for heterogeneity between studies. Gathering further evidence to support this 
biomarker is essential if it is to be implemented into clinical practice. Additionally, in the 
Cochrane review, there was little evidence for other endocrine therapies besides tamoxifen. 
With AIs, it is important to first determine whether density reductions truly occur whilst on the 
drug. Only then can AI-induced density reduction be tested as a biomarker for breast cancer 
incidence or death. It is therefore important to continue to test the effect of AIs on density 
change, for instance using volumetric methods that may capture changing breast phenotypes 
that area-based methods have so far failed to do. 
 
Another possible future study for consideration combines these two avenues of research. Whilst 
the addition of random slopes showed little benefit in estimating breast cancer risk in Chapter 3, 
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it should be noted that women in this cohort study were part of a population-based screening 
programme with a mixture of underlying baseline risks. Random slopes may in fact be more 
useful in high-risk populations of women undergoing active treatment to reduce their risk, or 
breast cancer patients on a course of adjuvant treatment. As seen in Chapter 4, multiple cut-
points are currently used to assess endocrine therapy-induced density reduction and breast 
cancer outcomes. It may be more useful to assess within-women changes in density across the 
course of endocrine therapy to assess whether they differ from individual random slopes 
predicted from a linear mixed model using data from before treatment commencement. A 
density decline greater than a woman’s predicted trajectory might signify a response to 
treatment, and it would be useful to investigate this hypothesis in a future study. 
 
7.3 Impact of the thesis findings 
 
The findings of this thesis have the potential to be useful for breast cancer prevention in several 
ways. Optimising the longitudinal density measure to better predict risk of breast cancer could 
help to identify women at low- and high-risk of developing breast cancer who would benefit 
from more tailored prevention regimes. For instance, risk-stratified screening would allow those 
at a higher risk of developing breast cancer to be screened more frequently, and those at a lower 
risk to be screened less frequently than the current practice of inviting all women for the same 
frequency of screening regardless of risk (134, 419). High-risk women may also benefit from 
supplemental imaging using modalities such as MRI or ultrasound (134), and having a greater 
amount of information on their risk of breast cancer could be useful for helping women to make 
more informed decisions about lifestyle choices that may be influencing their risk of developing 
the disease, such as diet, exercise and alcohol intake (420, 421). Alternatively, high-risk women 
may benefit from a course of treatment with a chemo-preventive drug to lower their risk (134, 
421). Recommendations for chemoprevention are already outlined in NICE guidelines, whereby 
a 5-year course of tamoxifen or raloxifene is advised for women at high or moderate familial 
risk (422, 423), and in 2017, these guidelines were updated to include a 5-year course of 
anastrozole for postmenopausal women at high or moderate familial risk, without severe 
osteoporosis (422). 
 
Chemoprevention highlights another potential use for the findings of this thesis. Chapter 4 
suggested that endocrine therapy-induced density reduction is a promising biomarker for 
reduction in breast cancer risk and mortality. If this biomarker were to be implemented in 
practice, it would act as a quick and cost-effective tool for assessing response to treatment that 
would be less invasive than the alternative tissue and blood sample biomarkers. Additionally, 
density change is an early biomarker that can be measured approximately a year after the start of 
treatment. In theory, this biomarker should therefore result in fewer diagnoses of breast cancer if 
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non-responders are given the chance to try alternative risk-reducing treatments early on when 
there is time to prevent the development of a potential tumour. This would also be relevant in 
the adjuvant setting whereby changing the treatment of non-responders and intervening at an 
early stage would be an improvement on the current “wait-and-see” approach whereby a lack of 
treatment response is often only revealed at the point of breast cancer recurrence or death. This 
makes density change a particularly useful biomarker with the potential to save a number of 
lives. 
 
To conclude, this thesis showed that changes in mammographic density were useful for the 
study of breast cancer risk and should be considered for personalised breast cancer prevention 
strategies. Future research into the area of changes in mammographic is a priority. It is 
important that health practitioners, policy makers and patients benefit from the findings of this 
thesis and make use of the great potential that changes in mammographic density have for breast 
cancer prevention. 
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Appendix A:  Supplementary material for Chapter 3 
A.I Histogram of body mass index 
 
 
Before imputation, before winsorising. 
47,390 women had one or more mammograms with missing body mass index (BMI): 
 
 3,409 women had only baseline mammogram with missing BMI (only baseline imputed) 
 2,638 women had baseline mammogram with missing BMI (baseline imputed) and at least 
one follow-up mammogram with missing BMI (carried forward) 
 41,343 women had only follow-up mammograms with missing BMI (carried forward) 
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A.II Table for number and frequency of mammograms per woman (by age 
at baseline group) 
 
Age at baseline 
(yr) 
Measure 
Median (IQR) 
Time (yr) 
0-5 5-10 10-15 15+ 
All 
Number of mammograms 
(except baseline) per woman 
1 (0-2) 2 (1-3) 2 (2-3) 2 (1-2) 
Frequency of mammograms 
(per yr) per woman 
0.4  
(0-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.9) 
40-44 
Number of mammograms 
(except baseline) per woman 
1 (0-2) 2 (1-3) 2 (2-3) 2 (1-2) 
Frequency of mammograms 
(per yr) per woman 
0.4  
(0-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.8) 
0.6 
(0.5-0.9) 
45-49 
Number of mammograms 
(except baseline) per woman 
1 (0-2) 2 (2-3) 3 (2-4) 2 (1-2) 
Frequency of mammograms 
(per yr) per woman 
0.4  
(0-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.9) 
50-54 
Number of mammograms 
(except baseline) per woman 
2 (1-2) 2 (2-3) 2 (2-4) 2 (1-2) 
Frequency of mammograms 
(per yr) per woman 
0.4 
(0.2-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.9) 
55-59 
Number of mammograms 
(except baseline) per woman 
2 (0-2) 2 (2-3) 2 (2-3) 1 (1-2) 
Frequency of mammograms 
(per yr) per woman 
0.4 
 (0-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.9) 
60-64 
Number of mammograms 
(except baseline) per woman 
2 (0-2) 3 (2-3) 1 (1-2) - 
Frequency of mammograms 
(per yr) per woman 
0.4  
(0-0.6) 
0.6 
(0.4-0.8) 
0.6 
(0.4-0.9) 
- 
65+ 
Number of mammograms 
(except baseline) per woman 
2 (1-2) 2 (1-2) - - 
Frequency of mammograms 
(per yr) per woman 
0.4 
(0.2-0.6) 
0.6 
(0.5-0.9) 
- - 
 
Frequency of mammograms is measured over the time at-risk for each woman in each time period. 
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A.III Plots of predicted density against age at baseline for a woman with 
body mass index 25kg/m2 
Likelihood ratio tests for model compared with previous model: 
Linear age 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗 + 𝑒𝑖𝑗   
 
Quadratic age 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=140.9, p=1.7x10-32 
 
Cubic age 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=1050.4, p=2.0x10-230 
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Quartic age 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3   + 𝛽5𝑎𝑔𝑒𝑖𝑗
4 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=77.1, p=1.6x10-18 
 
Age to the power of 5 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3   + 𝛽5𝑎𝑔𝑒𝑖𝑗
4   + 𝛽6𝑎𝑔𝑒𝑖𝑗
5 + 𝑒𝑖𝑗     
-> ΔLR-χ2(1)=9.6, p=0.002 
 
Age to the power of 6 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3   + 𝛽5𝑎𝑔𝑒𝑖𝑗
4   + 𝛽6𝑎𝑔𝑒𝑖𝑗
5   + 𝛽7𝑎𝑔𝑒𝑖𝑗
6 +
 𝑒𝑖𝑗    
-> ΔLR-χ2(1)=33.3, p=8.1x10-09 
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Age to the power of 7 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3   + 𝛽5𝑎𝑔𝑒𝑖𝑗
4   + 𝛽6𝑎𝑔𝑒𝑖𝑗
5  + 𝛽7𝑎𝑔𝑒𝑖𝑗
6  + 𝛽8𝑎𝑔𝑒𝑖𝑗
7 + 𝑒𝑖𝑗     
-> ΔLR-χ2(1)=31.9, p=1.6x10-08 
 
Age to the power of 8 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+𝛽1𝐵𝑀𝐼𝑖𝑗 + (𝛽2 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽3𝑎𝑔𝑒𝑖𝑗
2  + 𝛽4𝑎𝑔𝑒𝑖𝑗
3   + 𝛽5𝑎𝑔𝑒𝑖𝑗
4   + 𝛽6𝑎𝑔𝑒𝑖𝑗
5  + 𝛽7𝑎𝑔𝑒𝑖𝑗
6  + 𝛽8𝑎𝑔𝑒𝑖𝑗
7  + 𝛽9𝑎𝑔𝑒𝑖𝑗
8 + 𝑒𝑖𝑗     
-> ΔLR-χ2(1)=0.6, p=0.43 
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A.IV Plots of predicted density against body mass index for a woman 40 
years old at baseline 
Likelihood ratio tests for model compared with previous model: 
Linear BMI 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝑒𝑖𝑗   
 
Quadratic BMI 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=3.6, p=0.06 
 
Cubic BMI 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3 + 𝑒𝑖𝑗    
-> ΔLR-χ2(1)=43.1, p=5.1x10-11 
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Quartic BMI 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝑒𝑖𝑗     
-> ΔLR-χ2(1)=655.5, p=1.4x10-144 
 
BMI to the power of 5 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4  + 𝛽6𝐵𝑀𝐼𝑖𝑗
5 + 𝑒𝑖𝑗    
-> ΔLR-χ2(1)=15.7, p=7.3x10-05 
 
BMI to the power of 6 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 + 𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4  + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6 +
𝑒𝑖𝑗   
-> ΔLR-χ2(1)=171.4, p=3.7x10-39 
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BMI to the power of 7 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6  + 𝛽8𝐵𝑀𝐼𝑖𝑗
7 + 𝑒𝑖𝑗  
-> ΔLR-χ2(1)=18.3, p=1.9x10-05 
 
BMI to the power of 8 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6  + 𝛽8𝐵𝑀𝐼𝑖𝑗
7 +
 + 𝛽9𝐵𝑀𝐼𝑖𝑗
8 + 𝑒𝑖𝑗  
-> ΔLR-χ2(1)=26.1, p= 3.2x10-07 
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BMI to the power of 9 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6  + 𝛽8𝐵𝑀𝐼𝑖𝑗
7  + 𝛽9𝐵𝑀𝐼𝑖𝑗
8 +
 + 𝛽10𝐵𝑀𝐼𝑖𝑗
9 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=9.5, p= 0.002 
 
BMI to the power of 10 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6  + 𝛽8𝐵𝑀𝐼𝑖𝑗
7  + 𝛽9𝐵𝑀𝐼𝑖𝑗
8 +
 + 𝛽10𝐵𝑀𝐼𝑖𝑗
9  + 𝛽11𝐵𝑀𝐼𝑖𝑗
10 + 𝑒𝑖𝑗  
-> ΔLR-χ2(1)=19.0, p= 1.3x10-05 
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BMI to the power of 11 
 𝑦𝑖𝑗 = 𝛽0 + 𝑢0𝑖+(𝛽1 +
𝑢1𝑖)𝑎𝑔𝑒𝑖𝑗  + 𝛽2𝐵𝑀𝐼𝑖𝑗 + 𝛽3𝐵𝑀𝐼𝑖𝑗
2  + 𝛽4𝐵𝑀𝐼𝑖𝑗
3  + 𝛽5𝐵𝑀𝐼𝑖𝑗
4 + 𝛽6𝐵𝑀𝐼𝑖𝑗
5  + 𝛽7𝐵𝑀𝐼𝑖𝑗
6  + 𝛽8𝐵𝑀𝐼𝑖𝑗
7  + 𝛽9𝐵𝑀𝐼𝑖𝑗
8 +
 + 𝛽10𝐵𝑀𝐼𝑖𝑗
9  + 𝛽11𝐵𝑀𝐼𝑖𝑗
10 + 𝛽12𝐵𝑀𝐼𝑖𝑗
11 + 𝑒𝑖𝑗   
-> ΔLR-χ2(1)=1.9, p=0.17 
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A.V Comparison of observed relative risk distributions for most recent density and longitudinal density (40-50yr) 
 
 (a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for 45y/o for each 
model); (b) Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups a t each 6 month period. 
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A.VI Comparison of observed relative risk distributions for most recent density and longitudi nal density (50-60yr) 
 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for 55y/o for each 
model); (b) Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups at each 6 month period. 
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A.VII Comparison of observed relative risk distributions for most recent density and longitudinal density (60yr+)  
 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr and 10yr (HRs relative to the average HR at 0.5yr for 65y/o for each model); (b)  
Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups at each 6 mon th period. 
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A.VIII  Comparison of statistical information (proportional -hazards Cox 
model fit) in different breast density measures (body mass index not 
imputed) 
Model BMI Density df 
LR-χ2 
(model) 
AIC 
(model) 
df 
ΔLR-χ2 
(density) 
ΔAIC 
(density) 
1 Baseline Baseline 5 601.8 57,503.4 3 294.4 288.4 
2 
Most 
recent 
Most recent 5 604.8 57,500.5 3 291.8 285.8 
3 
Most 
recent 
Longitudinal 4 692.3 57,410.9 2 379.3 375.3 
 
Body mass index (BMI) windsorised; clock starts at new baseline mammogram; ΔLR-χ2 represents the 
difference in likelihood ratio statistics (LR-χ2) between a model fit to age at baseline and most recent BMI 
and a model additionally incorporating the density term(s); ΔAIC represents the difference in Akaike 
Information Criterion (AIC) between a model fit to age and BMI and a model additionally incorpora t ing  
the density term(s); n=129,748 women. 
 
A.IX Comparison of statistical information (proportional -hazards Cox 
model fit) in different breast density measures (no screen-detected 
mammograms) 
Model BMI Density df 
LR-χ2 
(model) 
AIC 
(model) 
df 
ΔLR-χ2 
(density) 
ΔAIC 
(density) 
1 Baseline Baseline 5 604.8 58,394.3 3 296.0 290.0 
2 
Most 
recent 
Most recent 5 628.0 58,371.1 3 314.5 308.5 
3 
Most 
recent 
Longitudinal 4 701.0 58,296.1 2 387.6 383.6 
 
Mammograms removed if up to 6 months before event; clock starts at new baseline mammogram; ΔLR-χ2 
represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at baseline and 
most recent body mass index (BMI) and a model additionally incorporating the density term(s); ΔAIC 
represents the difference in Akaike Information Criterion (AIC) between a model fit to age and BMI and a 
model additionally incorporating the density term(s); includes all women since everyone had at least a 
baseline mammogram and there were no screen-detected baseline mammograms (women excluded if 
breast cancer event occurred <0.5yr after start of follow-up). 
 
 
274 
 
 
 
A.X Comparison of statistical information (proportional -hazards Cox model 
fit) in different breast density measures (by age at baseline group) 
 
Age at baseline (yr) Density measure 
ΔLR-χ2 (density) 
Time (yr) 
All 0-5 5-10 10-15 15+ 
All 
Baseline 296.2 170.4 106.9 39.6 10.1 
Most recent 307.7 187.2 98.7 31.1 13.9 
Longitudinal 379.6 221.7 133.6 43.6 8.3 
40-44 
Baseline 50.0 14.4 18.0 8.5 2.6 
Most recent 36.9 13.6 12.6 12.3 2.1 
Longitudinal 45.4 13.3 21.9 10.4 1.2 
45-49 
Baseline 62.9 24.2 21.0 14.7 4.9 
Most recent 65.2 31.2 27.3 11.0 5.6 
Longitudinal 77.4 37.4 31.6 20.6 3.1 
50-54 
Baseline 50.5 27.6 18.8 10.0 5.4 
Most recent 59.5 36.1 24.2 11.3 4.1 
Longitudinal 71.5 39.0 28.3 11.0 2.8 
55-59 
Baseline 54.6 51.5 16.3 5.7 3.3 
Most recent 55.9 39.0 20.6 2.7 8.0 
Longitudinal 64.7 57.3 21.8 2.9 3.5 
60-64 
Baseline 39.6 23.6 23.8 10.0 - 
Most recent 56.2 32.6 22.9 6.8 - 
Longitudinal 70.1 39.1 24.5 10.9 - 
65+ 
Baseline 43.9 39.4 13.5 - - 
Most recent 49.8 47.2 8.1 - - 
Longitudinal 61.1 51.7 10.8 - - 
 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s); age at baseline fitted in the model is the age at the start of each time period. 
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A.XI Comparison of statistical information (proportional-hazards Cox 
model fit) in different breast density measures (by menopausal status 
at baseline) 
Menopausal status Density measure 
ΔLR-χ2 (density) 
Time (yr) 
All 0-5 5-10 10-15 15+ 
Premenopausal 
Baseline 87.9 25.3 43.6 18.1 8.5 
Most recent 95.6 33.7 44.8 16.7 10.9 
Longitudinal 108.0 33.3 59.0 21.0 6.1 
Postmenopausal 
Baseline 173.6 122.4 49.7 21.7 3.6 
Most recent 166.8 130.4 41.4 10.1 6.7 
Longitudinal 222.5 160.8 62.3 19.6 3.1 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s). 
A.XII Comparison of statistical information (proportional -hazards Cox 
model fit) in different breast density measures (in women with the 
longest follow-up (<60yr at baseline and before 2000)) 
Subgroup Density measure 
ΔLR-χ2 (density) 
Time (yr) 
All 0-5 5-10 10-15 15+ 
All 
Baseline 172.9 80.6 61.6 29.9 10.1 
Most recent 160.0 86.7 61.8 21.3 13.9 
Longitudinal 199.2 100.6 87.2 33.1 8.3 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s). 
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A.XIII  Comparison of statistical information (proportional -hazards Cox 
model fit) in different breast density measures (by menopausal status 
at baseline, in women with the longest follow-up (<60yr at baseline 
and before 2000)) 
Menopausal status Density measure 
ΔLR-χ2 (density) 
Time (yr) 
All 0-5 5-10 10-15 15+ 
Premenopausal 
Baseline 69.7 18.0 32.9 13.4 8.5 
Most recent 63.2 20.4 31.4 10.9 10.9 
Longitudinal 72.0 21.2 45.4 14.6 6.1 
Postmenopausal 
Baseline 92.8 53.0 31.7 18.5 3.6 
Most recent 80.2 60.1 27.0 7.0 6.7 
Longitudinal 112.6 73.9 45.6 14.5 3.1 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s). 
A.XIV Comparison of statistical information (proportional -hazards Cox 
model fit) in different breast density measures (by film/digital at 
baseline) 
Mammogram type Density measure 
ΔLR-χ2 (density) 
Time (yr) 
0-5 
Film 
Baseline 161.9 
Most recent 171.3 
Longitudinal 211.0 
Digital 
Baseline 14.3 
Most recent 21.3 
Longitudinal 24.5 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s); Film=baseline year <2007, digital= baseline year ≥2007; only assessing 0 -5yr to reduce 
overlap of follow-up from film to digital. 
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A.XV Comparison of statistical information (proportional-hazards Cox 
model fit) in different breast density measures (by BI-RADS 3rd/4th at 
baseline) 
Lexicon Density measure 
ΔLR-χ2 (density) 
Time (yr) 
0-5 
BI-RADS 3rd 
Baseline 143.9 
Most recent 147.3 
Longitudinal 183.3 
BI-RADS 4th 
Baseline 52.7 
Most recent 56.4 
Longitudinal 69.3 
 
ΔLR-χ2 represents the difference in likelihood ratio statistics (LR-χ2) between a model fit to age at 
baseline and most recent body mass index (BMI) and a model additionally incorporating the density 
term(s); BI-RADS 3rd lexicon=baseline year <2003, BI-RADS 4th lexicon=baseline year ≥2003; only 
assessing 0-5yr to reduce overlap of follow-up from BI-RADS 3rd lexicon to BI-RADS 4th lexicon. 
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A.XVI Comparison of observed relative risk distributions for most recent density and longitudinal density (women with at least 3 
mammograms, 40-50yr) 
 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for 45y/o for each 
model); (b) Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups a t each 6 month period. 
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A.XVII Comparison of observed relative risk distributions for most recent density and longitudinal density (women with at least 3 
mammograms, 50-60yr) 
 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr, 10yr and 15yr (HRs relative to the average HR at 0.5yr for 55y/o for each 
model); (b) Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups a t each 6 month period. 
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A.XVIII Comparison of observed relative risk distributions for most recent density and longitudi nal density (women with at least 3 
mammograms, 60yr+) 
 
(a) Histograms showing the distribution of relative hazard ratios (HRs) for each model at 0.5yr, 5yr and 10yr (HRs relative to the average HR at 0.5yr for 65y/o for each model); (b)  
Graph showing the percentage of women in the lowest (<1/2 relative HR) and highest (2+ relative HR) risk groups at each 6 month period.  
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Appendix B: Supplementary material for Chapter 4 
B.I Search: CENTRAL 
#1 MeSH descriptor: [Selective Estrogen Receptor Modulators] explode all trees 
#2 MeSH descriptor: [Aromatase Inhibitors] explode all trees 
#3 MeSH descriptor: [Tamoxifen] explode all trees 
#4 tamoxifen 
#5 MeSH descriptor: [Raloxifene Hydrochloride] explode all trees 
#6 raloxifene or lasofoxifene or arzoxifene or droloxifene or bazedoxifene or fulvestrant or 
anastrozole or letrozole or exemestane 
#7 #1 or #2 or #3 or #4 or #5 or #6 
#8 MeSH descriptor: [Breast Density] explode all trees 
#9 (mammogr* or breast or mammary) near dens* 
#10 MeSH descriptor: [Mammography] explode all trees 
#11 MeSH descriptor: [Mammary Glands, Human] explode all trees 
#12 dens* 
#13 (#10 or #11) and #12 
#14 #8 or #9 or #13 
#15 #7 and #14 
 
B.II Search: MEDLINE via OvidSP 
1. exp Selective Estrogen Receptor Modulators/ 
2. exp Aromatase Inhibitors/ 
3. exp TAMOXIFEN/ 
4. tamoxifen.mp. 
5. exp Raloxifene Hydrochloride/ 
6. raloxifene.mp. 
7. lasofoxifene.mp. 
8. arzoxifene.mp. 
9. droloxifene.mp. 
10. bazedoxifene.mp. 
11. fulvestrant.mp. 
12. anastrozole.mp. 
13. letrozole.mp. 
14. exemestane.mp. 
15. or/1-14 
16. exp Breast Density/ 
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17. exp MAMMOGRAPHY/ 
18. exp Mammary Glands, Human/ 
19. ((mammogr* or breast or mammary) adj6 dens*).tw. 
20. dens*.tw. 
21. (17 or 18) and 20 
22. 16 or 19 or 21 
23. 15 and 22 
24. Animals/ not Humans/ 
25. 23 not 24 
26. limit 25 to yr=“1996 -Current” 
 
B.III Search: Embase via OvidSP 
1. exp selective estrogen receptor modulator/ 
2. exp aromatase inhibitor/ 
3. exp tamoxifen/ 
4. tamoxifen.ti,ab. 
5. exp raloxifene/ 
6. raloxifene.ti,ab. 
7. exp lasofoxifene/ 
8. lasofoxifene.ti,ab. 
9. exp arzoxifene/ 
10. arzoxifene.ti,ab. 
11. exp droloxifene/ 
12. droloxifene.ti,ab. 
13. exp bazedoxifene/ 
14. bazedoxifene.ti,ab. 
15. exp fulvestrant/ 
16. fulvestrant.ti,ab. 
17. exp anastrozole/ 
18. anastrozole.ti,ab. 
19. exp letrozole/ 
20. letrozole.ti,ab. 
21. exp exemestane/ 
22. exemestane.ti,ab. 
23. or/1-22 
24. exp breast density/ 
25. ((mammogr$ or breast or mammary) adj6 dens$).ti,ab. 
26. dens$.ti,ab. 
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27. exp mammography/ 
28. exp mammary gland/ 
29. 26 and (27 or 28) 
30. 24 or 25 or 29 
31. 23 and 30 
32. limit 31 to (human and (conference abstracts or embase) and yr=“1996 -Current”) 
 
B.IV Search: WHO ICTRP 
Basic search: 
1. breast density OR mammographic density 
Advanced search: 
Title: density 
Condition: breast cancer 
Intervention: selective oestrogen receptor modulator OR serm OR aromatase inhibitor OR 
tamoxifen OR raloxifene OR lasofoxifene OR arzoxifene OR droloxifene OR bazedoxifene OR 
fulvestrant OR anastrozole OR letrozole OR exemestane 
Recruitment status: ALL 
 
B.V Search: ClinicalTrials.gov 
Advanced search: 
Condition or disease: breast cancer 
Other terms: breast density OR mammographic density 
Study type: All studies 
Study results: All studies 
Sex: All 
Intervention/treatment: selective oestrogen receptor modulator OR serm OR aromatase inhibitor 
OR tamoxifen OR raloxifene OR lasofoxifene OR arzoxifene OR droloxifene OR bazedoxifene 
OR fulvestrant OR anastrozole OR letrozole OR exemestane 
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B.VI Data capture forms 
B.VI.i Data capture forms – Options 
 
New blocks can be added for any of the below (or just enter one as appropriate) 
 Subgroup 
By DCIS/Invasive 
By stage 
By chemotherapy 
By targeted therapy 
By HRT 
By pre/peri/post menopausal 
By age group (e.g. <50/≥50y r) 
By BMI group (e.g. <25, 25 to <30, 30 to <35,  ≥35kg/m2) 
By baseline density 
 Endpoint 
Treatment 
Breast cancer mortality (time to death caused by breast cancer)  
Rate of all serious adverse events 
Recurrence 
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast)  
Any recurrence or any death (disease-free survival)  
Distant metastases  
Death from all causes (all-cause mortality)  
Recurrence of invasive cancer only 
Recurrence of DCIS cancer only  
Troublesome but not serious side effects observed for SERMs and AIs 
Prevention 
Incidence of invasive breast cancer and DCIS  
Rate of all serious adverse events 
Incidence of invasive cancer only  
Incidence of DCIS cancer only  
Troublesome but not serious side effects observed for SERMs and AIs 
 
 
 
 
 
285 
 
 
B.VI.ii Data capture form - Cuzick 2011 
Area Field Data 
Study design Type of study Nested case-control within a randomised trial 
 
Matching None 
 
Prognostic, predictive 
or both 
Both (prognostic phase II) 
 
Control group 558 randomised to receive placebo 
 
Prevention or treatment Prevention 
 
Intervention(s) Tamoxifen 20 mg/day 
 
Follow-up time period 
96 months mentioned for follow-up of whole IBIS-I trial but no 
detail given for this sub-study 
Setting Country Controls from UK, cases from UK and Finland 
 
High-risk clinic? No 
 
Treatment clinic? No 
 
Time period 
Diagnosis before October 1, 2007. Recruitment April 1992 – March 
2001. 
 
Urban/rural Not stated 
Participants 
(and 
characteristics 
at baseline) 
No. of participants 
7152 in trial, 126/224 with breast cancer to October 2007, 942 + 123 
= 1065 in this study, Tamoxifen cases=51, Tamoxifen controls=456, 
Placebo cases=72, Placebo controls=486 
 
Age (yr) 
Mean(SD)/Median(IQR): Tamoxifen cases=52(6)/51(48-54), 
Tamoxifen controls=51(6)/50(42-46), Placebo cases=51(6)/50(46-
56), Placebo controls=51(6)/49(46-54) 
 
Age <50 or ≥50 (yr) 
<50/≥50: Tamoxifen cases=26(51%)/25(49%), Tamoxifen 
controls=269(59%)/187(41%), Placebo cases=40(56%)/32(44%), 
Placebo controls=283(58%)/203(42%) 
 
BMI (kg/m2) 
Mean(SD)/Median(IQR): Tamoxifen cases=27(5)/26(24–31), 
Tamoxifen controls=27(5)/ 26(23–30), Placebo cases=27(5)/26(24–
28), Placebo controls=27(5)/26(23–29) 
 
BMI < 25, 25 to < 30, 30 
to < 35,  ≥35 (kg/m2) 
≤25/26 to ≤30/≥30: Tamoxifen cases=20(39%)/15(29%)/13(25%) 3 
missing, Tamoxifen controls=203(45%)/137(30%)/109(24%) 7 
missing, Placebo cases=26(36%)/32(44%)/14(19%) 0 missing, 
Placebo controls=207(43%)/171(35%)/102(21%) 6 missing 
 
Ethnicity Not stated 
 
Education Not stated 
 
Baseline risk (%) Approximately twice population risk 
 
Post/peri/pre-
menopausal 
Pre/Post: cases=58/62, controls=496/433 
 
Distribution of density 
at baseline 
Mean(SD)/Median(IQR): Tamoxifen cases=47(32)/45(20-80), 
Tamoxifen controls=44(30)/40(17-70), Placebo cases=53(30)/63(25-
80), Placebo controls=44(30)/43(15-70). Categories: 0%/1-10%/11-
25%/26-50%/51-75%/76-100%: Tamoxifen 
cases=5(10%)/5(10%)/7(14%)/10(20%)/11(21%)/13(25%), 
Tamoxifen 
controls=53(12%)/40(9%)/55(12%)/116(25%)/103(23%)/89(19%), 
Placebo cases=3(4%)/5(7%)/10(14%)/13(18%)/19(26%)/22(31%), 
Placebo 
controls=53(11%)/53(11%)/61(13%)/109(22%)/111(23%)/99(20%). 
 
Invasive/DCIS at 
baseline 
NA 
 
Stage (percentage 
regional spread) at 
baseline 
NA 
Cointerventions HRT use 
Never/Previous/Current: Tamoxifen 
cases=27(53%)/10(20%)/14(27%), Tamoxifen 
controls=398(65%)/63(14%)/95(21%), Placebo 
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cases=46(64%)/12(17%)/14(19%), Placebo 
controls=316(65%)/62(13%)/108(22%) 
 
Chemotherapy? NA 
 
Targeted therapy? NA 
 
Radiotherapy? NA 
 
Neoadjuvant endocrine 
therapy? 
NA 
Timing 
Time between baseline 
mammogram and 
diagnosis 
NA 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry) 
NA 
 
Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up mammogram 
At least 12m after randomisation, median=18m, IQR=16-19m 
 
Time between baseline 
mammogram and start 
of endocrine therapy 
(or study entry) 
At or up to 12m before randomisation 
 
Time between baseline 
mammogram and the 
follow-up mammogram 
Median=19m, IQR=18-23m 
Biomarker 
Film (digitised for 
density or not)/FFDM 
Film (Finnish mammograms were digitised films, UK mammograms 
were original films) 
 
Pre-processing for 
quality control of 
mammographic 
density? 
None stated (but original film used) 
 
Density measure(s) 
Percentage (i) visual assessment to nearest 5% by expert, 
contralateral MLO 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR 
 
n total in analysis 507 
 
n events / cases in 
analysis 
51 
 
Data 
Change density: increase, no change, reduction 5%, reduction ≥10%: 
cases: 4, 20, 12, 15; controls 16, 141, 82, 217 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate 2.13, REF, 0.90, 0.32 
 
SD - 
 
SE - 
 
95% CI (0.64 to 7.20), REF, (0.40 to 2.04), (0.14 to 0.72) 
 
p-value P trend=0.001 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Placebo arm 
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Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR 
 
n total in analysis 558 
 
n events / cases in 
analysis 
72 
 
Data 
Change density: increase, no change, reduction 5%, reduction ≥10%: 
cases: 9, 27, 21, 15; controls 57, 206, 98, 125 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate 1.23, REF, 1.35, 0.69 
 
SD - 
 
SE - 
 
95% CI (0.54 to 2.81), REF, (0.71 to 2.58), (0.34 to 1.41) 
 
p-value P trend=0.51 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Tamoxifen arm (prognostic marker) - worked out from raw data 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR 
 
n total in analysis 497 
 
n events / cases in 
analysis 
48 
 
Data <10% reduction, ≥10% reduction: cases: 35, 13; controls: 234, 215 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate REF, 0.32 
 
SD - 
 
SE - 
 
95% CI REF, (0.15 to 0.66) 
 
p-value REF, 0.002 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All (predictive marker) - worked out from paper 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR interaction 
 
n total in analysis 1065 
 
n events / cases in 
analysis 
123 
 
Data <10% reduction, ≥10% reduction: cases: 93, 30; controls: 600, 342 
 
Adjustment 
None – this test was not reported in the original paper – conducted 
post hoc based on available data 
 
Point estimate 0.60 
 
SD - 
 
SE - 
 
95% CI (0.25 to 1.45) 
 
p-value 0.74 (DLR=1.28) 
 
Comment on statistical 
method 
Only unadjusted possible from the data reported in the paper. 
Logistic regression using the reported data. 
 
Other Other point estimates: tamoxifen vs. placebo 0.95, density change 
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0.76 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All (predictive marker) - worked out from raw data 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR interaction 
 
n total in analysis 1049 
 
n events / cases in 
analysis 
120 
 
Data <10% reduction, ≥10% reduction: cases: 92, 28; controls: 591, 338 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate 0.53 
 
SD - 
 
SE - 
 
95% CI (0.21 to 1.32) 
 
p-value 0.17 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 1049 
 
n events / cases in 
analysis 
120 
 
Data 35 cases <10% reduction, 13 cases ≥10% 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate <10% 1.13, ≥10% 0.37 
 
SD - 
 
SE - 
 
95% CI (0.72 to 1.77), (0.20 to 0.69) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline breast density ≤10%, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 218 
 
n events / cases in 
analysis 
18 
 
Data 10 cases <10% reduction, 0 cases ≥10% reduction 
 
Adjustment 
Age at entry, history of atypical hyperplasia or lobular carcinoma in 
situ, and body mass index 
 
Point estimate All 1.36, <10% 1.45, ≥10% NA 
 
SD - 
 
SE - 
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95% CI (0.51 to 3.66), (0.54 to 3.88) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline breast density 11-50%, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 377 
 
n events / cases in 
analysis 
37 
 
Data 11 cases <10% reduction, 3 cases ≥10% reduction 
 
Adjustment 
Age at entry, history of atypical hyperplasia or lobular carcinoma in 
situ, and body mass index 
 
Point estimate All 0.55, <10% 0.97, ≥10% 0.21 
 
SD - 
 
SE - 
 
95% CI (0.27 to 1.13), (0.43 to 2.14), (0.06 to 0.75) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline breast density 51-100%, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 454 
 
n events / cases in 
analysis 
65 
 
Data 14 cases <10% reduction, 10 cases ≥10% reduction 
 
Adjustment 
Age at entry, history of atypical hyperplasia or lobular carcinoma in 
situ, and body mass index 
 
Point estimate All 0.68, <10% 1.09, ≥10% 0.44 
 
SD - 
 
SE - 
 
95% CI (0.39 to 1.18), (0.55 to 2.15), (0.21 to 0.93) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Premenopausal, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 554 
 
n events / cases in 
analysis 
58 
 
Data 14 cases <10% reduction, 6 cases ≥10% reduction 
 
Adjustment Age at entry, breast density at baseline, history of atypical 
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hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate All 0.59, <10% 1.18, ≥10% 0.27 
 
SD - 
 
SE - 
 
95% CI (0.33 to 1.06), (0.60 to 2.32), (0.11 to 0.66) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Postmenopausal, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 495 
 
n events / cases in 
analysis 
62 
 
Data 21 cases <10%reduction, 7 cases ≥10% reduction 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate All 0.87, <10% 1.10, ≥10% 0.53 
 
SD - 
 
SE - 
 
95% CI (0.51 to 1.50), (0.61 to 2.01), (0.22 to 1.28) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup HRT use – never, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 731 
 
n events / cases in 
analysis 
83 
 
Data 21 cases <10% reduction, 9 cases ≥10% reduction 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate All 0.60, <10% 0.97, ≥10% 0.31 
 
SD - 
 
SE - 
 
95% CI (0.37 to 0.98), (0.55 to 1.71), (0.15 to 0.67) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup HRT use – ever, Tamoxifen arm 
 
Endpoint Incidence of invasive breast cancer and DCIS 
 
Measure OR compared with placebo 
 
n total in analysis 318 
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n events / cases in 
analysis 
37 
 
Data 14 cases <10% reduction, 4 cases ≥10% reduction 
 
Adjustment 
Age at entry, breast density at baseline, history of atypical 
hyperplasia or lobular carcinoma in situ, and body mass index 
 
Point estimate All 1.08, <10% 1.54, ≥10% 0.53 
 
SD - 
 
SE - 
 
95% CI (0.54 to 2.18), (0.72 to 3.23), (0.17 to 1.66) 
 
p-value Not stated 
 
Comment on statistical 
method 
Logistic regression 
 
Other 
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B.VI.iii Data capture form - Kim 2012 
Area Field Data 
Study design Type of study Retrospective cohort 
 
Matching None 
 
Prognostic, predictive or 
both 
Prognostic (phase II) 
 
Control group None 
 
Prevention or treatment Treatment 
 
Intervention(s) 
Tamoxifen for up to 5yr, anastrozole and/or letrozole for up to 5yr, 
anastrozole and/or letrozole for up to 5yr after 2-3yr tamoxifen, 
tamoxifen for 5yr then an AI but no mention of duration on AI. No 
dose information or intake frequency. All women had at least 2yr 
treatment (however, duration of treatment in table 1: min=0.9yr, 
max=7.9yr). 
 
Follow-up time period Abstract says median follow-up 68.8m (text says 67.7m). 
Setting Country South Korea 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period Initial diagnosis October 2003-December 2006 
 
Urban/rural Seoul National University Hospital 
Participants 
(and 
characteristics 
at baseline) 
No. of participants 
Total 1065: Tamoxifen 5yr = 657, Tamoxifen 2-3yr + AI (total 
5yr) = 41, Tamoxifen 5yr + AI (unknown total time) = 192, no 
mention of AI 5yr but by deduction = 175 
 
Age (yr) Mean = 49.0 (40.1 in text), SD = 9.3, min = 24, max = 77 
 
Age <50 or ≥50 (yr) ≤50yr/>50yr = 680(64%)/385(36%) 
 
BMI (kg/m2) Not stated 
 
BMI < 25, 25 to < 30, 30 
to < 35,  ≥35 (kg/m2) 
Not stated 
 
Ethnicity  South Korean institution, otherwise not reported 
 
Education  Not stated 
 
Baseline risk (%) NA 
 
Post/peri/pre-menopausal Not stated 
 
Distribution of density at 
baseline 
Mean = 35.8%, (SD = 14.0%), min = 5.4%, max = 82.2%. 
Categories <10%/10-25%/25-50%/≥50%: 
26(2.4%)/223(20.9%)/641(60.2%)/175(16.4%). 
 
Invasive/DCIS at baseline 127 (12%) DCIS, 938 (88%) invasive 
 
Stage (percentage 
regional spread) at 
baseline 
Stage not reported, but lymph node+/-: 359(34%)/706(66%); 
>2cm/≤2cm: 427(40%)/638(60%) 
Cointerventions HRT use Not stated 
 
Chemotherapy? 
Neoadjuvant: No=1017(96%), Yes=48(5%), adjuvant: 
No=247(23%), Yes=818(77%) 
 
Targeted therapy? Not stated 
 
Radiotherapy? Yes 657 (62%), No 408 (38%) 
 
Neoadjuvant endocrine 
therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
2 weeks pre-surgery 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry)  
Not stated 
 
Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up mammogram  
‘Average’ 13.1m, range 8-20m 
 
Time between baseline 
mammogram and start of 
Not stated 
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endocrine therapy (or 
study entry)  
 
Time between baseline 
mammogram and the 
follow-up mammogram  
Not stated 
Biomarker 
Film (digitised for density 
or not)/FFDM 
Digital mammograms 
 
Pre-processing for quality 
control of 
mammographic density? 
Not stated 
 
Density measure(s) 
Percentage (iv) semi-automated thresholding software 
(CUMULUS) by one experienced reader, contralateral CC 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio, continuous density reduction, per 1%? 
 
n total in analysis 1065 
 
n events / cases in analysis 80 
 
Data No data presented on recurrence vs. density change 
 
Adjustment Age, Size, LN, Grade, Chemotherapy, Ki-67 
 
Point estimate 0.95 
 
SD - 
 
SE - 
 
95% CI (0.92 to 0.99) 
 
 p-value 0.005 
 
Comment on statistical 
method 
Cox regression, not clear when clock starts, nor reasons for 
censoring, loss to follow-up etc. 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis 1065, MDR: <5%, ≥5%: 505(47%), 560(53%) 
 
n events / cases in analysis 80 
 
Data No data presented on recurrence vs. density change 
 
Adjustment Size, LN, Ki67 (Forward stepwise selection) 
 
Point estimate 1.67 (equivalently 0.60 for ≥5% density reduction) 
 
SD - 
 
SE - 
 
95% CI (1.07 to 2.63) 
 
 p-value 0.025 
 
Comment on statistical 
method 
Cox regression, not clear when clock starts, nor reasons for 
censoring, loss to follow-up etc. 
 
Other 
Sup table 4: Size, LN, Ki67 (Forward stepwise selection), but in 
text: "adjusted for age and preMD by forward selection stepwise 
analysis" 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio, <0%, 0-5%, 5-10%, ≥10% 
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n total in analysis 
1065, MDR: <0%, 0-5%, 5-10%, ≥10%: 190(18%), 314(30%), 
276(26%), 285(27%) 
 
n events / cases in analysis 80 
 
Data No data presented on recurrence vs. density change 
 
Adjustment Size, LN, Grade, Chemotherapy, Ki67 
 
Point estimate ≥10% (REF), 5-10% 1.33, 0-5% 1.92, <0% 2.26 
 
SD - 
 
SE - 
 
95% CI REF, (0.67 to 2.65), (1.01 to 3.64), (1.10 to 4.64) 
 
 p-value REF, 0.413, 0.048, 0.027 
 
Comment on statistical 
method 
Cox regression, not clear when clock starts, nor reasons for 
censoring, loss to follow-up etc. 
 
Other Table 4: Also adjusted for age? 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Age ≤50yr 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis 680 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 1.13 
 
SD - 
 
SE - 
 
95% CI (0.62 to 2.04) 
 
 p-value 0.7 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc. 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Age >50yr 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis 385 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 3.11 
 
SD - 
 
SE - 
 
95% CI (1.19 to 8.14) 
 
 p-value 0.02 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc. 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Tamoxifen at entry 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis 890 (assumed) 
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n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 1.52 
 
SD - 
 
SE - 
 
95% CI (0.92 to 2.51) 
 
 p-value 0.11 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc.  
 
Other 
Tamoxifen 5yr = 657, Tamoxifen 2-3yr + AI (total 5yr) = 41, 
Tamoxifen 5yr + AI (unknown total time) = 192, no mention of AI 
5yr but by deduction = 175. Unclear which groups are reported in 
the subgroup analysis. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup AI at entry 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis 175 (assumed) 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 7.11 
 
SD - 
 
SE - 
 
95% CI (0.90 to 56.37) 
 
 p-value 0.06 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc.  
 
Other 
Tamoxifen 5yr = 657, Tamoxifen 2-3yr + AI (total 5yr) = 41, 
Tamoxifen 5yr + AI (unknown total time) = 192, no mention of AI 
5yr but by deduction = 175. Unclear which groups are reported in 
the subgroup analysis. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Chemotherapy - no 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis Unclear if neoadjuvant, adjuvant or both 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 2.20 
 
SD - 
 
SE - 
 
95% CI (0.54 to 8.88) 
 
 p-value 0.27 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc.  
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
Subgroup Chemotherapy - yes 
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combo) 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis Unclear if neoadjuvant, adjuvant or both 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 1.69 
 
SD - 
 
SE - 
 
95% CI (1.02 to 2.80) 
 
 p-value 0.04 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc.  
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio,  <5% vs. ≥5% density reduction 
 
n total in analysis Unclear 
 
n events / cases in analysis not stated 
 
Data not stated 
 
Adjustment not stated 
 
Point estimate 1.74 
 
SD - 
 
SE - 
 
95% CI (1.09-2.78) 
 
 p-value 0.02 
 
Comment on statistical 
method 
A lot not reported, Cox regression, not clear when clock starts, nor 
reasons for censoring, loss to follow-up etc.  
 
Other Different from earlier result 
  
N.B. Also reported results for relative mammographic density 
reduction 
Sources of 
funding and 
stated conflicts 
of interest 
Funding 
This work was supported by a National Research Foundation of 
Korea (NRF) Grant funded by the Korean Government 
(20110005753 and 20110031417) 
 
Conflict of interest The authors declare that they have no competing interests 
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B.VI.iv Data capture form - Knight 2018 
Area Field Data 
Study design Type of study Case-control 
 
Matching 
Cases were diagnosed with a second primary invasive CBC at least 2 
years later with no intervening cancer diagnosis, other than a non-
melanoma skin cancer or cervical carcinoma in situ. UBC controls 
had no history of subsequent cancer diagnosis except for 
nonmelanoma skin cancer or cervical carcinoma in situ up  to their 
reference date. Matched 1:1 on follow-up time, living in the same 
study area from first breast cancer to reference date, year of birth 
(5yr strata), year diagnosis (4yr strata), race / ethnicity  
 
Prognostic, predictive 
or both 
Prognostic (phase II) (although analysis not specific to any 
endocrine treatment i.e. ORs are adjusted for tamoxifen use) 
 
Control group N/A 
 
Prevention or 
treatment 
Treatment 
 
Intervention(s) 
Mainly tamoxifen and "study time period and age distribution means 
that few women received aromatase inhibitors", but specific 
treatments, doses and intake frequency not reported 
 
Follow-up time period Mean (SD): Cases=7.9yr (3.8), Controls=8.0yr (4.0) 
Setting Country 
3 US sites (Northern California (179 (49%) cases, 213 (53%) 
controls), Seattle (82 (23%) cases, 80 (20%) controls), Iowa (49 
(14%) cases, 46 (11%) controls), one Canada (Ontario (52 (14%) 
cases, 64 (16%) controls))). 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period 
First diagnosis 1990-2008. Only women in WECARE2 included 
(second stage of WECARE, recruited 2009-2012). 
 
Urban/rural Not stated 
Participants 
(and 
characteristics 
at baseline) 
No. of participants 
Mammograms at both time points = 467 women (224 out of 362 
cases, 243 out of 403 controls) 
 
Age (yr) 
Mean (SD) age at mammogram before/at 1st diagnosis: Cases=46 
(6), Controls=46 (6). Mean (SD) age at mammogram after 1st 
diagnosis: Cases=47 (6), Controls=47 (6). Diagnosis <55y r for all. 
 
Age <50 or ≥50 (yr) 
Baseline <45/45-<50/50-54: Cases=90(36%)/82(32%)/81(32%), 
Controls=100(37%)/93(35%)/76(28%). Follow-up <45/45-<50/50-
54: Cases=123(37%)/110(33%)/100(30%), 
Controls=137(36%)/127(34%)/113(30%). 
 
BMI (kg/m2) 
Mean (SD) BMI at 1st diagnosis: Cases=25.2 (5.5), Controls=25.2 
(5.7). 
Mean (SD) BMI at mammogram after 1st diagnosis: Cases=25.2 
(5.4), Controls=25.8 (5.7). 
 
BMI < 25, 25 to < 30, 30 
to < 35,  ≥35 (kg/m2) 
Not stated 
 
Ethnicity  
Non-Hispanic white/Other: Cases=295 (83%)/67 (17%), 
Controls=334 (81%)/69 (19%) 
 
Education  Not stated 
 
Baseline risk (%) 
Family history: yes/no/adopted or missing: 
cases=123(34%)/234(65%)/5(1%), 
controls=89(22%)/306(76%)/8(2%) 
 
Post/peri/pre-
menopausal 
Baseline Pre/Post: Case=184 (73%)/68 (27%), Control=211 
(79%)/57 (21%). Follow-up Pre/Post: Case=130 (39%)/202(61%), 
Control=147 (39%)/228 (61%) 
 
Distribution of density 
at baseline 
Mean (SD) Percent mammographic density before/at 1st diagnosis: 
Cases=37.6% (18.1)/Controls=35.8% (18.3%); <25%/25% to 
<50%/≥50%: Cases=67 (26%)/125 (49%)/61 (24%), Controls=81 
(30%), 130 (48%), 58 (22%). 
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Invasive/DCIS at 
baseline 
100% invasive 
 
Stage (percentage 
regional spread) at 
baseline 
Local/Regional/Missing: Cases=251 (69%)/106 (29%)/ 5(1%), 
Controls=254 (63%)/143 (35%)/6 (1%); ER+/ER-/Missing: 
Cases=213(59%)/129(36%)/20(6%), 
Controls=273(68%)/105(26%)/25(6%) 
Cointerventions HRT use Not stated 
 
Chemotherapy? 
Yes/No: Cases=236 (65%)/126 (35%), Controls=272 (67%)/131 
(33%) 
 
Targeted therapy? Tamoxifen cases=158 (44%), UNK=221 (55%) 
 
Radiotherapy? 
Yes/No: Cases=251 (69%)/111 (31%), Controls=179 (69%)/124 
(31%) 
 
Neoadjuvant endocrine 
therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
Prior to/at diagnosis mammogram (3yr prior to diagnosis - 1 month 
post diagnosis (as close as possible to 12 months prior to diagnosis - 
1 month post diagnosis)) 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry)  
Not stated 
 
Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up mammogram  
Not stated, but diagnosis to follow-up mammogram (>6 months - 
4yr (as close as possible to >6 months - 18 months)) 
 
Time between baseline 
mammogram and start 
of endocrine therapy 
(or study entry)  
Not stated 
 
Time between baseline 
mammogram and the 
follow-up mammogram  
Median=1yr 
Biomarker 
Film (digitised for 
density or not)/FFDM 
Digitised film – digital mammograms excluded (5 cases, 6 controls 
prior to diagnosis, 39 cases and 41 controls post diagnosis) 
 
Pre-processing for 
quality control of 
mammographic 
density? 
Excluded when visually assessed to be poor image quality (4 cases 
and 4 controls prior to diagnosis, 11 cases and 6 controls post 
diagnosis) 
 
Density measure(s) 
Percentage (iv) semi-automated thresholding software (CUMULUS) 
by experienced reader, contralateral CC 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
 
Measure OR, ≥10% vs. <10% density reduction 
 
n total in analysis 435 
 
n events / cases in 
analysis 
210 
 
Data 
<10%/≥10% reduction: Cases=150 (71%)/60 (29%), Controls=144 
(64%)/81 (36%) 
 
Adjustment 
Change in age, estimated body mass index, and menopausal status 
between prior to/at first diagnosis and post-diagnosis mammograms, 
and for initial %MD, study centre, race (non-Hispanic white vs. 
other), age at first diagnosis, age at menarche, number of full-term 
pregnancies, histologic type, stage, and oestrogen receptor status of 
first diagnosis, chemotherapy, 
radiation, and tamoxifen use after first diagnosis. 
 
Point estimate 0.63 
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SD - 
 
SE - 
 
95% CI (0.40 to 1.01) 
 
 p-value Not reported (but p>0.05) 
 
Comment on statistical 
method 
Unconditional logistic regression, Excluding those with missing 
menopausal status information and those with an increase ≥10%, 
note the adjustment for tamoxifen. 
 
Other 
Note that the analysis group did not all receive tamoxifen, not all 
were ER+ at first diagnosis. 
Sources of 
funding and 
stated conflicts 
of interest 
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interpretation of the data, or in writing the manuscript. 
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B.VI.v Data capture form - Ko 2013 
Area Field Data 
Study design Type of study Retrospective cohort 
 
Matching None 
 
Prognostic, predictive 
or both 
Prognostic (phase II) 
 
Control group None 
 
Prevention or 
treatment 
Treatment 
 
Intervention(s) 
Tamoxifen. All women had at least 2yr treatment. No dose 
information or intake frequency. 
 
Follow-up time period 
Mean follow-up 59m (SD=17.6), range (26–114m), but text says 
mean follow-up 61 months. 
Setting Country South Korea 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period January 2003 – December 2008 
 
Urban/rural National Cancer Center, Goyang 
Participants 
(and 
characteristics 
at baseline) 
No. of participants 
n=1066, 67 with total recurrence: 48 systemic, 16(17 also mentioned) 
loco-regional, 4 contralateral (numbers do not add up) 
 
Age (yr) 
Total: mean (SD)=45.3 (7.6), range=25-78. MDR+: mean (SD)=44 
(5.9), range=28-68. MDR-: mean (SD)=46 (8.1), range=25-78 
 
Age <50 or ≥50 (yr) 
Total: ≤50yr/>50yr = 888(83%)/178(17%). MDR+: ≤50yr/>50yr = 
308(91%)/30(9%). MDR-: ≤50yr/>50yr = 580(80%)/148(20%) 
 
BMI (kg/m2) 
Total: mean (SD)=23.4(3.2), range=15.6-50.2. MDR+: mean 
(SD)=22.9(3.1), range=17.5-35.5. MDR-: mean (SD)=23.1(3.2), 
range=15.6-50.2. 
 
BMI < 25, 25 to < 30, 
30 to < 35,  ≥35  
(kg/m2) 
Not stated 
 
Ethnicity  South Korean institution, otherwise not reported 
 
Education  Not stated 
 
Baseline risk (%) NA 
 
Post/peri/pre-
menopausal 
Unclear, title says premenopausal women but age range 25-78 and 
subgroup analysis of ≤50yr/>50yr used as a proxy for menopausal 
status and postmenopausal women mentioned in results 
 
Distribution of density 
at baseline 
BIRAD 1&2 n=141, BIRAD 3 n=503, BIRAD 4 n=422 
 
Invasive/DCIS at 
baseline 
134 (13%) DCIS, 932 (87%) invasive (implied) 
 
Stage (percentage 
regional spread) at 
baseline 
Histologic grade (1/2 vs. 3) = 840(78.8%)/226(21.2%). Lymph node-
/+ = 666(61.5%)/410(38.5%).  
Cointerventions HRT use Not stated 
 
Chemotherapy? 
No=303(28.4%), Yes (adjuvant)=588(55.5%), Yes 
(neoadjuvant)=175(16.4%) 
 
Targeted therapy? Not stated 
 
Radiotherapy? No=173, Yes=893 
 
Neoadjuvant 
endocrine therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
Before surgery but no mention of timeframe. 
 
Time between 
diagnosis and start of 
endocrine therapy (or 
study entry)  
Not stated 
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Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up 
mammogram  
Range=10–34 months in text (10-36 months in results), median=19 
months 
 
Time between baseline 
mammogram and 
start of endocrine 
therapy (or study 
entry)  
Not stated 
 
Time between baseline 
mammogram and the 
follow-up 
mammogram  
Not stated 
Biomarker 
Film (digitised for 
density or not)/FFDM 
Digital mammograms 
 
Pre-processing for 
quality control of 
mammographic 
density? 
Exclusion of women if digital mammogram not appropriate for 
evaluation, but no explanation as to what this means. Reliability not 
assessed (“We relied on a single radiologist who is a specialist in 
breast imaging studies, thereby eliminating interobserver variability. 
We did not seek to measure reproducibility as the BI-RADS density 
classifications are standardized.”). 
 
Density measure(s) 
Categorical (i) BI-RADS (qualitative & quantitative version) by 
experienced reader, no mention if contralateral or view 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 1066 
 
n events / cases in 
analysis 
67 
 
Data MDR+=10/338, MDR-=57/728 
 
Adjustment 
Age, BMI, tumor size, lymph node positivity, high histologic grade, 
HER2 positivity and Ki-67≥14% 
 
Point estimate 0.35 
 
SD - 
 
SE - 
 
95% CI (0.17 to 0.68) 
 
 p-value 0.002 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 1066 
 
n events / cases in 
analysis 
67 
 
Data MDR+=10/338, MDR-=57/728 
 
Adjustment 
Age, BMI, tumor size, lymph node status, high ER score, high PgR 
score and HER2 positivity  
 
Point estimate 0.36 
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SD 
 
 
SE 
 
 
95% CI (0.18 to 0.70) 
 
 p-value 0.003 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival): systemic recurrence 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 1046 
 
n events / cases in 
analysis 
48 
 
Data MDR+=9/337, MDR-=39/709 
 
Adjustment 
Age, BMI, tumor size, lymph node status, high ER score, high PgR 
score and HER2 positivity  
 
Point estimate 0.48 
 
SD - 
 
SE - 
 
95% CI (0.23 to 0.99) 
 
 p-value 0.048 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Recurrence (Recurrence-free survival): loco-regional recurrence 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 1014 
 
n events / cases in 
analysis 
16 (17 also mentioned in text) 
 
Data MDR+=1/329, MDR-=15/685 
 
Adjustment 
Age, BMI, tumor size, lymph node status, high ER score, high PgR 
score and HER2 positivity  
 
Point estimate 0.13 
 
SD - 
 
SE - 
 
95% CI (0.02 to 0.96) 
 
 p-value 0.045 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup ≤50 years 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 888 
 
n events / cases in 
analysis 
Not stated 
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Data Not stated 
 
Adjustment 
Age, BMI, tumor size, lymph node status, high ER score, high PgR 
score and HER2 positivity  
 
Point estimate 0.37 
 
SD - 
 
SE - 
 
95% CI (0.18 to 0.76) 
 
 p-value 0.007 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup >50 years 
 
Endpoint Recurrence (Recurrence-free survival) 
 
Measure Hazard ratio (MDR+ vs. MDR-) 
 
n total in analysis 178 
 
n events / cases in 
analysis 
Not stated 
 
Data Not stated 
 
Adjustment 
Age, BMI, tumor size, lymph node status, high ER score, high PgR 
score and HER2 positivity  
 
Point estimate 0.41 
 
SD - 
 
SE - 
 
95% CI (0.52 to 3.20) 
 
 p-value 0.4 
 
Comment on statistical 
method 
Age, BMI, tumour size continuous variables 
 
Other 
 
Sources of 
funding and 
stated conflicts 
of interest 
Funding 
This work was supported by grant from the National Cancer Center 
Korea (1211200-1). 
 
Conflict of interest Authors declare none. 
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B.VI.vi Data capture form - Li 2013 
Area Field Data 
Study design Type of study Cohort study  
 
Matching None 
 
Prognostic, predictive 
or both 
Prognostic (phase II) 
 
Control group 
Group of women not treated with tamoxifen included (might be on 
other endocrine treatment), no interaction tested in paper (could ask 
them to do this). 
 
Prevention or 
treatment 
Treatment 
 
Intervention(s) 
Daily tamoxifen: 231 on 20mg, 123 on 40mg, 108 on 20+40mg, 12 
on another dose. "Further adjustment for surgery (i.e., lumpectomy or 
mastectomy) and tamoxifen dosage, which ranged between 20 and 40 
mg per day, did not appreciably change the results". 
 
Follow-up time period Median 14.2 yr (range=1.0 to 15.3 yr) 
Setting Country Sweden 
 
High-risk clinic? No  
 
Treatment clinic? Yes 
 
Time period Breast cancer 1993-1995, follow-up to December 31, 2008 
 
Urban/rural Not stated 
Participants 
(and 
characteristics 
at baseline) 
No. of participants 
No tamoxifen censored=454 (90.8%), no tamoxifen event=46(9.2%), 
tamoxifen censored=399(84.2%), tamoxifen event=75(15.8%) 
 
Age (yr) 
At diagnosis: 50-59/60-69/≥70: no 
tamoxifen=207(41.4%)/227(45.4%)/66(13.2%) median 
(IQR)=62(10), tamoxifen=179(37.8%)/219(46.2%)/76(16.0%) 
median (IQR)=63(11). Censored median (IQR)=62(10), event 
median (IQR)=61(10). At baseline: 49-59/60-69/≥70: no 
tamoxifen=207(41.4%)/230(46%)/63(12.6%) median (IQR)=61(10), 
tamoxifen=181(38.2)/223(47%)/70(14.8%) median (IQR)=63(10). 
Censored median (IQR)=62(10), event median (IQR)=62(11). 
 
Age <50 or ≥50 (yr) All ≥50 years at diagnosis 
 
BMI (kg/m2) 
At diagnosis: <25/25-29.9/30-34.9/≥35: no 
tamoxifen=251(50.2%)/197(39.4%)/45(9%)/7(1.4%) median 
(IQR)=25(4.6), 
tamoxifen=246(51.9%)/168(35.4%)/51(10.8%)/9(1.9%) median 
(IQR)=24.8(5). Censored median (IQR)=24.8(4.8), event median 
(IQR)=26(4.8). 
 
BMI < 25, 25 to < 30, 
30 to < 35,  ≥35 (kg/m2) 
At diagnosis: <25/25-29.9/30-34.9/≥35: no 
tamoxifen=251(50.2%)/197(39.4%)/45(9%)/7(1.4%), 
tamoxifen=246(51.9%)/168(35.4%)/51(10.8%)/9(1.9%). 
 
Ethnicity  Not stated 
 
Education  Not stated 
 
Baseline risk (%) NA 
 
Post/peri/pre-
menopausal 
All postmenopausal 
 
Distribution of density 
at baseline 
0-10/11-25/26-50/51-75/>75: no 
tamoxifen=0(0%)/229(45.8%)/189(37.8%)/59(11.8%)/23(4.6%) 
median (IQR)=26.4cm2(22), 
tamoxifen=0(0%)/198(41.8%)/192(40.5%)/64(13.5%)/20(4.2%) 
median (IQR)=28.4cm2(23.4). Censored median 
(IQR)=27.3cm2(22.9), event median (IQR)=27.7cm2(24.1). DA on 
the baseline mammogram ranged from 10.8 to 135.4 cm2 with a 
median of 27.4 cm2. 
 
Invasive/DCIS at 
baseline 
All invasive 
 
Stage (percentage Metastatic nodes: none/1-3/4-9/>9: no 
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regional spread) at 
baseline 
tamoxifen=471(94.2%)/18(3.6%)/6(1.2%)/5(1%), 
tamoxifen=247(52.1%)/170(35.9%)/45(9.5%)/12(2.5%), 
censored=667(78.2%)/148(17.4%)/33(3.9%)/5(0.6%), 
event=51(42.1%)/40(33.1%)/18(14.9%)/12(9.9%). 
Cointerventions HRT use 
No/Yes: no tamoxifen=230(46%)/270(54%), 
tamoxifen=235(49.6%)/239(50.4%), 
censored=393(46.1%)/460(53.9%), event=72(59.5%)/49(40.5%). 
 
Chemotherapy? 
No/Yes: no tamoxifen=471(94.2%)/29(5.8%), 
tamoxifen=440(92.8%)/34(7.2%), censored=810(95%)/43(5%), 
event=101(83.5%)/20(16.5%). 
 
Targeted therapy? Not stated  
 
Radiotherapy? 
No/Yes: no tamoxifen=207(41.4%)/293(58.6%), 
tamoxifen=296(62.4%)/178(37.6%), 
censored=419(49.1%)/434(50.9%), event=84(69.4%)/37(30.6%). 
 
Neoadjuvant endocrine 
therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
At most 1yr before start of treatment or diagnosis date (no tamoxifen 
group) 
 
Time between 
diagnosis and start of 
endocrine therapy (or 
study entry)  
Median 45 days after diagnosis 
 
Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up 
mammogram  
6-36 months after start of treatment or diagnosis date (no tamoxifen 
group) 
 
Time between baseline 
mammogram and start 
of endocrine therapy 
(or study entry)  
At most 1yr before start of treatment or diagnosis date (no tamoxifen 
group) 
 
Time between baseline 
mammogram and the 
follow-up 
mammogram  
No tamoxifen mean(SD)=1.39yr (0.48), tamoxifen mean(SD)=1.42yr 
(0.48). No more than 3yr. 
Biomarker 
Film (digitised for 
density or not)/FFDM 
Digitised film 
 
Pre-processing for 
quality control of 
mammographic 
density? 
Deleted bad quality mammograms (Li 2012: High-throughput 
mammographic-density measurement: a tool for risk prediction of 
breast cancer). 
 
Density measure(s) 
Absolute (ii) automated area-based method (ImageJ), contralateral 
MLO 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All (tamoxifen treated) 
 
Endpoint Breast cancer mortality (time to death caused by breast cancer)  
 
Measure 
Hazard ratio for breast density change (relative change in absolute 
area) 
 
n total in analysis 474 
 
n events / cases in 
analysis 
75 
 
Data 
HR for ≥10% change (n=113), no change (-10% to 9%; n=89); 11-
20% reduction (n=55), >20% reduction (n=217) 
 
Adjustment Unadjusted 
 
Point estimate 0.66, REF, 0.73, 0.48 
 
SD - 
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SE - 
 
95% CI (0.35 to 1.24), (REF), (0.35 to 1.56), (0.27 to 0.85) 
 
 p-value 0.110 (trend: density change treated as an ordinal variable) 
 
Comment on statistical 
method 
Delayed-entry Cox proportional-hazards model 
 
Other 
The prognostic value of DA assessed from the baseline and follow-up 
mammogram is informative up to 15 years past diagnosis. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All (tamoxifen treated) 
 
Endpoint Breast cancer mortality (time to death caused by breast cancer)  
 
Measure 
Hazard ratio for breast density change (relative change in absolute 
area) 
 
n total in analysis 474 
 
n events / cases in 
analysis 
75 
 
Data 
HR for ≥10% change (n=113), no change (-10% to 9%; n=89); 11-
20% reduction (n=55), >20% reduction (n=217) 
 
Adjustment 
Time interval between baseline and follow-up mammograms (years), 
age at baseline mammogram (years), ever hormone replacement 
therapy use (yes/no), body mass index at interview (quartiles), time 
since menopause at baseline mammogram (years), oestrogen receptor 
status (positive, negative, or missing), tumour size (<10, 10-19, 20-
29, 30-39, 40-49 or ≥50 mm), number of metastatic nodes (none, 1-3, 
4-9 or >9), grade (well differentiated, moderately differentiated, 
poorly differentiated, or missing), radiotherapy treatment (yes/no), 
chemotherapy treatment (yes/no), change in absolute non-dense area 
(quartiles) and duration of tamoxifen treatment (months). 
 
Point estimate 0.99, REF, 0.90, 0.50 
 
SD - 
 
SE - 
 
95% CI (0.50 to 1.94), (REF), (0.40 to 2.04), (0.27 to 0.93) 
 
 p-value 0.017 (trend: density change treated as an ordinal variable) 
 
Comment on statistical 
method 
Delayed-entry Cox proportional-hazards model 
 
Other 
Further adjustment for surgery (i.e., lumpectomy or mastectomy) and 
tamoxifen dosage, which ranged between 20 and 40 mg per day, did 
not appreciably change the results. The prognostic value of DA 
assessed from the baseline and follow-up mammogram is informative 
up to 15 years past diagnosis. 
  
N.B. these results are also presented graphically. Also, there are 
more data on absolute dense area (absolute and relative density 
change measure, by quartiles) and percent density (absolute and 
relative density change measure, by quartiles) in supplement not 
included here, could be extracted. 
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B.VI.vii Data capture form - Nyante 2015 
Area Field Data 
Study design Type of study Case-control (nested design – from larger cohort) 
 
Matching 
Cases died of breast cancer, control patients were selected from 
breast cancer patients who were alive at the last tumour registry 
follow-up or who died from causes other than breast cancer (had at 
least as much follow-up time as matched cases). Matched 2:1 on 
age at diagnosis (≤50, 51-60, 61-70, >70years), year of diagnosis 
(1990-1993, 1994-1998, 1999-2002, 2003-2008) and disease stage 
(localised/regional spread). Mammograms were available for 61 
additional controls that were matched to cases without available 
mammograms. To increase statistical power, these controls were 
rematched to eligible cases. 
 
Prognostic, predictive or 
both 
Prognostic (phase II) 
 
Control group None 
 
Prevention or treatment Treatment 
 
Intervention(s) 
Tamoxifen, not stated explicitly what dose but should be standard 
20mg daily. At least 1 tamoxifen prescription started within 1yr of 
diagnosis. 
 
Follow-up time period Not stated 
Setting Country 
USA, Kaiser Permanente Northwest health plan (Portland, 
Oregon) 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period 
Primary invasive breast cancer (study entry) between 1990 and 
2008. Recruitment (follow-up) between January 1, 1991 and 
December 31, 2010. Checking for mammograms between January 
1, 1988 and December 31, 2010. Prescription records checked 
between 1986 and 2010. 
 
Urban/rural Kaiser Permanente Northwest health plan 
Participants 
(and 
characteristics 
at baseline) 
No. of participants n=349 (97 who died from breast cancer, 252 controls) 
 
Age (yr) 
Age at diagnosis: mean=59yr. Range: 32-87yr. ≤50/51-60/61-
70/>70: cases: 29(29.9%)/22(22.7%)/28(28.9%)/18(18.6%), 
controls: 73(29.0%)/66(26.2%)/77(30.6%)/36(14.3%). 
 
Age <50 or ≥50 (yr) 
≤50yr/>50yr: cases: 29(29.9%)/68(70.1%), controls: 
73(29.0%)/179(71%) 
 
BMI (kg/m2) 
At baseline: <25/25-29/30-34/≥35/missing: cases: 
22(26.2%)/29(34.5%)/17(20.2%)/16(19.1%)/13, controls: 
76(33.6%)/76(33.6%)/44(19.5%)/30(13.3%)/26 
 
BMI < 25, 25 to < 30, 30 
to < 35,  ≥35 (kg/m2) 
At baseline: <25/25-29/30-34/≥35/missing: cases: 
22(26.2%)/29(34.5%)/17(20.2%)/16(19.1%)/13, controls: 
76(33.6%)/76(33.6%)/44(19.5%)/30(13.3%)/26 
 
Ethnicity  
White/Non-white/missing: cases: 96(99%)/1(1%)/0, controls: 
244(97.2%)/7(2.8%)/1 
 
Education  Not stated 
 
Baseline risk (%) NA 
 
Post/peri/pre-menopausal Lacked information on menopausal status 
 
Distribution of density at 
baseline 
Percent density (%): Cases: mean (SD)=26.2 (16.3), median=23.7, 
range=3.4-80.8, ≤15/>15to23/>23to31/>31to43/>43: 
29(29.9%)/19(19.6%)/16(16.5%)/19(19.6%)/14(14.4%). Controls: 
mean (SD)=30.0 (17.4), median 27.7, range=0.8-79.4, 
≤15/>15to23/>23to31/>31to43/>43: 
51(20.2%)/50(19.8%)/51(20.2%)/47(18.7%)/53(21.0%). Absolute 
dense area (cm2): Cases: mean (SD)=36.5 (21.5), median 34.1, 
range=4.6-106.9, ≤21/>21to30/>30to42/>42to57/>57: 
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29(29.9%)/17(17.5%)/18(18.6%)/19(19.6%)/14(14.4%).Controls: 
mean (SD)=41.0 (27.9), median 35.2, range=2.0-
236.5,≤21/>21to30/>30to42/>42to57/>57: 
50(19.8%)/51(20.2%)/50(19.8%)/51(20.2%)/50(19.8%). 
 
Invasive/DCIS at baseline Invasive only (and ER-positive) 
 
Stage (percentage 
regional spread) at 
baseline 
Localised/regional spread: cases: 41(42.3%)/56(57.7%), controls: 
112(44.4%)/140(55.6%) 
Cointerventions HRT use 
Nonuser/former/current: cases: 47(48.5%)/17(17.5%)/33(34.0%), 
controls: 104(41.3%)/37(14.7%)/111(44.1%) 
 
Chemotherapy? 
No/Yes/missing: cases: 41(42.3%)/56(57.7%)/0, controls: 
121(48.2%)/130(51.8%)/1 
 
Targeted therapy? Not stated 
 
Radiotherapy? 
No/Yes: cases: 37(38.1%)/60(61.9%), controls: 
88(34.9%)/164(65.1%). 
 
Neoadjuvant endocrine 
therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
Baseline mammogram ≤720 days before diagnosis 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry)  
Tamoxifen started ≤1yr after diagnosis 
 
Time between start of 
endocrine therapy (or 
study entry) and the 
follow-up mammogram  
Follow-up mammogram 90 - 820 days after start of tamoxifen 
(and within 90 days of a current tamoxifen prescription, closest to 
365 days if multiple mammograms obtained), mean=12 months, 
range=3-26 months 
 
Time between baseline 
mammogram and start of 
endocrine therapy (or 
study entry)  
Baseline mammogram before start of treatment (or study entry for 
controls), mean=6 months, range=9-47 months 
 
Time between baseline 
mammogram and the 
follow-up mammogram  
Mean 18 months, 23 (24%) cases and 58 (23%) controls more than 
24 months; 40 (41%) cases and 115 (46%) controls within 12 
months 
Biomarker 
Film (digitised for density 
or not)/FFDM 
Digitised film 
 
Pre-processing for quality 
control of 
mammographic density? 
Not stated 
 
Density measure(s) 
Percentage (iv) semi-automated thresholding software 
(CUMULUS) by a single reader, contralateral CC 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 349 
 
n events / cases in analysis 97 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors 
 
Point estimate REF, 1.36, 0.44 
 
SD - 
 
SE - 
 
95% CI REF, (0.79 to 2.34), (0.22 to 0.88) 
 
 p-value 0.005 (heterogeneity test, df=2) 
 
Comment on statistical Conditional logistic regression 
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method 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density <20% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 124 
 
n events / cases in analysis 38 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors 
 
Point estimate REF, 2.23, NA (0 cases, 11 control) 
 
SD - 
 
SE - 
 
95% CI REF, (0.99 to 5.03), NA 
 
 p-value NA 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density 20% to <37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 121 
 
n events / cases in analysis 37 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors 
 
Point estimate REF, 0.69, 0.35 
 
SD - 
 
SE - 
 
95% CI REF, (0.28 to 1.71), (0.12 to 1.02) 
 
 p-value 0.16 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density ≥37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density 
 
n total in analysis 104 
 
n events / cases in analysis 22 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors 
 
Point estimate REF, 1.32,0.60 
 
SD - 
 
SE - 
 
95% CI REF, (0.35 to 4.94), (0.17 to 2.12) 
 
 p-value 0.38 (heterogeneity test, df=2) 
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Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density 
 
n total in analysis 349 
 
n events / cases in analysis 97  
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 1.38, 0.49 
 
SD - 
 
SE - 
 
95% CI REF, (0.80 to 2.40), (0.23 to 1.02) 
 
 p-value 0.01 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density <20% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 124 
 
n events / cases in analysis 38 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density 
 
Point estimate REF, 2.82, NA (0 cases, 11 control) 
 
SD - 
 
SE - 
 
95% CI REF, (1.17 to 6.76), NA 
 
 p-value NA 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density 20% to <37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 121 
 
n events / cases in analysis 37 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 0.70, 0.35 
 
SD - 
 
SE - 
 
95% CI REF, (0.28 to 1.72), (0.12 to 1.02) 
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 p-value 0.16 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density ≥37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 104 
 
n events / cases in analysis 22 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 1.34,0.59 
 
SD - 
 
SE - 
 
95% CI REF, (0.36 to 5.02), (0.17 to 2.11) 
 
 p-value 0.38 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 349 
 
n events / cases in analysis 97  
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density plus tamoxifen duration 
 
Point estimate REF, 1.27, 0.47 
 
SD - 
 
SE - 
 
95% CI REF, (0.71 to 2.25), (0.21 to 1.03) 
 
 p-value 0.04 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density <20% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 124 
 
n events / cases in analysis 38 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density plus tamoxifen duration 
 
Point estimate REF, 2.22, NA (0 cases, 11 control) 
 
SD - 
 
SE - 
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95% CI REF, (0.88 to 5.62), NA 
 
 p-value NA 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density 20% to <37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 121 
 
n events / cases in analysis 37 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density plus tamoxifen duration 
 
Point estimate REF, 0.78, 0.38 
 
SD - 
 
SE - 
 
95% CI REF, (0.31 to 1.96), (0.13 to 1.15) 
 
 p-value 0.23 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density ≥37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 104 
 
n events / cases in analysis 22 
 
Data 
OR in tertiles (controls). T1: > -0.5 (REF), T2: -8.7 to -0.5, T3: < -
8.7 
 
Adjustment Matching factors plus baseline density plus tamoxifen duration 
 
Point estimate REF, 1.31, 0.57 
 
SD - 
 
SE - 
 
95% CI REF, (0.30 to 5.68), (0.14 to 2.38) 
 
 p-value 0.43 (heterogeneity test, df=2) 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 349 
 
n events / cases in analysis 97  
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 14 cases 
and 70 controls with ≥10% reduction 
 
Adjustment Matching factors 
 
Point estimate REF, 0.42  
 
SD - 
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SE - 
 
95% CI REF, (0.22 to 0.80) 
 
 p-value 0.009 
 
Comment on statistical 
method 
Conditional logistic regression, relatively small numbers in ≥10% 
group 
 
Other 
Reported in supplementary material, tertiles was primary analysis 
(but this is cut-point used by others) 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup All 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 349 
 
n events / cases in analysis 97  
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 14 cases 
and 70 controls with ≥10% reduction 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 0.47 
 
SD - 
 
SE - 
 
95% CI REF, (0.23 to 0.94) 
 
 p-value 0.03 
 
Comment on statistical 
method 
Conditional logistic regression, relatively small numbers in ≥10% 
group 
 
Other 
Reported in supplementary material, tertiles was primary analysis 
(but this is cut-point used by others) 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density <20% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 124 
 
n events / cases in analysis 38 
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 0 cases and 
6 controls with ≥10% reduction 
 
Adjustment Matching factors 
 
Point estimate REF, NA (0 cases 6 controls≥ 10% change) 
 
SD - 
 
SE - 
 
95% CI NA 
 
 p-value NA 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density <20% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 124 
 
n events / cases in analysis 38 
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 0 cases and 
6 controls with ≥10% reduction 
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Adjustment Matching factors plus baseline density 
 
Point estimate REF, NA (0 cases 6 controls≥ 10% change) 
 
SD - 
 
SE - 
 
95% CI NA 
 
 p-value NA 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density 20-37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 121 
 
n events / cases in analysis 37 
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 7 cases and 
23 controls with ≥10% reduction 
 
Adjustment Matching factors 
 
Point estimate REF, 0.60 
 
SD - 
 
SE - 
 
95% CI REF, (0.22 to 1.59) 
 
 p-value 0.3 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density 20-37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 121 
 
n events / cases in analysis 37 
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 7 cases and 
23 controls with ≥10% reduction 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 0.59 
 
SD - 
 
SE - 
 
95% CI REF, (0.21 to 1.60) 
 
 p-value 0.3 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density ≥37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 104 
 
n events / cases in analysis 22 
 
Data OR by 10% cut-off: <10% reduction, ≥10% reduction. 7 cases and 
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41 controls with ≥10% reduction 
 
Adjustment Matching factors 
 
Point estimate REF, 0.40 
 
SD - 
 
SE - 
 
95% CI REF, (0.14 to 1.14) 
 
 p-value 0.09 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Baseline density ≥37% 
 
Endpoint Breast cancer mortality 
 
Measure Change in percentage density  
 
n total in analysis 104 
 
n events / cases in analysis 22 
 
Data 
OR by 10% cut-off: <10% reduction, ≥10% reduction. 7 cases and 
41 controls with ≥10% reduction 
 
Adjustment Matching factors plus baseline density  
 
Point estimate REF, 0.39 
 
SD - 
 
SE - 
 
95% CI REF, (0.14 to 1.14) 
 
 p-value 0.09 
 
Comment on statistical 
method 
Unconditional logistic regression 
 
Other 
 
  
N.B there are more data on absolute dense area, relative percent 
density and relative absolute dense area in supplement not 
included here. Also age subgroup results and supplementary 
subgroups for treatment duration etc. presented graphically, could 
be extracted. 
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B.VI.viii Data capture form - Sandberg 2013 
Area Field Data 
Study design Type of study Case-control 
 
Matching 
Cases had invasive CBC diagnosed more than 1 year after the 
first invasive cancer and with an available mammogram close to 
the first diagnosis, controls had invasive unilateral breast cancer 
in the same register (no CBC). Calendar period (+/- 2yr) of first 
breast cancer diagnosis, age at diagnosis (+/- 2yr), adjuvant 
therapy, follow-up time (control survived without distant 
metastasis or CBC at least as long as time between first and 
subsequent cancer). 
 
Prognostic, predictive or 
both 
Prognostic (phase II) 
 
Control group None 
 
Prevention or treatment Treatment 
 
Intervention(s) 
None (radiotherapy, endocrine therapy and/or chemotherapy (or 
none) administered for breast cancer treatment). Specific 
treatments, doses and intake frequency not reported. 
 
Follow-up time period Mean 8.25yr in both cases and controls 
Setting Country Sweden 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period 1976 to 2005 
 
Urban/rural Stockholm-Gotland health-care region 
Participants 
(and 
characteristics 
at baseline) 
No. of participants n=422 (211 cases, 211 controls) 
 
Age (yr) 
≤45yr/45-55yr/55-65yr/≥65yr: Cases=37(18%) 
/68(32%)/56(27%)/50(24%), 
Controls=37(18%)/68(32%)/56(27%)/50(24%), same proportion 
in cases and controls by design 
 
Age <50 or ≥50 (yr) 
≤45yr/45-55yr/55-65yr/≥65yr: Cases=37(18%) 
/68(32%)/56(27%)/50(24%), 
Controls=37(18%)/68(32%)/56(27%)/50(24%), same proportion 
in cases and controls by design 
 
BMI (kg/m2) 
Not available, but fat area used as proxy: Q1(≤67cm2)/Q2(67-
93cm2)/Q3(93-127cm2)/Q4(≥127cm2): 
Cases=42(20%)/58(27%)/50(24%)/61(29%), 
Controls=60(28%)/43(20%)/55(26%)/53(25%) 
 
BMI < 25, 25 to < 30, 30 to 
< 35,  ≥35 (kg/m2) 
Not stated 
 
Ethnicity  Not stated 
 
Education  Not stated  
 
Baseline risk (%) NA 
 
Post/peri/pre-menopausal 
Pre/Post: Cases=89(42%)/119(56%), 
Controls=84(40%)/124(59%). Six patients had uncertain 
menopause status (for example, hysterectomy). 
 
Distribution of density at 
baseline 
Mean PDA at baseline=28%. PDA Q1(≤5%)/Q2(5-25%)/Q3(25-
50%)/Q4(≥50%): Cases=13(6%)/87(41%)/97(46%)/14(7%), 
Controls=11(5%)/87(41%)/87(41%)/26(12%). DA 
Q1(≤20cm2)/Q2(20-34cm2)/Q3(34-53cm2)/Q4(≥53cm2): 
Cases=55(26%)/44(21%)/56(27%)/56(27%), 
Controls=55(26%)/56(27%)/49(23%)/51(24%) 
 
Invasive/DCIS at baseline All invasive 
 
Stage (percentage regional 
spread) at baseline 
Tumour-node metastasis stage (cases and controls combined): 
1/2/3/unknown: 244/157/16/5. Note 53 ER-negative, 295 ER-
positive. 
Cointerventions HRT use Current use at diagnosis/no current use at 
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diagnosis/postmenopausal unknown HRT status: 
51(21%)/127(52%)/65(27%) 
 
Chemotherapy? 
(W/ or w/o radiotherapy and/or endocrine therapy): 
cases=28(13% of adjuvant therapies), controls=28(13%) 
 
Targeted therapy? Not stated  
 
Radiotherapy? 
(Radiotherapy only): cases=57(27% of adjuvant therapies), 
controls=57(27%) 
 
Neoadjuvant endocrine 
therapy? 
Not stated  
Timing 
Time between baseline 
mammogram and diagnosis 
First available mammogram up to 1yr prior to diagnosis, and up 
to 2 weeks 
after diagnosis 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry)  
Not stated  
 
Time between start of 
endocrine therapy (or 
study entry) and the follow-
up mammogram  
Not stated, but time from diagnosis to first available follow-up 
mammogram (1-5yr after diagnosis): mean=1.6yr, 90% between 
1 and 2.2yr (cases and controls combined), cases 
mean(SD)=1.56yr(0.59), controls mean(SD)=1.54yr(0.57) 
 
Time between baseline 
mammogram and start of 
endocrine therapy (or 
study entry)  
Not stated  
 
Time between baseline 
mammogram and the 
follow-up mammogram  
Not stated  
Biomarker 
Film (digitised for density 
or not)/FFDM 
Digitised film 
 
Pre-processing for quality 
control of mammographic 
density? 
Yes, poor-quality excluded (88 cases excluded for this reason) 
 
Density measure(s) 
Percentage (v) fully-automated (based on area of density) 
(ImageJ) and absolute (ii) automated area-based methods 
(ImageJ), 86% MLO & 14% CC (same view at baseline and 
follow-up mammograms and same view in matched cases and 
controls 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup 
Entire sample (minus 66 with percentage density <10% or >90% 
at baseline since they could not move into extreme density 
change groups) 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
 
Measure 
Percentage density (≥10% reduction/<10% reduction to <10% 
increase/increase ≥10%) 
 
n total in analysis 356 
 
n events / cases in analysis 178 
 
Data 
≥10% reduction/<10% reduction to <10% increase/increase 
≥10%: 96/243/17 
 
Adjustment Matching factors 
 
Point estimate ≥10% reduction OR=0.49, REF, increase ≥10% OR=0.74 
 
SD - 
 
SE - 
 
95% CI (0.28-0.85), REF, (0.23-2.40) 
 
 p-value 0.04 (P-trend) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
This analysis does not focus on endocrine treated group, but is 
the main analysis in the paper, number of events not stated but 
calculated from 1:1 matching and use of conditional logistic 
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regression. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup 
Entire sample (minus 84 with area density <10cm2 or 70cm2 at 
baseline since they could not move into extreme density change 
groups) 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
 
Measure 
Area density (≥10cm2 reduction/<10cm2 reduction to <10cm2 
increase/increase ≥10cm2) 
 
n total in analysis 338 
 
n events / cases in analysis 169 
 
Data 
≥10cm2 reduction/<10cm2 reduction to <10cm2 increase/increase 
≥10cm2: 108/197/33 
 
Adjustment Matching factors 
 
Point estimate ≥10cm2 reduction OR=0.67, REF, increase ≥10cm2 OR=0.79 
 
SD - 
 
SE - 
 
95% CI (0.38-1.16), REF, (0.35-1.78) 
 
 p-value 0.35 (P-trend) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
This analysis does not focus on endocrine treated group, but is 
the main analysis in the paper, number of events not stated but 
calculated from 1:1 matching and use of conditional logistic 
regression. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup 
Entire sample (minus 66 with percentage density <10% or >90% 
at baseline since they could not move into extreme density 
change groups) 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
 
Measure 
Percentage density (≥10% reduction/<10% reduction to <10% 
increase/increase ≥10%) 
 
n total in analysis 356 
 
n events / cases in analysis 178 
 
Data 
≥10% reduction/<10% reduction to <10% increase/increase 
≥10%: 96/243/17 
 
Adjustment 
Matching factors plus percentage density and non-dense area at 
first mammogram (both categorised in quartiles) 
 
Point estimate ≥10% reduction OR=0.45, REF, increase ≥10% OR=0.83 
 
SD - 
 
SE - 
 
95% CI (0.24-0.84), REF, (0.24-2.87) 
 
 p-value 0.04 (P-trend) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
This analysis does not focus on endocrine treated group, but is 
the main analysis in the paper, number of events not stated but 
calculated from 1:1 matching and use of conditional logistic 
regression. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup 
Entire sample (minus 84 with area density <10cm2 or 70cm2 at 
baseline since they could not move into extreme density change 
groups) 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
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Measure 
Area density (≥10cm2 reduction/<10cm2 reduction to <10cm2 
increase/increase ≥10cm2) 
 
n total in analysis 338 
 
n events / cases in analysis 169 
 
Data 
≥10cm2 reduction/<10cm2 reduction to <10cm2 increase/increase 
≥10cm2: 108/197/33 
 
Adjustment 
Matching factors plus non-dense area at first mammogram (and 
dense area since indicated in methods but not table legend?) 
(both categorised in quartiles) 
 
Point estimate ≥10cm2 reduction OR=0.54, REF, increase ≥10cm2 OR=0.71 
 
SD - 
 
SE - 
 
95% CI (0.30-0.99), REF, (0.30-1.69) 
 
 p-value 0.13 (P-trend) 
 
Comment on statistical 
method 
Conditional logistic regression 
 
Other 
This analysis does not focus on endocrine treated group, but is 
the main analysis in the paper, number of events not stated but 
calculated from 1:1 matching and use of conditional logistic 
regression. 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Endocrine therapy only (w/ or w/o radiotherapy) 
 
Endpoint 
Incidence of a secondary primary breast cancer (e.g. in the 
contralateral breast)  
 
Measure 
Percentage density (≥10% reduction/<10% reduction to <10% 
increase/increase ≥10%) 
 
n total in analysis 
Cases=87(41% were on endocrine therapy), controls=87(41% 
were on endocrine therapy) - but not clear if all of these women 
were included in the analysis 
 
n events / cases in analysis 
Cases=87(41% were on endocrine therapy), controls=87(41% 
were on endocrine therapy) - but not clear if all of these women 
were included in the analysis 
 
Data Not stated 
 
Adjustment 
Unclear - matched factors (plus percentage density and non-
dense area?) 
 
Point estimate ≥10% reduction OR=0.52, REF, increase ≥10% not stated 
 
SD - 
 
SE - 
 
95% CI (0.18-1.51), REF, not stated 
 
 p-value Not stated (but p>0.05) 
 
Comment on statistical 
method 
Conditional logistic regression. Numbers, adjustments and 
results unclear. 
 
Other This is relevant for the review. 
  
N.B. other results for the entire sample adjusted for HRT, and by 
menopausal status and mammographic view, but these are not in 
the endocrine therapy only group so are not relevant for this 
review. 
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B.VI.ix Data capture form - van Nes 2015 
Area Field Data 
Study design Type of study Sub-cohort within a randomised trial 
 
Matching None 
 
Prognostic, predictive or 
both 
Prognostic (phase II) 
 
Control group None 
 
Prevention or treatment Treatment 
 
Intervention(s) 
Tamoxifen for 2–3 years followed by exemestane for 3–2 years 
(totalling five years) or exemestane alone for 5 years. Tamoxifen: 
20 mg once a day, orally; Exemestane: 25 mg once a day, orally. 
 
Follow-up time period Median 6yr (range 0-9yr) 
Setting Country Netherlands 
 
High-risk clinic? No 
 
Treatment clinic? Yes 
 
Time period 
Not stated - TEAM trial enrolment in 2001 but period of this 
study not reported 
 
Urban/rural 
13 hospitals out of 76 included in the TEAM trial (92 Dutch 
hospitals in total) 
Participants 
(and 
characteristics 
at baseline) 
No. of participants Exemestane n=197, sequential n=181 
 
Age (yr) 
Median (range): Sequential = 63 years (48–91), Exemestane = 62 
years (45–86). <50/50-59/60-69/≥70: Sequential = 
3(2%)/66(36%)/69(38%)/43(24%), Exemestane = 
8(4%)/67(34%)/66(34%)/56(28%). 
 
Age <50 or ≥50 (yr) 
<50/≥50: Sequential = 3(2%)/178(98%), Exemestane = 
8(4%)/189(96%). 
 
BMI (kg/m2) 
<25/25-30/≥30: Sequential = 61(36%)/68(40%)/39(23%), 
Exemestane = 79(42%)/70(37%)/38(20%) 
 
BMI < 25, 25 to < 30, 30 to 
< 35,  ≥35 (kg/m2) 
<25/25-30/≥30: Sequential = 61(36%)/68(40%)/39(23%), 
Exemestane = 79(42%)/70(37%)/38(20%) 
 
Ethnicity  Not stated 
 
Education  Not stated 
 
Baseline risk (%) NA 
 
Post/peri/pre-menopausal All postmenopausal 
 
Distribution of density at 
baseline 
Given as figure (by radiologists' scores), can be extracted 
 
Invasive/DCIS at baseline All invasive 
 
Stage (percentage regional 
spread) at baseline 
pT1/pT2/pT3 or 4: Sequential = 79(44%)/86(48%)/15(8%), 
Exemestane = 91(47%)/97(50%)/7(4%). Nodal status -/+: 
Sequential = 59(33%)/122(67%), Exemestane = 
61(31%)/136(69%) 
Cointerventions HRT use Not stated 
 
Chemotherapy? 
No/Yes: Sequential = 199(66%)/62(34%), Exemestane = 
142(72%)/55(28%) 
 
Targeted therapy? Not stated 
 
Radiotherapy? 
No/Yes: Sequential = 69(38%)/112(62%), Exemestane = 
70(36%)/126(64%) 
 
Neoadjuvant endocrine 
therapy? 
Not stated 
Timing 
Time between baseline 
mammogram and 
diagnosis 
(Baseline mammograms were preoperative) 
 
Time between diagnosis 
and start of endocrine 
therapy (or study entry)  
Not stated 
 
Time between start of T1 (range 6–18 months), T2 (range 18–30 months), and T3 
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endocrine therapy (or 
study entry) and the 
follow-up mammogram  
(range 30–42 months) 
 
Time between baseline 
mammogram and start of 
endocrine therapy (or 
study entry)  
Not stated 
 
Time between baseline 
mammogram and the 
follow-up mammogram  
Not stated 
Biomarker 
Film (digitised for density 
or not)/FFDM 
Film (FFDM excluded) 
 
Pre-processing for quality 
control of mammographic 
density? 
Not stated 
 
Density measure(s) 
Percentage (ii) visual assessment by  three experienced 
radiologists in 20% bands (Boyd categories), contralateral CC 
Results (add 
new rows each 
subgroup and 
endpoint 
combo) 
Subgroup Both treatment arms combined 
 
Endpoint 
Recurrence and Incidence of a secondary primary breast cancer 
(e.g. in the contralateral breast) combined (all of the study 
endpoints were included as the outcome: loco-regional 
recurrence, distance recurrence or contralateral breast cancer) 
 
Measure "Change in breast density" 
 
n total in analysis 
378 (Table IB: "Included in the current analysis" left-hand 
column is the column to use) 
 
n events / cases in analysis 
Loco-regional recurrence cases (4 in the sequential arm, 5 in the 
exemestane arm), distance recurrence cases (28 in the sequential 
arm, 20 in the exemestane arm), and contralateral breast cancer 
cases (4 in the sequential arm, 3 in the exemestane arm) 
 
Data Not stated 
 
Adjustment Not stated 
 
Point estimate 
“No association between change in breast density and the 
occurrence of an event” 
 
SD - 
 
SE - 
 
95% CI Not stated 
 
 p-value Not stated 
 
Comment on statistical 
method 
Cox regression? 
 
Other No analysis of change in density reported. 
Source of 
funding, 
conflicts 
Funding Pfizer, unrestricted research grant. 
 
Conflict of interest The authors report no conflicts of interest. 
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B.VII Risk of bias tables 
B.VII.i Risk of bias table - Cuzick 2011 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
The source population is 
described, based on entry 
criteria to the IBIS-I trial. 
“To be eligible for IBIS-I, a 
woman had to be between 35 
and 70 years old and have at 
least twice the average risk of 
a 50-year-old woman of 
developing breast cancer 
(14). Typically, therefore, an 
IBIS-I participant would 
have either a history of 
benign proliferative breast 
disease or a strong family 
history of breast cancer (i.e., 
a mother or sister who 
developed breast cancer 
before age 50 years). The 
absolute observed 10-year 
risk of developing breast 
cancer in the placebo arm of 
the main study was 6.4% 
(15).”, although no mention 
of BRCA 1/2 mutation 
carriers. Prior hormone 
therapy use is included.  
There were no 
cointerventions in the trial. 
Yes   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
The sampling frame is well 
described. “To minimize the 
administrative workload, 
control subjects were 
selected only from the major 
participating UK centers in 
Aberdeen, Bristol, Cardiff, 
Edinburgh, London, 
Manchester, Nottingham, and 
Southampton. We identified 
1064 potential control 
subjects (women who had 
completed 5 years of 
treatment with full 
compliance and had not 
Yes   
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developed breast cancer) and 
requested the mammograms 
for these women. A total of 
942 complete sets of 
mammograms (baseline and 
first follow-up) were 
recovered. The missing 
mammograms had either 
been lost or destroyed in 
accordance with the local 
archiving policy”. UK and 
Finnish cases. 
Recruitment 
period 
Period of recruitment is adequately 
described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are 
adequately described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Well described e.g. three 
cases who were diagnosed 
within the first 12 months of 
treatment were excluded 
from the analysis: “Three of 
these women had been 
diagnosed within the first 12 
months on study and were 
excluded from the analysis”. 
Yes   
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
942 of 1064 controls; 126 of 
224 cases from the centres. 
Films were obtainable for 
55% of the IBIS-I cases from 
the UK and Finland. No data 
to compare included and 
excluded samples, but 
reported that this was 
examined. “The control 
subjects who were selected 
for this case–control study 
did not differ with respect to 
demographic factors from the 
IBIS-I control subjects who 
were not selected (data not 
shown)” and “These women 
did not differ from the IBIS-I 
case subjects who were not 
selected for this case–control 
study with respect to 
demographic factors or tumor 
characteristics (data not 
shown)”. 
Yes   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Low 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
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completing and non-completing 
participants) 
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
All controls complied over 
the full 5yr follow-up period 
and were not censored due to 
loss to follow-up: “women 
who had completed 5 years 
of treatment with full 
compliance and had not 
developed breast cancer”.  
Yes   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of 
the study are described 
Not described, but 
withdrawals only reported 
n=44 Australian women in 
Cuzick 2015; Lancet 
Oncology; 16(1): 67-75 (and 
not included in density sub-
study). 
Partial   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
Not described, but 
withdrawals only reported 
n=44 Australian women in 
Cuzick 2015; Lancet 
Oncology; 16(1): 67-75 (and 
not included in density sub-
study). 
Partial   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
NA Yes   
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is 
not associated with key 
characteristics (i.e. the study data 
adequately represent the sample) 
sufficient to limit potential bias to 
the observed relationship between 
density change and outcome 
    Low 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear description provided: 
“visually estimated the 
proportion of the total breast 
area that 
was composed of dense 
tissue (to the nearest 5%)”, 
expert radiologist: 
“Mammographic density was 
assessed visually by one 
radiologist (R. M. L. 
Warren)”, contralateral 
breast: “The assessment of 
mammographic density for 
both case subjects and 
Yes   
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control subjects was based on 
a composite assessment of 
both the left and right 
mediolateral-oblique views, 
except for the 13 case 
subjects who were diagnosed 
at the first follow-up 
mammogram; those 
assessments were made using 
only the film for the 
contralateral breast”. 
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
High inter and intra-reader 
correlation: “correlation 
between the original and 
repeat mammographic breast 
density assessment readings 
was very high: the Pearson 
correlation coefficient for the 
baseline mammograms was 
0.98 (95% CI = 0.96 to 0.99), 
for the follow-up 
mammograms was 0.97 (95% 
CI = 0.97 to 0.99), and for 
the density change over 12–
18 months was 0.78 (95% CI 
= 0.63 to 0.87)” and 
“correlation between the 
original mammographic 
breast density assessment by 
R.M. L. Warren and the 
subsequent mammographic 
breast density assessments by 
the other four readers was 
also very high for the 
baseline mammograms (r 
ranged from 0.86 to 0.90) 
and for the follow-up 
mammograms (r ranged from 
0.87 to 0.91) but was only 
moderate for breast density 
change over 12–18 months (r 
ranged from 0.48 to 0.67)”, 
blinded: “original reader was 
blinded with regard to 
treatment allocation 
(tamoxifen or placebo) but 
not with regard to case–
control status. However, the 
fully blinded rereading of the 
original films for 40 control 
subjects and eight case 
subjects indicated high 
reproducibility of the original 
breast density assessment”. 
Partial   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
“The 10% cut point was 
chosen because it was the 
minimum change that could 
be reproducibly detected”. 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting same 
(“Mammographic density 
was assessed visually by one 
radiologist (R. M. L. 
Warren)”), same 
mammogram type (film). 
Median (IQR) baseline to 
follow-up=19 (18-23) 
months. 
Yes   
Proportion of 
data on 
Adequate proportion of the study 
sample has complete data for the 
All have complete data by 
definition of study design. 
Yes   
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prognostic 
factor available 
for analysis 
change in mammographic density 
variable 
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Clear definition, outcome is 
breast cancer diagnosis: “to 
examine associations 
between change in 
mammographic density and 
the risk of breast cancer”. 
Yes   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
From IBIS-I trial database. Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by 
age and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age and BMI measured. Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
“Age […] at entry to IBIS-I, 
body mass index (as a 
continuous variable)”. 
Yes   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Measurement is adequately 
valid. 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
1065 women, 1049 in main 
result (16 missing BMI) so 
no imputation used. 
Yes   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Yes, although no adjustment 
for change in BMI. 
Yes   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Low 
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6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Yes. Yes   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate 
and is based on a conceptual 
framework or model 
Conceptual framework – 
adjusted density change 
analysis for other prognostic 
factors or those associated 
with density. Does not appear 
to be variable selection. 
Yes   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Yes, adequate. However, an 
interaction test between 
density change and treatment 
arm was not reported. 
Partial   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    Low 
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B.VII.ii Risk of bias table - Kim 2012 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is not 
described, only analysis 
population. 
No   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Well described: "1,542 ER-
positive breast cancer 
patients who underwent 
curative surgery at Seoul 
National University 
Hospital between October 
2003 and December 2006". 
Yes   
Recruitment 
period 
Period of recruitment is adequately 
described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are adequately 
described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Adequately described: 
"Patients were excluded if: 
1) they did not receive 
adjuvant endocrine 
treatment, such as 
tamoxifen or an aromatase 
inhibitor, or were treated 
for less than 2 years; 2) 
their digital mammogram 
images were not available; 
3) they had bilateral breast 
cancer, or 4) distant 
metastasis was observed 
before the start of 
endocrine therapy", but no 
information on number of 
exclusions based on each 
exclusion criteria. 
Partial   
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Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
1065 of 1542 women 
included. No information 
on participation based on 
consent. No information on 
eligible participants vs. 
those not eligible (in source 
population or in 1542 
women). 
Partial   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
Only included patients with 
at least 2yr of endocrine 
treatment but discrepancy 
since "mean duration of 
overall endocrine therapy 
was 5.1 years (range, 0.9 to 
7.9 years)". 
Partial   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of the 
study are described 
No information found on 
drop out or reasons for 
censoring. 
No   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
No information found on 
loss to follow-up or reasons 
for censoring. 
No   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
No information found on 
loss to follow-up or reasons 
for censoring. 
No   
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is not 
associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
    Moderate 
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relationship between density 
change and outcome 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear definition: “Cumulus 
software 4.0 (University of 
Toronto, Toronto, Canada) 
by a single investigator 
(JK)”. Contralateral breast 
used. 
Yes   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
Valid and reliable method, 
with estimate of 
reproducibility - 
“Intraobserver 
reproducibility, tested for 
10% of randomly selected 
images (213/2,130), was 
0.93 (Pearson correlation 
coefficient)”. Blinded: 
“blinded to treatment 
outcome”, but no mention 
of blinding to treatment 
used. 
Partial   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
MDR cut-points: "the 5% 
and 10% absolute reduction 
cut-offs based on previous 
findings [5]", but MDR 
also analysed as a 
continuous variable. No 
mention of why cut-points 
used for MDRR (selective 
reporting?), and why 
0/10/25% used in main text 
but 15% used in 
supplementary analysis. 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting are the 
same. "All evaluated 
images were digital 
mammograms performed at 
our institution" and read by 
a single investigator. No 
mention of time between 
baseline and follow-up 
mammogram. 
Partial   
Proportion of 
data on 
prognostic 
factor available 
for analysis 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
variable 
All have complete data by 
definition of study design. 
Yes   
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of A clear definition of outcome is Adequate definition "All Partial   
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the outcome provided, including duration of 
follow-up and level and extent of 
the outcome construct 
loco-regional or distant 
disease recurrences were 
regarded as recurrence 
events in recurrence-free 
survival analysis", but no 
information on start of 
follow-up or reasons for 
censoring. Duration of 
follow-up given (although 
discrepancy between 
abstract and text, see data 
capture form). 
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
"Clinical and pathologic 
information on the 1,065 
subjects was obtained from 
the database". Single 
institution. 
Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by age 
and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age measured but not 
BMI. 
Partial   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
Timing of age not fully 
described - is age at 
diagnosis, start of 
treatment, baseline or 
follow-up mammogram? 
No   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
From institution’s 
prospectively maintained 
web based database? 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
From institution’s 
prospectively maintained 
web based database? 
Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
No mention of missing data 
or imputation. Age appears 
to be non-missing (Table 
1). 
Partial   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Unclear which analyses 
were adjusted for age. For 
example, supplementary 
table 4: Size, LN, Ki67 
included (Fwd stepwise 
selection), but in text: 
"adjusted for age and 
preMD by forward 
selection stepwise 
analysis". Unclear of 
adjustments (if any) when 
analysis separated by 
tamoxifen and AIs: "When 
adjusted by age and ET 
regimen the findings were 
consistent, showing low 
MDR as a significant risk 
factor for recurrence in 
Partial   
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patients who had 
undergone chemotherapy 
(HR 1.70, 95% CI 1.04 to 
2.77, P = 0.033)", but only 
mentioned for 
chemotherapy. No 
adjustment for BMI or 
change in BMI. 
Study 
confounding 
summary 
Important potential confounders are 
appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    High 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Details of methods not 
reported e.g. start of 
follow-up and censoring, 
women with <2yr treatment 
excluded but minimum 
duration of treatment 
reported is 0.9yr, errors in 
tables (e.g. no number of 
women on AIs in Table 1), 
mismatching information 
between text and figures 
e.g. adjustments used. 
Description of women in 
endocrine treatment 
subgroups and number of 
women in subgroups not 
reported (unclear if 
subgroups are tamoxifen 
only, AI only or women 
who switched), therefore 
we can't separate out 
treatments - some women 
might have had cross-over 
of treatments between 
mammograms hence 
affecting density change. 
No   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate and 
is based on a conceptual framework 
or model 
Partially: "factors with P < 
0.05 were considered 
statistically significant", 
but unclear which 
confounders were initially 
considered for stepwise 
regression and which (if 
any were used for the 
endocrine therapy 
subgroups relevant for this 
review). Adjusting factors 
included in some models 
and not others with no 
consistency. 
Partial   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Cox model appropriate but 
delayed-entry perhaps 
better (taking into account 
time between 
mammograms where 
women would not be at-
risk). Unsure of follow-up 
and results in subgroups 
relevant for this review. 
Some selective reporting of 
results – no consistency 
with adjustments. 
No   
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Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    High 
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B.VII.iii Risk of bias table - Knight 2018 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is not 
described, only analysis 
population, but information 
on WECARE can be found 
elsewhere e.g. Memorial 
Sloan Kettering website. 
Partial   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Well described: "Each 
study center identified 
eligible women through 
one or more population-
based cancer registries". 
"WECARE study 
participants were diagnosed 
prior to age 55 years, 
between 1990 and 2008, 
with a first primary local or 
regional-stage invasive 
breast cancer. Cases were 
also diagnosed with a 
second primary invasive 
CBC at least 2 years later 
with no intervening cancer 
diagnosis, other than a non-
melanoma skin cancer or 
cervical carcinoma in situ". 
Matched "UBC controls 
had no history of 
subsequent cancer 
diagnosis except for 
nonmelanoma skin cancer 
or cervical carcinoma in 
situ up to their reference 
date". UBC "controls must 
not have undergone 
prophylactic mastectomy of 
the contralateral breast. All 
Yes   
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women had to be alive at 
the time of contact for 
interview". 
Recruitment 
period 
Period of recruitment is adequately 
described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are adequately 
described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Well described: "excluded 
the few mammograms that 
were digital from the 
analysis (5 CBC cases and 
6 UBC controls prior to/at 
first diagnosis, 39 CBC 
cases and 41 UBC controls 
post diagnosis)", "excluded 
a small number of films in 
which MD could not be 
read because of poor image 
quality (4 CBC cases and 4 
UBC controls prior to/at 
first diagnosis, 11 CBC 
cases and 6 UBC controls 
post diagnosis)", "excluded 
mammograms taken more 
than 36 months prior to or 
48 months following first 
diagnosis", excluded 6% of 
CBC cases and 7% of UBC 
controls with a density 
change of 10% or more 
(unsure why), and excluded 
women with missing 
menopausal status 
information in the density 
change analysis. 
Yes   
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
The uptake rate is not 
reported. This is a 
retrospective design, so 
requires individuals to still 
be alive at time of 
recruitment. This may lead 
to some selection bias – 
those who died before this 
date would not be included, 
particularly those 
diagnosed at the start of the 
period. Could bias against 
density change. “Women in 
whom we could not obtain 
a mammogram in an 
appropriate time window 
(see below) were more 
likely to have an earlier 
year of first breast cancer 
diagnosis (65% diagnosed 
in 1990–1996 vs. 40% in 
1990–1996) and to be 
missing ER status (14% vs. 
6%), and were slightly 
younger (mean age 45 
years vs. mean age 46 
years). Both groups had 
similar distributions of 
histologic type (10% and 
13% lobular), stage (68% 
and 66% local), and, after 
excluding those with 
missing status, ER status 
Yes   
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(65% and 68% positive). 
There were also no 
differences in first-degree 
family history (27% and 
28%)”. However, women 
with mammograms outside 
final selected timeframe 
had similar risks as those 
with mammograms inside 
timeframe (supplementary 
tables). 
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
These are given, but not for 
sample where density 
change analysed. 
Partial   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
No information found on 
response rate (i.e. 
compliance). 
No   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of the 
study are described 
No information found on 
drop out. Registry linkage – 
no drop out?  
No   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
Retrospective study, no 
information on loss to 
follow-up (does not include 
women who died and could 
not consent / provide 
questionnaire e.g. "women 
in whom we could not 
obtain a mammogram in an 
appropriate time window 
(see below) were more 
likely to have an earlier 
year of first breast cancer 
diagnosis (65% diagnosed 
in 1990–1996 vs. 40% in 
1990–1996)" - survival bias 
whereby women included 
more likely to have 
survived at time of 
interview than wider 
cohort, we don't know 
about women who died 
before the study). 
No   
Outcome and 
prognostic 
factor 
information on 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
No information. No   
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those lost to 
follow-up 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is not 
associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
relationship between density 
change and outcome 
    High 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear definition: "MD 
measurements were all 
done in Toronto by one 
experienced reader (KB) 
using Cumulus". 
Contralateral breast used. 
Yes   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
Valid and reliable method, 
with estimate of 
reproducibility - "We 
randomly selected 10% of 
each batch for repeat 
readings within and 
between batches. The 
Pearson correlation was 
0.94 for both intra- and 
inter batch repeats". 
Blinded: "the reader was 
blinded to case control 
status and time sequence of 
the mammogram", but not 
reported if blinded to 
treatment. 
Yes   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
10% percentage change 
cut-point used, not justified 
in text. But noted to be 
used in other prior studies 
(particularly Sandbery et al, 
their ref [12]). 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting are the 
same (KB read all 
mammograms), 
"Mammograms were read 
in batches with both 
mammograms from the 
same woman read in the 
same batch. Mammogram 
order within each batch 
was randomized prior to 
reading" and "The film 
mammograms were 
digitized at two locations, 
Yes   
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Seattle (all US 
mammograms) and 
Toronto (Ontario 
mammograms), both using 
a Kodak Lumisys Digital 
Scanner". Median baseline 
to follow-up=1yr. 
Proportion of 
data on 
prognostic 
factor available 
for analysis 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
variable 
812 CBC and 812 UBC 
recruited from WECARE II 
and at least one 
mammogram obtained 
from 464 CBC and 500 
UBC (potential for bias if 
ended up with fewer CBC 
than UBC, so not having 
mammogram available a 
risk factor for CBC?). 
224/362 CBC and 243/403 
UBC with mammograms at 
both time points but 210 
CBC and 225 UBC used in 
the density change analysis 
(reason for difference not 
given explicitly, but could 
be digital mammogram or 
quality of image or other 
exclusions broadly 
discussed or missing 
adjusting factors). 
Partial   
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
Complete case analysis. Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Clear definition: "We 
assessed whether change in 
%MD (defined as the 
difference between 
measurements of %MD 
between the two time 
points) was associated with 
CBC in the subset of 
women who had 
mammograms at both time 
points". Date of search of 
cancer registries (i.e. 
follow-up) not given. 
Partial   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
Yes – population registry. Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by age 
and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
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another factor that is related to 
density reductions and the 
outcome) 
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age, change in age, BMI, 
change in estimated BMI 
measured. 
Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
Age at first diagnosis, 
change in age between 
prior to/at first diagnosis 
and post-diagnosis 
mammograms, BMI at first 
diagnosis, change in 
estimated BMI between 
prior to/at first diagnosis 
and post-diagnosis 
mammograms (BMI at 
post-diagnostic 
mammogram was 
estimated from the BMI 
reported at first breast 
cancer diagnosis and at 
reference date, using linear 
interpolation - same for 
BMI at prior to/at first 
diagnosis mammogram?) 
Yes   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Risk factors for breast 
cancer were obtained 
retrospectively by 
telephone survey - potential 
for recall bias. 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
Not explicit, but 210/224 
CBC and 225/243 UBC 
used in the density change 
analysis (could be due to 
missing adjusting factors). 
Partial   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Adjusted for age, change in 
age, and change in 
estimated BMI (why not 
BMI at diagnosis as well 
since between-women BMI 
also associated with risk?). 
Yes   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Moderate 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Characteristics of a wider 
sample given in Table 1, 
but not of the sample 
analysed for density 
change. "Note that other 
types of hormonal therapies 
(e.g., aromatase inhibitors) 
were not common in this 
population", but unable to 
separate effects for this 
review. 
Partial   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate and 
is based on a conceptual 
Reason for choosing the 
breast cancer risk factors 
used not included. Model 
adjusted for tamoxifen 
Partial   
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framework or model treatment instead of 
assessing density change in 
only women on treatment, 
therefore model does not 
estimate this review's 
primary measure. The 
model includes women 
who did not receive 
tamoxifen (but no 
predictive analysis was 
done, instead an adjustment 
was made for tamoxifen 
use), and ER-negative 
disease (different 
prognosis, adjusted for in 
model instead of separated 
out).         
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Model appears adequate for 
design of study, but not for 
this review's analysis. Full 
model fit not given. Focus 
of paper was on prognostic 
ability of mammographic 
density, change is a 
secondary aim. Not clear if 
this is selective reporting. 
Also not clear why 
appropriate to exclude 10% 
or more density increase. 
Partial   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    High 
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B.VII.iv Risk of bias table - Ko 2013 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the 
overall judgement of potential bias 
for each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is 
adequately described for: a) 
treatment: (i) proportion with 
DCIS, (ii) cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is not 
described, only analysis 
population. 
No   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Well described: "A total of 
2,402 ER-positive breast 
cancer patients who were 
enrolled in this study 
underwent curative surgery 
at our institution between 
January 2003 and December 
2008". 1,526/2,402 women 
who received adjuvant 
tamoxifen for at least 2 
years. 
Yes   
Recruitment 
period 
Period of recruitment is 
adequately described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are 
adequately described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria 
are adequately described 
Adequately described: 
1336/2402 women excluded 
"if their digital 
mammograms were not 
available or not appropriate 
for evaluation or if they had 
bilateral breast cancer or 
occult breast cancer" 
(n=1066), but no 
information on number of 
exclusions based on each 
exclusion criteria. Women 
not on tamoxifen should be 
included in 1336 excluded 
Partial   
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women but this is not 
detailed. 
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
1066 of 1526 tamoxifen-
treated patients included.  
No information on 
participation based on 
consent. No information on 
eligible participants vs. 
those not eligible (in source 
population or 1526 women). 
Partial   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for 
(treatment and prevention) age, 
menopausal status, 
cointerventions; (treatment) % 
DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement 
therapy use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline 
sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
Only included patients with 
at least 2yr of endocrine 
treatment. 
Yes   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of 
the study are described 
No information found on 
drop out or reasons for 
censoring. 
No   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
No information found on 
loss to follow-up or reasons 
for censoring. 
No   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
No information found on 
loss to follow-up or reasons 
for censoring. 
No   
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline 
sample to study population 
analysed) is not associated with 
key characteristics (i.e. the study 
data adequately represent the 
    Moderate 
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sample) sufficient to limit 
potential bias to the observed 
relationship between density 
change and outcome 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is 
provided (e.g. including the 
method of measurement, if 
subjective then who undertook it, 
if treatment then whether 
contralateral breast assessed) 
Method of measurement not 
completely clear: what is the 
"computerized system"? 
Also, "a single radiologist 
(K. Ko: 10 years of 
experience in interpreting 
mammograms) reviewed 
2,132 preoperative and 
postoperative mammograms 
classified breast density 
patterns according to 
BIRADS". No restriction to 
contralateral breast? E.g. 
each woman had 2 
mammograms (2132 
mammograms for 1066 
women) so perhaps both 
breasts were examined in 1 
view or one breast was 
examined in 2 views?  
No   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
No test of reliability: "We 
relied on a single radiologist 
who is a specialist in breast 
imaging studies, thereby 
eliminating interobserver 
variability. We did not seek 
to measure reproducibility 
as the BI-RADS density 
classifications are 
standardized", although BI-
RADS measures can still 
have intra-reader variability. 
Not stated if blinded to 
patient’s identity or breast 
cancer event status etc. 
No   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
BI-RADS cut-points, 
although combining BI-
RADS 1 & 2 means that BI-
RADS 2 can no longer 
move down a category so 
losing information about 
density change (better to just 
exclude BI-RADS 1 at 
baseline as they cannot 
move down a category?). 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting are the 
same: read by a single 
radiologist, all women and 
mammograms from the 
same institution. No 
mention of time between 
baseline and follow-up 
mammogram. 
Partial   
Proportion of 
data on 
prognostic 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
All have complete data by 
definition of study design. 
Yes   
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factor available 
for analysis 
variable 
Method used 
for missing 
data 
Appropriate methods of 
imputation are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential 
measurement of outcome related 
to the density reductions) 
 
    
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Adequate definition: 
outcome is loco-regional or 
systemic recurrence, or 
contralateral breast cancer, 
but discrepancy with 
numbers (48+16+4=68, not 
67 as stated). "The 
association of MDR with 
disease-free survival 
according to patterns of 
recurrent disease (loco-
regional, systemic, and 
contralateral recurrence) 
was analyzed", but no 
information on start of 
follow-up or reasons for 
censoring. Duration of 
follow-up given (mean 61 
months). 
Partial   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
 Single institution: "we 
collected the 
clinicopathologic 
information on 1,066 
patients by reviewing the 
prospective database of our 
institution and the data of 
disease recurrence by 
additional medical record 
review". 
Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of 
outcome measurement is the same 
for all study participants, including 
by age and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age and BMI measured. Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
Body mass index (BMI) was 
calculated as weight/height2 
(kg/m2), but timing of age 
and BMI not fully described 
- are they at diagnosis, start 
of treatment, baseline or 
follow-up mammogram? 
Partial   
Valid and 
reliable 
Measurement of all important 
confounders is adequately valid 
From institution’s 
prospective database? 
Yes   
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measurement 
of confounders 
and reliable 
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
From institution’s 
prospective database? 
Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
No mention of missing data 
or imputation. Age appears 
to be non-missing (Table 1: 
≤50yr vs. >50yr).  
Partial   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Analysis reported with 
adjustment for age and BMI, 
also other prognostic 
factors. However, no 
adjustment for 
chemotherapy although this 
was associated with 
mammographic density 
reduction. So not clear if 
tamoxifen-induced, or 
chemotherapy-induced 
differences in survival. Also 
no adjustment for breast 
density at entry, which is 
strongly associated with 
density change in the data. 
No adjustment for change in 
BMI. 
Partial   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Moderate 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Details of methods not 
reported e.g. start of follow-
up and censoring, errors e.g. 
total number of events do 
not add up, unclear 
adjustments e.g. results from 
Fig 3 don't match table 6 
(are these unadjusted?), title 
says premenopausal women 
but age range 25-78 and 
subgroup analysis of 
≤50yr/>50yr used as a proxy 
for menopausal status and 
postmenopausal women 
mentioned in results. "Our 
institution’s guidelines 
recommend aromatase 
inhibitors as the first choice 
endocrine therapy for ER-
positive postmenopausal 
breast cancer patients" - 
does this mean the 
postmenopausal women 
could have been on AIs 
before their tamoxifen 
treatment?  
No   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate 
and is based on a conceptual 
framework or model 
Adjustment for some 
prognostic factors, but not 
others that are also 
associated with 
mammographic density 
change (baseline density, 
Partial   
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chemotherapy). Not clear 
how model developed / 
criteria for building. 
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Cox model appropriate but 
delayed-entry perhaps better 
(taking into account time 
between mammograms 
where women would not be 
at-risk). Unsure of follow-up 
and may be some selective 
reporting of results – why 
were other adjustments not 
considered / included? 
No   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    High 
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B.VII.v Risk of bias table - Li 2013 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is not 
described, only analysis 
population, but indication 
of size given: "all women 
born in Sweden who were 
age 50 to 74 years old at 
first diagnosis of invasive 
breast cancer in the 
Swedish Cancer Register 
were eligible (n=3,979)". 
Partial   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Adequately described 
e.g."84% (n=3,345) 
participated by answering a 
mailed questionnaire". 
Yes   
Recruitment 
period 
Period of recruitment is adequately 
described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are adequately 
described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Well described e.g. Figure 
1 & exclusions based on 
questionnaire data, 
previous cancer, 
premenopausal or unknown 
menopausal status, medical 
records or registers,  non-
invasive breast cancer, 
duplicate records, breast 
cancer diagnosis before or 
after study period, non-
breast-cancer, no informed 
consent, mammogram data, 
no mammograms, no 
follow-up mammogram, 
follow-up mammogram 
>3yr after baseline, 
baseline density, quintile 
with smallest dense area, 
and incomplete covariate 
Yes   
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information. 
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
634 women declined 
participation, 701 were 
excluded for sensible 
reasons (including previous 
cancer, duplicate records, 
non-invasive breast 
cancer), 1603 excluded due 
to mammograms (including 
243 in quintile with 
smallest dense area), 67 
incomplete covariates, 974 
in analysis. No information 
on eligible participants vs. 
those not eligible. 
Partial   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
37 (7.8%) received 
tamoxifen for <12 months. 
Yes   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of the 
study are described 
Registry based, some 
censoring due to emigration 
but not stated what amount 
(but in this population & 
age group it is likely to be 
small). 
Partial   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
Censored due to: "death, 
emigration, or end of 
follow-up (December 31, 
2008)". 
Yes   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
Only reason for loss to 
follow-up is emigration and 
these are not described, but 
likely to be small.  
Partial   
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is not 
    Low 
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associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
relationship between density 
change and outcome 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear definition: "All 
density measurements were 
obtained by using an 
automated thresholding 
method previously 
described in Li et al.(17). 
The machine learning 
method incorporates the 
knowledge of a trained 
reader (L.E.) by using 
segmentations obtained by 
Cumulus (19) as training 
data". Contralateral breast: 
"Only mediolateral oblique 
views of the breast 
unaffected by breast cancer 
were used". 
Yes   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
Appears adequately valid: 
"Externally validated 
results showed a high 
correspondence between 
the automated method and 
the user-assisted threshold 
method (Pearson’s 
correlation coefficient   
0.872 for DA)". 
Yes   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
Categories used were 
chosen "a priori", but no 
reference of evidence to 
support this e.g. prior 
publication using same cut-
points or SAP. 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting are the 
same. All film 
mammograms scanned on 
same scanner: "Film 
mammograms were 
digitized by using an Array 
2905HD Laser Film 
Digitizer (Array Corp, 
Tokyo, Japan)". Mean 
1.4yr (SD 0.5) between 
mammogram, maximum 
3yr. 
Yes   
Proportion of 
data on 
prognostic 
factor available 
for analysis 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
variable 
All have complete data by 
definition of study design. 
Yes   
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
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4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Clear definition: "Women 
were observed from the 
date of breast cancer 
diagnosis until death" and 
"Cause-specific deaths as a 
result of breast cancer were 
ascertained by using the 
cause of death register", 
duration of follow-up given 
(see data capture form), 
extent of outcome construct 
given from wider eligible 
population. 
Yes   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
Yes – population registry. Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by age 
and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age, BMI and change in 
non-dense area (proxy for 
BMI) measured. 
Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
Age at baseline 
mammogram (years), body 
mass index (BMI) at 
interview (quartiles), 
quartile of percentage 
change in non-dense area 
was used as a proxy for 
BMI. 
Yes   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Measurement is adequately 
valid. 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
67 excluded from analysis 
due to missing covariate 
data so no imputation used. 
Grade and ER status 
unknown were coded as 
such. 
Yes   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Yes, including adjustments 
for age, BMI, change in 
non-dense area and 
chemotherapy. Adjustment 
for baseline density 
included in the relative 
density change measure. 
Yes   
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Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Low 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Yes. Yes   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate and 
is based on a conceptual 
framework or model 
Conceptual framework – 
adjusted for other 
prognostic factors or those 
associated with density. 
Does not appear to be 
variable selection. 
Yes   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Appears adequate. Not 
clear though, why 
appropriate to exclude low 
density up front – might 
have been a subgroup 
analysis chosen as a 
primary analysis. 
Partial   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    Low 
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B.VII.vi Risk of bias table - Nyante 2015 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is not 
described, only analysis 
population, but indication 
of size given: "Patients 
were selected from a cohort 
of 2315 KPNW members 
diagnosed with ER-positive 
primary invasive breast 
cancer between 1990 and 
2008 and treated with 
adjuvant tamoxifen". 
Partial   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Well described e.g. "Two 
control patients were 
matched to each case 
patient (Figure  1) and 
sampled to have at least as 
much follow-up time as the 
matched case patient" and 
61 controls matched to 
cases without 
mammograms were "re-
matched [...] to eligible 
cases", 401 women were 
not included in the 
sampling due to lack of 
mammograms. 
Yes   
Recruitment 
period 
Period of recruitment is adequately 
described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are adequately 
described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Well described e.g. after 
exclusions for bilateral 
disease (or laterality 
unknown), prophylactic 
mastectomy of contralateral 
breast, death or recurrence 
within 1yr of initial 
diagnosis, distant 
metastases or unstaged 
diagnosis, never disease-
Yes   
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free, first course of 
treatment outside KPNW 
system (n=2142), after 
exclusions for 
mammograms not 
identified (n=1741): cases 
identified (n=134) of which 
had mammograms 
obtainable for digitisation 
(n=97), and 252 matched 
controls with 
mammograms obtainable 
for digitisation. 
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
37/134 (28%) of cases not 
included due to lack of 
mammograms obtainable 
for digitisation. No 
information on eligible 
participants vs. those not 
eligible. 
Partial   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
34% cases and 68% 
controls received tamoxifen 
>52 months, follow-up 
mammogram within 90 
days of prescription. 
Yes   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of the 
study are described 
Registry linkage to death, 
so no drop out. 
Yes   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
"Follow-up time was 
calculated as the time 
between the first tamoxifen 
prescription and the earliest 
of the following: breast 
cancer death, death from 
another cause, last tumor 
registry follow-up, or 
December 31, 2010". 
Yes   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
No information on density 
change vs. death from other 
causes in controls – those 
who could be censored 
before being included as a 
control. Expect very few 
but some older women. 
Partial   
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Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is not 
associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
relationship between density 
change and outcome 
    Low 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear definition: "Absolute 
dense area (cm2) and total 
breast area (cm2) were 
measured using Cumulus 
[…] by a single reader". 
Contralateral breast used. 
Partial   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
Valid and reliable method, 
with estimate of 
reproducibility - 
“Reevaluation of 50 
randomly selected films 
yielded intraclass 
correlation coefficients and 
coefficients of variation of 
0.95 and 8.5% for dense 
area, 0.99 and 0.5% for 
total breast area, and 0.96 
and 8.5% for percent 
density“. Blinded: "Masked 
baseline and follow up 
mammograms from each 
patient". 
Yes   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
Tertiles are used as primary 
analysis, but "assessed 
absolute change in percent 
density using the 10% or 
greater cut-point to assess a 
comparable level of change 
as reported in the 
IBIS-1 study". 
Yes   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
Method and setting are the 
same. All film 
mammograms scanned on 
same scanner: "digitized 
using an Array Corporation 
2095 Laser 
Film Digitizer (Roden, the 
Netherlands; optical 
density  =  4.0)". Time 
between mammograms 
mean 18 months, 75% with 
<24 months – relatively 
low variability. 
Yes   
Proportion of Adequate proportion of the study All have complete data by Yes   
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data on 
prognostic 
factor available 
for analysis 
sample has complete data for the 
change in mammographic density 
variable 
definition of study design. 
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Clear definition: "Case 
patients were defined as 
patients who died of breast 
cancer between January 1, 
1991 and December 31, 
2010", duration of follow-
up given (see data capture 
form). Not clear how 
extensive in the wider 
database (including women 
with mammograms).  
Partial   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
Yes – population registry. Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by age 
and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age and BMI measured. Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
"Age […] at diagnosis" and 
"Body mass index (BMI) 
was calculated as kg/m2". 
Yes   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Self-reported height and 
weight from clinical 
records, obtained within 3 
months of both 
mammograms. 13/97 cases 
and 26/252 controls 
missing baseline BMI; 
25/97 cases and 59/252 
controls missing BMI 
change. 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
Appropriate methods are used if 
imputation is used for missing 
Missing weight or height 
values used to calculate 
Yes   
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data confounder data BMI were multiply-
imputed using IVEWare. 
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
It is adjusted for age 
through design, also for 
baseline density in 
additional model. Not 
adjusted for BMI or change 
in BMI (but "neither 
baseline BMI nor change in 
BMI altered the 
associations"). No evidence 
of interaction (between 
density change?) and 
chemotherapy. 
Yes   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Low 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Yes, except for the multiple 
imputation where little 
detail is provided. Multiple 
imputation not used for the 
main analysis however. 6 
women on AIs but 
"Associations were also 
similar after excluding […] 
women treated with 
aromatase inhibitors".  
Partial   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate and 
is based on a conceptual 
framework or model 
Yes. "Multivariable models 
were constructed to assess 
confounding. Smoking 
status, tumor size, 
antidepressant use, and 
baseline percent density 
were identified as potential 
confounders based on 
literature review and 
covariable associations 
with breast cancer death 
and change in percent 
density among control 
patients and included in a 
preliminary model. Only 
baseline density was 
retained in final models 
after removing variables 
sequentially and retaining 
those where removal 
altered the change in 
density regression 
parameter by more than 
10%. Tumor size and 
baseline dense area were 
assessed similarly in 
multivariable models for 
absolute change in dense 
area, and both were 
retained". 
Yes   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Yes adequate. No selective 
reporting apparent. 
Yes   
Statistical 
analysis and 
The statistical analysis is 
appropriate for the design of the 
    Low 
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presentation 
summary 
study, limiting potential for 
presentation of invalid or spurious 
results 
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B.VII.vii Risk of bias table - Sandberg 2013 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the 
overall judgement of potential 
bias for each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is 
adequately described for: a) 
treatment: (i) proportion with 
DCIS, (ii) cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 
mutation carriers, (ii) prior 
hormone replacement therapy use, 
(iii) cointerventions such as diet 
or exercise regimens, or both 
Source population is not 
described, only analysis 
population, but indication of 
size given: "Stockholm 
Breast Cancer Register, a 
population based register of 
all breast cancer patients 
diagnosed since 1976 in the 
Stockholm-Gotland health-
care region (n>30,000)". 
Partial   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Well described: "Women 
with invasive CBC 
diagnosed more than one 
year after the first invasive 
cancer and with an available 
mammogram close to the 
first diagnosis (N=458) were 
identified as potential cases. 
Patients with invasive 
unilateral breast cancer in the 
same register were identified 
as potential controls". No 
metastasis or second primary 
ipsilateral breast cancer to 
limit bias of 
misclassification of outcome. 
Yes   
Recruitment 
period 
Period of recruitment is 
adequately described 
Well described (see data 
capture form). 
Yes   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are 
adequately described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria 
are adequately described 
Well described: "Women 
with a first primary cancer 
other than breast cancer and 
women with distant 
metastasis at the first or 
second breast cancer 
diagnosis were excluded in 
order to minimize the risk of 
the CBC being a 
Yes   
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misclassified metastasis" and 
second primary breast cancer 
in the ipsilateral breast 
excluded. Women with 
<10% or >90% PDA (N = 
66), or <10 cm2 or >70 cm2 
DA (N = 84) at baseline 
were excluded (can't undergo 
defined changes - why 
70cm2?) 
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
187 (41%) of cases 
excluded: "For 99 of the 458 
eligible CBC-cases we could 
not locate any follow-up 
mammogram and for 88 of 
the CBC-cases either the 
baseline or the follow-up 
mammogram could not be 
used (for example, due to 
low quality of the 
mammogram)", therefore 
"for 271 patients (59%) both 
the baseline and at least one 
follow-up mammogram of 
the unaffected breast from 
the same view was 
assessable and could be 
used". 211 controls with 
correct side and view so 211 
matched case-control pairs. 
Availability of 
mammograms "driven by 
archiving policies, rather 
than patients not having 
mammograms taken". 
Patients excluded due to lack 
of eligible mammograms did 
not differ from those 
included in relation to age at 
first diagnosis (P-value: 
0.23) and calendar period of 
first diagnosis (P-value: 
0.12). More patients 
included received 
radiotherapy and endocrine 
therapy than excluded 
patients (radiotherapy; 29% 
vs. 23%, endocrine therapy; 
39% vs. 29%, 
(chemotherapy?)). 
Yes   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for 
(treatment and prevention) age, 
menopausal status, 
cointerventions; (treatment) % 
DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement 
therapy use 
Adequately described in 
Table 1. No breakdown by 
type of endocrine therapy, 
but most likely to be 
tamoxifen according to time 
frame. 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Moderate 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
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between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
Proportion of 
baseline 
sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
41% of cases and 41% of 
controls (minority of 
women) on endocrine 
treatment, but no information 
found on response rate (i.e. 
compliance). 
No   
Attempts to 
collect 
information on 
participants 
who dropped 
out 
Attempts to collect information on 
participants who dropped out of 
the study are described 
No information found on 
drop out. Registry linkage – 
no drop out? Exception of 
informed consent. 
No   
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
No information found on 
loss to follow-up. 
No   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve 
mammograms, or both, was likely 
related to the study outcome 
No information found on 
loss to follow-up. 
No   
Study attrition 
summary 
There are no important 
differences between these 
characteristics in participants who 
completed the study and those 
who did not. Loss to follow-up 
(from baseline sample to study 
population analysed) is not 
associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
relationship between density 
change and outcome 
    Moderate 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description 
of mammographic density is 
provided (e.g. including the 
method of measurement, if 
subjective then who undertook it, 
if treatment then whether 
contralateral breast assessed) 
Clear definition: 
"Mammographic density was 
measured using our 
automated thresholding 
method [24], which 
incorporates the knowledge 
of a trained observer by 
using measurements 
obtained by an established 
user-assisted 
threshold method - Cumulus 
[25] - as training data". 
Contralateral breast used. 
Yes   
Valid and 
reliable 
measurement 
Method of mammographic density 
change measurement is 
adequately valid and reliable to 
Appears adequately valid: 
"The externally validated 
results showed a high 
Yes   
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of prognostic 
factor 
limit misclassification bias (e.g. 
may include relevant outside 
sources of information on 
measurement properties; also 
characteristics, such as 
measurement blinded to case 
status) 
correspondence between our 
automated method and the 
established user-assisted 
thresholding method 
Cumulus (r percent 
mammographic density) = 
0.88 (95% CI: 0.87 to 0.89)". 
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
Cut-point for percentage 
density (10%) chosen 
following IBIS-I: "absolute 
decrease ≥10%, stable (-10% 
to +10%, reference level) 
and absolute increase ≥10%, 
in agreement with previous 
literature [20]". Cut-point for 
area density not stated, but 
similar proportion to percent 
measure in different 
categories (Table 1). 
Partial   
Method and 
setting of 
prognostic 
factor 
measurement 
The method and setting of 
measurement of mammographic 
density is the same for all study 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline 
and follow-up mammograms have 
low variability between 
participants 
Method and setting are the 
same. "The mammograms 
were digitized using an 
Array 2905HD Laser Film 
Digitizer (Array 
Corporation, Tokyo, Japan), 
which covers a range of 0 to 
4.7 optical density. The 
density resolution was set at 
12-bit spatial resolution". 
"90% of the follow-up 
mammograms were taken 
between 1 and 2.2 years after 
diagnosis of the first breast 
cancer and there was no 
difference between cases and 
controls"; some up to 5yr. 
Yes   
Proportion of 
data on 
prognostic 
factor available 
for analysis 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
variable 
Women with <10% or >90% 
PDA (N = 66), or <10 cm2 or 
>70 cm2 DA (N = 84) at 
baseline were excluded (can't 
undergo defined changes - 
why 70cm2?). For the 
primary interest of this 
review (women who 
received endocrine therapy) 
numbers are not reported. 
Partial   
Method used 
for missing 
data 
Appropriate methods of 
imputation are used for missing 
mammographic density data 
NA for study sample, 
unclear for women who 
received endocrine therapy. 
Partial   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Moderate 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential 
measurement of outcome related 
to the density reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Clear definition: "For our 
main analysis, conditional 
logistic regression was used 
for analyzing risk of CBC", 
duration of follow-up given. 
Extend of the outcome 
construct in the wider 
database not indicated (only 
number with mammogram). 
Partial   
Valid and 
reliable 
The method of outcome 
measurement used is adequately 
Yes – population registry. Yes   
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measurement 
of outcome 
valid and reliable to limit 
misclassification bias 
Method and 
setting of 
outcome 
measurement 
The method and setting of 
outcome measurement is the same 
for all study participants, 
including by age and obesity 
groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
outcome) 
      
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age measured, FA at 
baseline used as a proxy for 
BMI at baseline (justified by 
Lokate 2011; Breast Cancer 
Res; 13:R103). 
Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
Age at the first breast cancer 
diagnosis (+/- two years), FA 
categorized into quartiles. 
Yes   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Measurement is adequately 
valid. 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
Imputation not used. Yes   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Adjusted for age through 
matching. PDA change 
model additionally adjusted 
for FA and PDA baseline 
(was DA change model also 
adjusted for FA and DA 
baseline?). No adjustment 
for change in BMI (or FA) or 
chemotherapy-although this 
group is ‘under-represented’. 
Not clear if subgroup 
analysis of primary interest 
to this review (i.e. women on 
endocrine treatment) was 
adjusted for other factors 
besides matching factors. 
Partial   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with 
respect to the relationship 
between prognostic factor and 
outcome 
    Moderate 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Partially. Odds ratios are 
presented but not number of 
cases and controls by density 
change group. Can't separate 
out endocrine treatments. 
Partial   
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Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate 
and is based on a conceptual 
framework or model 
Appropriate per the study 
design. Not clear if further 
adjustment for the primary 
analysis of interest to this 
review. 
Partial   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Appropriate. May be some 
selective reporting of results, 
but main focus was not on 
the comparison of interest 
for our review. 
Partial   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    Moderate 
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B.VII.viii Risk of bias table - van Nes 2015 
 
Biases 
Issues to consider for judging 
overall rating of risk of bias 
Study Methods & 
Comments 
Rating of 
reporting 
(adequacy 
of 
reporting: 
"yes", 
"partial", 
"no" or 
"unsure") 
Rating of 
Risk of bias 
("High", 
"Moderate", 
or "Low") 
Instructions to 
assess the risk 
of each 
potential bias 
These issues will guide your 
thinking and judgement about the 
overall risk of bias within each of 
the six domains. These issues are 
taken together to inform the overall 
judgement of potential bias for 
each of the six domains 
      
1. Study 
participation 
Goal: to judge the risk of selection 
bias (likelihood that relationship 
between density reductions and 
outcome is different for 
participants and eligible non-
participants) 
      
Source of 
target 
population 
The source population or 
population of interest is adequately 
described for: a) treatment: (i) 
proportion with DCIS, (ii) 
cointerventions 
(chemotherapy/targeted therapy), 
(iii) severity of cancer at baseline 
(stage, % regional spread); b) 
prevention: (i) level of risk in 
population, including whether 
some or all are BRCA1/2 mutation 
carriers, (ii) prior hormone 
replacement therapy use, (iii) 
cointerventions such as diet or 
exercise regimens, or both 
Source population is 
TEAM trial (n=2753), 
although not described, can 
be found in a referenced 
paper van de Velde 2011; 
Lancet; 377:321-31. 
Yes   
Method used to 
identify 
population 
The sampling frame and 
recruitment are adequately 
described, including methods to 
identify the sample sufficient to 
limit potential bias 
Sampling frame and 
recruitment adequately 
described: 13 hospitals 
contributing to the TEAM 
sub-study (supplementary 
material), "based on 
adequate inclusion rate, 
geographical distribution 
and availability of analogue 
mammograms over time" 
(n=774). 
Yes   
Recruitment 
period 
Period of recruitment is adequately 
described 
Not described. No   
Place of 
recruitment 
Place of recruitment (setting and 
geographic location) are 
adequately described 
Well described (see data 
capture form). 
Yes   
Inclusion and 
exclusion 
criteria 
Inclusion and exclusion criteria are 
adequately described 
Well described: (203/774 
considered ineligible 
because hospital switched 
to digital during study 
period or contralateral 
mastectomy (n=571 
eligible), 129/571 did not 
have available analogue 
mammograms (n=442). 219 
in sequential arm and 223 
in exemestane arm). "Of 
the 219 patients randomised 
Yes   
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to the sequential arm, 28 
stopped therapy within one 
year, five had no 
preoperative mammogram 
available, four had no 
(available) follow-up 
mammogram, and one did 
not start study medication, 
totalling 181 patients for 
the current analyses. Of the 
223 patients randomised to 
exemestane, 21 stopped 
therapy within one year, 
three had no preoperative  
mammogram available and 
two had  no follow-up 
mammogram available, 
leaving 197 patients for the 
current analyses". 
Adequate study 
participation 
There is adequate participation in 
the study by eligible individuals 
203/774 considered 
ineligible because hospital 
switched to digital during 
study period or 
contralateral mastectomy 
(n=571 eligible), 129/571 
did not have available 
analogue mammograms 
(n=442). 219 in sequential 
arm and 223 in exemestane 
arm. After exclusions, 
sequential n=181 and 
exemestane n=197. Total 
included sample (n=378) 
compared with sampling 
frame not included (n=774-
378=396) in Table IB. 
Yes   
Baseline 
characteristics 
The baseline study sample (i.e. 
individuals entering the study) is 
adequately described for (treatment 
and prevention) age, menopausal 
status, cointerventions; (treatment) 
% DCIS, disease severity; 
(prevention) breast cancer risk, 
prior hormone replacement therapy 
use 
Well described (see data 
capture form). 
Yes   
Summary study 
participation 
The study sample represents the 
population of interest on key 
characteristics, sufficient to limit 
potential bias of the observed 
relationship between density 
change and outcome 
    Low 
          
2. Study 
attrition 
Goal: to judge the risk of attrition 
bias (likelihood that relationship 
between density reductions and 
outcome are different for 
completing and non-completing 
participants) 
      
Proportion of 
baseline sample 
available for 
analysis 
Response rate (i.e. proportion of 
study sample allocated treatment 
who received treatment) is 
adequate 
"Of the 219 patients 
randomised to the 
sequential arm, 28 stopped 
therapy within one year [...] 
and one did not start study 
medication." and "Of the 
223 patients randomised to 
exemestane, 21 stopped 
therapy within one year". 
Yes   
Attempts to 
collect 
Attempts to collect information on 
participants who dropped out of the 
Not described (for 378 
women in study sample) 
No   
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information on 
participants 
who dropped 
out 
study are described but whole trial information 
should be available. 
Reasons and 
potential 
impact of 
subjects lost to 
follow-up 
Reasons for loss to follow-up are 
provided 
Not described (for 378 
women in study sample) 
but whole trial information 
should be available. 
No   
Outcome and 
prognostic 
factor 
information on 
those lost to 
follow-up 
Participants lost to follow-up are 
adequately described for age at 
entry and cointerventions (if any), 
and for a) treatment: (i) DCIS, (ii) 
disease severity; b) prevention: (i) 
risk of breast cancer including 
BRCA1/2 carriers and testing. 
Whether loss to follow-up or 
inability to retrieve mammograms, 
or both, was likely related to the 
study outcome 
Not described. No   
Study attrition 
summary 
There are no important differences 
between these characteristics in 
participants who completed the 
study and those who did not. Loss 
to follow-up (from baseline sample 
to study population analysed) is not 
associated with key characteristics 
(i.e. the study data adequately 
represent the sample) sufficient to 
limit potential bias to the observed 
relationship between density 
change and outcome 
    Moderate 
          
3. Prognostic 
factor 
measurement 
Goal: to judge the risk of 
measurement bias related to how 
mammographic density was 
measured (differential 
measurement of mammographic 
density related to the level of 
outcome) 
      
Definition of 
the prognostic 
factor 
A clear definition or description of 
mammographic density is provided 
(e.g. including the method of 
measurement, if subjective then 
who undertook it, if treatment then 
whether contralateral breast 
assessed) 
Clear definition: "visual 
estimation technique 
classifying the percentage 
of mammographic breast 
density into one of six 
categories: 0%, <10%, 10–
25%, 25–50%, 50–75%, 
and >75%" by "three 
independent radiologists 
being very experienced in 
reading mammograms". 
Contralateral breast used. 
Yes   
Valid and 
reliable 
measurement 
of prognostic 
factor 
Method of mammographic density 
change measurement is adequately 
valid and reliable to limit 
misclassification bias (e.g. may 
include relevant outside sources of 
information on measurement 
properties; also characteristics, 
such as measurement blinded to 
case status) 
"The interclass correlation 
coefficient between the 
three radiologists (raters) 
was satisfactory: 0.74". 
"The patient’s identity, date 
of mammogram and 
randomisation arm were 
blinded to the radiologists", 
but no mention if blinded to 
case status. 
Yes   
  
Continuous variables are reported 
or appropriate cut-points (i.e. not 
data-dependent (except for 
percentiles)) are used 
Boyd 6-category scale. Yes   
Method and 
setting of 
prognostic 
The method and setting of 
measurement of mammographic 
density is the same for all study 
Method and setting same 
(three radiologists read all 
mammograms, although 
Partial   
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factor 
measurement 
participants. The same 
mammogram type (film/digital) is 
used for both baseline and follow-
up. The time at which baseline and 
follow-up mammograms have low 
variability between participants 
whether each one read 
mammograms per woman 
etc. not mentioned), same 
mammogram type (film). 
Unknown time from 
baseline to follow-up 
mammograms. 
Proportion of 
data on 
prognostic 
factor available 
for analysis 
Adequate proportion of the study 
sample has complete data for the 
change in mammographic density 
variable 
8 had no preoperative 
mammogram and 6 had no 
follow-up mammogram 
(but not included in final 
study sample n=378). "Of 
the total group of 378 
patients, 359 mammograms 
(171 sequential arm, 188 
exemestane arm) were 
reviewed after one year of 
endocrine therapy, 292 
mammograms (123 
sequential arm, 169 
exemestane arm) after two 
years, and 116 
mammograms (17 of 
tamoxifen patients and 99 
of exemestane patients) 
after three years of 
endocrine therapy" - it is 
unclear which follow-up 
mammogram(s) were used 
to calculate density change. 
Partial   
Method used 
for missing 
data 
Appropriate methods of imputation 
are used for missing 
mammographic density data 
NA Yes   
Summary 
Prognostic factor is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
4. Outcome 
measurement 
Goal: to judge the risk of bias 
related to the measurement of 
outcome (differential measurement 
of outcome related to the density 
reductions) 
      
Definition of 
the outcome 
A clear definition of outcome is 
provided, including duration of 
follow-up and level and extent of 
the outcome construct 
Adequate definition "Time 
to LRR, DR or CBC was 
calculated from the start of 
endocrine therapy up to the 
date of a LRR, a DR or 
CBC, respectively", but no 
reasons for censoring (per 
protocol so censored when 
stopped treatment but no 
other reasons provided). 
Partial   
Valid and 
reliable 
measurement 
of outcome 
The method of outcome 
measurement used is adequately 
valid and reliable to limit 
misclassification bias 
From TEAM trial database. Yes   
Method and 
setting of 
outcome 
measurement 
The method and setting of outcome 
measurement is the same for all 
study participants, including by age 
and obesity groups 
Yes. Yes   
Outcome 
measurement 
summary 
Outcome of interest is adequately 
measured in study participants to 
sufficiently limit potential bias 
    Low 
          
5. Study 
confounding 
Goal: to judge the risk of bias due 
to confounding (i.e. the effect of 
density reductions is distorted by 
another factor that is related to 
density reductions and the 
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outcome) 
Important 
confounders 
measured 
Age, BMI, or another measure of 
adiposity are measured 
Age and BMI measured. Yes   
Definition of 
the 
confounding 
factor 
Clear definitions are provided 
No definition on how BMI 
measured. 
No   
Valid and 
reliable 
measurement 
of confounders 
Measurement of all important 
confounders is adequately valid 
and reliable 
Appears adequate (from 
trial). 
Yes   
Method and 
setting of 
confounding 
measurement 
The method and setting of 
confounding measurement are the 
same for all study participants 
Yes. Yes   
Method used 
for missing 
data 
Appropriate methods are used if 
imputation is used for missing 
confounder data 
23 missing BMI, not stated 
if imputed. 
No   
Appropriate 
accounting for 
confounding 
The primary analysis will be 
adjusted for at least age, either 
through the study design and 
analysis, or through adjustment in 
the analysis only; and other 
prognostic factors 
Does not appear to be 
adjusted. 
No   
Study 
confounding 
summary 
Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to the relationship between 
prognostic factor and outcome 
    Moderate 
          
6. Statistical 
analysis and 
reporting 
Goal: to judge the risk of bias 
related to the statistical analysis 
and presentation of results 
      
Presentation of 
analytical 
strategy, model 
development 
strategy 
There is sufficient presentation of 
data to assess the adequacy of the 
analysis 
Not sufficient presentation 
of data. No data presented 
on density change. Both 
treatment arms combined. 
No   
Model 
development 
strategy 
The strategy for model building 
(i.e. inclusion of variables in the 
statistical model) is appropriate and 
is based on a conceptual 
framework or model 
No model building done. Yes   
Reporting of 
results 
The selected statistical model is 
adequate for the design of the 
study. There is no selective 
reporting of results 
Statistical model for density 
change analysis unclear, no 
results presented for density 
change. 
No   
Statistical 
analysis and 
presentation 
summary 
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid or spurious 
results 
    High 
 
 
 
 
 
 
 
 
369 
 
B.VII.ix ROBINS-I tool for Cuzick 2011 
ROBINS-I tool (Stage I): At protocol stage  
 
Specify the review question  
Participants See review ‘Types of participants’ section 
Experimental intervention See review ‘Interventions’ section 
Comparator See review ‘Comparators’ section 
Outcomes See review ‘Types of outcome measures’ section 
 
List the confounding domains relevant to all or most studies 
Age 
Menopausal status 
Body mass index 
Family history of disease 
Hormone replacement therapy use 
Benign breast disease 
Previous cancer other than breast cancer 
Ethnicity 
List co-interventions that could be different between intervention groups and that could impact on outcomes 
Hormone replacement therapy 
Risk-reducing surgery 
 
ROBINS-I tool (Stage II): For each study 
 
Specify a target randomized trial specific to the study  
Design Individually randomized/Cluster randomized/Matched (e.g. cross-over) (block randomisation (permuted block sizes of six, eight or ten)) 
Participants IBIS-I participants: 35 - 70 years old with at least twice the average risk of a 50-year-old woman of developing breast cancer 
Experimental intervention Oral Tamoxifen 20mg/daily 
Comparator Oral placebo/daily 
 
Is your aim for this study…? 
☐ to assess the effect of assignment to intervention 
☒ to assess the effect of starting and adhering to intervention 
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Specify the outcome 
Specify which outcome is being assessed for risk of bias (typically from among those earmarked for the Summary of Findings table). Specify whether this is a proposed benefit or harm of intervention. 
Proposed benefit of intervention - Prevention: incidence of invasive breast cancer and DCIS 
 
Specify the numerical result being assessed 
In case of multiple alternative analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the 
result being assessed. 
Predictive biomarker worked out from raw data: OR=0.53 (95% CI, 0.21 to 1.32), p=0.17 
 
Preliminary consideration of confounders 
Complete a row for each important confounding domain (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as potentially 
important. 
“Important” confounding domains are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention. “Validity” 
refers to whether the confounding variable or variables fully measure the domain, while “reliability” refers to the precision of the measurement (more measurement error means less reliability). 
(i) Confounding domains listed in the review protocol 
Confounding domain Measured variable(s) Is there evidence that controlling for this 
variable was unnecessary?* 
Is the confounding domain 
measured validly and reliably by 
this variable (or these variables)? 
OPTIONAL: Is failure to adjust for this 
variable (alone) expected to favour the 
experimental intervention or the 
comparator? 
Age Age at entry (years) No Yes / No / No information 
Favour experimental / Favour 
comparator / No information 
Menopausal status 
Menopausal status at entry 
(Premenopausal/Postmenopausal) 
No Yes / No / No information  
Body mass index Body mass index at entry (kg/m2) No Yes / No / No information  
Family history of disease 
Extensive family history collected as 
part of Tyrer-Cuzick risk model at entry  
(%) 
No Yes / No / No information  
Hormone replacement therapy use 
Use of hormone replacement therapy 
during study (Never/Previous/Current) 
No Yes / No / No information  
Benign breast disease 
Atypical hyperplasia or LCIS at entry 
(No/Yes) 
No Yes / No / No information  
Previous cancer other than breast 
cancer 
Women with a history of any invasive 
cancer (excluding skin cancer) were 
excluded 
Yes - women with a history of any invasive 
cancer (excluding skin cancer) were 
excluded from the trial. 
Yes / No / No information  
Ethnicity Mixed No Yes / No / No information  
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* In the context of a particular study, variables can be demonstrated not to be confounders and so not included in the analysis: (a) if they are not predictive of the outcome; (b) if they are not predictive of 
intervention; or (c) because adjustment makes no or minimal difference to the estimated effect of the primary parameter. Note that “no statistically significant association” is not the same as “not 
predictive”. 
 
Preliminary consideration of co-interventions 
Complete a row for each important co-intervention (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study  authors identified as important. 
“Important” co-interventions are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention. 
(i) Co-interventions listed in the review protocol 
Co-intervention Is there evidence that controlling for this co-intervention was 
unnecessary (e.g. because it was not administered)? 
Is presence of this co-intervention likely to favour outcomes 
in the experimental intervention or the comparator 
Hormone replacement therapy No Favour experimental / Favour comparator / No information 
Risk-reducing surgery No Favour experimental / Favour comparator / No information 
 
Risk of bias assessment  
Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions relate only to sign posts to other questions, no 
formatting is used. 
 Signalling questions Description Response options 
Bias due to confounding 
 1.1 Is there potential for confounding of the effect of 
intervention in this study? 
If N/PN to 1.1: the study can be considered to be at low risk of 
bias due to confounding and no further signalling questions 
need be considered 
 Analysis adjusted for age, body mass index, and benign breast disease. 
 Women with a history of any invasive cancer (excluding skin cancer) were 
excluded from the trial (Cuzick 2015; Lancet Oncology; 16(1): 67-75). 
 “Adjusting for HRT use had no material impact on the estimate of risk reduction 
associated with a reduction in breast density”. 
 Although not everyone had a family history of breast cancer, all women were “at 
least twice the average risk of a 50-year-old woman of developing breast cancer”. 
 Menopausal status: “Overall, tamoxifen was more effective in preventing 
estrogen receptor–positive breast cancer than it was in preventing estrogen 
receptor– negative breast cancer and was more effective in women who were 
premenopausal, had never taken HRT, or who had a previous diagnosis of 
atypical hyperplasia or LCIS, but there were no statistically significant 
differences in the odds ratios between the subgroup”. 
 There was no adjustment for ethnicity, but all women were living in the UK or 
Finland. 
Y / PY / PN / N 
Risk of bias judgement  Low 
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Bias in selection of participants into the study 
 2.1. Was selection of participants into the study (or into the 
analysis) based on participant characteristics observed after the 
start of intervention? 
If N/PN to 2.1: go to 2.4 
No: “To minimize the administrative workload, control subjects were selected only 
from the major participating UK centers in Aberdeen, Bristol, Cardiff, Edinburgh, 
London, Manchester, Nottingham, and Southampton”. Cases from the UK and 
Finland. 
Y / PY / PN / N / NI 
2.4. Do start of follow-up and start of intervention coincide for 
most participants? 
Yes: start of follow-up at start of treatment. Y / PY / PN / N / NI 
Risk of bias judgement  Low 
 
Bias in classification of interventions  
 3.1 Were intervention groups clearly defined?  Yes – randomised controlled trial. Y / PY / PN / N / NI 
3.2 Was the information used to define intervention groups 
recorded at the start of the intervention? 
Yes – randomised controlled trial. Y / PY / PN / N / NI 
3.3 Could classification of intervention status have been 
affected by knowledge of the outcome or risk of the outcome? 
No – double-blind randomised controlled trial whereby breast cancer event reported to 
trial by local co-ordinating centres and Office for National Statistics unaware of 
intervention allocation (Cuzick 2015; Lancet Oncology; 16(1): 67-75). 
Y / PY / PN / N / NI 
Risk of bias judgement  Low 
 
Bias due to deviations from intended interventions 
 4.3. Were important co-interventions balanced across 
intervention groups? 
Hormone replacement therapy – yes. 
Risk-reducing surgery – not described, although mammography required so ineligible. 
Y / PY / PN / N / NI 
4.4. Was the intervention implemented successfully for most 
participants? 
Yes – all women consented to the trial, withdrawals only reported n=44 Australian 
women in Cuzick 2015; Lancet Oncology; 16(1): 67-75 (and not included in density 
sub-study). 
Y / PY / PN / N / NI 
4.5. Did study participants adhere to the assigned intervention 
regimen? 
Yes – not described, but withdrawals only reported n=44 Australian women in Cuzick 
2015; Lancet Oncology; 16(1): 67-75 (and not included in density sub-study). Analysis 
of compliance in cases: “no statistically significant difference between subjects in the 
tamoxifen arm who experienced a reduction in mammographic density of less than 10% 
and subjects in the tamoxifen arm who experienced a greater reduction (P = .25)”. 
Y / PY / PN / N / NI 
Risk of bias judgement  Low 
 
 
 
 
 
373 
 
Bias due to missing data 
 5.1 Were outcome data available for all, or nearly all, 
participants? 
Yes, randomised controlled trial database of outcomes, Also, “In the UK, cancers and 
deaths are also reported to the IBIS-I central office by the Office for National Statistics” 
(Cuzick 2015; Lancet Oncology; 16(1): 67-75). 
Y / PY / PN / N / NI 
5.2 Were participants excluded due to missing data on 
intervention status? 
No, no missing data on intervention as randomised controlled trial  
Y / PY / PN / N / NI 
5.3 Were participants excluded due to missing data on other 
variables needed for the analysis? 
Yes, 1065-1049=16 women missing in main result due to missing BMI  
Y / PY / PN / N / NI 
5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion 
of participants and reasons for missing data similar across 
interventions? 
Not described but low number of women with missing BMI so unlikely to affect result 
(comparison between interventions). 
NA / Y / PY / PN / N / NI 
5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence 
that results were robust to the presence of missing data? 
Not described but low number of women with missing BMI so unlikely to affect result 
(comparison between interventions). 
NA / Y / PY / PN / N / NI 
Risk of bias judgement  Low 
 
Bias in measurement of outcomes  
 6.1 Could the outcome measure have been influenced by 
knowledge of the intervention received? 
No, randomised controlled trial database of outcomes. Also, “In the UK, cancers and 
deaths are also reported to the IBIS-I central office by the Office for National Statistics” 
(Cuzick 2015; Lancet Oncology; 16(1): 67-75). 
Y / PY / PN / N / NI 
6.2 Were outcome assessors aware of the intervention 
received by study participants? 
No, double-blind randomised controlled trial whereby breast cancer event reported to 
trial by local co-ordinating centres or Office for National Statistics who were unaware 
of intervention allocation. 
Y / PY / PN / N / NI 
6.3 Were the methods of outcome assessment comparable 
across intervention groups? 
Yes, randomised controlled trial database of outcomes. Also, “In the UK, cancers and 
deaths are also reported to the IBIS-I central office by the Office for National Statistics” 
(Cuzick 2015; Lancet Oncology; 16(1): 67-75). 
Y / PY / PN / N / NI 
6.4 Were any systematic errors in measurement of the 
outcome related to intervention received? 
No, double-blind randomised controlled trial whereby breast cancer event reported to 
trial by local co-ordinating centres or Office for National Statistics unaware of 
intervention allocation. 
Y / PY / PN / N / NI 
Risk of bias judgement  Low 
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Bias in selection of the reported result 
 Is the reported effect estimate likely to be selected, on the 
basis of the results, from... 
  
7.1. ... multiple outcome measurements within the outcome 
domain?  
No, one outcome of incidence of invasive breast cancer and DCIS. Y / PY / PN / N / NI 
7.2 ... multiple analyses of the intervention-outcome 
relationship? 
No, interaction effect not reported but is worked out from the paper (unadjusted) and from the 
raw data (adjusted). 
Y / PY / PN / N / NI 
7.3 ... different subgroups? No, effect estimate calculated in all women, no subgroups for interaction analysis. Y / PY / PN / N / NI 
Risk of bias judgement  Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall bias 
Risk of bias judgement  Low 
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Appendix C:  Supplementary material for Chapters 5 and 6 
C.I Weighting IBIS-I postmenopausal density changes based on IBIS-II age structure (placebo cases). 
No. in IBIS-I stratified by density change category and age group (A)      
         -30 -25 -20 -15 -10 -5 0 5 10 15 Total % 
35-39 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0 0.00% 
40-44 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0 0.00% 
45-49 0 0 0 0 0 2 2 0 0 0 4 11.76% 
50-54 0 0 1 0 1 3 5 1 0 1 12 35.29% 
55-59 0 0 0 0 0 2 7 3 0 0 12 35.29% 
60-64 0 0 0 0 0 2 2 0 0 0 4 11.76% 
65-69 0 0 0 0 1 0 1 0 0 0 2 5.88% 
70-74 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0 0.00% 
Total 0 0 1 0 2 9 17 4 0 1 34 100.00% 
Density Change Distribution % 0.00% 0.00% 2.94% 0.00% 5.88% 26.47% 50.00% 11.76% 0.00% 2.94% 100.00%   
      
 
Age groups 
      35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 Total 
   IBIS-II distribution % (B) 0.00% 0.35% 2.95% 19.23% 28.29% 29.51% 17.77% 1.90% 100.00% 
   IBIS-I distribution % (C) 0.00% 0.00% 11.76% 35.29% 35.29% 11.76% 5.88% 0.00% 100.00% 
   Weight = B/C (D) N/A N/A 0.25 0.54 0.80 2.51 3.02 N/A 7.13 
   No. in IBIS-I (E) 0 0 4 12 12 4 2 0 34 
   E*D N/A N/A 1.00 6.54 9.62 10.04 6.04 N/A 33.23 
   Reweighted IBIS-I distribution % (F) N/A N/A 3.02% 19.67% 28.94% 30.19% 18.18% N/A 100.00% 
                
A*D           
         -30 -25 -20 -15 -10 -5 0 5 10 15 Total % 
35-39 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.00 0.00% 
40-44 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.00 0.00% 
45-49 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.00 0.00 0.00 1.00 3.02% 
50-54 0.00 0.00 0.54 0.00 0.54 1.63 2.72 0.54 0.00 0.54 6.54 19.67% 
55-59 0.00 0.00 0.00 0.00 0.00 1.60 5.61 2.40 0.00 0.00 9.62 28.94% 
60-64 0.00 0.00 0.00 0.00 0.00 5.02 5.02 0.00 0.00 0.00 10.04 30.19% 
65-69 0.00 0.00 0.00 0.00 3.02 0.00 3.02 0.00 0.00 0.00 6.04 18.18% 
70-74 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.00 0.00% 
Total 0.00 0.00 0.54 0.00 3.57 8.76 16.87 2.95 0.00 0.54 33.23 100.00% 
Density Change Distribution % 0.00% 0.00% 1.64% 0.00% 10.73% 26.35% 50.77% 8.87% 0.00% 1.64% 100.00%   
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C.II Weighting IBIS-I postmenopausal density changes based on IBIS-II age structure (placebo controls). 
No. in IBIS-I stratified by density change category and age group (A)  
           -30 -25 -20 -15 -10 -5 0 5 10 15 Total % 
35-39 0 0 0 0 0 0 1 0 0 0 1 0.44% 
40-44 0 0 1 0 0 1 2 0 0 0 4 1.78% 
45-49 0 1 2 2 3 6 17 4 1 1 37 16.44% 
50-54 1 2 3 2 10 19 35 5 0 1 78 34.67% 
55-59 0 1 1 5 10 14 27 4 1 1 64 28.44% 
60-64 1 1 0 1 2 6 19 3 1 1 35 15.56% 
65-69 0 0 0 0 0 1 3 1 1 0 6 2.67% 
70-74 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0 0.00% 
Total 2 5 7 10 25 47 104 17 4 4 225 100.00% 
Density Change Distribution % 0.89% 2.22% 3.11% 4.44% 11.11% 20.89% 46.22% 7.56% 1.78% 1.78% 100.00%   
             
 
Age groups 
     35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 Total 
   IBIS-II distribution % (B) 0.00% 0.35% 2.95% 19.23% 28.29% 29.51% 17.77% 1.90% 100.00% 
   IBIS-I distribution % (C) 0.44% 1.78% 16.44% 34.67% 28.44% 15.56% 2.67% 0.00% 100.00% 
   Weight = B/C (D) 0.00 0.20 0.18 0.55 0.99 1.90 6.66 N/A 10.49 
   No. in IBIS-I (E) 1 4 37 78 64 35 6 0 225 
   E*D 0.00 0.79 6.64 43.26 63.65 66.41 39.98 N/A 220.73 
   Reweighted IBIS-I distribution % (F) 0.00% 0.36% 3.01% 19.60% 28.84% 30.09% 18.11% N/A 100.00% 
                A*D      
         -30 -25 -20 -15 -10 -5 0 5 10 15 Total % 
35-39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00% 
40-44 0.00 0.00 0.20 0.00 0.00 0.20 0.39 0.00 0.00 0.00 0.79 0.36% 
45-49 0.00 0.18 0.36 0.36 0.54 1.08 3.05 0.72 0.18 0.18 6.64 3.01% 
50-54 0.55 1.11 1.66 1.11 5.55 10.54 19.41 2.77 0.00 0.55 43.26 19.60% 
55-59 0.00 0.99 0.99 4.97 9.94 13.92 26.85 3.98 0.99 0.99 63.65 28.84% 
60-64 1.90 1.90 0.00 1.90 3.79 11.38 36.05 5.69 1.90 1.90 66.41 30.09% 
65-69 0.00 0.00 0.00 0.00 0.00 6.66 19.99 6.66 6.66 0.00 39.98 18.11% 
70-74 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.00 0.00% 
Total 2.45 4.18 3.21 8.34 19.82 43.78 105.75 19.82 9.73 3.63 220.73 100.00% 
Density Change Distribution % 1.11% 1.89% 1.46% 3.78% 8.98% 19.84% 47.91% 8.98% 4.41% 1.64% 100.00%   
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C.III Weighting IBIS-I postmenopausal density changes based on IBIS-II age structure (anastrozole cases). 
No. in IBIS-I stratified by density change category and age group (A)  
 
  
          -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 50 Total % 
40-44 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% 
45-49 0 0 0 1 0 1 0 1 1 0 0 0 4 13.79% 
50-54 0 0 0 0 0 2 2 5 4 1 0 0 14 48.28% 
55-59 0 0 0 0 0 0 0 1 4 0 0 0 5 17.24% 
60-64 0 0 0 0 0 1 1 0 2 0 0 0 4 13.79% 
65-69 0 0 0 0 0 0 0 1 1 0 0 0 2 6.90% 
70-74 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00% 
Total 0 0 0 1 0 4 3 8 12 1 0 0 29 100.00% 
Density Change Distribution % 0.00% 0.00% 0.00% 3.45% 0.00% 13.79% 10.34% 27.59% 41.38% 3.45% 0.00% 0.00% 100.00%   
               
 
Age groups 
         40-44 45-49 50-54 55-59 60-64 65-69 70-74 Total 
      IBIS-II distribution % (B) 0.35% 2.95% 19.23% 28.29% 29.51% 17.77% 1.90% 100.00% 
      IBIS-I distribution % (C) 0.00% 13.79% 48.28% 17.24% 13.79% 6.90% 0.00% 100.00% 
      Weight = B/C (D) N/A 0.21 0.40 1.64 2.14 2.58 N/A 6.97 
      No. in IBIS-I (E) 0 4 14 5 4 2 0 29 
      E*D N/A 0.86 5.58 8.20 8.56 5.15 N/A 28.35 
      Reweighted IBIS-I distribution % (F) N/A 3.02% 19.67% 28.94% 30.19% 18.18% N/A 100.00% 
                     A*D             
          -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 50 Total % 
40-44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00% 
45-49 0.00 0.00 0.00 0.21 0.00 0.21 0.00 0.21 0.21 0.00 0.00 0.00 0.86 3.02% 
50-54 0.00 0.00 0.00 0.00 0.00 0.80 0.80 1.99 1.59 0.40 0.00 0.00 5.58 19.67% 
55-59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.64 6.56 0.00 0.00 0.00 8.20 28.94% 
60-64 0.00 0.00 0.00 0.00 0.00 2.14 2.14 0.00 4.28 0.00 0.00 0.00 8.56 30.19% 
65-69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.58 2.58 0.00 0.00 0.00 5.15 18.18% 
70-74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00% 
Total 0.00 0.00 0.00 0.21 0.00 3.15 2.94 6.42 15.23 0.40 0.00 0.00 28.35 100.00% 
Density Change Distribution % 0.00% 0.00% 0.00% 0.75% 0.00% 11.11% 10.36% 22.66% 53.71% 1.41% 0.00% 0.00% 100.00%   
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C.IV Weighting IBIS-I postmenopausal density changes based on IBIS-II age structure (anastrozole controls). 
No. in IBIS-I stratified by density change category and age group (A)      
          -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 50 Total % 
40-44 0 0 0 0 0 0 2 0 0 0 0 0 2 0.93% 
45-49 0 1 0 2 3 5 8 5 10 0 0 0 34 15.89% 
50-54 1 2 1 2 5 5 14 19 28 4 0 1 82 38.32% 
55-59 1 1 0 0 1 3 10 13 22 2 1 0 54 25.23% 
60-64 0 0 0 0 0 2 7 3 20 0 2 0 34 15.89% 
65-69 0 0 0 0 0 0 0 0 5 2 0 0 7 3.27% 
70-74 0 0 0 0 0 0 0 0 1 0 0 0 1 0.47% 
Total 2 4 1 4 9 15 41 40 86 8 3 1 214 100.00% 
Density Change Distribution % 0.93% 1.87% 0.47% 1.87% 4.21% 7.01% 19.16% 18.69% 40.19% 3.74% 1.40% 0.47% 100.00%   
               
 
Age groups 
         40-44 45-49 50-54 55-59 60-64 65-69 70-74 Total 
      IBIS-II distribution % (B) 0.35% 2.95% 19.23% 28.29% 29.51% 17.77% 1.90% 100.00% 
      IBIS-I distribution % (C) 0.93% 15.89% 38.32% 25.23% 15.89% 3.27% 0.47% 100.00% 
      Weight = B/C (D) 0.38 0.19 0.50 1.12 1.86 5.43 4.06 13.54 
      No. in IBIS-I (E) 2 34 82 54 34 7 1 214 
      E*D 0.75 6.32 41.15 60.54 63.16 38.02 4.06 214.00 
      Reweighted IBIS-I distribution % (F) 0.35% 2.95% 19.23% 28.29% 29.51% 17.77% 1.90% 100.00% 
                     A*D             
          -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 50 Total % 
40-44 0.00 0.00 0.00 0.00 0.00 0.00 0.75 0.00 0.00 0.00 0.00 0.00 0.75 0.35% 
45-49 0.00 0.19 0.00 0.37 0.56 0.93 1.49 0.93 1.86 0.00 0.00 0.00 6.32 2.95% 
50-54 0.50 1.00 0.50 1.00 2.51 2.51 7.03 9.53 14.05 2.01 0.00 0.50 41.15 19.23% 
55-59 1.12 1.12 0.00 0.00 1.12 3.36 11.21 14.57 24.66 2.24 1.12 0.00 60.54 28.29% 
60-64 0.00 0.00 0.00 0.00 0.00 3.72 13.00 5.57 37.15 0.00 3.72 0.00 63.16 29.51% 
65-69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27.16 10.86 0.00 0.00 38.02 17.77% 
70-74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.06 0.00 0.00 0.00 4.06 1.90% 
Total 1.62 2.31 0.50 1.38 4.19 10.52 33.48 30.61 108.95 15.11 4.84 0.50 214.00 100.00% 
Density Change Distribution % 0.76% 1.08% 0.23% 0.64% 1.96% 4.91% 15.64% 14.30% 50.91% 7.06% 2.26% 0.23% 100.00%   
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C.V Distribution of density changes at different effect sizes of anastrozole. 
 
Cases 
     
Controls 
Density 
Change 
Placebo 
Distribution % 
1 effect size 
Distribution % 
3/4 effect size 
Distribution % 
1/2 effect size 
Distribution %  
Density 
Change 
Placebo 
Distribution % 
1 effect size 
Distribution % 
3/4 effect size 
Distribution % 
1/2 effect size 
Distribution % 
-40 0.00% 0.00% 0.00% 0.00% 
 
-40 0.00% 0.76% 0.57% 0.38% 
-35 0.00% 0.00% 0.00% 0.00% 
 
-35 0.00% 1.08% 0.81% 0.54% 
-30 0.00% 0.00% 0.00% 0.00% 
 
-30 1.11% 0.23% 0.45% 0.67% 
-25 0.00% 0.75% 0.57% 0.38% 
 
-25 1.89% 0.64% 0.96% 1.27% 
-20 1.64% 0.00% 0.41% 0.82% 
 
-20 1.46% 1.96% 1.83% 1.71% 
-15 0.00% 11.11% 8.34% 5.56% 
 
-15 3.78% 4.91% 4.63% 4.35% 
-10 10.73% 10.36% 10.45% 10.54% 
 
-10 8.98% 15.64% 13.98% 12.31% 
-5 26.35% 22.66% 23.58% 24.50% 
 
-5 19.84% 14.30% 15.69% 17.07% 
0 50.77% 53.71% 52.98% 52.24% 
 
0 47.91% 50.91% 50.16% 49.41% 
5 8.87% 1.41% 3.27% 5.14% 
 
5 8.98% 7.06% 7.54% 8.02% 
10 0.00% 0.00% 0.00% 0.00% 
 
10 4.41% 2.26% 2.80% 3.34% 
15 1.64% 0.00% 0.41% 0.82% 
 
15 1.64% 0.00% 0.41% 0.82% 
50 0.00% 0.00% 0.00% 0.00% 
 
50 0.00% 0.23% 0.18% 0.12% 
Total 100.00% 100.00% 100.00% 100.00% 
 
Total 100.00% 100.00% 100.00% 100.00% 
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C.VI Case/control weighted distribution of density changes at different effect sizes of anastrozole. 
Estimated distributions based on IBIS-I: placebo: cases=4%, controls=96%, anastrozole: cases=2%, controls=98%. 
 
Cases & Controls 
Density Change Placebo Distribution % 1 effect size Distribution % 3/4 effect size Distribution % 1/2 effect size Distribution % 
-40 0.00% 0.74% 0.56% 0.37% 
-35 0.00% 1.06% 0.79% 0.53% 
-30 1.06% 0.23% 0.44% 0.66% 
-25 1.81% 0.64% 0.95% 1.25% 
-20 1.46% 1.92% 1.80% 1.69% 
-15 3.61% 5.04% 4.71% 4.37% 
-10 9.06% 15.53% 13.90% 12.28% 
-5 20.12% 14.48% 15.85% 17.22% 
0 48.03% 50.97% 50.22% 49.47% 
5 8.98% 6.94% 7.45% 7.96% 
10 4.22% 2.21% 2.74% 3.27% 
15 1.64% 0.00% 0.41% 0.82% 
50 0.00% 0.23% 0.17% 0.11% 
Total 100.00% 100.00% 100.00% 100.00% 
 
 
C.VII Case/control weighted distribution of dichotomised density changes at different effect sizes of anastrozole . 
Estimated distributions based on IBIS-I: placebo: cases=4%, controls=96%, anastrozole: cases=2%, controls=98%. 
 
Density Change Placebo Distribution % 1 effect size Distribution % 3/4 effect size Distribution % 1/2 effect size Distribution % 
≥10% reduction 17.01% 25.17% 23.15% 21.14% 
<10% reduction 82.99% 74.83% 76.85% 78.86% 
Total 100.00% 100.00% 100.00% 100.00% 
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C.VIII Power calculation for different sample sizes and effect sizes of 
anastrozole. 
Continuous Effect size 
Sample size per arm 1  3/4  1/2 
400 0.616 0.400 0.214 
450 0.663 0.432 0.239 
500 0.720 0.487 0.257 
550 0.752 0.525 0.275 
600 0.791 0.552 0.295 
    <10% vs. ≥10% Effect size 
Sample size per arm 1  3/4  1/2 
400 0.810 0.583 0.308 
450 0.854 0.639 0.347 
500 0.890 0.677 0.380 
550 0.907 0.725 0.416 
600 0.937 0.763 0.446 
 
C.IX Case/control weighted distribution of 600 women per arm 
Estimated distributions based on IBIS-I: placebo: cases=4%, controls=96%, anastrozole: 
cases=2%, controls=98%. 
 
 
Cases Controls Total 
Placebo 4% of 600=24 96% of 600=576 600 
Anastrozole 2% of 600=12 98% of 600=588 600 
Total 36 1164 1200 
 
C.X Case/control weighted distribution of 600 women per arm, accounting 
for baseline density <10% in IBIS-I postmenopausal women. 
Estimated distributions based on IBIS-I: placebo: cases=4%, controls=96%, anastrozole: 
cases=2%, controls=98%. There were 81% of postmenopausal cases who had baseline density 
<10% and 79% of postmenopausal controls who had baseline density <10% in IBIS-I. 
 
 
Cases Controls Total 
Placebo 24/0.81=30 576/0.79=729 759 
Anastrozole 12/0.81=15 588/0.79=744 759 
Total 44 1473 1518 
Because the trial was randomised, there was no reason for variation in these proportions of density by 
treatment arm at baseline; there were some rounding errors for the total amounts. 
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C.XI Density change distribution in cases and controls: 1st follow-up vs. 2nd 
follow-up (all women and subgroup with available final follow-up) 
All women and subgroup with available final follow-up; left and right, respectively: 
 
C.XII Density change distribution in controls: 1st follow-up vs. 2nd follow-up 
(all women and subgroup with available final follow-up) 
All women and subgroup with available final follow-up; left and right, respectively: 
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C.XIII Density change distribution in cases: 1st follow-up vs. 2nd follow-up 
(all women and subgroup with available final follow-up) 
All women and subgroup with available final follow-up; left and right, respectively: 
 
C.XIV Density change distribution in placebo: 1st follow-up vs. 2nd follow-up 
(all placebo and subgroup with available final follow-up) 
All placebo and subgroup with available final follow-up; left and right, respectively: 
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C.XV  Density change distribution in anastrozole: 1st follow-up vs. 2nd 
follow-up (all anastrozole and subgroup with available final follow-
up) 
All anastrozole and subgroup with available final follow-up; left and right, respectively: 
 
 
C.XVI  Density change distribution in placebo vs. anastrozole (all women at 
first follow-up, subgroup with available final follow-up at first follow-
up and final follow-up) 
All women at first follow-up, subgroup with available final follow-up at first follow-up and 
final follow-up; top left, top right, bottom left, respectively: 
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C.XVII Density change distribution in placebo controls: 1st follow-up vs. 2nd 
follow-up (all placebo controls and subgroup with available final 
follow-up) 
All placebo controls and subgroup with available final follow-up; left and right, respectively: 
 
 
C.XVIII Density change distribution in anastrozole controls: 1st follow-up 
vs. 2nd follow-up (all anastrozole controls and subgroup with available 
final follow-up) 
All anastrozole controls and subgroup with available final follow-up; left and right, 
respectively: 
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C.XIX Density change distribution in placebo controls vs. anastrozole 
controls (all women at first follow-up, subgroup with available final 
follow-up at first follow-up and final follow-up) 
All women at first follow-up, subgroup with available final follow-up at first follow-up and 
final follow-up; top left, top right, bottom left, respectively: 
 
 
C.XX Density change distribution in placebo cases: 1st follow-up vs. 2nd 
follow-up (all placebo cases and subgroup with available final follow-
up) 
All placebo cases and subgroup with available final follow-up; left, right, respectively: 
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C.XXI Density change distribution in anastrozole cases: 1st follow-up vs. 2nd 
follow-up (all anastrozole cases and subgroup with available final 
follow-up) 
All anastrozole cases and subgroup with available final follow-up; left, right, respectively: 
 
 
C.XXII Density change distribution in placebo cases vs. anastrozole cases 
(all women at first follow-up, subgroup with available final follow-up 
at first follow-up and final follow-up) 
All women at first follow-up, subgroup with available final follow-up at first follow-up and 
final follow-up; top left, top right, bottom left, respectively: 
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C.XXIII Statistical Analysis Plan for Chapter 5 
1. INTRODUCTION  
This document describes the statistical analysis plan for the IBIS-II mammographic 
density study examining change in density between anastrozole and placebo-treated 
patients in the IBIS-II Prevention trial. 
 
2. OBJECTIVES OF THE ANALYSIS 
 
2.1 Primary objective 
To determine whether women on anastrozole experience different age-adjusted changes 
in density at first follow-up mammogram than women on placebo in the IBIS-II 
Prevention trial. 
 
2.2 Secondary objective I 
To determine whether women on anastrozole experience different changes in density at 
first follow-up mammogram than women on placebo in the IBIS-II Prevention trial, 
after adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, 
image type and time between baseline and first follow-up mammogram. 
 
2.3 Secondary objective II 
To determine whether women on anastrozole experience different age-adjusted changes 
in density at final follow-up mammogram than women on placebo in the IBIS-II 
Prevention trial. 
 
2.4 Secondary objective III 
To determine whether women on anastrozole experience different changes in density at 
final follow-up mammogram than women on placebo in the IBIS-II Prevention trial, 
after adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, 
image type and time between baseline and final follow-up mammogram. 
 
2.5 Secondary objective IV 
To examine the effect of anastrozole on first density change in subgroups of covariates 
in the IBIS-II Prevention trial (age at randomisation, body mass index at randomisation, 
age at menarche, age at menopause, Tyrer-Cuzick 10-year risk, baseline density, age at 
first birth, oral contraception use, hormone replacement therapy use up to 12 months 
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before randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
 
2.6 Secondary objective V 
To examine the effect of anastrozole on final density change in subgroups of covariates 
in the IBIS-II Prevention trial (age at randomisation, body mass index at randomisation, 
age at menarche, age at menopause, Tyrer-Cuzick 10-year risk, baseline density, age at 
first birth, oral contraception use, hormone replacement therapy use up to 12 months 
before randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
 
3. PERSONNEL  
The major statistical analysis will be undertaken by Emma Atakpa at the Centre for 
Cancer Prevention, Wolfson Institute, Queen Mary University of London, London UK. 
 
4. TIMING OF ANALYSIS  
The major statistical analysis will begin in October 2018 (approximate date). 
 
5. STUDY PARTICIPANTS 
 
5.1 Eligible participants 
 The primary and secondary (I, IV) statistical analyses will include all randomised 
women with an appropriate baseline and first follow-up mammogram (within specified 
timeframes - see below, good quality - as assessed by the experienced radiologist, MLO 
view only) who are breast cancer-free at the time of their first follow-up mammogram. 
 
 The secondary (II, III, V) statistical analyses will include all randomised women with 
an appropriate baseline, first follow-up and final follow-up mammogram (within 
specified timeframes - see below, good quality - as assessed by the experienced 
radiologist, MLO view only) who are breast cancer-free at the time of their final follow-
up mammogram. This will be a subgroup of participants from the primary analysis. 
 
 Baseline mammograms will range from ≥0 months prior to the date of randomisation to 
<12.5 months prior to the date of randomisation. First follow-up mammograms will 
range from ≥8.5 months after the date of randomisation to <38.5 months after the date 
of randomisation. Final follow-up mammograms will range from ≥47.5 months after the 
date of randomisation to <60.5 months after the date of randomisation. These time 
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frames are in accordance with analysis from IBIS-I (19) and standard operating 
procedures for IBIS-II co-ordinating centres. 
 
 Only women with all mammograms of the same image type (i.e. all film or all digital) 
will be included. 
 
 Only women with ≥10% baseline density will be included. 
 
 Breast cancer-free ‘controls’ are defined as women who had not been diagnosed with 
breast cancer at the time of study design. ‘Cases’ are defined as women who had been 
clinically diagnosed with breast cancer at the time of study design. Cases will be 
included if they are diagnosed with breast cancer after their first follow-up 
mammogram. Final follow-up mammograms for cases will be included if they occur 
before the breast cancer diagnosis.  
 
 Contralateral mammograms will be used for cases and mammograms from a randomly 
selected breast side will be used for breast cancer-free controls. 
 
5.2 Sample size calculation 
Density change for postmenopausal women in IBIS-I was weighted based on age at 
randomisation of the IBIS-II cohort, to estimate the expected density change in a cohort 
with the same age structure as IBIS-II. This was done separately for controls on 
placebo, controls on tamoxifen, cases on placebo and cases on tamoxifen. By weighting 
the density change distribution according to the distribution of cases and controls by 
treatment arm in IBIS-II, an overall density change distribution was formulated. 
Simulations (10,000 repeats) were conducted to count the number of times there was a 
significant difference in density change between arms using a Wilcoxon rank sum test 
and a Pearson chi-squared test (of density change dichotomised into ≥10% reduction 
and <10% reduction). Simulations were repeated for chosen sample sizes between 400 
and 500 women per arm. Different effect sizes (1/2 and 3/4) for tamoxifen were also 
tested by taking a weighting of the placebo and tamoxifen density change distributions 
corresponding to the proposed effect size. This was done to allow anastrozole to have a 
weaker effect on density change than tamoxifen. With 80% power and 3/4 the effect 
size of tamoxifen, 450 women per arm are required to show a difference in density 
change from baseline to first follow-up mammogram between the two treatment arms at 
the 5% type-I error level. In total, 569 anastrozole and 569 placebo-treated women are 
required, after accounting for exclusions with baseline density <10% based on the 
number of postmenopausal women with baseline density <10% in IBIS-I. This equates 
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to approximately 1105 breast cancer-free women and 33 breast-cancer cases. A sample 
size larger than this is currently impracticable given the resources and number of 
mammograms received (suitable mammograms, which meet the criteria outlined in 
section 5.1, have been received for 35 breast-cancer cases and 938 breast cancer-free 
controls, providing power to detect a difference in density change from baseline to first 
follow-up mammogram between the two treatment arms at the 5% type-I error level of 
85%). 
 
6. OUTCOMES 
 
6.1 Primary outcome 
 The primary outcome is defined as the change in density from baseline mammogram to 
first follow-up mammogram (9-38 months post randomisation). Density will be 
visually-assessed by an experienced reader (Linda Metaxa) using 5% intervals, 
following the same method as in IBIS-I. Randomisation of mammograms will be per 
woman (so that mammograms for each woman will be read in comparison with the 
other mammograms for that woman), and mammograms will be ordered sequentially. 
For each woman, density at baseline will be read first, followed by first follow-up 
mammogram (compared with baseline mammogram) and finally, final follow-up 
mammogram (compared with both baseline and first follow-up mammogram). First 
density change will therefore be defined as the difference between baseline density and 
first follow-up mammogram density; semi-continuously, and dichotomised into <10% 
or ≥10% absolute reduction. The reader will be blinded to treatment group, case status 
and risk factors, and images will be appropriately anonymised. 
 
6.2 Secondary outcome 
 The secondary outcome is defined as the change in density from baseline mammogram 
to final follow-up mammogram (48-60 months post randomisation). Density will be 
visually-assessed by an experienced reader (Linda Metaxa) using 5% intervals, 
following the same method as in IBIS-I. Randomisation of mammograms will be per 
woman (so that mammograms for each woman will be read in comparison with the 
other mammograms for that woman), and mammograms will be ordered sequentially. 
For each woman, density at baseline will be read first, followed by first follow-up 
mammogram (compared with baseline mammogram) and finally, final follow-up 
mammogram (compared with both baseline and first follow-up mammogram). Final 
density change will therefore be defined as the difference between baseline density and 
final follow-up mammogram density; semi-continuously, and dichotomised into <10% 
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or ≥10% absolute reduction. The reader will be blinded to treatment group, case status 
and risk factors, and images will be appropriately anonymised. 
 
7. STATISTICAL METHODS  
 
7.1 Hypotheses to be tested 
 
7.1.1 Primary hypothesis 
 H0: There is no difference in age-adjusted change in density from baseline to first 
follow-up mammogram between patients in the anastrozole arm and patients in the 
placebo arm. 
 H1: Age-adjusted change in density from baseline to first follow-up mammogram is 
different between patients in the anastrozole arm and patients in the placebo arm. 
 
7.1.2 Secondary hypothesis I 
 H0: There is no difference in change in density from baseline to first follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm, 
after adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, 
image type, and time between baseline and first follow-up mammogram. 
 H1: Change in density from baseline to first follow-up mammogram is different between 
patients in the anastrozole arm and patients in the placebo arm, after adjustment for age 
at randomisation, body mass index at randomisation, hormone replacement therapy use 
up to 12 months before randomisation, age at menopause, image type, and time between 
baseline and first follow-up mammogram. 
 
7.1.3 Secondary hypothesis II 
 H0: There is no difference in age-adjusted change in density from baseline to final 
follow-up mammogram between patients in the anastrozole arm and patients in the 
placebo arm. 
 H1: Age-adjusted change in density from baseline to final follow-up mammogram is 
different between patients in the anastrozole arm and patients in the placebo arm. 
 
7.1.4 Secondary hypothesis III 
 H0: There is no difference in change in density from baseline to final follow-up 
mammogram between patients in the anastrozole arm and patients in the placebo arm, 
after adjustment for age at randomisation, body mass index at randomisation, hormone 
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replacement therapy use up to 12 months before randomisation, age at menopause, 
image type, and time between baseline and first follow-up mammogram. 
 H1: Change in density from baseline to final follow-up mammogram is different 
between patients in the anastrozole arm and patients in the placebo arm, after 
adjustment for age at randomisation, body mass index at randomisation, hormone 
replacement therapy use up to 12 months before randomisation, age at menopause, 
image type, and time between baseline and first follow-up mammogram. 
 
7.1.5 Secondary hypothesis IV 
 H0: There is no difference in anastrozole-induced change in density from baseline to 
first follow-up mammogram between subgroups of covariates (age at randomisation, 
body mass index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 
10-year risk, baseline density, age at first birth, oral contraception use, hormone 
replacement therapy use up to 12 months before randomisation, smoking status, history 
of atypical hyperplasia or LCIS, image type, and time between baseline mammogram 
and follow-up mammogram). 
 H1: Anastrozole-induced change in density from baseline to first follow-up 
mammogram is different between subgroups of covariates (age at randomisation, body 
mass index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 10-year 
risk, baseline density, age at first birth, oral contraception use, hormone replacement 
therapy use up to 12 months before randomisation, smoking status, history of atypical 
hyperplasia or LCIS, image type, and time between baseline mammogram and follow-
up mammogram). 
 
7.1.6 Secondary hypothesis V 
 H0: There is no difference in anastrozole-induced change in density from baseline to 
final follow-up mammogram between subgroups of covariates (age at randomisation, 
body mass index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 
10-year risk, baseline density, age at first birth, oral contraception use, hormone 
replacement therapy use up to 12 months before randomisation, smoking status, history 
of atypical hyperplasia or LCIS, image type, and time between baseline mammogram 
and follow-up mammogram). 
 H1: Anastrozole-induced change in density from baseline to final follow-up 
mammogram is different between subgroups of covariates (age at randomisation, body 
mass index at randomisation, age at menarche, age at menopause, Tyrer-Cuzick 10-year 
risk, baseline density, age at first birth, oral contraception use, hormone replacement 
therapy use up to 12 months before randomisation, smoking status, history of atypical 
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hyperplasia or LCIS, image type, and time between baseline mammogram and follow-
up mammogram). 
 
7.2 Analysis methods 
All statistical analysis will be conducted in STATA 13. All tests (see below) will be 
two-sided with a significance level of 5%. Results will be omitted if subgroup numbers 
are small enough in order to un-blind the statistician. 
 
7.2.1 Baseline characteristics 
The following baseline characteristics will be summarised in a frequency table, overall 
and by treatment. Frequency counts & percentages will be provided for categorical data 
and means (standard deviation, SD) and medians (interquartile range, IQR) will be 
provided for continuous data. Two-sample t-tests (STATA’s “ttest” command) and 
Wilcoxon rank sum tests (STATA’s “ranksum” command) will test differences between 
treatment arms in continuous data and Pearson chi-squared tests (STATA’s “tab, chi2” 
command) will test differences between treatment arms in categorical data: 
 
 Age at randomisation (mean (SD), median (IQR)) 
 Body Mass Index (BMI) at randomisation (mean (SD), median (IQR)) 
 Age at menarche (mean (SD), median (IQR)) 
 Age at menopause (mean (SD), median (IQR)) 
 Tyrer-Cuzick 10-year risk (mean (SD), median (IQR)) 
 Baseline density (mean (SD), median (IQR)) 
 Age at first birth (nulliparous/>27/21-27/≤20) 
 Oral contraception use (never/previously/currently) 
 Hormone Replacement Therapy (HRT) use up to 12 months before randomisation 
(no/yes) 
 Smoking status (never/former/current) 
 History of atypical hyperplasia or LCIS (no/yes) 
 Image type (film/digital) 
 
7.2.2 Baseline characteristics and baseline density 
 Univariate bootstrap linear regression models of baseline density on baseline covariates 
(excluding baseline density), adjusted for age at randomisation (except age at 
randomisation): n, β-coefficient, 95% confidence interval, P-value. 
STATA’s “regress” command 
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 Multivariable bootstrap linear regression models of baseline density on baseline 
covariates (excluding baseline density). All covariates will be included in the 
multivariable model: n, β-coefficient, 95% confidence interval, P-value. 
STATA’s “bootstrap”, “estat bootstrap, all” & “regress” commands 
 Univariate logistic regression models of baseline density (dichotomised into <50% or 
≥50%) on baseline covariates (excluding baseline density), adjusted for age at 
randomisation (except age at randomisation): n, odds ratio, 95% confidence interval, P-
value. 
STATA’s “logistic” command 
 Multivariable logistic regression models of baseline density (dichotomised into <50% 
or ≥50%) on baseline covariates (excluding baseline density). All covariates will be 
included in the multivariable model: n, odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
7.2.3 Primary analysis  
 Wilcoxon rank sum test comparing density change in the anastrozole and placebo arms: 
P-value. 
STATA’s “summarize, detail” command 
STATA’s “tabstat, statistics(iqr)” command 
STATA’s “ranksum, by(treatment)” command 
 Pearson chi-squared test comparing density change in the anastrozole and placebo arms 
(density change dichotomised into <10% absolute reduction and ≥10% absolute 
reduction): P-value. 
STATA’s “tabulate, chi2” command 
 Bootstrap linear regression model of change in density on treatment arm and age at 
randomisation: n, β-coefficient, 95% confidence interval, P-value. 
STATA’s “bootstrap”, “estat bootstrap, all” & “regress” commands 
 Logistic regression model of change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction) on treatment arm and age at randomisation: n, 
odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
7.2.4 Secondary analysis I 
 Bootstrap linear regression model of change in density on treatment arm, adjusted for 
covariates. All covariates will be included in the multivariable model: n, β-coefficient, 
95% confidence interval, P-value. 
STATA’s “bootstrap”, “estat bootstrap, all” & “regress” commands 
 
396 
 
 Logistic regression model of change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction) on treatment arm, adjusted for covariates. All 
covariates will be included in the multivariable model: n, odds ratio, 95% confidence 
interval, P-value. 
STATA’s “logistic” command 
 
7.2.5 Secondary analysis II 
 Wilcoxon rank sum test comparing density change in the anastrozole and placebo arms: 
P-value. 
STATA’s “summarize, detail” command 
STATA’s “tabstat, statistics(iqr)” command 
STATA’s “ranksum, by(treatment)” command 
 Pearson chi-squared test comparing density change in the anastrozole and placebo arms 
(density change dichotomised into <10% absolute reduction and ≥10% absolute 
reduction): P-value. 
STATA’s “tabulate, chi2” command 
 Bootstrap linear regression model of change in density on treatment arm and age at 
randomisation: n, β-coefficient, 95% confidence interval, P-value. 
STATA’s “bootstrap”, “estat bootstrap, all” & “regress” commands 
 Logistic regression model of change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction) on treatment arm and age at randomisation: n, 
odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
7.2.6 Secondary analysis III 
 Bootstrap linear regression model of change in density on treatment arm, adjusted for 
covariates. All covariates will be included in the multivariable model: n, β-coefficient, 
95% confidence interval, P-value. 
STATA’s “bootstrap”, “estat bootstrap, all” & “regress” commands 
 Logistic regression model of change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction) on treatment arm, adjusted for covariates. All 
covariates will be included in the multivariable model: n, odds ratio, 95% confidence 
interval, P-value. 
STATA’s “logistic” command 
 
7.2.7 Secondary analysis IV 
 Wilcoxon rank-sum test comparing first density change between subgroups of 
covariates in the anastrozole arm only (for covariates with 2 subgroups): P-value. 
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STATA’s “ranksum, by(subgroup)” command 
 Cuzick’s trend test comparing first density change between subgroups of covariates in 
the anastrozole arm only (for covariates with >2 ordered subgroups): P-value. 
STATA’s “nptrend, by(subgroup)” command 
 Logistic regression to assess the odds of a higher first density reduction (≥10% absolute 
reduction) in one subgroup compared to the reference subgroup in the anastrozole arm 
only: Odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
7.2.8 Secondary analysis V 
 Wilcoxon rank-sum test comparing final density change between subgroups of 
covariates in the anastrozole arm only (for covariates with 2 subgroups): P-value. 
STATA’s “ranksum, by(subgroup)” command 
 Cuzick’s trend test comparing final density change between subgroups of covariates in 
the anastrozole arm only (for covariates with >2 ordered subgroups): P-value. 
STATA’s “nptrend, by(subgroup)” command 
 Logistic regression to assess the odds of a higher final density reduction (≥10% absolute 
reduction) in one subgroup compared to the reference subgroup in the anastrozole arm 
only: Odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
7.2.9 Adjustment covariates 
The following covariates are chosen as potential confounders for density change based 
on previous literature and significant covariates in the analysis from IBIS-I (203) 
(Cuzick 2004) and hence will be included in adjusted regression models (7.2.4 & 7.2.6): 
 
 Age at randomisation (continuous) 
 BMI at randomisation (continuous) 
 Age at menopause (continuous) 
 HRT use up to 12 months before randomisation (no/yes) 
 Image type (film/digital) 
 Time between baseline mammogram and follow-up mammogram (continuous) 
 
A separate model will be conducted, including an adjustment for baseline density 
(continuous) and age at randomisation only (7.2.4 & 7.2.6). 
 
A separate model will be conducted, including an adjustment for baseline density 
(continuous) and the covariates above (7.2.4 & 7.2.6). 
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Time on treatment will not be included in adjustments because an intention-to-treat 
analysis will be conducted. 
 
7.2.10 Subgroup covariates 
The following covariates will be considered in subgroup analyses (7.2.7 & 7.2.8): 
 
 Age at randomisation (<median age, ≥median age) 
 BMI at randomisation (<median BMI, ≥median BMI) 
 Age at menarche (<median age at menarche, ≥median age at menarche) 
 Age at menopause (<median age at menopause, ≥median age at menopause) 
 Tyrer-Cuzick 10-year risk (<median risk, ≥median risk) 
 Baseline density (<median baseline density, ≥median baseline density) 
 Age at first birth (nulliparous/>27/21-27/≤20) 
 Oral contraception use (never/previously/currently) 
 HRT use up to 12 months before randomisation (no/yes) 
 Smoking status (never/former/current) 
 History of atypical hyperplasia or LCIS (no/yes) 
 Image type (film/digital) 
 Time between baseline mammogram and follow-up mammogram (<median time 
between baseline mammogram and follow-up mammogram, ≥median time between 
baseline mammogram and follow-up mammogram) 
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7.3 Tables 
 
Table 1: Baseline characteristics overall and by treatment. *P-value from two-sample t-test 
(corresponding to mean column) and Wilcoxon rank sum test (corresponding to median 
column), **p-value from Pearson chi-squared test of association.  
 
Variable 
Overall Placebo Anastrozole 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Age at randomisation (yr)       
P*       
Body Mass Index (kg/m2)       
P*       
Age at menarche (yr)       
P*       
Age at menopause (yr)       
P*       
Tyrer-Cuzick 10-year risk 
(%) 
      
P*       
Baseline density (%)       
P*       
 N % N % N % 
Age at first birth (yr)       
Nulliparous       
>27       
21-27       
≤20       
P**       
Oral contraception use       
Never       
Previously       
Currently       
P**       
HRT use up to 12 months 
before randomisation 
      
No       
Yes       
P**       
Smoking status       
Never       
Former       
Current       
P**       
History of Atypical 
Hyperplasia or LCIS 
      
No       
Yes       
P**       
Image type       
Film       
Digital       
P**       
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 Univariate 
Linear (bootstrap) 
regression 
Multivariable 
Linear (bootstrap) 
regression1 
Univariate 
Logistic 
regression 
Multivariable 
Logistic 
regression1 
Variable β-
coefficien
t 
(95% 
CI)*** 
Bootstra
p SE 
β-
coefficien
t 
(95% 
CI)*** 
Bootstra
p SE 
OR 
(95
% 
CI)# 
P-
value
# 
OR 
(95
% 
CI)# 
P-
value
# 
Age at 
randomisation 
(yr)* 
        
Body Mass 
Index (kg/m2)* 
        
Age at 
menarche (yr)* 
        
Age at 
menopause 
(yr)* 
        
Tyrer-Cuzick 
10-year risk 
(%)* 
        
Age at first 
birth (yr)** 
        
Nulliparous Ref  Ref  Ref  Ref  
>27         
21-27         
≤20         
Oral 
contraception 
use** 
        
Never Ref  Ref  Ref  Ref  
Previously         
Currently         
HRT use up to 
12 months 
before 
randomisation*
* 
        
No Ref  Ref  Ref  Ref  
Yes         
Smoking 
status** 
        
Never Ref  Ref  Ref  Ref  
Former         
Current         
History of 
Atypical 
Hyperplasia or 
LCIS** 
        
No Ref  Ref  Ref  Ref  
Yes         
Image type**         
Film Ref  Ref  Ref  Ref  
Digital         
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Table 2: Association between baseline covariates and baseline breast density (semi-continuous 
and dichotomised ≥50% and <50%) in univariate and multivariable models. All covariates 
adjusted for age at randomisation in univariate models (except for age at randomisation). * β-
coefficient represents effect on baseline density per unit increase in covariate, OR represents 
odds of having ≥50% baseline density per unit increase in covariate. ** β-coefficient represents 
difference in baseline density from reference category, OR represents odds of having ≥50% 
baseline density relative to the reference category. *** Percentile 95% CI. # 95% CI and p-
value from a Wald test. 1Model includes all covariates. N=. 
 
Boyd 
catego
ry at 
entry 
Number of women 
Boyd category at first follow-up 
Tot
al 
Boyd category at final follow-up 
Tot
al 
0
% 
1-
10
% 
11-
25
% 
26-
50
% 
51-
75
% 
76-
100
% 
0
% 
1-
10
% 
11-
25
% 
26-
50
% 
51-
75
% 
76-
100
% 
0%               
1-10%               
11-
25% 
              
26-
50% 
              
51-
75% 
              
76-
100% 
              
Total               
 
Table 3: Cross tabulation of number of women in each Boyd category at entry to the study with 
category at first and final follow-up. The first number in each cell is the total number of 
subjects. Numbers in parentheses are the placebo and anastrozole groups, respectively. 
 
 N  Median IQR P-value 
First Follow-up     
Placebo    
Anastrozole    
Final Follow-up     
Placebo    
Anastrozole    
Table 4: Semi-continuous density change by treatment arm. P-value from Wilcoxon rank sum 
test. 
 
 N (% of follow-up) χ2 
P-value 
 <10% reduction ≥10% reduction 
First Follow-up     
Placebo   
Anastrozole   
Final Follow-up     
Placebo   
Anastrozole   
Table 5: Dichotomised density change by treatment arm. P-value from Pearson chi-squared test. 
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 Univariate Adjusted1 Adjusted2 Adjusted3 
 β-
coeffici
ent 
(95% 
CI)*** 
Bootstr
ap SE 
β-
coeffici
ent 
(95% 
CI)*** 
Bootstr
ap SE 
β-
coeffici
ent 
(95% 
CI)*** 
Bootstr
ap SE 
β-
coeffici
ent 
(95% 
CI)*** 
Bootstr
ap SE 
 First follow-up 
Treatment**
# 
        
Placebo Ref  Ref  Ref  Ref  
Anastrozole         
Age at 
randomisatio
n (yr)* 
        
Body Mass 
Index 
(kg/m2)* 
    - -   
Age at 
menopause 
(yr)* 
    - -   
Baseline 
density (%)* 
  - -     
HRT use up 
to 12 months 
before 
randomisatio
n** 
        
No Ref  Ref  - - Ref  
Yes     - -   
Image 
type** 
        
Film Ref  Ref  - - Ref  
Digital     - -   
Time 
between 
baseline 
mammogra
m and first 
follow-up 
mammogra
m (yr)* 
    - -   
 Final follow-up 
Treatment**
# 
        
Placebo Ref  Ref  Ref  Ref  
Anastrozole         
Age at 
randomisatio
n (yr)* 
        
Body Mass 
Index 
(kg/m2)* 
    - -   
Age at 
menopause 
    - -   
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(yr)* 
Baseline 
density (%)* 
  - -     
HRT use up 
to 12 months 
before 
randomisatio
n** 
        
No Ref  Ref  - - Ref  
Yes     - -   
Image 
type** 
        
Film Ref  Ref  - - Ref  
Digital     - -   
Time 
between 
baseline 
mammogra
m and final 
follow-up 
mammogra
m (yr)* 
    - -   
Table 6: Bootstrap linear regression results for change in density on treatment arm in univariate 
and adjusted models. * β-coefficient represents effect on density change per unit increase in 
covariate, ** β-coefficient represents difference in density change from reference category. *** 
Percentile 95% CI. #Additionally adjusted for age at randomisation in univariate model. 1Model 
includes all variables except for baseline density, 2Model includes treatment, age at 
randomisation and baseline density, 3Model includes all covariates. N= for first follow-up, N= 
for final follow-up. 
 Univariate Adjusted1 Adjusted2 Adjusted3 
 OR 
(95% 
CI) 
P-
value 
OR 
(95% 
CI) 
P-
value 
OR 
(95% 
CI) 
P-
value 
OR 
(95% 
CI) 
P-
value 
 First follow-up 
Treatment**#         
Placebo Ref  Ref  Ref  Ref  
Anastrozole         
Age at randomisation 
(yr)* 
        
Body Mass Index 
(kg/m2)* 
    - -   
Age at menopause (yr)*     - -   
Baseline density (%)*   - -     
HRT use up to 12 
months before 
randomisation** 
        
No Ref  Ref  - - Ref  
Yes     - -   
Image type**         
Film Ref  Ref  - - Ref  
Digital     - -   
Time between baseline 
mammogram and first 
follow-up mammogram 
(yr)* 
    - -   
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 Final follow-up 
Treatment**#         
Placebo Ref  Ref  Ref  Ref  
Anastrozole         
Age at randomisation 
(yr)* 
        
Body Mass Index 
(kg/m2)* 
    - -   
Age at menopause (yr)*     - -   
Baseline density (%)*   - -     
HRT use up to 12 
months before 
randomisation** 
        
No Ref  Ref  - - Ref  
Yes     - -   
Image type**         
Film Ref  Ref  - - Ref  
Digital     - -   
Time between baseline 
mammogram and final 
follow-up mammogram 
(yr)* 
    - -   
Table 7: Logistic regression results for change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction) on treatment arm in univariate and adjusted models. * 
OR represents odds of ≥10% density reduction per unit increase in covariate, ** OR represents 
odds of ≥10% density reduction relative to the reference category. #Additionally adjusted for 
age at randomisation in univariate model. P-values from logistic regression model Wald test of 
covariate. 1Model includes all variables except for baseline density, 2Model includes treatment, 
age at randomisation and baseline density, 3Model includes all covariates. N= for first follow-
up, N= for final follow-up. 
 
 First follow-up Final follow-up 
 N Media
n 
(IQR) 
P-
value
# 
OR 
(95
% 
CI) 
## 
P-
value##
# 
N Media
n 
(IQR) 
P-
value
# 
OR 
(95
% 
CI) 
## 
P-
value##
# 
Age at 
randomisatio
n (yr)* 
          
Younger age 
at 
randomisatio
n 
   Ref     Ref  
Older age at 
randomisatio
n 
          
Body Mass 
Index 
(kg/m2)* 
          
Lower Body 
Mass Index 
   Ref     Ref  
Higher Body 
Mass Index 
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Age at 
menarche 
(yr)* 
          
Younger age 
at menarche 
   Ref     Ref  
Older age at 
menarche 
          
Age at 
menopause 
(yr)* 
          
Younger age 
at 
menopause 
   Ref     Ref  
Older age at 
menopause 
          
Tyrer-Cuzick 
10-year risk 
(%)* 
          
Lower Tyrer-
Cuzick 10-
year risk 
   Ref     Ref  
Higher 
Tyrer-Cuzick 
10-year risk 
          
Baseline 
density (%)* 
          
Lower 
baseline 
density 
   Ref     Ref  
Higher 
baseline 
density 
          
Age at first 
birth (yr) 
          
Nulliparous    Ref     Ref  
>27           
21-27           
≤20           
Oral 
contraception 
use 
          
Never    Ref     Ref  
Previously           
Currently           
HRT use up 
to 12 months 
before 
randomisatio
n 
          
No    Ref     Ref  
Yes           
Smoking 
status 
          
Never    Ref     Ref  
Former           
Current           
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History of 
Atypical 
Hyperplasia 
or LCIS 
          
No    Ref     Ref  
Yes           
Image type           
Film    Ref     Ref  
Digital           
Time 
between 
baseline 
mammogram 
and follow-
up 
mammogram 
(yr)* 
          
Shorter time 
between 
mammogram
s 
   Ref     Ref  
Longer time 
between 
mammogram
s 
          
 
Table 8: First and final change in density by subgroups of covariates in the anastrozole arm 
only. *Continuous variables dichotomised by median of variable in all women. #P-value from 
Wilcoxon rank-sum test for covariates with 2 subgroups, P-value from Cuzick’s trend test for 
covariates with >2 subgroups. ## OR represents odds of ≥10% density reduction relative to the 
reference category. ###P-value of odds ratio from a univariate logistic regression model Wald 
test of covariate. 
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C.XXIV Proforma for Chapter 5 
Request 
Originator: 
 
Ms Emma Atakpa 
PhD student, Centre for Cancer Prevention, Wolfson Institute 
 
Supervisors: 
Professor Jack Cuzick 
Dr Adam Brentnall 
Reason for 
request: 
To complete an analysis comparing mammographic density change between the 
placebo and anastrozole arms of the IBIS-II Prevention trial. 
Background: Mammographic density (herein referred to as ‘density’) is one of the strongest 
known risk factors for breast cancer. Women in the highest density category 
(≥75%) are at a 4 to 6-fold increased risk of developing breast cancer relative to 
those with little or no density (79). 
 
Whilst postmenopausal hormone replacement therapy (HRT) is associated with 
an increase in risk of breast cancer (424) and density (188, 193); selective 
oestrogen receptor modulators (SERMs), such as tamoxifen, decrease risk (198, 
199, 425) and density (203-205). Most importantly, high-risk women who 
experienced ≥10% density reduction after approximately 18 months of 
prophylactic tamoxifen were shown to be at approximately 68% lower risk of 
developing breast cancer compared with women who experienced <10% density 
reduction after the same treatment in the IBIS-I trial (19). 
 
Similar to SERMs, aromatase inhibitors (AIs) are an anti-oestrogenic drug given 
to women in the treatment of breast cancer. In 2014, analysis from IBIS-II 
showed that anastrozole (an AI) reduced the risk of breast cancer in high-risk 
postmenopausal women (208). However, studies looking into the relationship 
between AIs and density have so far shown modest or insignificant results (267-
269, 426). Many of these studies lack statistical power due to their small sample 
size (12 month density change was assessed in only 43 women in Prowell et al. 
(426), 49 women in Ciglar et al. (268), and 65 women in Ciglar et al. (269)), 
whilst larger studies such as Vachon et al. (267) are based on adjuvant AI 
treatment only. It is still unknown whether preventive anastrozole treatment 
reduces density more than the natural decline which tends to occur with age. 
Aims: 
 
 
Primary objective: To determine whether women on anastrozole experience 
different age-adjusted changes in density at first follow-up mammogram than 
women on placebo in the IBIS-II Prevention trial. 
Primary hypothesis: Age-adjusted change in density from baseline to first 
follow-up mammogram is different between patients in the anastrozole arm and 
patients in the placebo arm. 
 
Secondary objective I: To determine whether women on anastrozole experience 
different changes in density at first follow-up mammogram than women on 
placebo in the IBIS-II Prevention trial, after adjustment for age at randomisation, 
body mass index at randomisation, hormone replacement therapy use up to 12 
months before randomisation, age at menopause, image type and time between 
baseline and first follow-up mammogram. 
Secondary hypothesis I: Change in density from baseline to first follow-up 
mammogram is different between patients in the anastrozole arm and patients in 
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the placebo arm, after adjustment for age at randomisation, body mass index at 
randomisation, hormone replacement therapy use up to 12 months before 
randomisation, age at menopause, image type, and time between baseline and 
first follow-up mammogram. 
 
Secondary objective II: To determine whether women on anastrozole experience 
different age-adjusted changes in density at final follow-up mammogram than 
women on placebo in the IBIS-II Prevention trial. 
Secondary hypothesis II: Age-adjusted change in density from baseline to final 
follow-up mammogram is different between patients in the anastrozole arm and 
patients in the placebo arm. 
 
Secondary objective III: To determine whether women on anastrozole 
experience different changes in density at final follow-up mammogram than 
women on placebo in the IBIS-II Prevention trial, after adjustment for age at 
randomisation, body mass index at randomisation, hormone replacement therapy 
use up to 12 months before randomisation, age at menopause, image type and 
time between baseline and final follow-up mammogram. 
Secondary hypothesis III: Change in density from baseline to final follow-up 
mammogram is different between patients in the anastrozole arm and patients in 
the placebo arm, after adjustment for age at randomisation, body mass index at 
randomisation, hormone replacement therapy use up to 12 months before 
randomisation, age at menopause, image type, and time between baseline and 
first follow-up mammogram. 
 
Secondary objective IV: To examine the effect of anastrozole on first density 
change in subgroups of covariates in the IBIS-II Prevention trial (age at 
randomisation, body mass index at randomisation, age at menarche, age at 
menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral 
contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
Secondary hypothesis IV: Anastrozole-induced change in density from baseline 
to first follow-up mammogram is different between subgroups of covariates (age 
at randomisation, body mass index at randomisation, age at menarche, age at 
menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral 
contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
 
Secondary objective V: To examine the effect of anastrozole on final density 
change in subgroups of covariates in the IBIS-II Prevention trial (age at 
randomisation, body mass index at randomisation, age at menarche, age at 
menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral 
contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
Secondary hypothesis V: Anastrozole-induced change in density from baseline to 
final follow-up mammogram is different between subgroups of covariates (age at 
randomisation, body mass index at randomisation, age at menarche, age at 
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menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, oral 
contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram). 
Data 
required: 
 
 
Suitable mammograms (within the following specified timeframes, before breast 
cancer diagnosis, MLO view, deemed to be good quality) have been received for 
35 breast-cancer cases and 938 breast cancer-free controls. Baseline (up to 12 
months before randomisation) and first follow-up (9-38 months post 
randomisation) mammograms for these 973 women were batched and sent to a 
radiologist at St Bartholomew’s hospital for density scoring. A final (48-60 
months post randomisation) follow-up mammogram was also sent for scoring if 
it was available. 
 
With 973 women, the power to detect a difference in density change from 
baseline to first follow-up mammogram between the two treatment arms at the 
5% type-I error level is 85%. This calculation allows for a weaker effect of 
anastrozole on density change than tamoxifen (3/4 the effect size observed in 
IBIS-I with tamoxifen). 
 
Since the requestor is blinded to treatment allocation, a set of STATA code will 
be sent to Dr Sestak to run on the un-blinded data for these 973 women. 
Describe the 
specific 
analyses or 
tables 
requested: 
Methods: 
 
Mammograms were visually assessed by a radiologist (Dr Metaxa) at St 
Bartholomew’s hospital. 
Each mammogram was scored in 5% increments, following the same method as 
in IBIS-I. 
Contralateral mammograms were used for cases and mammograms from a 
randomly selected breast side were used for breast cancer-free controls. 
Density change will be defined as the difference between baseline and first 
follow-up mammogram as well as baseline and final follow-up mammogram. 
Only women with ≥10% baseline density will be included. 
Only women with all mammograms of the same image type (i.e. all film or all 
digital) will be included. 
 
Statistical analysis: 
 
Baseline characteristics will be summarised by treatment arm using frequency 
tables with age at randomisation, body mass index at randomisation, age at 
menarche, age at menopause, Tyrer-Cuzick 10-year risk, baseline density, age at 
first birth, oral contraception use, hormone replacement therapy use up to 12 
months before randomisation, smoking status, history of atypical hyperplasia or 
LCIS, and image type. An exploratory analysis will also assess the association 
between baseline covariates and baseline density using univariate (adjusted for 
age at randomisation) and multivariable linear regression and univariate 
(adjusted for age at randomisation) and multivariable logistic regression. 
 
The primary analysis will compare the density change at first follow-up in 
anastrozole-treated patients with placebo-treated patients in the IBIS-II 
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Prevention trial. A linear regression model will examine the association between 
treatment arm and change in density, adjusted for age at randomisation. A 
logistic regression model will also be used to examine the association between 
treatment arm and change in density (dichotomised into <10% absolute 
reduction and ≥10% absolute reduction), adjusted for age at randomisation. 
 
The secondary analysis (I) will repeat the primary analysis, adjusted for age at 
randomisation, body mass index at randomisation, hormone replacement therapy 
use up to 12 months before randomisation, age at menopause, image type and 
time between baseline and first follow-up mammogram. 
 
The secondary analysis (II) will repeat the primary analysis but for final follow-
up density change, in a subgroup of women who have an available final 
mammogram density score. 
 
The secondary analysis (III) will repeat the primary analysis but for final follow-
up density change, in a subgroup of women who have an available final 
mammogram density score, adjusted for age at randomisation, body mass index 
at randomisation, hormone replacement therapy use up to 12 months before 
randomisation, age at menopause, image type and time between baseline and 
final follow-up mammogram. 
 
The secondary analysis (IV) will use Wilcoxon rank-sum or Cuzick trend tests to 
assess whether the effect of anastrozole on first density change varies between 
different covariate subgroups, and logistic regression to assess the odds of a high 
density reduction (≥10% absolute reduction) in one subgroup relative to another 
subgroup, in anastrozole treated patients. Covariates to be split into subgroups 
are: age at randomisation, body mass index at randomisation, age at menarche, 
age at menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, 
oral contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram. 
 
The secondary analysis (V) will use Wilcoxon rank-sum or Cuzick trend tests to 
assess whether the effect of anastrozole on final density change varies between 
different covariate subgroups, and logistic regression to assess the odds of a high 
density reduction (≥10% absolute reduction) in one subgroup relative to another 
subgroup, in anastrozole treated patients. Covariates to be split into subgroups 
are: age at randomisation, body mass index at randomisation, age at menarche, 
age at menopause, Tyrer-Cuzick 10-year risk, baseline density, age at first birth, 
oral contraception use, hormone replacement therapy use up to 12 months before 
randomisation, smoking status, history of atypical hyperplasia or LCIS, image 
type, and time between baseline mammogram and follow-up mammogram. 
 
All statistical analysis will be conducted in STATA 13. All tests will be two-
sided with a significance level of 5%. 
 
Results will be omitted if subgroup numbers are small enough to un-blind the 
requestor. 
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What will 
the data be 
used for?  
The results of the analysis will form a chapter in Ms Emma Atakpa’s PhD thesis.  
 
The results will also be prepared for publication in a peer-reviewed journal 
(dependent on results and TSC permitting). 
Date 
required by: 
 
Analysis will begin as soon as possible after responses from the TSC. 
Other 
comments: 
 
Proposed 
authorship: 
E. Atakpa, A. Brentnall, L. Metaxa, I. Sestak, J.F. Forbes, A. Howell, J. Cuzick 
This section to be completed by IBIS-II Trial Steering Committee 
Does the Request 
have Executive 
Committee 
Approval? 
Please place a X 
in appropriate 
box 
  Yes                No 
If no, reason for 
rejection: 
 
Date received by IBIS-II CCO: 
Date decision sent to applicant: 
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C.XXV Statistical Analysis Plan for Chapter 6 
 
1. INTRODUCTION  
This document describes the statistical analysis plan for the IBIS-II mammographic 
density study examining anastrozole-induced change in density and risk of breast cancer 
in patients from the IBIS-II Prevention trial. 
 
2. OBJECTIVES OF THE ANALYSIS 
 
2.1 Primary objective 
To determine whether women on anastrozole who experience a ≥10% reduction in 
density at first follow-up mammogram have a different level of age-adjusted risk of 
breast cancer than women on anastrozole who experience a <10% reduction in density 
at first follow-up mammogram in the IBIS-II Prevention trial. 
 
2.2 Secondary objective I 
To determine whether women on anastrozole who experience a ≥5% reduction in 
density at first follow-up mammogram have a different level of age-adjusted risk of 
breast cancer than women on anastrozole who experience a <5% reduction in density at 
first follow-up mammogram in the IBIS-II Prevention trial. 
 
2.3 Secondary objective II 
To determine whether women on anastrozole who experience a ≥10% reduction in 
density at first follow-up mammogram have a different level of risk of breast cancer 
than women on anastrozole who experience a <10% reduction in density at first follow-
up mammogram in the IBIS-II Prevention trial, after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and Tyrer-Cuzick 
10-year risk. 
 
2.4 Secondary objective III 
To determine whether women on anastrozole who experience a ≥5% reduction in 
density at first follow-up mammogram have a different level of risk of breast cancer 
than women on anastrozole who experience a <5% reduction in density at first follow-
up mammogram in the IBIS-II Prevention trial, after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and Tyrer-Cuzick 
10-year risk. 
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2.5 Secondary objective IV 
To determine whether the age-adjusted effect of ≥10% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <10% reduction) is different 
between anastrozole-treated and placebo-treated patients (interaction test for 
anastrozole-induced density change as a predictive biomarker for breast cancer risk 
reduction). 
 
2.6 Secondary objective V 
To determine whether the age-adjusted effect of ≥5% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <5% reduction) is different 
between anastrozole-treated and placebo-treated patients (interaction test for 
anastrozole-induced density change as a predictive biomarker for breast cancer risk 
reduction). 
 
2.5 Secondary objective VI 
To determine whether the effect of ≥10% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <10% reduction) is different between 
anastrozole-treated and placebo-treated patients (interaction test for anastrozole-induced 
density change as a predictive biomarker for breast cancer risk reduction), after 
adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 
2.6 Secondary objective VII 
To determine whether the effect of ≥5% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <5% reduction) is different between 
anastrozole-treated and placebo-treated patients (interaction test for anastrozole-induced 
density change as a predictive biomarker for breast cancer risk reduction), after 
adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 
2.7 Secondary objective VIII 
To determine whether women on anastrozole who experience a ≥10% reduction in 
density at first follow-up mammogram have a different level of age-adjusted risk of 
breast cancer than women on placebo, and whether women on anastrozole who 
experience a <10% reduction in density at first follow-up mammogram have a different 
level of age-adjusted risk of breast cancer than women on placebo in the IBIS-II 
Prevention trial (test for anastrozole-induced density change as a predictive biomarker 
for breast cancer risk reduction). 
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2.8 Secondary objective IX 
To determine whether women on anastrozole who experience a ≥5% reduction in 
density at first follow-up mammogram have a different level of age-adjusted risk of 
breast cancer than women on placebo, and whether women on anastrozole who 
experience a <5% reduction in density at first follow-up mammogram have a different 
level of age-adjusted risk of breast cancer than women on placebo in the IBIS-II 
Prevention trial (test for anastrozole-induced density change as a predictive biomarker 
for breast cancer risk reduction). 
 
2.9 Secondary objective X 
To determine whether women on anastrozole who experience a ≥10% reduction in 
density at first follow-up mammogram have a different level of risk of breast cancer 
than women on placebo, and whether women on anastrozole who experience a <10% 
reduction in density at first follow-up mammogram have a different level of risk of 
breast cancer than women on placebo in the IBIS-II Prevention trial (test for 
anastrozole-induced density change as a predictive biomarker for breast cancer risk 
reduction), after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
2.10 Secondary objective XI 
To determine whether women on anastrozole who experience a ≥5% reduction in 
density at first follow-up mammogram have a different level of risk of breast cancer 
than women on placebo, and whether women on anastrozole who experience a <5% 
reduction in density at first follow-up mammogram have a different level of risk of 
breast cancer than women on placebo in the IBIS-II Prevention trial (test for 
anastrozole-induced density change as a predictive biomarker for breast cancer risk 
reduction), after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
2.11 Secondary objective XII 
To examine the effect of anastrozole-induced first density reduction of ≥10% on breast 
cancer risk in different subgroups of covariates in the IBIS-II Prevention trial 
(subgroups: tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement use up 
to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time 
between baseline mammogram and first follow-up mammogram). 
 
2.12 Secondary objective XIII 
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To examine the effect of anastrozole-induced first density reduction of ≥5% on breast 
cancer risk in different subgroups of covariates in the IBIS-II Prevention trial 
(subgroups: tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement use up 
to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time 
between baseline mammogram and first follow-up mammogram). 
 
3. PERSONNEL  
The major statistical analysis will be undertaken by Emma Atakpa at the Centre for 
Cancer Prevention, Wolfson Institute, Queen Mary University of London, London UK. 
 
4. TIMING OF ANALYSIS  
The major statistical analysis will begin in October 2018 (approximate date). 
 
5. STUDY PARTICIPANTS 
 
5.1 Eligible participants 
 The primary and secondary statistical analyses will include all randomised women with 
an appropriate baseline and first follow-up mammogram (within specified timeframes - 
see below, good quality - as assessed by the experienced radiologist, MLO view only) 
who are breast cancer-free at the time of their first follow-up mammogram. 
 
 Baseline mammograms will range from ≥0 months prior to the date of randomisation to 
<12.5 months prior to the date of randomisation. First follow-up mammograms will 
range from ≥8.5 months after the date of randomisation to <38.5 months after the date 
of randomisation. These time frames are in accordance with analysis from IBIS-I (19) 
and standard operating procedures for IBIS-II co-ordinating centres. 
 
 Only women with all mammograms of the same image type (i.e. all film or all digital) 
will be included. 
 
 Only women with ≥10% baseline density will be included. 
 
 Breast cancer-free ‘controls’ are defined as women who had not been diagnosed with 
breast cancer at the time of study design. ‘Cases’ are defined as women who had been 
clinically diagnosed with breast cancer at the time of study design. Cases will be 
included if they are diagnosed with breast cancer after their first follow-up 
mammogram. 
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 Contralateral mammograms will be used for cases and mammograms from a randomly 
selected breast side will be used for breast cancer-free controls. 
 
5.2 Sample size calculation 
The estimated distribution of IBIS-II cases and controls with <10% and ≥10% density 
reduction per treatment arm was calculated by weighting these distributions observed in 
IBIS-I (19) with hazard ratios from IBIS-I (200) and IBIS-II (208). The sample size 
from IBIS-I (19) was then weighted using chosen multipliers to obtain a variety of 
distributions for different sample sizes. The chosen sample sizes were 50, 100, 150 and 
200 cases, with 3 controls per 1 case. Using a difference of proportions sample size 
calculation, 247 cases and 1013 controls are required to show a difference in risk 
between anastrozole-treated patients experiencing ≥10% density change and 
anastrozole-treated patients experiencing <10% density change from baseline to first 
follow-up mammogram at the 5% type-I error level and with 80% power. This number 
also accounts for exclusions with baseline density <10% based on the number of 
postmenopausal women with baseline density <10% in IBIS-I. The study is currently 
underpowered since suitable mammograms (meeting the criteria outlined in section 5.1) 
have been received for only 35 breast-cancer cases and 938 breast cancer-free controls. 
With 35 cases and 105 controls (1:3 ratio of cases to controls), the power to detect a 
difference in risk of breast cancer in anastrozole-treated patients who experience a 
≥10% reduction in density at first follow-up mammogram relative to anastrozole-treated 
patients who experience a <10% reduction in density at first follow-up mammogram is 
22% at the 5% type-I error level. A sample size larger than this is currently 
impracticable given the resources and number of mammograms received. 
 
6. COVARIATES OF INTEREST 
 
6.1 Primary covariate of interest 
The primary covariate of interest is defined as the change in density from baseline 
mammogram to first follow-up mammogram (9-38 months post randomisation). 
Density will be visually-assessed by an experienced reader (Linda Metaxa) using 5% 
intervals, following the same method as in IBIS-I. Randomisation of mammograms will 
be per woman (so that mammograms for each woman will be read in comparison with 
the other mammograms for that woman), and mammograms will be ordered 
sequentially. For each woman, density at baseline will be read first, followed by first 
follow-up mammogram (compared with baseline mammogram). Density change will 
therefore be defined as the difference between baseline density and first follow-up 
 
417 
 
mammogram density; semi-continuously, dichotomised into <10% or ≥10% absolute 
reduction and <5% or ≥5% absolute reduction. The reader will be blinded to treatment 
group, case status and risk factors, and images will be appropriately anonymised. 
 
7. OUTCOMES 
 
7.1 Primary outcome 
The primary outcome is defined as the risk of developing breast cancer. 
 
8. STATISTICAL METHODS  
 
8.1 Hypotheses to be tested 
 
8.1.1 Primary hypothesis 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥10% reduction in density at first follow-up mammogram and 
anastrozole-treated patients who experience a <10% reduction in density at first follow-up 
mammogram 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a 
≥10% reduction in density at first follow-up mammogram is different to age-adjusted risk of 
breast cancer in anastrozole-treated patients who experience a <10% reduction in density at 
first follow-up mammogram 
 
8.1.2 Secondary hypothesis I 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥5% reduction in density at first follow-up mammogram and 
anastrozole-treated patients who experience a <5% reduction in density at first follow-up 
mammogram 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a ≥5% 
reduction in density at first follow-up mammogram is different to age-adjusted risk of breast 
cancer in anastrozole-treated patients who experience a <5% reduction in density at first 
follow-up mammogram 
 
8.1.3 Secondary hypothesis II 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥10% reduction in density at first follow-up mammogram and anastrozole-
treated patients who experience a <10% reduction in density at first follow-up 
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mammogram, after adjustment for age at randomisation, body mass index at randomisation, 
baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥10% reduction 
in density at first follow-up mammogram is different to risk of breast cancer in anastrozole-
treated patients who experience a <10% reduction in density at first follow-up 
mammogram, after adjustment for age at randomisation, body mass index at randomisation, 
baseline density, and Tyrer-Cuzick 10-year risk. 
 
8.1.4 Secondary hypothesis III 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥5% reduction in density at first follow-up mammogram and anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram, 
after adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥5% reduction in 
density at first follow-up mammogram is different to risk of breast cancer in anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram, 
after adjustment for age at randomisation, body mass index at randomisation, baseline 
density, and Tyrer-Cuzick 10-year risk. 
 
8.1.5 Secondary hypothesis IV 
 H0: There is no difference in the age-adjusted effect of ≥10% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <10% reduction) between 
anastrozole-treated patients and placebo-treated patients. 
 H1: The age-adjusted effect of ≥10% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <10% reduction) in anastrozole-treated patients is different to 
the age-adjusted effect of ≥10% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <10% reduction) in placebo-treated patients. 
 
8.1.6 Secondary hypothesis V 
 H0: There is no difference in the age-adjusted effect of ≥5% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <5% reduction) between 
anastrozole-treated patients and placebo-treated patients. 
 H1: The age-adjusted effect of ≥5% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <5% reduction) in anastrozole-treated patients is different to 
the age-adjusted effect of ≥5% reduction in density at first follow-up mammogram on 
breast cancer risk (relative to <5% reduction) in placebo-treated patients. 
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8.1.7 Secondary hypothesis VI 
 H0: There is no difference in the effect of ≥10% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <10% reduction) between anastrozole-treated 
patients and placebo-treated patients, after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: The effect of ≥10% reduction in density at first follow-up mammogram on breast 
cancer risk (relative to <10% reduction) in anastrozole-treated patients is different to the 
effect of ≥10% reduction in density at first follow-up mammogram on breast cancer risk 
(relative to <10% reduction) in placebo-treated patients, after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and Tyrer-Cuzick 10-
year risk. 
 
8.1.8 Secondary hypothesis VII 
 H0: There is no difference in the effect of ≥5% reduction in density at first follow-up 
mammogram on breast cancer risk (relative to <5% reduction) between anastrozole-treated 
patients and placebo-treated patients, after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: The effect of ≥5% reduction in density at first follow-up mammogram on breast cancer 
risk (relative to <5% reduction) in anastrozole-treated patients is different to the effect of 
≥5% reduction in density at first follow-up mammogram on breast cancer risk (relative to 
<5% reduction) in placebo-treated patients, after adjustment for age at randomisation, body 
mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
8.1.9 Secondary hypothesis VIII 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥10% reduction in density at first follow-up mammogram and 
placebo-treated patients, and there is no difference in age-adjusted risk of breast cancer 
between anastrozole-treated patients who experience a <10% reduction in density at first 
follow-up mammogram and placebo-treated patients. 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a 
≥10% reduction in density at first follow-up mammogram is different to age-adjusted risk of 
breast cancer in placebo-treated patients, and age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a <10% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in placebo-treated patients. 
 
8.1.10 Secondary hypothesis IX 
 H0: There is no difference in age-adjusted risk of breast cancer between anastrozole-treated 
patients who experience a ≥5% reduction in density at first follow-up mammogram and 
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placebo-treated patients, and there is no difference in age-adjusted risk of breast cancer 
between anastrozole-treated patients who experience a <5% reduction in density at first 
follow-up mammogram and placebo-treated patients 
 H1: Age-adjusted risk of breast cancer in anastrozole-treated patients who experience a ≥5% 
reduction in density at first follow-up mammogram is different to age-adjusted risk of breast 
cancer in placebo-treated patients, and age-adjusted risk of breast cancer in anastrozole-
treated patients who experience a <5% reduction in density at first follow-up mammogram 
is different to age-adjusted risk of breast cancer in placebo-treated patients. 
 
8.1.11 Secondary hypothesis X 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥10% reduction in density at first follow-up mammogram and placebo-treated 
patients, and there is no difference in risk of breast cancer between anastrozole-treated 
patients who experience a <10% reduction in density at first follow-up mammogram and 
placebo-treated patients, after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥10% reduction 
in density at first follow-up mammogram is different to risk of breast cancer in placebo-
treated patients, and risk of breast cancer in anastrozole-treated patients who experience a 
<10% reduction in density at first follow-up mammogram is different to risk of breast 
cancer in placebo-treated patients, after adjustment for age at randomisation, body mass 
index at randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
8.1.12 Secondary hypothesis XI 
 H0: There is no difference in risk of breast cancer between anastrozole-treated patients who 
experience a ≥5% reduction in density at first follow-up mammogram and placebo-treated 
patients, and there is no difference in risk of breast cancer between anastrozole-treated 
patients who experience a <5% reduction in density at first follow-up mammogram and 
placebo-treated patients, after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 H1: Risk of breast cancer in anastrozole-treated patients who experience a ≥5% reduction in 
density at first follow-up mammogram is different to risk of breast cancer in placebo-treated 
patients, and risk of breast cancer in anastrozole-treated patients who experience a <5% 
reduction in density at first follow-up mammogram is different to risk of breast cancer in 
placebo-treated patients, after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
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8.1.13 Secondary hypothesis XII 
 H0: There is no difference in breast cancer risk between subgroups of covariates (tumour ER 
status, age at randomisation, body mass index at randomisation, baseline density, history of 
atypical hyperplasia or LCIS, hormone replacement use up to 12 months before 
randomisation, Tyrer-Cuzick 10-year risk, image type, and time between baseline 
mammogram and first follow-up mammogram) in women who experience an anastrozole-
induced ≥10% reduction in density from baseline to first follow-up mammogram. 
 H1: Breast cancer risk in women who experience an anastrozole-induced ≥10% reduction in 
density from baseline to first follow-up mammogram is different between subgroups of 
covariates (tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement use up to 12 
months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time between 
baseline mammogram and first follow-up mammogram). 
 
8.1.14 Secondary hypothesis XIII 
 H0: There is no difference in breast cancer risk between subgroups of covariates (tumour ER 
status, age at randomisation, body mass index at randomisation, baseline density, history of 
atypical hyperplasia or LCIS, hormone replacement use up to 12 months before 
randomisation, Tyrer-Cuzick 10-year risk, image type, and time between baseline 
mammogram and first follow-up mammogram) in women who experience an anastrozole-
induced ≥5% reduction in density from baseline to first follow-up mammogram. 
 H1: Breast cancer risk in women who experience an anastrozole-induced ≥5% reduction in 
density from baseline to first follow-up mammogram is different between subgroups of 
covariates (tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone replacement use up to 12 
months before randomisation, Tyrer-Cuzick 10-year risk, image type, and time between 
baseline mammogram and first follow-up mammogram). 
 
8.2 Analysis methods 
All statistical analysis will be conducted in STATA 13. All tests (see below) will be two-
sided with a significance level of 5%. Results will be omitted if subgroup numbers are small 
enough in order to un-blind the statistician. 
 
8.2.1 Baseline characteristics and risk 
The following baseline characteristics will be summarised in a frequency table by 
treatment arm and case status, along with univariate and multivariable odds ratios for 
risk of developing breast cancer. Frequency counts & percentages will be provided for 
categorical data and means (standard deviation, SD) and medians (interquartile range, 
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IQR) will be provided for continuous data. Two-sample t-tests (STATA’s “ttest” 
command) and Wilcoxon rank sum tests (STATA’s “ranksum” command) will test 
differences between cases and controls in continuous data and Pearson chi-squared tests 
(STATA’s “tab, chi2” command) will test differences between cases and controls in 
categorical data: 
 
 Age at randomisation (mean (SD), median (IQR)) 
 Body Mass Index (BMI) at randomisation (mean (SD), median (IQR)) 
 Age at menarche (mean (SD), median (IQR)) 
 Age at menopause (mean (SD), median (IQR)) 
 Tyrer-Cuzick 10-year risk (mean (SD), median (IQR)) 
 Baseline density (mean (SD), median (IQR)) 
 Age at first birth (nulliparous/>27/21-27/≤20) 
 Oral contraception use (never/previously/currently) 
 Hormone Replacement Therapy (HRT) use up to 12 months before randomisation 
(no/yes) 
 Smoking status (never/former/current) 
 History of atypical hyperplasia or LCIS (no/yes) 
 Image type (film/digital) 
 
 Univariate logistic regression models of risk of breast cancer on baseline covariates, 
adjusted for age at randomisation (except age at randomisation): n, odds ratio, 95% 
confidence interval, P-value. 
STATA’s “logistic” command 
 Multivariable logistic regression models of risk of breast cancer on baseline covariates. 
All covariates will be included in the multivariable model: n, odds ratio, 95% 
confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.2 Primary analysis  
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<10% absolute reduction and ≥10% absolute reduction; reference group: <10% absolute 
reduction) and age at randomisation in anastrozole-treated patients: n, odds ratio, 95% 
confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.3 Secondary analysis I 
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 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<5% absolute reduction and ≥5% absolute reduction; reference group: <5% absolute 
reduction) and age at randomisation in anastrozole-treated patients: n, odds ratio, 95% 
confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.4 Secondary analysis II 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<10% absolute reduction and ≥10% absolute reduction; reference group: <10% absolute 
reduction) in anastrozole-treated patients, adjusted for covariates. All covariates will be 
included in the multivariable model: n, odds ratios, 95% confidence intervals, P-values. 
STATA’s “logistic” command 
 
8.2.5 Secondary analysis III 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<5% absolute reduction and ≥5% absolute reduction; reference group: <5% absolute 
reduction) in anastrozole-treated patients, adjusted for covariates. All covariates will be 
included in the multivariable model: n, odds ratios, 95% confidence intervals, P-values. 
STATA’s “logistic” command 
 
8.2.6 Secondary analysis IV 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<10% absolute reduction and ≥10% absolute reduction), treatment and an interaction 
between both, and age at randomisation: n, odds ratios, 95% confidence intervals, P-
values. 
STATA’s “logistic” command 
 
8.2.7 Secondary analysis V 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<5% absolute reduction and ≥5% absolute reduction), treatment and an interaction 
between both, and age at randomisation: n, odds ratios, 95% confidence intervals, P-
values. 
STATA’s “logistic” command 
 
8.2.8 Secondary analysis VI 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<10% absolute reduction and ≥10% absolute reduction), treatment and an interaction 
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between both, adjusted for covariates. All covariates will be included in the 
multivariable model: n, odds ratios, 95% confidence intervals, P-values. 
STATA’s “logistic” command 
 
8.2.9 Secondary analysis VII 
 Logistic regression model of breast cancer risk on change in density (dichotomised into 
<5% absolute reduction and ≥5% absolute reduction), treatment and an interaction 
between both, adjusted for covariates. All covariates will be included in the 
multivariable model: n, odds ratios, 95% confidence intervals, P-values. 
STATA’s “logistic” command 
 
8.2.10 Secondary analysis VIII 
 Logistic regression model of breast cancer risk on a variable for change in density and 
treatment (factorised into: anastrozole-induced <10% absolute reduction, anastrozole-
induced ≥10% absolute reduction, and placebo; reference category: placebo) and age at 
randomisation: n, odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.11 Secondary analysis IX 
 Logistic regression model of breast cancer risk on a variable for change in density and 
treatment (factorised into: anastrozole-induced <5% absolute reduction, anastrozole-
induced ≥5% absolute reduction, and placebo; reference category: placebo) and age at 
randomisation: n, odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.12 Secondary analysis X 
 Logistic regression model of breast cancer risk on a variable for change in density and 
treatment (factorised into: anastrozole-induced <10% absolute reduction, anastrozole-
induced ≥10% absolute reduction, and placebo; reference category: placebo), adjusted 
for covariates. All covariates will be included in the multivariable model: n, odds ratio, 
95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.13 Secondary analysis XI 
 Logistic regression model of breast cancer risk on a variable for change in density and 
treatment (factorised into: anastrozole-induced <5% absolute reduction, anastrozole-
induced ≥5% absolute reduction, and placebo; reference category: placebo), adjusted for 
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covariates. All covariates will be included in the multivariable model: n, odds ratio, 
95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.14 Secondary analysis XII 
 Odds ratios to assess the odds of breast cancer for anastrozole-induced ≥10% density 
reduction in each subgroup (relative to a reference subgroup), in the anastrozole arm 
only: n, odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.15 Secondary analysis XIII 
 Odds ratios to assess the odds of breast cancer for anastrozole-induced ≥5% density 
reduction in each subgroup (relative to a reference subgroup), in the anastrozole arm 
only: n, odds ratio, 95% confidence interval, P-value. 
STATA’s “logistic” command 
 
8.2.12 Adjustment covariates 
The following covariates will be included in adjusted regression models (8.2.4, 8.2.5, 
8.2.8 & 8.2.9): 
 
 Age at randomisation (continuous) 
 BMI at randomisation (continuous) 
 Baseline density (continuous) 
 Tyrer-Cuzick 10-year risk (continuous) 
 
Time on treatment will not be included in adjustments because an intention-to-treat 
analysis will be conducted. 
 
8.2.13 Subgroup covariates 
The following covariates will be considered in subgroup analyses (8.2.10 & 8.2.11): 
 
 Tumour ER status (negative/positive) 
 Age at randomisation (<median age, ≥median age) 
 BMI at randomisation (<median BMI, ≥median BMI) 
 Baseline density (<median baseline density, ≥median baseline density) 
 History of atypical hyperplasia or LCIS (no/yes) 
 HRT use up to 12 months before randomisation (no/yes) 
 Tyrer-Cuzick 10-year risk (<median risk, ≥median risk) 
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 Image type (film/digital) 
 Time between baseline and first mammogram (<median time between baseline and first 
mammogram, ≥median time between baseline and first mammogram) 
 
8.2.14 Sensitivity analysis for compliance  
It is possible that the greater reduction in breast cancer risk we might observe in 
subjects from the anastrozole arm who experience a density reduction of at least 10% or 
5% (compared with similar women who experience <10% or <5% density reduction) 
reflects better treatment compliance and is not a measure of biological response to 
treatment. To test this, we will use Kaplan–Meier curves (censored ~3 months (90 days) 
before cancer diagnosis) (STATA’s “sts graph” command) and log rank tests (STATA’s 
“sts test, logrank” command) to assess the difference in time to stopping treatment 
between cases on anastrozole with ≥10% vs. <10% reduction in density and ≥5% vs. 
<5% reduction in density. 
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8.3 Tables 
 
Table 1: Baseline characteristics by case status and treatment, with odds ratios (ORs) for the risk of developing breast cancer from univariate and multivariable 
logistic regression models. *P-value from two-sample t-test, **p-value from Wilcoxon rank sum test, ***p-value from logistic regression model Wald test of 
covariate, +++p-value from Pearson chi-squared test of association. +OR represents odds of breast cancer per unit increase in covariate, ++OR represents odds of breast 
cancer relative to the reference category. #All univariate models (except that for age at randomisation) are adjusted for age at randomisation. ##Multivariable models 
include all variables. N=. 
 
 
Variable 
All Placebo Anastrozole 
Cases Controls Univariate 
OR (95% 
CI) 
***#
 
Multivariable 
OR (95% CI) 
***##
 
Cases Controls Univariate 
OR (95% 
CI) 
***#
 
Multivariable 
OR (95% CI) 
***##
 
Cases Controls Univariate 
OR (95% 
CI) 
***#
 
Multivariable 
OR (95% CI) 
***##
 
Mean 
(SD)* 
Median 
(IQR)** 
Mean 
(SD)* 
Median 
(IQR)** 
Mean 
(SD)* 
Median 
(IQR)** 
Mean 
(SD)* 
Median 
(IQR)** 
Mean 
(SD)* 
Median 
(IQR)** 
Mean 
(SD)* 
Median 
(IQR)** 
Age at 
randomisation+ 
(y r) 
                  
P                   
Body  Mass 
Index+ (kg/m 2) 
                  
P                   
Baseline 
density + (%) 
                  
P                   
Ty rer-Cuzick 
10-year risk+ 
(%) 
                  
                   
 N+++ % N+++ %   N+++ % N+++ %   N+++ % N+++ %   
History  of 
atypical 
hyperplasia or 
LCIS++ 
                  
No     Ref Ref     Ref Ref     Ref Ref 
Yes                   
P                   
HRT use up to 
12 months 
before 
randomisation ++ 
                  
No     Ref Ref     Ref Ref     Ref Ref 
Yes                   
P                   
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 Number of women 
Boyd 
category at 
entry 
Boyd category at first follow-up: Cases Total Boyd category at first follow-up: Controls Total 
 0% 1-10% 11-25% 26-50% 51-75% 76-100%  0% 1-10% 11-25% 26-50% 51-75% 76-100%  
0%               
1-10%               
11-25%               
26-50%               
51-75%               
76-100%               
Total               
Table 2: Cross tabulation of number of women in each Boyd category at entry to the study with category at first follow-up, by case status. The first number in each 
cell is the total number of subjects. Numbers in parentheses are the placebo and anastrozole groups, respectively. 
 
Change in breast 
density, No. (%) 
Placebo Anastrozole 
Cases (N=) Controls (N=) Cases (N=) Controls (N=) 
Mean (SD)     
Median (IQR)     
<5% reduction     
≥5% reduction     
<10% reduction     
≥10% reduction     
P trend     
Table 3: Density change by treatment and case status. P-value from Wald test of change in density from a logistic regression model of breast cancer risk on change 
in density (semi-continuous) in each treatment arm. 
 
429 
 
 
Table 4: Logistic regression results for risk of breast cancer on first change in density (dichotomised into <5% reduction or ≥5% reduction, and <10% reduction or 
≥10% reduction) in anastrozole arm only, in univariate and adjusted models. *OR represents odds of breast cancer relative to the reference category, **OR 
represents odds of breast cancer per unit increase in covariate. #Multivariable models include all variables. +Additionally adjusted for age at randomisation in 
univariate model. P-values from logistic regression model Wald test. N=. 
 
 
 
 
 
 
 
 
 
 
Variable 
≥5% reduction ≥10% reduction 
N 
Univariate Adjusted# 
N 
Univariate Adjusted# 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Density change*+           
<5% reduction  Ref Ref Ref Ref  - - - - 
≥5% reduction       - - - - 
<10% reduction  - - - -  Ref Ref Ref Ref 
≥10% reduction  - - - -      
Age at randomisation (yr)**           
BMI at randomisation (kg/m2)**           
Baseline density (%)**           
Tyrer-Cuzick 10-year risk (%)**           
 
430 
 
 
Table 5: Logistic regression results for risk of breast cancer on first change in density (dichotomised into <5% reduction or ≥5% reduction, and <10% reduction or 
≥10% reduction) in anastrozole-treated women relative to all women in the placebo arm, in univariate and adjusted models. *OR represents odds of breast cancer 
relative to all women in the placebo arm, **OR represents odds of breast cancer per unit increase in covariate. #Multivariable models include all variables. 
+Additionally adjusted for age at randomisation in univariate model. P-values from logistic regression model Wald test. N=. 
 
Variable 
No. of control 
subjects/No. of case 
subjects 
Anastrozole, density reduction ≥5% P
###
 Anastrozole, density reduction ≥10% P
###
 
No. of case 
subjects 
OR
#
 (95% CI)  
No. of case 
subjects 
OR
##
 (95% 
CI) 
 
Overall        
Tumour ER status        
Negative        
Positive        
Age at randomisation (yr)*        
Younger age at randomisation        
Older age at randomisation        
Body Mass Index (kg/m
2
)*        
Lower Body Mass Index        
Higher Body Mass Index        
Baseline density*        
Lower baseline density        
Variable 
<5% or ≥5% reduction <10% or ≥10% reduction 
N 
Univariate Adjusted# 
N 
Univariate Adjusted# 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
OR 
(95% CI) 
P-value 
Density change*+           
<5% reduction       - - - - 
≥5% reduction       - - - - 
<10% reduction  - - - -      
≥10% reduction  - - - -      
Age at randomisation (yr)**           
BMI at randomisation (kg/m2)**           
Baseline density (%)**           
Tyrer-Cuzick 10-year risk (%)**           
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Higher baseline density        
History of atypical hyperplasia or LCIS        
No        
Yes        
HRT use up to 12 months before randomisation        
No        
Yes        
Tyrer-Cuzick 10-year risk (%)*        
Lower Tyrer-Cuzick 10-year risk        
Higher Tyrer-Cuzick 10-year risk        
Image type        
Film        
Digital        
Time between baseline mammogram and first 
follow-up mammogram (yr)* 
       
Shorter time between mammograms        
Longer time between mammograms        
Table 6: Risk of breast cancer on anastrozole-induced first change in density by subgroups of covariates. *Continuous variables dichotomised by median of variable 
in all women, #OR represents odds of developing breast cancer for women with ≥5% density reduction (relative to women with <5% density reduction) in different 
subgroups. ##OR represents odds of developing breast cancer for women with ≥10% density reduction (relative to women with <10% density reduction) in different 
subgroups. ###P-values from a Wald test. 
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C.XXVI Proforma for Chapter 6 
 
Request 
Originator: 
 
Ms Emma Atakpa 
PhD student, Centre for Cancer Prevention, Wolfson Institute 
 
Supervisors: 
Professor Jack Cuzick 
Dr Adam Brentnall 
Reason for 
request: 
To complete an analysis assessing anastrozole-induced change in 
mammographic density as a biomarker for breast cancer risk in patients from the 
IBIS-II Prevention trial. 
Background: Mammographic density (herein referred to as ‘density’) is one of the strongest 
known risk factors for breast cancer. Women in the highest density category 
(≥75%) are at a 4 to 6-fold increased risk of developing breast cancer relative to 
those with little or no density (79). 
 
Whilst postmenopausal hormone replacement therapy (HRT) is associated with 
an increase in risk of breast cancer (424) and density (188, 193); selective 
oestrogen receptor modulators (SERMs), such as tamoxifen, decrease risk (198, 
199, 425) and density (203-205). Most importantly, high-risk women who 
experienced ≥10% density reduction after approximately 18 months of 
prophylactic tamoxifen were shown to be at approximately 68% lower risk of 
developing breast cancer compared with women who experienced <10% density 
reduction after the same treatment in the IBIS-I trial (19). This makes 
tamoxifen-induced density reduction a potential biomarker for risk reduction. 
 
Similar to SERMs, aromatase inhibitors (AIs) are an anti-oestrogenic drug given 
to women in the treatment of breast cancer. In 2014, analysis from IBIS-II 
showed that anastrozole (an AI) reduced the risk of breast cancer in high-risk 
postmenopausal women (208). It is not yet known whether anastrozole-induced 
density reduction can also be used as a biomarker for risk reduction, whereby a 
≥10% reduction in density after approximately 18 months of preventive 
anastrozole treatment would be associated with a lower risk of breast cancer 
compared with <10% density reduction after the same treatment. 
Aims: 
 
 
 Primary objective: To determine whether women on anastrozole who 
experience a ≥10% reduction in density at first follow-up mammogram have 
a different level of age-adjusted risk of breast cancer than women on 
anastrozole who experience a <10% reduction in density at first follow-up 
mammogram in the IBIS-II Prevention trial. 
 Primary hypothesis: Age-adjusted risk of breast cancer in anastrozole-
treated patients who experience a ≥10% reduction in density at first follow-
up mammogram is different to age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a <10% reduction in density at 
first follow-up mammogram. 
 
 Secondary objective I: To determine whether women on anastrozole who 
experience a ≥5% reduction in density at first follow-up mammogram have 
a different level of age-adjusted risk of breast cancer than women on 
anastrozole who experience a <5% reduction in density at first follow-up 
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mammogram in the IBIS-II Prevention trial. 
 Secondary hypothesis I: Age-adjusted risk of breast cancer in anastrozole-
treated patients who experience a ≥5% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a <5% reduction in density at 
first follow-up mammogram. 
 
 Secondary objective II: To determine whether women on anastrozole who 
experience a ≥10% reduction in density at first follow-up mammogram have 
a different level of risk of breast cancer than women on anastrozole who 
experience a <10% reduction in density at first follow-up mammogram in 
the IBIS-II Prevention trial, after adjustment for age at randomisation, body 
mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year 
risk. 
 Secondary hypothesis II: Risk of breast cancer in anastrozole-treated 
patients who experience a ≥10% reduction in density at first follow-up 
mammogram is different to risk of breast cancer in anastrozole-treated 
patients who experience a <10% reduction in density at first follow-up 
mammogram, after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
 Secondary objective III: To determine whether women on anastrozole who 
experience a ≥5% reduction in density at first follow-up mammogram have 
a different level of risk of breast cancer than women on anastrozole who 
experience a <5% reduction in density at first follow-up mammogram in the 
IBIS-II Prevention trial, after adjustment for age at randomisation, body 
mass index at randomisation, baseline density, and Tyrer-Cuzick 10-year 
risk. 
 Secondary hypothesis III: Risk of breast cancer in anastrozole-treated 
patients who experience a ≥5% reduction in density at first follow-up 
mammogram is different to risk of breast cancer in anastrozole-treated 
patients who experience a <5% reduction in density at first follow-up 
mammogram, after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
 Secondary objective IV: To determine whether the age-adjusted effect of 
≥10% reduction in density at first follow-up mammogram on breast cancer 
risk (relative to <10% reduction) is different between anastrozole-treated 
and placebo-treated patients (interaction test for anastrozole-induced density 
change as a predictive biomarker for breast cancer risk reduction). 
 Secondary hypothesis IV: The age-adjusted effect of ≥10% reduction in 
density at first follow-up mammogram on breast cancer risk (relative to 
<10% reduction) in anastrozole-treated patients is different to the age-
adjusted effect of ≥10% reduction in density at first follow-up mammogram 
on breast cancer risk (relative to <10% reduction) in placebo-treated 
patients. 
 
 Secondary objective V: To determine whether the age-adjusted effect of 
≥5% reduction in density at first follow-up mammogram on breast cancer 
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risk (relative to <5% reduction) is different between anastrozole-treated and 
placebo-treated patients (interaction test for anastrozole-induced density 
change as a predictive biomarker for breast cancer risk reduction). 
 Secondary hypothesis V: The age-adjusted effect of ≥5% reduction in 
density at first follow-up mammogram on breast cancer risk (relative to 
<5% reduction) in anastrozole-treated patients is different to the age-
adjusted effect of ≥5% reduction in density at first follow-up mammogram 
on breast cancer risk (relative to <5% reduction) in placebo-treated patients. 
 
 Secondary objective VI: To determine whether the effect of ≥10% reduction 
in density at first follow-up mammogram on breast cancer risk (relative to 
<10% reduction) is different between anastrozole-treated and placebo-
treated patients (interaction test for anastrozole-induced density change as a 
predictive biomarker for breast cancer risk reduction), after adjustment for 
age at randomisation, body mass index at randomisation, baseline density, 
and Tyrer-Cuzick 10-year risk. 
 Secondary hypothesis VI: The effect of ≥10% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <10% reduction) in 
anastrozole-treated patients is different to the effect of ≥10% reduction in 
density at first follow-up mammogram on breast cancer risk (relative to 
<10% reduction) in placebo-treated patients, after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 Secondary objective VII: To determine whether the effect of ≥5% reduction 
in density at first follow-up mammogram on breast cancer risk (relative to 
<5% reduction) is different between anastrozole-treated and placebo-treated 
patients (interaction test for anastrozole-induced density change as a 
predictive biomarker for breast cancer risk reduction), after adjustment for 
age at randomisation, body mass index at randomisation, baseline density, 
and Tyrer-Cuzick 10-year risk. 
 Secondary hypothesis VII: The effect of ≥5% reduction in density at first 
follow-up mammogram on breast cancer risk (relative to <5% reduction) in 
anastrozole-treated patients is different to the effect of ≥5% reduction in 
density at first follow-up mammogram on breast cancer risk (relative to 
<5% reduction) in placebo-treated patients, after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 Secondary objective VIII: To determine whether women on anastrozole who 
experience a ≥10% reduction in density at first follow-up mammogram have 
a different level of age-adjusted risk of breast cancer than women on 
placebo, and whether women on anastrozole who experience a <10% 
reduction in density at first follow-up mammogram have a different level of 
age-adjusted risk of breast cancer than women on placebo in the IBIS-II 
Prevention trial (test for anastrozole-induced density change as a predictive 
biomarker for breast cancer risk reduction). 
 Secondary hypothesis VIII: Age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a ≥10% reduction in density at 
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first follow-up mammogram is different to age-adjusted risk of breast cancer 
in placebo-treated patients, and age-adjusted risk of breast cancer in 
anastrozole-treated patients who experience a <10% reduction in density at 
first follow-up mammogram is different to age-adjusted risk of breast cancer 
in placebo-treated patients. 
 
 Secondary objective IX: To determine whether women on anastrozole who 
experience a ≥5% reduction in density at first follow-up mammogram have 
a different level of age-adjusted risk of breast cancer than women on 
placebo, and whether women on anastrozole who experience a <5% 
reduction in density at first follow-up mammogram have a different level of 
age-adjusted risk of breast cancer than women on placebo in the IBIS-II 
Prevention trial (test for anastrozole-induced density change as a predictive 
biomarker for breast cancer risk reduction). 
 Secondary hypothesis IX: Age-adjusted risk of breast cancer in anastrozole-
treated patients who experience a ≥5% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in placebo-
treated patients, and age-adjusted risk of breast cancer in anastrozole-treated 
patients who experience a <5% reduction in density at first follow-up 
mammogram is different to age-adjusted risk of breast cancer in placebo-
treated patients. 
 
 Secondary objective X: To determine whether women on anastrozole who 
experience a ≥10% reduction in density at first follow-up mammogram have 
a different level of risk of breast cancer than women on placebo, and 
whether women on anastrozole who experience a <10% reduction in density 
at first follow-up mammogram have a different level of risk of breast cancer 
than women on placebo in the IBIS-II Prevention trial (test for anastrozole-
induced density change as a predictive biomarker for breast cancer risk 
reduction), after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 Secondary hypothesis X: Risk of breast cancer in anastrozole-treated 
patients who experience a ≥10% reduction in density at first follow-up 
mammogram is different to risk of breast cancer in placebo-treated patients, 
and risk of breast cancer in anastrozole-treated patients who experience a 
<10% reduction in density at first follow-up mammogram is different to risk 
of breast cancer in placebo-treated patients, both after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 Secondary objective XI: To determine whether women on anastrozole who 
experience a ≥5% reduction in density at first follow-up mammogram have 
a different level of risk of breast cancer than women on placebo, and 
whether women on anastrozole who experience a <5% reduction in density 
at first follow-up mammogram have a different level of risk of breast cancer 
than women on placebo in the IBIS-II Prevention trial (test for anastrozole-
induced density change as a predictive biomarker for breast cancer risk 
reduction), after adjustment for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
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 Secondary hypothesis XI: Risk of breast cancer in anastrozole-treated 
patients who experience a ≥5% reduction in density at first follow-up 
mammogram is different to risk of breast cancer in placebo-treated patients, 
and risk of breast cancer in anastrozole-treated patients who experience a 
<5% reduction in density at first follow-up mammogram is different to risk 
of breast cancer in placebo-treated patients, both after adjustment for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 Secondary objective XII: To examine the effect of anastrozole-induced first 
density reduction of ≥10% on breast cancer risk in different subgroups of 
covariates in the IBIS-II Prevention trial (covariates to be split into 
subgroups are: tumour ER status, age at randomisation, body mass index at 
randomisation, baseline density, history of atypical hyperplasia or LCIS, 
hormone replacement use up to 12 months before randomisation, Tyrer-
Cuzick 10-year risk, image type, and time between baseline mammogram 
and first follow-up mammogram). 
 Secondary hypothesis XII: Breast cancer risk in women who experience an 
anastrozole-induced ≥10% reduction in density from baseline to first follow-
up mammogram is different between subgroups of covariates (tumour ER 
status, age at randomisation, body mass index at randomisation, baseline 
density, history of atypical hyperplasia or LCIS, hormone replacement use 
up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image 
type, and time between baseline mammogram and first follow-up 
mammogram). 
 
 Secondary objective XIII: To examine the effect of anastrozole-induced first 
density reduction of ≥5% on breast cancer risk in different subgroups of 
covariates in the IBIS-II Prevention trial (covariates to be split into 
subgroups are: tumour ER status, age at randomisation, body mass index at 
randomisation, baseline density, history of atypical hyperplasia or LCIS, 
hormone replacement use up to 12 months before randomisation, Tyrer-
Cuzick 10-year risk, image type, and time between baseline mammogram 
and first follow-up mammogram). 
 Secondary hypothesis XIII: Breast cancer risk in women who experience an 
anastrozole-induced ≥5% reduction in density from baseline to first follow-
up mammogram is different between subgroups of covariates (tumour ER 
status, age at randomisation, body mass index at randomisation, baseline 
density, history of atypical hyperplasia or LCIS, hormone replacement use 
up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image 
type, and time between baseline mammogram and first follow-up 
mammogram). 
Data 
required: 
 
 
Suitable mammograms (within the following specified timeframes, before breast 
cancer diagnosis, MLO view, deemed to be good quality) have been received for 
35 breast-cancer cases and 938 breast cancer-free controls. Baseline (up to 12 
months before randomisation) and first follow-up (9-38 months post 
randomisation) mammograms for these 973 women were batched and sent to a 
radiologist at St Bartholomew’s hospital for density scoring. 
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The study is currently underpowered. With 35 cases and 105 controls (1:3 ratio 
of cases to controls), the power to detect a difference in risk of breast cancer in 
anastrozole-treated patients who experience a ≥10% reduction in density at first 
follow-up mammogram relative to anastrozole-treated patients who experience a 
<10% reduction in density at first follow-up mammogram is 22% at the 5% 
type-I error level (please see ‘Other comments’). 
 
Since the requestor is blinded to treatment allocation, a set of STATA code will 
be sent to Dr Sestak to run on the un-blinded data for these 973 women. 
 
Describe the 
specific 
analyses or 
tables 
requested: 
Methods: 
 
 Mammograms were visually assessed by a radiologist (Dr Metaxa) at St 
Bartholomew’s hospital. 
 Each mammogram was scored in 5% increments, following the same 
method as in IBIS-I. 
 Contralateral mammograms were used for cases and mammograms from a 
randomly selected breast side were used for breast cancer-free controls. 
 Density change will be defined as the difference between baseline and first 
follow-up mammogram. 
 Only women with ≥10% baseline density will be included. 
 Only women with all mammograms of the same image type (i.e. all film or 
all digital) will be included. 
 
Statistical analysis: 
 
 Baseline characteristics will be summarised by treatment arm and case 
status using frequency tables with age at randomisation, body mass index at 
randomisation, age at menarche, age at menopause, Tyrer-Cuzick 10-year 
risk, baseline density, age at first birth, oral contraception use, hormone 
replacement therapy use up to 12 months before randomisation, smoking 
status, history of atypical hyperplasia or LCIS, and image type. An 
exploratory analysis will also assess the association between risk of 
developing breast cancer and baseline characteristics using univariate 
(adjusted for age at randomisation) and multivariable logistic regression. 
 
 The primary analysis will use a logistic regression model to examine the 
association between risk of breast cancer and anastrozole-induced ≥10% 
first follow-up density reduction (relative to anastrozole-induced <10% 
absolute reduction), adjusted for age at randomisation, in anastrozole-treated 
patients. 
 
 The secondary analysis (I) will use a logistic regression model to examine 
the association between risk of breast cancer and anastrozole-induced ≥5% 
first follow-up density reduction (relative to anastrozole-induced <5% 
absolute reduction), adjusted for age at randomisation, in anastrozole-treated 
patients. 
 
 The secondary analysis (II) will use a logistic regression model to examine 
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the association between risk of breast cancer and anastrozole-induced ≥10% 
first follow-up density reduction (relative to anastrozole-induced <10% 
absolute reduction), adjusted for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk; in 
anastrozole-treated patients. 
 
 The secondary analysis (III) will use a logistic regression model to examine 
the association between risk of breast cancer and anastrozole-induced ≥5% 
first follow-up density reduction (relative to anastrozole-induced <5% 
absolute reduction), adjusted for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk; in 
anastrozole-treated patients. 
 
 The secondary analysis (IV) will use a logistic regression model to examine 
the association between risk of breast cancer and first follow-up density 
reduction (dichotomised into <10% absolute reduction and ≥10% absolute 
reduction), treatment and an interaction between density reduction and 
treatment, adjusted for age at randomisation. 
 
 The secondary analysis (V) will use a logistic regression model to examine 
the association between risk of breast cancer and first follow-up density 
reduction (dichotomised into <5% absolute reduction and ≥5% absolute 
reduction), treatment and an interaction between density reduction and 
treatment, adjusted for age at randomisation. 
 
 The secondary analysis (VI) will use a logistic regression model to examine 
the association between risk of breast cancer and first follow-up density 
reduction (dichotomised into <10% absolute reduction and ≥10% absolute 
reduction), treatment and an interaction between density reduction and 
treatment, adjusted for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
 The secondary analysis (VII) will use a logistic regression model to examine 
the association between risk of breast cancer and first follow-up density 
reduction (dichotomised into <5% absolute reduction and ≥5% absolute 
reduction), treatment and an interaction between density reduction and 
treatment, adjusted for age at randomisation, body mass index at 
randomisation, baseline density, and Tyrer-Cuzick 10-year risk. 
 
 The secondary analysis (VIII) will use a logistic regression model to 
examine the association between risk of breast cancer and anastrozole-
induced ≥10% first follow-up density reduction (relative to placebo-treated 
women), and risk of breast cancer and anastrozole-induced <10% first 
follow-up density reduction (relative to placebo-treated women), adjusted 
for age at randomisation. 
 
 The secondary analysis (IX) will use a logistic regression model to examine 
the association between risk of breast cancer and anastrozole-induced ≥5% 
first follow-up density reduction (relative to placebo-treated women), and 
 
439 
 
risk of breast cancer and anastrozole-induced <5% first follow-up density 
reduction (relative to placebo-treated women), adjusted for age at 
randomisation. 
 
 The secondary analysis (X) will use a logistic regression model to examine 
the association between risk of breast cancer and anastrozole-induced ≥10% 
first follow-up density reduction (relative to placebo-treated women), and 
risk of breast cancer and anastrozole-induced <10% first follow-up density 
reduction (relative to placebo-treated women), adjusted for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 The secondary analysis (XI) will use a logistic regression model to examine 
the association between risk of breast cancer and anastrozole-induced ≥5% 
first follow-up density reduction (relative to placebo-treated women), and 
risk of breast cancer and anastrozole-induced <5% first follow-up density 
reduction (relative to placebo-treated women), adjusted for age at 
randomisation, body mass index at randomisation, baseline density, and 
Tyrer-Cuzick 10-year risk. 
 
 The secondary analysis (XII) will use logistic regression to assess the odds 
of developing breast cancer in women who have experienced anastrozole-
induced ≥10% density reduction in different subgroups of covariates 
(tumour ER status, age at randomisation, body mass index at randomisation, 
baseline density, history of atypical hyperplasia or LCIS, hormone 
replacement use up to 12 months before randomisation, Tyrer-Cuzick 10-
year risk, image type, and time between baseline mammogram and first 
follow-up mammogram). 
 
 The secondary analysis (XIII) will use logistic regression to assess the odds 
of developing breast cancer in women who have experienced anastrozole-
induced ≥5% density reduction in different subgroups of covariates (tumour 
ER status, age at randomisation, body mass index at randomisation, baseline 
density, history of atypical hyperplasia or LCIS, hormone replacement use 
up to 12 months before randomisation, Tyrer-Cuzick 10-year risk, image 
type, and time between baseline mammogram and first follow-up 
mammogram). 
 
 All statistical analysis will be conducted in STATA 13. All tests will be 
two-sided with a significance level of 5%. 
 
 Results will be omitted if subgroup numbers are small enough to un-blind 
the requestor. 
What will 
the data be 
used for?  
The results of the analysis will form a chapter in Ms Emma Atakpa’s PhD 
thesis. 
 
The results will also be prepared for publication in a peer-reviewed journal 
(dependent on results and TSC permitting). 
Date Analysis will begin as soon as possible after responses from the TSC. 
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required by: 
 
Other 
comments: 
There is currently not enough power to complete the primary objective. 
However, Kim et al. (264) found a provocative result of increased risk of 
recurrence in oestrogen receptor-positive breast cancer cases on AIs who lost 
<5% density after 8-20 months of treatment relative to similarly treated women 
who lost ≥5% density, although results were not significant (HR=7.11; 95% CI: 
0.90-56.37; p=0.06). The number of recurrences on AIs was not reported but it 
is estimated to be 13 from other numbers reported in the paper. Assuming 32% 
of the 35 cases in this study were on anastrozole (40 anastrozole cases/125 cases 
in Cuzick et al. (208)) we estimate there to be approximately 11 anastrozole 
cases. There may therefore be enough power in this study to detect an effect if 
density change is dichotomised into <5% and ≥5% reduction (secondary 
objectives). 
Proposed 
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E. Atakpa, A. Brentnall, L. Metaxa, I. Sestak, J.F. Forbes, A. Howell, J. Cuzick 
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